EPA/635/R-14/312b
External Review Draft
www.epa.gov/iris

Toxicological Review of Benzo[a]pyrene

(CASRN 50-32-8)

In Support of Summary Information on the Integrated Risk Information System (IRIS)

Supplemental Information

September 2014

NOTICE

This document is an **External Review draft**. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications.

National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Washington, DC

DISCLAIMER

This document is a preliminary draft for review purposes only. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement of recommendation for use.

ED_006137A_00009570-00002

CONTENTS

APPENDIX A. CHEMICAL PROPERTIES AND EXPOSURE INFORMATION A-1

APPENDIX B. ASSESSMENTS BY OTHER NATIONAL AND INTERNATIONAL HEALTH AGENCIES B-1

APPENDIX C. LITERATURE SEARCH STRATEGY KEYWORDS C-1

APPENDIX D. INFORMATION IN SUPPORT OF HAZARD IDENTIFICATION AND DOSE-RESPONSE ANALYSIS D-1

D.1. TOXICOKINETICS D-1

D.1.1. Overview D-1

D.1.2. Absorption D-1

D.1.3. Distribution D-3

D.1.4. Metabolism D-4

D.1.5. Elimination D-11

D.2. PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS D-12

D.2.1. Recommendations for the Use of PBPK Models in Toxicity Value Derivation D-14

D.3. HUMAN STUDIES D-15

D.3.1. Noncancer Endpoints D-15

D.3.2. Cancer-related Endpoints D-26

D.3.3. Epidemiologic Findings in Humans D-28

D.4. ANIMAL STUDIES D-38

D.4.1. Oral Bioassays D-38

D.4.2. Inhalation Studies D-58

D.4.3. Dermal studies D-61

D.4.4. Reproductive and Developmental Toxicity Studies D-71

D.4.5. Inhalation D-87

D.5. OTHER PERTINENT TOXICITY INFORMATION D-91

D.5.1. Genotoxicity Information D-91

D.5.2. Tumor Promotion and Progression D-114

D.5.3. Benzo[a]pyrene Transcriptomic Microarray Analysis D-118

APPENDIX E. DOSE-RESPONSE MODELING FOR THE DERIVATION OF REFERENCE VALUES FOR EFFECTS OTHER THAN CANCER AND THE DERIVATION OF CANCER RISK ESTIMATES E-1

E.1. NONCANCER ENDPOINTS E-1

E.1.1. Reference Dose (RfD) E-1

E.1.2. Reference Concentration (RfC) E-28

E.2. Cancer Endpoints E-31

E.2.1. Dose-Response Modeling for the Oral Slope Factor E-31

E.2.2. Dose-Response Modeling for the Inhalation Unit Risk E-66

E.2.3. Dose-Response Modeling for the Dermal Slope Factor E-75

APPENDIX F. DOCUMENTATION OF IMPLEMENTATION OF THE 2011 NATIONAL RESEARCH COUNCIL RECOMMENDATIONS F-1

APPENDIX G. SUMMARY OF EXTERNAL PEER REVIEW AND PUBLIC COMMENTS AND EPA'S DISPOSITION G-1

REFERENCES FOR APPENDICES R-1

TABLES

Table A-1. Chemical and physical properties of benzo[a]pyrene A-2
Table A-2. Benzo[a]pyrene concentrations in air....A-4
Table A-3. Benzo[a]pyrene levels in food A-5
Table A-4. Levels of benzo[a]pyrene in soil A-7
Table B-1. Health assessments and regulatory limits by other national and international agencies B-1
Table C-1. Literature search strategy keywords for benzo[a]pyrene C-1
Table D-1. Exposure to benzo[a]pyrene and mortality from cardiovascular diseases in a European cohort of asphalt paving workers.... D-16
Table D-2. Exposure to benzo[a]pyrene and mortality from cardiovascular diseases in a Canadian cohort of male aluminum smelter workers D-18
Table D-3. Exposure-related effects in Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace D-23
Table D-4. Exposure-related effects in Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace, stratified by urinary metabolite levels D-24
Table D-5. Background information on Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace D-25
Table D-6. Studies examining skin cancer risk in relation to therapeutic coal tar D-34
Table D-7. Exposure-related effects in male Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 5 weeks D-39
Table D-8. Exposure-related effects in Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 5 weeks D-43
Table D-9. Means ± SD for liver and thymus weights in Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 90 days D-45
Table D-10. Incidences of exposure-related neoplasms in Wistar rats treated by gavage with benzo[a]pyrene, 5 days/week, for 104 weeks.... D-47
Table D-11. Incidences of alimentary tract tumors in Sprague-Dawley rats chronically exposed to benzo[a]pyrene in the diet or by gavage in caffeine solution D-51
Table D-12. Incidence of nonneoplastic and neoplastic lesions in female B6C3F$_1$ mice fed benzo[a]pyrene in the diet for up to 2 years.... D-53
Table D-13. Other oral exposure cancer bioassays in mice D-54
Table D-14. Tumor incidence in the respiratory tract and upper digestive tract for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime—Thyssen et al. (1981) D-60
Table D-15. Skin tumor incidence and time of appearance in male C57L mice dermally exposed to benzo[a]pyrene for up to 103 weeks D-63
Table D-16. Skin tumor incidence and time of appearance in male SWR, C3HeB, and A/He mice dermally exposed to benzo[a]pyrene for life or until a skin tumor was detected D-64
Table D-17. Tumor incidence in female Swiss mice dermally exposed to benzo[a]pyrene for up to 93 weeks.... D-65
Table D-18. Skin tumor incidence in female NMRI and Swiss mice dermally exposed to benzo[a]pyrene.... D-66
Table D-19. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene D-67
Table D-20. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene D-67

ED_006137A_00009570-00005

Table D-21. Skin tumor incidence and time of appearance in female CFLP mice dermally exposed to benzo[a]pyrene for 104 weeks D-68
Table D-22. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene for life D-69
Table D-23. Skin tumor incidence in male C3H/HeJ mice dermally exposed to benzo[a]pyrene for 24 months D-70
Table D-24. Mortality and cervical histopathology incidences in female ICR mice exposed to benzo[a]pyrene via gavage for 14 weeks D-74
Table D-25. Means ± SD for ovary weight in female Sprague-Dawley rats D-77
Table D-26. Reproductive effects in male and female CD-1 F1 mice exposed in utero to benzo[a]pyrene D-79
Table D-27. Effect of prenatal exposure to benzo[a]pyrene on indices of reproductive performance in F1 female NMRI mice D-80
Table D-28. Exposure-related effects in Long-Evans Hooded rats exposed to benzo[a]pyrene by gavage daily in utero from GD 14 to 17 ..... D-84
Table D-29. Exposure-related pup body weight effects in Swiss Albino OF1 mice exposed as pups to benzo[a]pyrene in breast milk from dams treated by gavage daily from PND 1 to 14 ..... D-85
Table D-30. Pregnancy outcomes in female F344 rats treated with benzo[a]pyrene on GDs 11–21 by inhalation D-88
Table D-31. In vitro genotoxicity studies of benzo[a]pyrene in non-mammalian cells D-91
Table D-32. In vitro genotoxicity studies of benzo[a]pyrene in mammalian cells D-93
Table D-33. In vivo genotoxicity studies of benzo[a]pyrene D-98
Table D-34. Search terms and the number of studies retrieved from the gene expression omnibus and array express microarray repositories D-118
Table D-35. Mapping of group numbers to time/dose groups D-121
Table E-1. Noncancer endpoints selected for dose-response modeling for benzo[a]pyrene: RfD E-2
Table E-2. Summary of BMD modeling results for decreased thymus weight in male Wistar rats exposed to benzo[a]pyrene by gavage for 90 days (Kroese et al., 2001); BMR = 1 SD change from the control mean E-3
Table E-3. Summary of BMD modeling results for decreased thymus weight in female Wistar rats exposed to benzo[a]pyrene by gavage for 90 days (Kroese et al., 2001); BMR = 1 SD change from the control mean E-7
Table E-4. Summary of BMD modeling results for decreased ovary weight in female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 60 days (Xu et al., 2010); BMR = 1 SD change from the control mean E-11
Table E-5. Summary of BMD modeling results for Morris water maze: escape latency in male and female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 90 days (Chen et al., 2012); BMR = 1 SD change from the control mean E-14
Table E-6. Summary of BMD modeling results for Morris water maze: time spent in quadrant for in male and female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 90 days (Chen et al., 2012); BMR = 1 SD change from the control mean E-18
Table E-7. Summary of BMD modeling results for elevated plus maze: open arm entries for females at PND 70 (Chen et al., 2012); BMR = 1 SD change from the control mean E-21
Table E-8. Summary of BMD modeling results for incidence of cervical epithelial hyperplasia in female ICR mice exposed to benzo[a]pyrene by oral exposure for 98 days (Gao et al., 2011); BMR = 1 SD change from the control mean E-25

ED_006137A_00009570-00006

Table E-9. Tumor incidence data, with time to death with tumor for male Wistar rats exposed by gavage to benzo[a]pyrene for 104 weeks (Kroese et al., 2001) E-34
Table E-10. Tumor incidence data, with time to death with tumor for female Wistar rats exposed by gavage to benzo[a]pyrene for 104 weeks (Kroese et al., 2001) E-37
Table E-11. Tumor incidence, with time to death with tumor; B6C3F$_1$ female mice exposed to benzo[a]pyrene via diet for 2 years (Beland and Culp, 1998) E-40
Table E-12. Derivation of HEDs to use for BMD modeling of Wistar rat tumor incidence data from Kroese et al. (2001) E-43
Table E-13. Derivation of HEDs for dose-response modeling of B6C3F$_1$ female mouse tumor incidence data from Beland and Culp (1998) E-43
Table E-14. Summary of BMD modeling results for best-fitting multistage-Weibull models, using time-to-tumor data for Wistar rats exposed to benzo[a]pyrene via gavage for 104 weeks (Kroese et al., 2001); BMR = 10% extra risk E-44
Table E-15. Summary of human equivalent overall oral slope factors, based on tumor incidence in male and female Wistar rats exposed to benzo[a]pyrene by gavage for 104 weeks (Kroese et al., 2001) E-63
Table E-16. Summary of BMD model selection among multistage-Weibull models fit to alimentary tract tumor data for female B6C3F$_1$ mice exposed to benzo[a]pyrene for 2 years (Beland and Culp, 1998) E-63
Table E-17. Individual pathology and tumor incidence data for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime—Thyssen et al. (1981) E-67
Table E-18. Summary of BMD model selection among multistage-Weibull models fit to tumor data for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime (Thyssen et al., 1981) E-70
Table E-19. Tumor incidence, with time to observation of tumor or death; CeH/HeJ male mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997; Arthur D Little, 1989) E-78
Table E-20. Skin tumor incidence, benign or malignant in female Swiss or NMRI mice dermally exposed to benzo[a]pyrene; data from Roe et al. (1970), Schmidt et al. (1973), Schmähl et al. (1977), Habs et al. (1980), Habs et al. (1984) E-79
Table E-21. Skin tumor incidence, benign or malignant, in C57L male mice dermally exposed to benzo[a]pyrene; data from Poel (1959) E-80
Table E-22. Skin tumor incidence, benign or malignant, in female CFLP mice dermally exposed to benzo[a]pyrene; data from Grimmer et al. (1983), Grimmer et al. (1984) E-80
Table E-23. Summary of BMD modeling results for best-fitting multistage-Weibull models, using time-to-tumor data for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997; Arthur D Little, 1989) E-81
Table E-24. Summary of BMD model selection and modeling results using multistage models, for multiple data sets of skin tumors in mice following lifetime dermal benzo[a]pyrene exposure E-86
Table E-25. Alternative approaches to cross-species scaling E-115
Table F-1. The EPA's implementation of the National Research Council's recommendations in the benzo[a]pyrene assessment F-2
Table F-2. National Research Council recommendations that the EPA is generally implementing in the long term F-7

ED_006137A_00009570-00007

FIGURES

Figure A-1. Structural formula of benzo[a]pyrene. A-1
Figure D-1. Metabolic pathways for benzo[a]pyrene. D-5
Figure D-2. The stereospecific activation of benzo[a]pyrene. D-7
Figure D-3. Interaction of PAHs with the AhR. D-115
Figure D-4. AhR pathway. For Figures D-4–D-6, the "thermometers" display the fold change gene expression. The numbers under the thermometer represent the group within the two studies (see Table D-34). For instance, NRF2 is upregulated in the 25 mg/kg. D-122
Figure D-5. DNA damage pathway. Activation of transcriptional targets of *p53*, including *p21* and *GADD45*, and upregulation of the downstream transcriptional target, PCNA, suggests that *p53* is activated. D-123
Figure D-6. Nrf2 pathway. Nrf2 is upregulated by benzo[a]pyrene exposure, which results in the upregulation of Phase II detoxifying enzymes. This appears to be a compensatory response due to increased oxidative status within cells. D-125
Figure E-1. Fit of linear model (nonconstant variance) to data on decreased thymus weight in male Wistar rats—90 days (Kroese et al., 2001). E-4
Figure E-2. Fit of linear model (constant variance) to data on decreased thymus weight in female Wistar rats—90 days (Kroese et al., 2001). E-8
Figure E-3. Fit of linear/polynomial (1°) model to data on decreased ovary weight (Xu et al., 2010). E-11
Figure E-4. Fit of Hill model to data on Morris water maze test escape latency (Chen et al., 2012). E-15
Figure E-5. Fit of Exponential 4 model to data on Morris water maze time spent in target quadrant (Chen et al., 2012). E-18
Figure E-6. Fit of exponential model (4) to data on elevated plus maze open arm maze entries (Chen et al., 2012). E-22
Figure E-7. Fit of log-logistic model to data on cervical epithelial hyperplasia (Gao et al., 2011) E-25
Figure E-8. Human fractional deposition. E-29
Figure E-9. Rat fractional deposition. E-30
Figure E-10. Fit of multistage Weibull model to squamous cell papillomas or carcinomas in oral cavity or forestomach of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-46
Figure E-11. Fit of multistage Weibull model to hepatocellular adenomas or carcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-48
Figure E-12. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-50
Figure E-13. Fit of multistage Weibull model to skin or mammary gland basal cell tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-52
Figure E-14. Fit of multistage Weibull model to skin or mammary gland squamous cell tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-54
Figure E-15. Fit of multistage Weibull model to kidney urothelial tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-56
Figure E-16. Fit of multistage Weibull model to squamous cell papillomas or carcinomas in oral cavity or forestomach of female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-58

ED_006137A_00009570-00008

Figure E-17. Fit of multistage Weibull model to hepatocellular adenomas or carcinomas in female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-60
Figure E-18. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-62
Figure E-19. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001) E-65
Figure E-20. Fit of multistage Weibull model to respiratory tract tumors in male hamsters exposed via inhalation to benzo[a]pyrene (Thyssen et al., 1981); tumors treated as incidental to death. E-72
Figure E-21. Fit of multistage Weibull model to respiratory tract tumors in male hamsters exposed via inhalation to benzo[a]pyrene (Thyssen et al., 1981); tumors treated as cause of death. E-74
Figure E-22. Fit of multistage Weibull model to skin carcinomas or papilloma for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997); BMR = 10% extra risk E-83
Figure E-23. Fit of multistage Weibull model to skin carcinomas, keratoacanthoma or papilloma for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997); BMR = 10% extra risk E-85
Figure E-24. Fit of multistage model to skin tumors in C57L mice exposed dermally to benzo[a]pyrene (Poel, 1959). E-87
Figure E-25. Fit of multistage model to skin tumors in female Swiss mice exposed dermally to benzo[a]pyrene (Roe et al., 1970). E-90
Figure E-26. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Schmidt et al., 1973). E-92
Figure E-27. Fit of multistage model to skin tumors in female Swiss mice exposed dermally to benzo[a]pyrene (Schmidt et al., 1973). E-94
Figure E-28. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Schmähl et al., 1977). E-96
Figure E-29. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Habs et al., 1980). E-98
Figure E-30. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Habs et al., 1984). E-100
Figure E-31. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1983). E-102
Figure E-32. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984). E-104
Figure E-33. Fit of log-logistic model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984). E-106
Figure E-34. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984), highest dose dropped. E-108
Figure E-35. Fit of multistage model to skin tumors in male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997). E-110

ED_006137A_00009570-00009

ABBREVIATIONS

1-OH-Py	1-hydroxypyrene
AchE	acetylcholine esterase
ADAF	age-dependent adjustment factor
Ah	aryl hydrocarbon
AHH	aryl hydrocarbon hydroxylase
AhR	aryl hydrocarbon receptor
AIC	Akaike's Information Criterion
AKR	aldo-keto reductase
AMI	acute myocardial infarction
ANOVA	analysis of variance
ARNT	Ah receptor nuclear translocator
AST	aspartate transaminase
ATSDR	Agency for Toxic Substances and Disease Registry
BMC	benchmark concentration
BMCL	benchmark concentration lower confidence limit
BMD	benchmark dose
BMDL	benchmark dose, 95% lower bound
BMDS	Benchmark Dose Software
BMR	benchmark response
BPDE	benzo[a]pyrene-7,8-diol-9,10-epoxide
BPQ	benzo[a]pyrene semiquinone
BrdU	bromodeoxyuridine
BSM	benzene-soluble matter
BUN	blood urea nitrogen
BW	body weight
CA	chromosomal aberration
CAL/EPA	California Environmental Protection Agency
CASRN	Chemical Abstracts Service Registry Number
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CHO	Chinese hamster ovary
CI	confidence interval
CYP	cytochrome
CYP450	cytochrome P450
DAF	dosimetric adjustment factor
dbcAMP	dibutyl cyclic adenosine monophosphate
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
EC	European Commission
EH	epoxide hydrolase
ELISA	enzyme-linked immunosorbent assay
EPA	Environmental Protection Agency
EROD	7-ethoxyresorufin-O-deethylase
ETS	environmental tobacco smoke
EU	European Union
Fe_2O_3	ferrous oxide
FSH	follicle stimulating hormone
GABA	gamma-aminobutyric acid
GD	gestational day
GI	gastrointestinal
GJIC	gap junctional intercellular communication
GSH	reduced glutathione
GST	glutathione-S-transferase
GSTM1	glutathione-S-transferase M1
hCG	human chorionic gonadotropin
HEC	human equivalent concentration
HED	human equivalent dose
HERO	Health and Environmental Research Online
HFC	high-frequency cell
HPLC	high-performance liquid chromatography
hprt	hypoxanthine guanine phosphoribosyl transferase
HR	hazard ratio
Hsp90	heat shock protein 90
i.p.	intraperitoneal
i.v.	intravenous
Ig	immunoglobulin
IHD	ischemic heart disease
IRIS	Integrated Risk Information System
LDH	lactate dehydrogenase
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
MAP	mitogen-activated protein
MCL	Maximum Contaminant Level
MCLG	Maximum Contaminant Level Goal
MIAME	Minimum Information About a Microarray Experiment
MLE	maximum likelihood estimate
MMAD	mass median aerodynamic diameter
MN	micronucleus
MPPD	Multi-Path Particle Deposition
mRNA	messenger ribonucleic acid
MS	mass spectrometry
NCE	normochromatic erythrocyte
NCEA	National Center for Environmental Assessment
NIOSH	National Institute for Occupational Safety and Health
NK	natural-killer

ED_006137A_00009570-00010

NMDA	N-methyl-D-aspartate
NOAEL	no-observed-adverse-effect level
NPL	National Priorities List
NQO	NADPH:quinone oxidoreductase
NRC	National Research Council
NTP	National Toxicology Program
OECD	Organisation for Economic Co-operation and Development
OR	odds ratio
ORD	Office of Research and Development
PAH	polycyclic aromatic hydrocarbon
PBMC	peripheral blood mononuclear cell
PBPK	physiologically based pharmacokinetic
PCA	Principal Components Analysis
PCE	polychromatic erythrocyte
PCNA	proliferating cell nuclear antigen
PND	postnatal day
POD	point of departure
PUVA	psoralen plus ultraviolet-A
RBC	red blood cell
$RDDR_{ER}$	regional deposited dose ratio for extrarespiratory effects
RfC	inhalation reference concentration
RfD	oral reference dose
RNA	ribonucleic acid
ROS	reactive oxygen species
RR	relative risk
s.c.	subcutaneous
SCC	squamous cell carcinoma
SCE	sister chromatid exchange
SCSA	sperm chromatin structure assay
SD	standard deviation
SE	standard error
SEM	standard error of the mean
SHE	Syrian hamster embryo
SIR	standardized incidence ratio
SMR	standardized mortality ratio
SOAR	Systematic Omics Analysis Review
SOD	superoxide dismutase
SRBC	sheep red blood cells
SSB	single-strand break
TCDD	2,3,7,8-tetrachlorodibenzo-p-dioxin
TK	thymidine kinase
ToxR	Toxicological Reliability Assessment
TPA	12-O-tetradecanoylphorbol-13-acetate
TUNEL	terminal deoxynucleotidyl transferase dUTP nick end labeling
TWA	time-weighted average
UCL	upper confidence limit
UDP-UGT	uridine diphosphate-glucuronosyltransferase
UDS	unscheduled DNA synthesis
UF	uncertainty factor
UF_A	interspecies uncertainty factor
UF_D	database deficiencies uncertainty factor
UF_H	intraspecies uncertainty factor
UF_L	LOAEL-to-NOAEL uncertainty factor
UF_S	subchronic-to-chronic uncertainty factor
UVA	ultraviolet-A
UVB	ultraviolet-B
WBC	white blood cell
WESPOC	water escape pole climbing
WT	wild type
WTC	World Trade Center
XPA	xeroderma pigmentosum group A

ED_006137A_00009570-00011

APPENDIX A. CHEMICAL PROPERTIES AND EXPOSURE INFORMATION

Benzo[a]pyrene is a five-ring polycyclic aromatic hydrocarbon (PAH) (Figure A-1). It is a pale yellow crystalline solid with a faint aromatic odor. It is relatively insoluble in water and has low volatility. Benzo[a]pyrene is released to the air from both natural and anthropogenic sources and removed from the atmosphere by photochemical oxidation; reaction with nitrogen oxides, hydroxy and hydroperoxy radicals, ozone, sulfur oxides, and peroxyacetyl nitrate; and wet and dry deposition to land or water. In air, benzo[a]pyrene is predominantly adsorbed to particulates, but may also exist as a vapor at high temperatures (HSDB, 2012). The half-lives for degradation of benzo[a]pyrene in soil, air, water, and sediment are 229–309, 0.02–7, 39–71, and 196–2293 days, respectively (HSDB, 2012; GLC, 2007).

The structural formula is presented in Figure A-1. The physical and chemical properties of benzo[a]pyrene are shown in Table A-1.



Benzo[a]pyrene

Figure A-1. Structural formula of benzo[a]pyrene.

Table A-1. Chemical and physical properties of benzo[a]pyrene

CASRN 50-32-8		
Synonyms	Benzo[d,e,f]chrysene; 3,4-benzopyrene, 3,4-benzpyrene; benz[a]pyrene; BP; BaP	ChemIDplus (2012)
Melting point	179–179.3°C	O'Neil et al. (2001)
Boiling point	310–312°C at 10 mm Hg	O'Neil et al. (2001)
Vapor pressure, at 20°C	5×10^{-7} mm Hg	Verschueren (2001)
Density	1.351 g/cm^3	IARC (1973)
Flashpoint (open cup)	No data	
Water solubility at 25°C	$1.6–2.3 \times 10^{-3}$ mg/L	(Howard and Meylan (1997); ATSDR (1995))
Log K_{ow}	6.04	Verschueren (2001)
Odor threshold	No data	
Molecular weight	252.32	O'Neil et al. (2001)
Conversion factors[a]	1 ppm = 10.32 mg/m^3	Verschueren (2001)
Empirical formula	$C_{20}H_{12}$	ChemIDplus (2012)

[a]Calculated based on the ideal gas law, PV = *n*RT at 25°C: ppm = mg/m^3 × 24.45 ÷ molecular weight.

No reference to any commercial use for purified benzo[a]pyrene, other than for research purposes, was found. The earliest research reference for benzo[a]pyrene was related to the identification of coal tar constituents associated with human skin tumors (Phillips, 1983; Cook et al., 1933). It is found ubiquitously in the environment, primarily as a result of incomplete combustion emissions (Boström et al., 2002). It is released to the environment via both natural sources (such as forest fires) and anthropogenic sources including stoves/furnaces burning fossil fuels (especially wood and coal), motor vehicle exhaust, cigarette smoke, and various industrial combustion processes (ATSDR, 1995). Benzo[a]pyrene is also found in soot and coal tars. Studies have reported that urban run-off from asphalt-paved car parks treated with coats of coal-tar emulsion seal could account for the majority of PAHs in many watersheds (Rowe and O'Connor, 2011; Van Metre and Mahler, 2010; Mahler et al., 2005). Occupational exposure to PAHs occurs primarily through inhalation and skin contact during the production and use of coal tar and coal-tar-derived products, such as roofing tars, creosote, and asphalt (IARC, 1973). Chimney sweeping can result in exposure to benzo[a]pyrene-contaminated soot (ATSDR, 1995). Workers involved in the production of aluminum, coke, graphite, and silicon carbide may also be exposed to benzo[a]pyrene (see Table A-2).

Benzo[a]pyrene concentrations have been well documented in samples of ground, drinking, and surface water (HSDB, 2012). An assessment of benzo[a]pyrene emissions in the Great Lakes

ED_006137A_00009570-00013

Region in 2002 indicated that the largest source categories are metal production (33%), petroleum refineries (11%), residential wood burning (28%), open burning (13%), on-road vehicles (6%), and off-highway gasoline engines (3%) (GLC, 2007).

Inhalation Exposure. The Agency for Toxic Substances and Disease Registry (ATSDR, 1995) reported average indoor concentrations of benzo[a]pyrene of 0.37–1.7 ng/m^3 for smokers and 0.27–0.58 ng/m^3 for nonsmokers. Naumova et al. (2002) measured PAHs in 55 nonsmoking residences in three urban areas during June 1999–May 2000. Mean indoor benzo[a]pyrene levels ranged from 0.02 to 0.078 ng/m^3; outdoor levels were 0.025–0.14 ng/m^3. The authors concluded that indoor levels of the 5–7-ring PAHs (such as benzo[a]pyrene) were dominated by outdoor sources and observed an average indoor/outdoor ratio of approximately 0.7 (Naumova et al., 2002). Mitra and Wilson (1992) measured benzo[a]pyrene air levels in Columbus, Ohio, and found elevated indoor levels in homes with smokers. The measured average concentration was 1.38 ng/m^3 for outdoor air; indoor concentrations were 0.07 ng/m^3 for homes with electrical utilities, 0.91 ng/m^3 for homes with gas utilities, 0.80 ng/m^3 for homes with gas utilities and a fireplace, 2.75 ng/m^3 for homes with gas utilities and smokers, and 1.82 ng/m^3 for homes with gas utilities, smokers, and a fireplace (Mitra and Wilson, 1992). Mitra and Ray (1995) evaluated data on benzo[a]pyrene air levels in Columbus, Ohio, and reported average concentrations of 0.77 ng/m^3 inside homes and 0.23 ng/m^3 outdoors. Park et al. (2001) measured an average ambient level of benzo[a]pyrene in Seabrook, Texas during 1995–1996 of 0.05 ng/m^3 (vapor plus particulate). Park et al. (2001) also reported average ambient air levels from earlier studies as 1.0 ng/m^3 for Chicago, 0.19 ng/m^3 for Lake Michigan, 0.01 ng/m^3 for Chesapeake Bay, and 0.02 ng/m^3 for Corpus Christie, Texas. Petry et al. (1996) conducted personal air sampling during 1992 at five workplaces in Switzerland: carbon anode production, graphite production, silicon carbide production, bitumen paving work, and metal recycling. Table A-2 summarizes the benzo[a]pyrene air concentration data from the previous studies.

ED_006137A_00009570-00014

Table A-2. Benzo[a]pyrene concentrations in air

Setting	Years	n	Concentration (ng/m^3)	Reference
Outdoor, urban				
Los Angeles, California	1999–2000	19	0.065	Naumova et al. (2002)
Houston, Texas	1999–2000	21	0.025	Naumova et al. (2002)
Elizabeth, New Jersey	1999–2000	15	0.14	Naumova et al. (2002)
Seabrook, Texas	1995–1996	NA	0.05	Park et al. (2001)
Columbus, Ohio	1986–1987	8	0.23	Mitra and Ray (1995)
Indoor, residential				
Los Angeles, California	1999–2000	19	0.078	Naumova et al. (2002)
Houston, Texas	1999–2000	21	0.020	Naumova et al. (2002)
Elizabeth, New Jersey	1999–2000	15	0.055	Naumova et al. (2002)
Columbus, Ohio	1986–1987	8	0.77	Mitra and Ray (1995)
Columbus, Ohio		10	0.07–2.75	Mitra and Wilson (1992)
Homes with smokers			0.37–1.7	ATSDR (1995)
Homes without smokers			0.27–0.58	ATSDR (1995)
Occupational				
Aluminum production			30–530	ATSDR (1995)
Coke production			150–6,720; 8,000	(Petry et al. (1996); ATSDR (1995))
Carbon anode production, Switzerland	1992	30	1,100	Petry et al. (1996)
Graphite production, Switzerland	1992	16	83	Petry et al. (1996)
Silicon carbide production, Switzerland	1992	14	36	Petry et al. (1996)
Metal recovery, Switzerland	1992	5	14	Petry et al. (1996)
Bitumen paving, Switzerland	1992	9	10	Petry et al. (1996)

NA = not available.

Santodonato et al. (1981) estimated the adult daily intake from inhalation as 9–43 ng/day. The European Commission (EC, 2002) reported benzo[a]pyrene air levels in Europe during the 1990s as 0.1–1 ng/m^3 in rural areas and 0.5–3 ng/m^3 in urban areas. The amount of benzo[a]pyrene is reported to be 5–80 ng per cigarette in mainstream cigarette smoke, but significantly higher, 25–200 ng per cigarette in sidestream smoke. Concentrations of 400–760,000 ng/m^3 have been reported in a cigarette smoke-polluted environment (Cal/EPA,

ED_006137A_00009570-00015

2010). The mean intake via inhalation for an adult nonsmoker was estimated as 20 ng/day. Naumova et al. (2002) focused on nonsmoking residences and suggested that typical air exposures are <0.14 ng/m^3, which would result in an intake of <3 ng/day assuming an inhalation rate of 20 m^3/day.

Oral Exposure. The processing and cooking of foods is viewed as the dominant pathway of PAH contamination in foods (Boström et al., 2002). Among the cooking methods that lead to PAH contamination are the grilling, roasting, and frying of meats. Raw meat, milk, poultry, and eggs normally do not contain high levels of PAHs due to rapid metabolism of these compounds in the species of origin. However, some marine organisms, such as mussels and lobsters, are known to adsorb and accumulate PAHs from contaminated water (e.g., oil spills). Vegetables and cereal grains can become contaminated primarily through aerial deposition of PAHs present in the atmosphere (Li et al., 2009).

Kazerouni et al. (2001) measured benzo[a]pyrene in a variety of commonly consumed foods collected from grocery stores and restaurants in Maryland (analyzed as a composite from 4–6 samples of each food type). The foods were tested after various methods of cooking; the results are reported in Table A-3. The concentrations were combined with food consumption data to estimate intake. The intakes of the 228 subjects ranged from approximately 10 to 160 ng/day, with about 30% in the 40–60 ng/day range. The largest contributions to total intake were reported as bread, cereal, and grain (29%) and grilled/barbecued meats (21%).

Table A-3. Benzo[a]pyrene levels in food

Food	Concentration (ng/g)
Meat	
Fried or broiled beef	0.01–0.02
Grilled beef	0.09–4.9
Fried or broiled chicken	0.08–0.48
Grilled chicken	0.39–4.57
Fish	0.01–0.24
Smoked fish	0.1
Bread	0.1
Breakfast cereals	0.02–0.3
Vegetable oil	0.02
Eggs	0.03
Cheese	<0.005
Butter	<0.005

ED_006137A_00009570-00016

Food	Concentration (ng/g)
Milk	0.02
Fruit	0.01–0.17

Source: Kazerouni et al. (2001).

Kishikawa et al. (2003) measured benzo[a]pyrene levels in cow milk, infant formula, and human milk from Japan, with means of 0.03 ng/g (n = 14) in cow milk, 0.05 ng/g (n = 3) in infant formula, and 0.002 (n = 51) in human milk.

From the surveys conducted in six EU countries, the mean or national-averaged dietary intake of benzo[a]pyrene for an adult person was estimated in the range of 0.05–0.29 μg/day (EC, 2002). Children may be subject to higher oral intake of benzo[a]pyrene. In a Spanish study in which benzo[a]pyrene was detected in foods, children ages 4–9 years old were found to have the highest estimated daily intake, as compared to adults and adolescents (Falco et al., 2003). In the United Kingdom, average intakes on a ng kg^{-1} day^{-1} basis were estimated for the following age groups: adults, 1.6; 15–18 years, 1.4; 11–14 years, 1.8; 7–10 years, 2.6; 4–6 years, 3.3; and toddlers, 3.1–3.8. The major contributors were the oils and fats group (50%), cereals (30%), and vegetables (8%) (EC, 2002). The contribution from grilled foods appeared less important in Europe than in the United States because grilled foods are consumed less often (EC, 2002). In the United States, the ingested dose of benzo[a]pyrene may be much higher than the amount inhaled. A study in New Jersey estimated a daily median total ingested dose of 176 ng based on a urinary biomarker study of 14 adult volunteers over 14 consecutive days, which exceeded the winter inhalation dose (11 ng/day) by 16-fold and the summer/fall inhalation dose (2.3 ng/day) by 122-fold (Buckley et al., 1995).

Dermal Exposure. The general population can be exposed dermally to benzo[a]pyrene when contacting soils or materials that contain benzo[a]pyrene, such as soot or tar. Exposure can also occur via the use of dermally applied pharmaceutical products that contain coal tars, including shampoos and formulations used to treat conditions such as eczema and psoriasis (IARC, 2010).

PAHs are commonly found in all types of soils. ATSDR (1995) reported benzo[a]pyrene levels in soil of 2–1,300 μg/kg in rural areas, 4.6–900 μg/kg in agricultural areas, 165–220 μg/kg in urban areas, and 14,000–159,000 μg/kg at contaminated sites (before remediation). The soil levels for all land uses appear highly variable. The levels are affected by proximity to roads/combustion sources, use of sewage-sludge-derived amendments on agricultural lands, particle size, and organic carbon content. Weinberg et al. (1989) reported that PAH levels in soils generally increased during the 1900s and that sediment studies suggest that some declines may have occurred since the 1970s. An illustration of benzo[a]pyrene levels in soil is presented in Table A-4.

ED_006137A_00009570-00017

1 **Table A-4. Levels of benzo[a]pyrene in soil**

Reference	Location	Land type	Concentration mean (µg/kg)
Butler et al. (1984)	United Kingdom	Urban	1,165
Vogt et al. (1987)	Norway	Industrial	321
	Norway	Rural	14
Yang et al. (1991)	Australia	Residential	363
	Poland	Agricultural	22
Trapido (1999)	Estonia	Urban	106
	Estonia	Urban	398
	Estonia	Urban	1,113
	Estonia	Urban	1,224
	Estonia	Rural	6.8
	Estonia	Rural	15
	Estonia	Rural	27
	Estonia	Rural	31
Nam et al. (2008)	United Kingdom	Rural	46
	Norway	Rural	5.3
Mielke et al. (2001)	New Orleans	Urban	276
Nadal et al. (2004)	Spain	Industrial-chemical	100
	Spain	Industrial-petrochemical	18
	Spain	Residential	56
	Spain	Rural	22
Maliszewska-Kordybach et al. (2009)	Poland	Agricultural	30
Wilcke (2000)	Various temperate	Arable	18
	Various temperate	Grassland	19
	Various temperate	Forest	39
	Various temperate	Urban	350
	Bangkok	Urban-tropical	5.5
	Brazil	Forest-tropical	0.3

APPENDIX B. ASSESSMENTS BY OTHER NATIONAL AND INTERNATIONAL HEALTH AGENCIES

Table B-1. Health assessments and regulatory limits by other national and international agencies

Organization	Toxicity value or determination
Oral value	
(WHO (2003), 1996))	The guideline value for benzo[a]pyrene in drinking water of 0.7 μg/L was based on a cancer slope factor of **0.46 (mg/kg-d)**$^{-1}$ derived from Neal and Rigdon (1967) and a lifetime excess cancer risk of 10^{-5}.
(Health Canada (2010), 1998))	The Maximum Acceptable Concentration for benzo[a]pyrene in drinking water of 0.01 μg/L was derived from Neal and Rigdon (1967) using a drinking water consumption rate of 1.5 L/day, a body weight of 70 kg, and a lifetime cancer risk of 5×10^{-7}. (The concentrations of **2, 0.2, and 0.02 μg/L** benzo[a]pyrene correspond to lifetime excess cancer risks of 10^{-4}, 10^{-5}, and 10^{-6}.)
Inhalation value	
(WHO (2000), 1997))	Does not recommend specific guideline values for polycyclic aromatic hydrocarbons (PAHs) in air. A unit risk of **87 (mg/m^3)**$^{-1}$ for benzo[a]pyrene, as an indicator a PAH mixtures, was derived from U.S. EPA's inhalation unit risk from coke oven emissions.
EU (2005)	Target value of **1 ng/m^3** benzo[a]pyrene (averaged over 1 calendar year) as a marker of PAH carcinogenic risk. Does not include information for how target value was derived.
Cancer characterization	
IARC (2010)	Carcinogenic to humans (Group 1) (based on mechanistic data).
NTP (2011)	Reasonably anticipated to be a human carcinogen. (First classified in 1981.)
Health Canada (1998)	Probably carcinogenic to man.

EU = European Union; IARC = International Agency for Research on Cancer; NTP = National Toxicology Program; WHO = World Health Organization.

ED_006137A_00009570-00019

APPENDIX C. LITERATURE SEARCH STRATEGY KEYWORDS

Table C-1. Literature search strategy keywords for benzo[a]pyrene

Database	Set #	Terms	Hits
Initial strategy			
PubMed Date range: 1950's to 2/14/2012 Search date: 2/14/2012	1A	("Benzo(a)pyrene"[MeSH Terms] AND (("Benzo(a)pyrene/adverse effects"[MeSH Terms] OR "Benzo(a)pyrene/antagonists and inhibitors"[MeSH Terms] OR "Benzo(a)pyrene/blood"[MeSH Terms] OR "Benzo(a)pyrene/pharmacokinetics"[MeSH Terms] OR "Benzo(a)pyrene/poisoning"[MeSH Terms] OR "Benzo(a)pyrene/toxicity"[MeSH Terms] OR "Benzo(a)pyrene/urine"[MeSH Terms]) OR ("chemically induced"[Subheading] OR "environmental exposure"[MeSH Terms] OR "endocrine system"[MeSH Terms] OR "hormones, hormone substitutes, and hormone antagonists"[MeSH Terms] OR "endocrine disruptors"[MeSH Terms] OR "dose-response relationship, drug"[MeSH Terms] OR ((pharmacokinetics[MeSH Terms] OR metabolism[MeSH Terms]) AND (humans[MeSH Terms] OR animals[MeSH Terms])) OR risk[MeSH Terms] OR (cancer[sb] AND "Benzo(a)pyrene"[majr]) OR ("benzo a pyrene/metabolism"[MeSH Terms] AND (humans[MeSH Terms] OR animals[MeSH Terms]))))) AND 2008/10/01 : 3000[mhda]) OR ((("Benzo a pyrene"[tw] OR "Benzo d, e, f chrysene"[tw] OR "Benzo def chrysene"[tw] OR "3,4-Benzopyrene"[tw] OR "1,2-Benzpyrene"[tw] OR "3,4-BP"[tw] OR "Benz(a)pyrene"[tw] OR "3,4-Benzpyren"[tw] OR "3,4-Benzpyrene"[tw] OR "4,5-Benzpyrene"[tw] OR "6,7-Benzopyrene"[tw] OR Benzopirene[tw] OR "benzo[alpha]pyrene"[tw] OR (("B(a)P"[tw] OR BaP[tw]) AND (pyrene*[tw] OR benzopyrene*[tw] OR pah[tw] OR pahs[tw] OR polycyclic aromatic hydrocarbon[tw] OR polycyclic aromatic hydrocarbons[tw]))) NOT medline[sb]) AND 2008/10/01 : 3000[edat]) OR ((("Benzo(a)pyrene"[MeSH Terms] AND (("Benzo(a)pyrene/adverse effects"[MeSH Terms] OR "Benzo(a)pyrene/antagonists and inhibitors"[MeSH Terms] OR "Benzo(a)pyrene/blood"[MeSH Terms] OR "Benzo(a)pyrene/pharmacokinetics"[MeSH Terms] OR "Benzo(a)pyrene/poisoning"[MeSH Terms] OR "Benzo(a)pyrene/toxicity"[MeSH Terms] OR "Benzo(a)pyrene/urine"[MeSH Terms]) OR ("chemically induced"[Subheading] OR "environmental exposure"[MeSH Terms] OR "endocrine system"[MeSH Terms] OR "hormones, hormone substitutes, and hormone antagonists"[MeSH Terms] OR "endocrine disruptors"[MeSH Terms] OR "dose-response relationship, drug"[MeSH Terms] OR ((pharmacokinetics[MeSH Terms] OR metabolism[MeSH Terms]) AND (humans[MeSH Terms] OR animals[MeSH Terms])) OR risk[MeSH Terms] OR (cancer[sb] AND "Benzo(a)pyrene"[majr]) OR ("benzo a pyrene/metabolism"[MeSH Terms] AND (humans[MeSH	5,184

ED_006137A_00009570-00020

Database	Set #	Terms	Hits
		Terms] OR animals[MeSH Terms])))))) OR (("Benzo a pyrene"[tw] OR "Benzo d, e, f chrysene"[tw] OR "Benzo def chrysene"[tw] OR "3,4-Benzopyrene"[tw] OR "1,2-Benzpyrene"[tw] OR "3,4-BP"[tw] OR "Benz(a)pyrene"[tw] OR "3,4-Benzpyren"[tw] OR "3,4-Benzpyrene"[tw] OR "4,5-Benzpyrene"[tw] OR "6,7-Benzopyrene"[tw] OR Benzopirene[tw] OR "benzo[alpha]pyrene"[tw] OR (("B(a)P"[tw] OR BaP[tw]) AND (pyrene*[tw] OR benzopyrene*[tw] OR pah[tw] OR pahs[tw] OR polycyclic aromatic hydrocarbon[tw] OR polycyclic aromatic hydrocarbons[tw])))AND ("Benzopyrenes/adverse effects"[MeSH Terms] OR "Benzopyrenes/antagonists and inhibitors"[MeSH Terms] OR "Benzopyrenes/blood"[MeSH Terms] OR "Benzopyrenes/pharmacokinetics"[MeSH Terms] OR "Benzopyrenes/poisoning"[MeSH Terms] OR "Benzopyrenes/toxicity"[MeSH Terms] OR "Benzopyrenes/urine"[MeSH Terms] OR ("benzopyrenes"[MeSH Terms] AND ("chemically induced"[Subheading] OR "environmental exposure"[MeSH Terms])) OR "benzopyrenes/metabolism"[Mesh Terms]) AND 1966[PDAT] : 1984[PDAT])) AND (cancer[sb] OR "genes"[MeSH Terms] OR "genetic processes"[MeSH Terms] OR "mutagenicity tests"[MeSH Terms] OR "mutagenesis"[MeSH Terms] OR "mutagens"[MeSH Terms] OR "mutation"[MeSH Terms] OR "neurotoxicity syndromes"[MeSH Terms] OR "nervous system"[MeSH Terms] OR "nervous system diseases"[MeSH Terms] OR "immune system"[MeSH Terms] OR "immune system diseases"[MeSH Terms] OR "immunologic factors"[MeSH Terms] OR "reproductive physiological phenomena"[MeSH Terms] OR ("growth and development"[Subheading] OR "urogenital system"[MeSH Terms] OR "congenital, hereditary, and neonatal diseases and abnormalities"[MeSH Terms] OR "teratogens"[MeSH Terms]))	
ToxLine Date range: 1960's- 2/14/2012 Search date: 2/14/2012	1B	(((50-32-8 [rn] OR "benzo a pyrene" OR "benzo d e f chrysene" OR "benzo def chrysene" OR "3 4 benzopyrene" OR "1 2 benzpyrene" OR "3 4 bp" OR "benz (a) pyrene" OR "3 4 benzpyren" OR "3 4 benzpyrene" OR "4 5 benzpyrene" OR "6 7 benzopyrene" OR benzopirene OR "benzo (alpha) pyrene") AND 2008:2012 [yr] NOT PubMed [org] NOT pubdart [org]) NOT crisp[org]) OR (((50-32-8 [rn] OR "benzo a pyrene" OR "benzo d e f chrysene" OR "benzo def chrysene" OR "3 4 benzopyrene" OR "1 2 benzpyrene" OR "3 4 bp" OR "benz (a) pyrene" OR "3 4 benzpyren" OR "3 4 benzpyrene" OR "4 5 benzpyrene" OR "6 7 benzopyrene" OR benzopirene OR "benzo (alpha) pyrene") NOT PubMed [org] NOT pubdart [org]) AND (brain OR brains OR cephalic OR cerebral OR cerebrum OR cognition OR cognitive OR corpus OR encephalopathies OR encephalopathy OR nerve OR nerves OR nervous OR neural OR neurologic OR neurological OR neurology OR neuronal OR neuropathies OR neuropathy OR neurotoxic OR neurotoxicities OR neurotoxicity OR neurotoxin OR neurotoxins OR spinal cord) OR (antibodies OR antibody OR antigen OR antigenic OR antigens OR autoimmune OR autoimmunities OR autoimmunity OR cytokine OR cytokines OR granulocyte OR granulocytes OR immune OR immunities OR immunity OR immunologic OR immunological OR immunology OR immunoproliferation OR immunosuppression OR immunosuppressive OR inflammation OR inflammatory OR interferon OR interferons OR interleukin OR interleukins OR leukocyte OR leukocytes OR lymph OR lymphatic OR	25,621

ED_006137A_00009570-00021

Database	Set #	Terms	Hits
		lymphocyte OR lymphocytes OR lymphocytosis OR lymphokines OR monocyte OR monocytes) OR (abnormal OR abnormalities OR abnormality OR abort OR aborted OR abortion OR aborts OR cleft OR clefts OR development OR developmental OR embryo OR embryologic OR embryology OR embryonic OR embryos OR fertile OR fertilities OR fertility OR fetal OR fetus OR fetuses OR foetal OR foetus OR foetuses OR gestation OR gestational OR infertile OR infertility OR malform OR malformation OR malformations OR malformed OR malforms OR neonatal OR neonatally OR neonate OR neonates OR newborn OR newborns OR ova OR ovaries OR ovary OR ovum OR perinatal OR perinatally OR placenta OR placental OR placentas OR postnatal OR postnatally OR pregnancies OR pregnancy OR pregnant OR prenatal OR prenatally OR reproduction OR reproductive OR sperm OR spermatid OR spermatids OR spermatocidal OR spermatocyte OR spermatocytes OR spermatogenesis OR spermatogonia OR spermatozoa OR sterile OR sterility OR teratogen OR teratogenesis OR teratogenic OR teratogenicities OR teratogenicity OR teratogens OR weaned OR weaning OR weanling OR weanlings OR zygote OR zygotes) OR (ames OR aneuploid OR aneuploidy OR chromosomal OR chromosome OR chromosomes OR clastogen OR clastogenesis OR clastogenic OR clastogenicities OR clastogenicity OR clastogens OR cytogenesis OR cytogenetic OR cytogenetics OR dna OR dominant lethal OR gene OR genes OR genetic OR genotoxic OR genotoxicities OR genotoxicity OR genotoxin OR genotoxins OR hyperploid OR hyperploidy OR micronuclei OR micronucleus OR mitotic OR mutagen OR mutagenesis OR mutagenicities OR mutagenicity OR mutagens OR mutate OR mutated OR mutating OR mutation OR mutations OR recessive lethal OR sister chromatid) OR (cancer OR cancerous OR cancers OR carcinogen OR carcinogenesis OR carcinogenic OR carcinogenicities OR carcinogenicity OR carcinogens OR carcinoma OR carcinomas OR cocarcinogen OR cocarcinogenesis OR cocarcinogenic OR cocarcinogens OR lymphoma OR lymphomas OR neoplasm OR neoplasms OR neoplastic OR oncogene OR oncogenes OR oncogenic OR precancerous OR tumor OR tumorigenesis OR tumorigenic OR tumorigenicities OR tumorigenicity OR tumors OR tumour OR tumourigenesis OR tumourigenic OR tumourigenicity OR tumours))	
TSCATS, TSCATS2, TSCA recent notices Date range: TSCATS2 2000-2/14/2012; TSCATS, TSCA notices no limit Search date: 2/14/2012	1C	50-32-8	62 TSCATS (health effects) 0 TSCATS2 1 recent notices
Toxcenter Date range: 2000-2/14/2012 Search date:	1D1	((50-32-8 NOT (patent/dt OR tscats/fs)) AND (py>2007 OR ed>20080930) AND (chronic OR immunotox? OR neurotox? OR toxicokin? OR biomarker? OR neurolog? OR pharmacokin? OR subchronic OR pbpk OR epidemiology/st,ct, it) OR acute OR subacute OR ld50# OR lc50# OR	4,344

Database	Set #	Terms	Hits
2/14/2012		(toxicity OR adverse OR poisoning)/st,ct,it OR inhal? OR pulmon? OR nasal? OR lung? OR respir? OR occupation? OR workplace? OR worker? OR oral OR orally OR ingest? OR gavage? OR diet OR diets OR dietary OR drinking(w)water OR (maximum and concentration? and (allowable OR permissible)) OR (abort? OR abnormalit? OR embryo? OR cleft? OR fetus? OR foetus? OR fetal? OR foetal? OR fertil? OR malform? OR ovum OR ova OR ovary OR placenta? OR pregnan? OR prenatal OR perinatal? OR postnatal? OR reproduc? OR steril? OR teratogen? OR sperm OR spermac? OR spermag? OR spermati? OR spermas? OR spermatob? OR spermatoc? OR spermatog? OR spermatoi? OR spermatol? OR spermator? OR spermatox? OR spermatoz? OR spermatu? OR spermi? OR spermo? OR neonat? OR newborn OR development OR developmental? OR zygote? OR child OR children OR adolescen? OR infant OR wean? OR offspring OR age(w)factor? OR dermal? OR dermis OR skin OR epiderm? OR cutaneous? OR carcinog? OR cocarcinog? OR cancer? OR precancer? OR neoplas? OR tumor? OR tumour? OR oncogen? OR lymphoma? OR carcinom? OR genetox? OR genotox? OR mutagen? OR genetic(w)toxic? OR nephrotox? OR hepatotox? OR endocrin? OR estrogen? OR androgen? OR hormon? OR rat OR rats OR mouse OR mice OR muridae OR dog OR dogs OR rabbit? OR hamster? OR pig OR pigs OR swine OR porcine OR goat OR goats OR sheep OR monkey? OR macaque? OR marmoset? OR primate? OR mammal? OR ferret? OR gerbil? OR rodent? OR lagomorpha OR baboon? OR bovine OR canine OR cat OR cats OR feline OR pigeon? OR occupation? OR worker? OR epidem?) AND (biosis/fs OR (caplus/fs AND (rat OR rats OR mouse OR mice OR guinea pig OR muridae OR dog OR dogs OR rabbit? OR hamster? OR pig OR pigs OR swine OR porcine OR goat OR goats OR sheep OR monkey? OR macaque? OR marmoset? OR primate? OR mammal? OR ferret? OR gerbil? OR rodent? OR lagomorpha OR baboon? OR bovine OR canine OR cat OR cats OR feline OR pigeon? OR occupation? OR worker? OR epidem? OR human? OR hominidae OR mammal? OR subject? OR patient? OR genotox? OR mutat? OR mutag?)))) OR (((50-32-8 NOT (patent/dt OR tscats/fs)) NOT (py>2007 OR ed>20080930)) AND py>1999 AND (((caplus/fs OR biosis/fs) AND (cancer? OR carcinog? OR carcinom? OR cocarcinog? OR lymphoma? OR neoplas? OR oncogen? OR precancer? OR tumor? OR tumour?)/ti,ct,st,it OR (ames assay OR ames test OR aneuploid? OR chromosom? OR clastogen? OR cytogen? OR dna OR dominant lethal OR genetic OR gene? OR genotox? OR hyperploid? OR micronucle? OR mitotic OR mutagen? OR mutat? OR recessive lethal OR sister chromatid)/ti,ct,st,it OR (brain OR cerebral OR cognition OR cognitive OR encephal? OR nerve? OR nervous OR neural OR neurolog? OR neuron? OR neurop? OR neurotox? OR spinal cord)/ti,ct,st,it OR (antibod? OR antigen? OR autoimmun? OR cytokine? OR granulocyte? OR immun? OR inflamm? OR interferon? OR interleukin? OR leukocyte? OR lymph? OR lymphocyt? OR monocyt?)/ti,ct,st,it OR (abnormal? OR abort? OR cleft? OR development OR developmental OR embryo? OR endocrine OR fertil? OR fetal? OR fetus? OR foetal? OR foetus? OR gestation? OR infertil? OR malform? OR neonat? OR newborn? OR ova OR ovaries OR ovary OR ovum)/ti,ct,st,it OR (perinatal? OR placenta? OR postnatal? OR pregnan? OR prenatal? OR reproduc? OR sperm? OR steril? OR teratogen? OR wean? OR zygote?)/ti,ct,st,it) OR ((chronic OR immunotox? OR neurotox? OR	

Database	Set #	Terms	Hits
		toxicokin? OR biomarker? OR neurolog? OR pharmacokin? OR subchronic OR pbpk OR epidemiology/st,ct, it) OR acute OR subacute OR ld50# OR lc50# OR (toxicity OR adverse OR poisoning)/st,ct,it OR inhal? OR pulmon? OR nasal? OR lung? OR respir? OR occupation? OR workplace? OR worker? OR oral OR orally OR ingest? OR gavage? OR diet OR diets OR dietary OR drinking(w)water OR (maximum and concentration? and (allowable OR permissible)) OR (abort? OR abnormalit? OR embryo? OR cleft? OR fetus? OR foetus? OR fetal? OR foetal? OR fertil? OR malform? OR ovum OR ova OR ovary OR placenta? OR pregnan? OR prenatal OR perinatal? OR postnatal? OR reproduc? OR steril? OR teratogen? OR sperm OR spermac? OR spermag? OR spermati? OR spermas? OR spermatob? OR spermatoc? OR spermatog? OR spermatoi? OR spermatol? OR spermator? OR spermatox? OR spermatoz? OR spermatu? OR spermi? OR spermo? OR neonat? OR newborn OR development OR developmental? OR zygote? OR child OR children OR adolescen? OR infant OR wean? OR offspring OR age(w)factor? OR dermal? OR dermis OR skin OR epiderm? OR cutaneous? OR carcinog? OR cocarcinog? OR cancer? OR precancer? OR neoplas? OR tumor? OR tumour? OR oncogen? OR lymphoma? OR carcinom? OR genetox? OR genotox? OR mutagen? OR genetic(w)toxic? OR nephrotox? OR hepatotox? OR endocrin? OR estrogen? OR androgen? OR hormon? OR rat OR rats OR mouse OR mice OR muridae OR dog OR dogs OR rabbit? OR hamster? OR pig OR pigs OR swine OR porcine OR goat OR goats OR sheep OR monkey? OR macaque? OR marmoset? OR primate? OR mammal? OR ferret? OR gerbil? OR rodent? OR lagomorpha OR baboon? OR bovine OR canine OR cat OR cats OR feline OR pigeon? OR occupation? OR worker? OR epidem?) AND (cancer? OR carcinog? OR carcinom? OR cocarcinog? OR lymphoma? OR neoplas? OR oncogen? OR precancer? OR tumor? OR tumour?) OR (ames assay OR ames test OR aneuploid? OR chromosom? OR clastogen? OR cytogen? OR dna OR dominant lethal OR genetic OR gene? OR genotox? OR hyperploid? OR micronucle? OR mitotic OR mutagen? OR mutat? OR recessive lethal OR sister chromatid) OR (brain OR cerebral OR cognition OR cognitive OR encephal? OR nerve? OR nervous OR neural OR neurolog? OR neuron? OR neurop? OR neurotox? OR spinal cord) OR (antibod? OR antigen? OR autoimmun? OR cytokine? OR granulocyte? OR immun? OR inflamm? OR interferon? OR interleukin? OR leukocyte? OR lymph? OR lymphocyt? OR monocyt?) OR (abnormal? OR abort? OR cleft? OR development OR developmental OR embryo? OR endocrine OR fertil? OR fetal? OR fetus? OR foetal? OR foetus? OR gestation? OR infertil? OR malform? OR neonat? OR newborn? OR ova OR ovaries OR ovary OR ovum) OR (perinatal? OR placenta? OR postnatal? OR pregnan? OR prenatal? OR reproduc? OR sperm? OR steril? OR teratogen? OR wean? OR zygote?) AND (medline/fs OR biosis/fs OR (caplus/fs AND (rat OR rats OR mouse OR mice OR guinea pig OR muridae OR dog OR dogs OR rabbit? OR hamster? OR pig OR pigs OR swine OR porcine OR goat OR goats OR sheep OR monkey? OR macaque? OR marmoset? OR primate? OR mammal? OR ferret? OR gerbil? OR rodent? OR lagomorpha OR baboon? OR bovine OR canine OR cat OR cats OR feline OR occupation? OR worker? OR epidem? OR human? OR hominidae OR mammal? OR subject? OR patient? OR genotox? OR mutat? OR mutag?))))))	

ED_006137A_00009570-00024

Database	Set #	Terms	Hits
Combined Reference Set	1	(duplicates eliminated through electronic screen)	20,700
Secondary refinement			
Combined Reference Set with Additional Terms Applied	2	forestomach* OR tongue* OR (auditory AND canal*) OR (ear* AND canal*) OR esophagus* OR esophageal* OR larynx* OR laryngeal* OR pharynx* OR pharyngeal* OR ((lung* OR pulmonary OR skin*) AND (neoplasm* OR tumor* OR tumour* OR papilloma* OR carcinoma*)) OR leukemia* OR leukaemia* OR sperm* OR testic* OR fertilit*OR infertilit* OR testosterone OR ((testis OR testes) AND (weight* OR mass*)) OR epididymis* OR epididymal* OR seminiferous OR ((cervical* OR cervix*) AND hyperplasia*) OR ovary OR ovaries OR ovarian OR primordial OR corpora lutea OR corpus luteum OR estrous* OR estrus* OR thymus* OR spleen* OR spleno* OR immunoglobulin* OR immunoglobin* OR ((immune OR immun*) AND (suppress* OR immunosuppress*)) OR (functional AND observational AND battery) OR neurobehavioral*OR neurobehavioural* OR rotarod* OR nerve* AND conduction* OR locomotor* OR neuromuscular* OR weight* OR neurodevelopment* OR ((neuro* OR brain*) AND (development* OR developing)) OR intelligence* OR cognition* OR cognitive* OR learn* OR memory OR righting*	6,130

1

APPENDIX D. INFORMATION IN SUPPORT OF HAZARD IDENTIFICATION AND DOSE-RESPONSE ANALYSIS

D.1. TOXICOKINETICS

D.1.1. Overview

Benzo[a]pyrene is absorbed following exposure by oral, inhalation, and dermal routes. The rate and extent of absorption are dependent upon the exposure medium. The presence of benzo[a]pyrene in body fat, blood, liver, and kidney and the presence of benzo[a]pyrene metabolites in serum and excreta demonstrate wide systemic tissue distribution. Benzo[a]pyrene metabolism occurs in essentially all tissues, with high metabolic capacity in the liver and significant metabolism in tissues at the portal of entry (lung, skin, and gastrointestinal [GI] tract) and in reproductive tissues. Stable metabolic products identified in body tissues and excreta are very diverse and include phenols, quinones, and dihydrodiols. These classes of metabolites are typically isolated as glucuronide or sulfate ester conjugates in the excreta, but can also include glutathione conjugates formed from quinones or intermediary epoxides. The primary route of metabolite elimination is in the feces via biliary excretion, particularly following exposure by the inhalation route. To a lesser degree, benzo[a]pyrene metabolites are eliminated via urine. Overall, benzo[a]pyrene is eliminated quickly with a biological half-life of several hours.

D.1.2. Absorption

The absorption of benzo[a]pyrene has been studied in humans and laboratory animals for inhalation, ingestion, and dermal exposure. In the environment, human exposure to benzo[a]pyrene predominantly occurs via contact with insoluble carbonaceous particles (e.g., soot, diesel particles) to which organic compounds, such as polycyclic aromatic hydrocarbons (PAHs), are adsorbed.

Studies of workers occupationally exposed to benzo[a]pyrene have qualitatively demonstrated absorption via inhalation by correlating concentrations of benzo[a]pyrene in the air and benzo[a]pyrene metabolites in the exposed workers' urine. Occupational exposures to benzo[a]pyrene measured with personal air samplers were correlated to urine concentrations of benzo[a]pyrene-9,10-dihydrodiol, a specific metabolite of benzo[a]pyrene, in 24-hour aggregate urine samples by Grimmer et al. (1994). The amount of benzo[a]pyrene extracted from personal air monitoring devices (a surrogate for ambient PAHs) of coke oven workers were correlated with

ED_006137A_00009570-00026

r-7,t-8,9,c 10 tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (trans-anti-benzo[a]pyrene-tetrol, a specific metabolite of benzo[a]pyrene) in the workers' urine by Wu et al. (2002). In both of these studies, only a very small fraction (<1%) of the inhaled benzo[a]pyrene was recovered from urine, consistent with studies in animals that find that urine is not a major route of elimination for benzo[a]pyrene (as described in the excretion section below). These occupational studies cannot be used to quantify absorption through inhalation-only exposure in humans because the persistence of benzo[a]pyrene-contaminated particulate matter on surfaces and food may lead to exposures via additional routes (Boström et al., 2002). Nevertheless, the observation of benzo[a]pyrene metabolites in excreta of exposed humans provides qualitative evidence for benzo[a]pyrene absorption, at least some of which is likely to occur via inhalation. This conclusion is supported by studies in experimental animals, which indicate that benzo[a]pyrene is readily absorbed from carbonaceous particles following inhalation exposure (Gerde et al., 2001; Hood et al., 2000).

Results from studies of animals following intratracheal instillation of benzo[a]pyrene provide supporting, quantitative evidence that absorption by the respiratory tract is rapid (Gerde et al., 1993; Bevan and Ulman, 1991; Weyand and Bevan, 1987, 1986). Following intratracheal instillation of 1 μg tritiated benzo[a]pyrene/kg dissolved in triethylene glycol to Sprague-Dawley rats, radioactivity rapidly appeared in the liver (reaching a maximum of about 21% of the administered dose within 10 minutes). Elimination of radioactivity from the lung was biphasic, with elimination half-times of 5 and 116 minutes (Weyand and Bevan, 1986). In bile-cannulated rats, bile collected for 6 hours after instillation accounted for 74% of the administered radioactivity (Weyand and Bevan, 1986). The results are consistent with rapid and extensive absorption by the respiratory tract and rapid entry into hepatobiliary circulation following intratracheal instillation. The respiratory tract absorption may also be affected by the vehicle, since higher amounts of benzo[a]pyrene were excreted in bile when administered with hydrophilic triethylene glycol than with lipophilic solvents ethyl laurate or tricaprylin (Bevan and Ulman, 1991). Particle-bound benzo[a]pyrene deposited in the respiratory tract is absorbed and cleared more slowly than the neat compound (Gerde et al., 2001).

Studies conducted to assess levels of benzo[a]pyrene metabolites or benzo[a]pyrene-deoxyribonucleic acid (DNA) adduct levels in humans exposed to benzo[a]pyrene by the oral route are not adequate to develop quantitative estimates of oral bioavailability. The concentration of benzo[a]pyrene was below detection limits (<0.1 μg/person) in the feces of eight volunteers who had ingested broiled meat containing approximately 8.6 μg of benzo[a]pyrene (Hecht et al., 1979). However, studies in laboratory animals demonstrate that benzo[a]pyrene is absorbed via ingestion. Studies of rats and pigs measured the oral bioavailability of benzo[a]pyrene in the range of 10–40% (Cavret et al., 2003; Ramesh et al., 2001b; Foth et al., 1988; Hecht et al., 1979). The absorption of benzo[a]pyrene may depend on the vehicle. Intestinal absorption of benzo[a]pyrene was enhanced in rats when the compound was solubilized in lipophilic compounds such as triolein, soybean oil,

and high-fat diets, as compared with fiber- or protein-rich diets (O'Neill et al., 1991; Kawamura et al., 1988). Aqueous vehicles, quercetin, chlorogenic acid, or carbon particles reduced biliary excretion of benzo[a]pyrene, while lipid media such as corn oil increased it (Stavric and Klassen, 1994). The addition of wheat bran to the benzo[a]pyrene-containing diets increased fecal excretion of benzo[a]pyrene (Mirvish et al., 1981).

Studies of benzo[a]pyrene metabolites or DNA adducts measured in humans exposed dermally to benzo[a]pyrene-containing PAH mixtures demonstrate that benzo[a]pyrene is absorbed dermally. One study of dermal absorption in volunteers found absorption rate constants ranging from 0.036 to 0.135/hour over a 45-minute exposure, suggesting that 20–56% of the dose would be absorbed within 6 hours (VanRooij et al., 1993). Dermal absorption rates varied 69% between different anatomical sites (forehead, shoulder, volar forearm, palmar side of the hand, groin, and ankle) and only 7% between different individual volunteers (VanRooij et al., 1993). Metabolism is also an important determinant of permeation, with very low rates observed in nonviable skin (Kao et al., 1985). The overall absorbed amount of benzo[a]pyrene in explanted viable skin samples from tissue donors (maintained in short-term organ cultures) exposed for 24 hours ranged from 0.09 to 2.6% of the dose (Wester et al., 1990; Kao et al., 1985). Similar amounts of penetration were measured in skin samples from other species including marmosets, rats, and rabbits (Kao et al., 1985). Skin from mice allowed more of the dose to penetrate (>10%), while that of guinea pig let only a negligible percentage of the dose penetrate (Kao et al., 1985).

The vehicle for benzo[a]pyrene exposure is an important factor in skin penetration. Exposure of female Sprague-Dawley rats and female rhesus monkeys topically to benzo[a]pyrene in crude oil or acetone caused approximately fourfold more extensive absorption than benzo[a]pyrene in soil (Wester et al., 1990; Yang et al., 1989). The viscosity of oil product used as a vehicle also changed skin penetration with increased uptake of benzo[a]pyrene for oils with decreased viscosity (Potter et al., 1999). Soil properties also greatly impact dermal absorption. Reduced absorption of benzo[a]pyrene occurs with increasing organic carbon content of the soil and increased soil aging (i.e., contact time between soil and chemical) (Turkall et al., 2008; Roy and Singh, 2001; Yang et al., 1989).

D.1.3. Distribution

No adequate quantitative studies of benzo[a]pyrene tissue distribution in exposed humans were identified. Obana et al. (1981) observed low levels of benzo[a]pyrene in liver and fat tissues from autopsy samples. However, prior exposure histories were not available for the donors. Nevertheless, the identification of benzo[a]pyrene metabolites or DNA adducts in tissues and excreta of PAH-exposed populations suggest that benzo[a]pyrene is widely distributed.

Distribution of benzo[a]pyrene has been studied in laboratory animals for multiple routes of exposure, including inhalation, ingestion, dermal, and intravenous (i.v.). Exposure to benzo[a]pyrene in various species (Sprague-Dawley rats, Gunn rats, guinea pigs, and hamsters)

results in wide distribution throughout the body and rapid uptake into well-perfused tissues (i.e., lung, kidney, and liver) (Weyand and Bevan, 1987, 1986). Benzo[a]pyrene and its metabolites are distributed systemically after administration via many routes of administration including inhalation (or intratracheal instillation), oral, i.v., and dermal exposures (Saunders et al., 2002; Moir et al., 1998; Neubert and Tapken, 1988; Weyand and Bevan, 1987, 1986; Morse and Carlson, 1985). Intratracheal instillation of radiolabeled benzo[a]pyrene in mice resulted in increased radioactivity in lung-associated lymph nodes, suggesting distribution of benzo[a]pyrene or its metabolites via the lymph (Schnizlein et al., 1987). Rats with biliary cannulas had high excretion of benzo[a]pyrene and benzo[a]pyrene metabolites in bile. The benzo[a]pyrene thioether and glucuronic acid-conjugated metabolites in intestines indicated enterohepatic recirculation of benzo[a]pyrene and benzo[a]pyrene metabolites (Weyand and Bevan, 1986). The vehicle for delivery of inhalated benzo[a]pyrene impacts the distribution, with aerosolized benzo[a]pyrene more readily absorbed directly in the respiratory tract than particle-adsorbed benzo[a]pyrene (which is cleared by the mucociliary and then ingested) (Sun et al., 1982). Exposure of pregnant rats and mice to benzo[a]pyrene via inhalation and ingestion showed a wide tissue distribution of benzo[a]pyrene, consistent with other studies, and demonstrated placental transfer of benzo[a]pyrene and its metabolites (Withey et al., 1993; Neubert and Tapken, 1988; Shendrikova and Aleksandrov, 1974). The reactive metabolites of benzo[a]pyrene are also transported in the blood and may be distributed to tissues incapable of benzo[a]pyrene metabolism. Serum of benzo[a]pyrene-treated mice incubated with splenocytes or salmon sperm DNA resulted in adduct formation, suggesting that reactive benzo[a]pyrene metabolites were systemically distributed and available for interaction with target tissues (Ginsberg and Atherholt, 1989).

D.1.4. Metabolism

The metabolic pathways of benzo[a]pyrene (Figure D-1) and variation in species, strain, organ system, age, and sex have been studied extensively with in vitro and in vivo experiments. In addition, there have been numerous studies of exposed humans or animals with subsequent detection of benzo[a]pyrene metabolites in tissues or excreta. For example, elevated frequency of a detected urinary metabolite (7,8,9,10-tetrol) was observed in patients treated with coal tar medication (Bowman et al., 1997), demonstrating extensive metabolism of benzo[a]pyrene in humans.



Source: Miller and Ramos (2001).

Figure D-1. Metabolic pathways for benzo[a]pyrene.

Phase I metabolism results in a number of reactive metabolites such as epoxides, dihydrodiols, phenols, quinones, and their various combinations that are likely to contribute to the toxic effects of benzo[a]pyrene (e.g., phenols, dihydrodiols, epoxides, and quinones). Phase II metabolism of benzo[a]pyrene metabolites protects the cells and tissues from the toxic effects of benzo[a]pyrene phenols, dihydrodiols and epoxides by converting them to water soluble products that are eliminated. In addition, Phase II metabolism of some benzo[a]pyrene dihydrodiols prevents them from further bioactivation to reactive forms that bind to cellular macromolecules. These metabolic process include glutathione conjugation of diol epoxides, sulfation and glucuronidation of phenols, and reduction of quinones by NADPH:quinone oxidoreductase (NQO). Numerous reviews on the metabolism of benzo[a]pyrene are available (Miller and Ramos, 2001; IPCS, 1998; ATSDR, 1995; Conney et al., 1994; Grover, 1986; Levin et al., 1982; Gelboin, 1980). Key concepts have been adapted largely from these reviews and supplemented with recent findings.

ED_006137A_00009570-00030

Phase I Metabolism

Phase I reactions of benzo[a]pyrene are catalyzed primarily by cytochrome P450 (CYP450) and produce metabolites including epoxides, dihydrodiols, phenols, and quinones (Figure D-2). The first step of Phase I metabolism is the oxidation of benzo[a]pyrene that forms a series of epoxides, the four major forms of which are the 2,3-, 4,5-, 7,8-, and 9,10-isomers (Gelboin, 1980). Once formed, these epoxides may undergo three different routes of metabolism: (1) spontaneous rearrangement to phenols; (2) hydration to trans-dihydrodiols catalyzed by microsomal epoxide hydrolase (EH); or (3) the Phase II detoxification of binding with glutathione (either spontaneously or catalyzed by cytosolic glutathione-S-transferases (GSTs) (IARC, 1983)). The metabolism of benzo[a]pyrene to phenols results in five phenol isomers (1-, 3-, 6-, 7, and 9-OH benzo[a]pyrene) (Pelkonen and Nebert, 1982). Four benzo[a]pyrene epoxides (2,3-, 4,5-, 7,8-, and 9,10-) are hydrated to trans-dihydrodiols. Benzo[a]pyrene-7,8-diol (formed from benzo[a]pyrene-7,8-oxide) has been the focus of much of the study of benzo[a]pyrene metabolism. Benzo[a]pyrene-7,8-diol is the metabolic precursor to the potent DNA-binding metabolite, benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE). BPDE is formed from trans-benzo[a]pyrene 7,8-diol by multiple mechanisms including catalysis by cytochromes (CYPs) (Grover, 1986; Deutsch et al., 1979), myeloperoxidase (Mallet et al., 1991), or prostaglandin h synthase (also known as cyclooxygenase) (Marnett, 1990), and lipid peroxidation (Byczkowski and Kulkarni, 1990). The diolepoxides can react further by spontaneously hydrolyzing to tetrols (Hall and Grover, 1988).

The metabolism of benzo[a]pyrene proceeds with a high degree of stereoselectivity. Liver microsomes from rats stereospecifically oxidize the 7,8-bond of benzo[a]pyrene to yield almost exclusively the (+)-benzo[a]pyrene-(7,8)-oxide (see Figure D-2). Each enantiomer of benzo[a]pyrene-7,8-oxide is stereospecifically converted by EH to a different stereoisomeric trans dihydrodiol. The (+)-benzo[a]pyrene-7,8-oxide is preferentially hydrated to the (−)-trans-benzo[a]pyrene-7,8-dihydrodiol enantiomer by rat CYP enzymes and the (−)-trans-benzo[a]pyrene-7,8-dihydrodiol is preferentially oxidized by CYP enzymes to (+)-benzo[a]pyrene-7R,8S-diol-9S,10R-epoxide [(+)-anti- BPDE], which is the most potent carcinogen among the four stereoisomers (Figure D-2). Formation of these stereoisomers does not occur at equimolar ratios, and the ratios differ between biological systems. For example, a study in rabbit livers demonstrated that purified microsomes oxidized the (-)-benzo[a]pyrene-7,8-dihydrodiol to isomeric diol epoxides in a ratio ranging from 1.8:1 to 11:1 in favor of the (+)-anti-BPDE isomer (Deutsch et al., 1979).



Source: Grover (1986).

Figure D-2. The stereospecific activation of benzo[a]pyrene.

Several studies have attempted to determine which CYP isozyme is predominantly responsible for the metabolism of benzo[a]pyrene. Dermal administration of tritiated benzo[a]pyrene to mice that have an aryl hydrocarbon (Ah) receptor (AhR) knock-out (AhR−/−) had significantly decreased formation of (+)-anti-BPDE-DNA adducts compared to wild type (WT) and 1B1−/− mice (Kleiner et al., 2004). Gavage administration of benzo[a]pyrene in AhR knock-out mice found that the AhR−/− mice (with lower levels of CYP1A1) had higher levels of protein adducts and unmetabolized benzo[a]pyrene than the AhR+/+ or +/− mice (Sagredo et al., 2006). Similarly, CYP1A1 (−/−) knock-out mice administered benzo[a]pyrene in feed for 18 days had higher steady-state blood levels of benzo[a]pyrene and benzo[a]pyrene-DNA adducts (Uno et al., 2006). These findings establish important roles in benzo[a]pyrene metabolism for CYP1A1, but the relationship is not clear between the CYP enzymes and biological activation or detoxification.

Another important factor in evaluating variability in the metabolic activation of benzo[a]pyrene by CYP450s is the effect of functional polymorphisms, which has been the subject of numerous reviews (e.g., Wormhoudt et al., 1999). Recombinant CYP1A1 allelic variants produced BPDE with generally lower catalytic activity and Km values than the WT allele (Schwarz et al., 2001). However, the formation of diol epoxides is stereospecific, with the allelic variants producing about 3 times the amount of (±)-anti-BPDE isomers as compared to the stereoisomer, (±)-syn-BPDE (Schwarz et al., 2001). In a study of occupational exposures to benzo[a]pyrene, no

ED_006137A_00009570-00032

relationship was observed between benzo[a]pyrene metabolite formation and the CYP1A1 MspI polymorphism (Wu et al., 2002).

Another pathway of benzo[a]pyrene metabolism is the conversion of benzo[a]pyrene to 6-OH benzo[a]pyrene, which can be further oxidized into quinones, primarily the 1,6-, 3,6-, and 6,12- isomers. Trans-benzo[a]pyrene-7,8-dihydrodiol can be converted by aldo-keto reductases (AKR) to 7,8-dihydroxybenzo[a]pyrene (benzo[a]pyrene-7,8-catechol), which auto-oxidizes to benzo[a]pyrene-7,8-quinone (BPQ). BPQ can undergo redox cycling in the presence of cellular reducing equivalents. This reaction pathway produces reactive oxygen species (ROS), including peroxide anion radicals, benzo[a]pyrene semiquinone radicals, hydroxyl radicals, and H_2O_2, which in turn can causes extensive DNA fragmentation (Penning et al., 1999; Flowers et al., 1997; Flowers et al., 1996). 6-Hydroxybenzo[a]pyrene can be oxidized into 6-oxo-benzo[a]pyrene semi-quinone radical and further metabolized into 1,6-, 3,6-, or 6,12-quinones spontaneously, or catalytically by prostaglandin endoperoxide synthetase (Eling et al., 1986). The CYP and AKR enzymes both can metabolize trans-benzo[a]pyrene-7,8-dihydrodiol to different metabolites, BPDE and BPQ. Reconstituted in vitro systems of human lung cells show that CYP enzymes have faster steady-state reaction rate constants than AKR and basal expression of AKR is higher than CYP in lung cells, suggesting that AKR and CYP enzymes compete for metabolism of trans-benzo[a]pyrene-7,8-dihydrodiol (Quinn and Penning, 2008).

Phase II Metabolism

The reactive products of Phase I metabolism are subject to the action of several Phase II conjugation and detoxification enzyme systems that display preferential activity for specific oxidation products of benzo[a]pyrene. These Phase II reactions play a critical role in protecting cellular macromolecules from binding with reactive benzo[a]pyrene diolepoxides, radical cations, or ROS. Therefore, the balance between Phase I activation of benzo[a]pyrene and its metabolites and detoxification by Phase II processes is an important determinant of toxicity.

The diol epoxides formed from benzo[a]pyrene metabolism by Phase I reactions are not usually found as urinary metabolites. Rather, they are detected as adducts of nucleic acids or proteins or further metabolized by glutathione (GSH) conjugation, glucuronidation, and sulfation. These metabolites make up a significant portion of total metabolites in excreta or tissues. For example, the identified metabolites in bile 6 hours after a 2 μg/kg benzo[a]pyrene dose by intratracheal instillation to male Sprague-Dawley rats were 49% glucuronides (quinol diglucuronides or monglucuronides), 30.4% thioether conjugates, 6.2% sulfate conjugates, and 14.4% unconjugated metabolites (Bevan and Sadler, 1992).

Conjugation of benzo[a]pyrene with GSH is catalyzed by GSTs. Numerous studies using human GSTs expressed in mammalian cell lines have demonstrated the ability of GST to metabolize benzo[a]pyrene diol epoxides. Isolated human GSTs have significant catalytic activity toward benzo[a]pyrene-derived diol epoxides and (±)anti-BPDE with variation in activity across GST isoforms (Dreij et al., 2002; Rojas et al., 1998; Robertson et al., 1986). Benzo[a]pyrene quinones

ED_006137A_00009570-00033

can also be conjugated with GSH (Agarwal et al., 1991; IARC, 1983). This compelling evidence for a role of GSTs in the metabolism of reactive benzo[a]pyrene metabolites has triggered several molecular epidemiology studies. However, recent studies on the impact of polymorphism on adduct levels in PAH-exposed human populations did not show a clear relationship between the Phase I (CYP1A1, EH) or Phase II (GST) enzyme polymorphisms and the formation of DNA adducts (Hemminki et al., 1997) or blood protein adducts (Pastorelli et al., 1998).

Conjugation with uridine diphosphate-glucuronide catalyzed by uridine diphosphate-glucuronosyltransferase (UDP-UGT) enzymes is another important detoxification mechanism for oxidative benzo[a]pyrene metabolites. UGT isoforms, as well as their allelic variants, are expressed, and have glucuronidation activity toward, benzo[a]pyrene-derived phenols and diols in the aerodigestive tract (tongue, tonsil, floor of the mouth, larynx, esophagus), but not in the lung or liver (Fang and Lazarus, 2004; Zheng et al., 2002). UGT activity also shows significant interindividual variability. Incubation of lymphocytes with benzo[a]pyrene resulted in covalent binding to protein with a 143-fold interindividual variability and a statistically significant inverse correlation between glucuronidation and protein binding (Hu and Wells, 2004).

Sulfotransferases can catalyze the formation of sulfates of benzo[a]pyrene metabolites. In rat or mouse liver, cytosolic sulfotransferase (in the presence of 3'-phosphoadenosine 5'-phosphosulfate) catalyzes formation of sulfates of three benzo[a]pyrene metabolites: benzo[a]pyrene-7,8,9,10-tetrahydro-7-ol, benzo[a]pyrene-7,8-dihydrodiol, and benzo[a]pyrene-7,8,9,10-tetrol. The benzo[a]pyrene-7,8,9,10-tetrahydro-7-ol-sulfate is able to form potentially damaging DNA adducts (Surh and Tannenbaum, 1995). In human lung tissue 3-hydroxybenzo[a]pyrene conjugation to sulfate produces benzo[a]pyrene-3-yl-hydrogen sulfate, a very lipid soluble compound that would not be readily excreted in the urine (Cohen et al., 1976).

Although not specific for benzo[a]pyrene, there is now considerable evidence that genetic polymorphisms of the GST, UGT, and EH genes impart an added risk to humans for developing cancer. Of some significance to the assessment of benzo[a]pyrene may be that smoking, in combination with genetic polymorphism at several gene loci, increases the risk for bladder cancer (Moore et al., 2004; Choi et al., 2003; Park et al., 2003) and lung cancer (Alexandrie et al., 2004; Lin et al., 2003). Coke oven workers (who are exposed to PAHs, including benzo[a]pyrene) homozygous at the P187S site of the NQO1 gene (an inhibitor of benzo[a]pyrene-quinone adducts with DNA), or carrying the null variant of the glutathione-S-transferase M1 (GSTM1) gene, had a significantly increased risk of chromosomal damage in peripheral blood lymphocytes. Meanwhile, the risk was much lower than controls in subjects with a variant allele at the H113Y site of the EH gene (Leng et al., 2004).

Tissue-Specific Metabolism

Benzo[a]pyrene metabolism has been demonstrated in vivo in laboratory animals for various tissues via multiple routes including inhalation, ingestion, and dermal absorption. Metabolism of benzo[a]pyrene at the site of administration such as in the respiratory tract, the GI

ED_006137A_00009570-00034

tract, or the skin impact the amount of benzo[a]pyrene and its form as benzo[a]pyrene or one of the metabolites that reach systemic circulation. Nasal instillation or inhalation of benzo[a]pyrene in monkeys, dogs, rats, and hamsters resulted in the formation of dihydrodiols, phenols, quinones, and tetrols in the nasal mucus and lung (Wolff et al., 1989; Petridou-Fischer et al., 1988; Weyand and Lavoie, 1988; Weyand and Bevan, 1987, 1986; Dahl et al., 1985). In rats, the fractions of metabolites in the lung at 6 hours after instillation were: 20% unmetabolized benzo[a]pyrene, 16% conjugates or polyhydroxylated compounds, 10.7% 4,5-, 7,8-, and 9,10-dihydrodiols, 9.3% 1,6-, 3,6-, and 6,12-quinone, and 6.9% 3- and 9-hydroxybenzo[a]pyrene (Weyand and Bevan, 1986). In hamsters, approximately 50% of the benzo[a]pyrene instilled was metabolized in the nose (nasal tissues had the highest metabolic activity per-gram of the respiratory tract tissues), and the metabolites produced were similar to other species (Dahl et al., 1985).

In vitro studies of human and laboratory cells and cell lines provide further quantitative and mechanistic details of the metabolism of benzo[a]pyrene in the cells of the respiratory tract, skin, liver, and other tissues. Tracheobronchial tissues in culture of several species (including humans, mice, rats, hamsters, and bovines) were all found to metabolize benzo[a]pyrene extensively to phenols, diols, tetrols, quinones, and their conjugates (Autrup et al., 1980). The results show a high degree of interindividual variability (a 33-fold difference in human bronchus, a 5-fold variation in human trachea, and a 3-fold difference in bovine bronchus), but minimal variation among individuals of the laboratory animal species (Autrup et al., 1980). Human bronchial epithelial and lung tissue conjugated benzo[a]pyrene metabolites to glutathione and sulfates, but not with glucuronide (Kiefer et al., 1988; Autrup et al., 1978; Cohen et al., 1976). Lung tissue slices exposed to benzo[a]pyrene induced expression of CYP1A1 and CYP1B1 at levels 10–20 times higher than in the liver (Harrigan et al., 2006) and total levels of benzo[a]pyrene-DNA adducts were approximately 2–6 times greater in the lung slices than liver (Harrigan et al., 2004).

Benzo[a]pyrene undergoes extensive metabolism in the GI tract and liver after oral administration. In rats after administration of an oral dose, the majority of benzo[a]pyrene detected in organs is as metabolites (Ramesh et al., 2004; Ramesh et al., 2001b; Yamazaki and Kakiuchi, 1989). In rats administered a 100-nmol dose, >90% was recovered in portal blood as metabolites (Bock et al., 1979). Orally administered benzo[a]pyrene produced strong induction of CYP1A1 in the intestine of mice (Brooks et al., 1999). DNA post-labeling studies of mice administered benzo[a]pyrene by gavage demonstrated higher benzo[a]pyrene-DNA adduct levels in CYP1A1(−/−) than CYP1A1(+/+) mice in small intestines (Uno et al., 2004). To compare the relative roles of the liver and intestine in benzo[a]pyrene metabolism and absorption, a multicompartment perfusion system was developed; it was found that benzo[a]pyrene is extensively metabolized by the intestinal Caco-2 cells and that benzo[a]pyrene and its metabolites are transported to the apical side of the Caco-2 cells away from the liver HepG2 cells (Choi et al., 2004).

Dermal exposure in humans and animals resulted in benzo[a]pyrene metabolism, and the permeation of benzo[a]pyrene in skin is linked to benzo[a]pyrene metabolism. Human skin samples maintained in short-term organ culture (i.e., human epithelial tissue, samples from human hair follicles, and melanocytes isolated from adult human skin) can metabolize benzo[a]pyrene into dihydrodiols, phenols, quinones, and glucuronide and sulfate conjugates (Agarwal et al., 1991; Alexandrov et al., 1990; Hall and Grover, 1988; Merk et al., 1987). Nonviable skin is unable to metabolize benzo[a]pyrene (the permeation into nonviable skin is lower than viable skin) as measured in a range of species including humans, rats, mice, rabbits, and marmosets (Kao et al., 1985). Viable human skin samples treated with 2 μg/cm^2 [^{14}C]-benzo[a]pyrene in acetone and incubated for 24 hours produced the following percentages of benzo[a]pyrene metabolites: 52% water-soluble compounds, 8% polar compounds, 17% diols, 1% phenols, 2.5% quinones, and 18% unmetabolized benzo[a]pyrene (Kao et al., 1985).

Benzo[a]pyrene that reaches systemic circulation is also metabolized by multiple tissues that are targets of benzo[a]pyrene toxicity, including reproductive tissues such as prostate, endometrium, cervical epithelial and stromal, and testes (Ramesh et al., 2003; Bao et al., 2002; Williams et al., 2000; Melikian et al., 1999).

Age-Specific Metabolism

Metabolism of benzo[a]pyrene occurs in the developing fetus and in children, as indicated by DNA or protein adducts or urinary metabolites (Naufal et al., 2010; Ruchirawat et al., 2010; Suter et al., 2010; Mielzyńska et al., 2006; Perera et al., 2005a; Tang et al., 1999; Whyatt et al., 1998). Transport of benzo[a]pyrene and benzo[a]pyrene metabolites to fetal tissues including plasma, liver, hippocampus, and cerebral cortex has been demonstrated in multiple studies (McCabe and Flynn, 1990; Neubert and Tapken, 1988; Shendrikova and Aleksandrov, 1974), and benzo[a]pyrene is metabolized by human fetal esophageal cell culture (Chakradeo et al., 1993). While expression of CYP enzymes are lower in fetuses and infants, the liver to body mass ratio and increased blood flow to liver in fetuses and infants may compensate for the decreased expression of CYP enzymes (Ginsberg et al., 2004). Prenatal exposure to benzo[a]pyrene upregulates CYP1A1 and may increase the formation of benzo[a]pyrene-DNA adducts (Wu et al., 2003a). Activity of Phase II detoxifying enzymes in neonates and children is adequate for sulfation, but decreased for glucuronidation and glutathione conjugation (Ginsberg et al., 2004). The conjugation of benzo[a]pyrene-4,5-oxide with glutathione was approximately one-third less in human fetal than adult liver cytosol (Pacifici et al., 1988). The differential Phase I and II enzyme expression and activity in the developing fetus and in children are consistent with an expectation that these lifestages can be more susceptible to benzo[a]pyrene toxicity.

D.1.5. Elimination

Benzo[a]pyrene metabolites have been detected in the urine of exposed humans, but fecal excretion has not been investigated in any detail. Studies of benzo[a]pyrene elimination in animals

following exposure via inhalation, ingestion, and dermal routes have shown that benzo[a]pyrene is excreted preferentially in the feces in multiple species of laboratory animals including rat, mice, hamsters, guinea pigs, monkeys, and dogs (Wang et al., 2003; Likhachev et al., 1992; Wolff et al., 1989; Yang et al., 1989; Petridou-Fischer et al., 1988; Weyand and Bevan, 1987; Sun et al., 1982; Hecht et al., 1979). The metabolites in bile are primarily benzo[a]pyrene conjugates, predominantly thioether conjugates of varying extent in different species (Weyand and Bevan, 1987). Six hours after a single intratracheal instillation of benzo[a]pyrene (2 μg/kg) to male Sprague-Dawley rats, relative metabolite levels were 31.2% diglucuronides, 30.4% thioether conjugates, 17.8% monoglucuronides, 6.2% sulfate conjugates, and 14.4% unconjugated metabolites (Bevan and Sadler, 1992). Rats administered benzo[a]pyrene via i.v. excrete a larger fraction in urine than via inhalation or oral exposure, suggesting an important role for enterohepatic circulation of benzo[a]pyrene metabolite conjugates (Moir et al., 1998; Weyand and Bevan, 1986; Hirom et al., 1983). The vehicle impacts the amount of benzo[a]pyrene excreted and may, in part, be due to the elimination rate or to other factors such as the absorption rate. For tritiated benzo[a]pyrene administered to Sprague-Dawley rats in hydrophilic triethylene glycol, 70.5% of the dose was excreted into bile within 6 hours. When the lipophilic solvents, ethyl laurate and tricaprylin, were used as vehicles, 58.4 and 56.2% of the dose was excreted, respectively (Bevan and Ulman, 1991). In addition to benzo[a]pyrene and its metabolites, adducts of benzo[a]pyrene with nucleotides have also been identified as a small fraction of the administered dose in feces and urine of animals. The level of BPDE adducts with guanine detected in urine of male Wistar rats was dose-dependent. Forty-eight hours after dosing with 100 μg/kg tritiated benzo[a]pyrene, 0.15% of the administered benzo[a]pyrene dose was excreted in the urine as an adduct with guanine (Autrup and Seremet, 1986). Overall, the data in humans and laboratory animals are sufficient to describe benzo[a]pyrene elimination qualitatively, but are limited in estimating quantitative rates of elimination.

D.2. PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS

Several toxicokinetic or pharmacokinetic models of benzo[a]pyrene have been developed for rodents (rat and hamster). However, human models have only been developed via allometric scaling, and metabolic parameters in humans have not been calibrated against in vivo toxicokinetic data or in vitro experiments.

Bevan and Weyand (1988) performed compartmental pharmacokinetic analysis of distribution of radioactivity in male Sprague-Dawley rats, following the intratracheal instillation of benzo[a]pyrene to normal and bile duct-cannulated animals (Weyand and Bevan, 1987, 1986). However, implicit simulation approaches were used, as opposed to physiologically-based approaches. The model calculated linear rate constants among compartments, and assumed that the kinetics of benzo[a]pyrene and its metabolites were the same.

ED_006137A_00009570-00037

Roth and Vinegar (1990) reviewed the capacity of the lung to impact the disposition of chemicals and used benzo[a]pyrene as a case study. A PBPK model was presented based on data from (Wiersma and Roth (1983a), 1983b)) and was evaluated against tissue concentration data from Schlede et al. (1970). The model was structured with compartments for arterial blood, venous blood, lung, liver, fat, and slowly and rapidly perfused tissues and an adequate fit was obtained for some compartments; however, tissue-level data for calibration and validation of this model were limited. Metabolism in liver and lung was estimated using kinetic data from control rats and rats pretreated with 3-methylcholanthrene to induce benzo[a]pyrene metabolism. In microsomal preparations from control and 3-methylcholanthrene induced rat livers and lungs, benzo[a]pyrene hydroxylase activity was 1,000-fold greater in liver. In isolated rat lungs, the clearance of benzo[a]pyrene was about one-sixth of the clearance in isolated rat livers and in 3-methylcholanthrene-pretreated rats the clearance in lungs and livers were of similar magnitude. The PBPK simulations model based on these data showed that for a bolus intravascular injection of benzo[a]pyrene in rats, the majority of benzo[a]pyrene metabolism usually occurs in the liver. Except for cases when rats are pretreated with enzyme-inducing agents or where the exposure occurs via inhalation, the metabolic clearance in the lung is minor.

Moir et al. (1998) conducted a pharmacokinetic study on benzo[a]pyrene to obtain data for model development. Rats were injected with varying doses of [^{14}C]-benzo[a]pyrene to 15 mg/kg, and blood, liver, fat, and richly perfused tissue were sampled varying time points after dosing. Moir (1999) then described a model for lung, liver, fat, richly and slowly perfused tissues, and venous blood, with saturable metabolism occurring in the liver. The fat and richly perfused tissues were modeled as diffusion-limited, while the other tissues were flow-limited. The model predicted the blood benzo[a]pyrene concentrations well, although it overestimated the 6 mg/kg results at longer times (>100 minutes). The model also produced a poor fit to the liver data. The model simulations were also compared to data of Schlede et al. (1970), who injected rats with 0.056 mg/kg body weight of benzo[a]pyrene. The model predicted blood and fat benzo[a]pyrene concentrations well, but still poorly predicted liver benzo[a]pyrene concentrations. The model included only one saturable metabolic pathway, and only parent chemical concentrations were used to establish the model. No metabolites were included in the model. This model was re-calibrated by Crowell et al. (2011) by optimizing against additional rodent data and altering partition coefficient derivation. However, it still did not incorporate metabolites, and some tissues continued to exhibit poor model fits.

An attempt to scale the Moir et al. (1998) rodent PBPK model to humans, relevant to risk assessment of oral exposures to benzo[a]pyrene, was presented by Zeilmaker et al. (1999a) and Zeilmaker et al. (1999b). The PBPK model for benzo[a]pyrene was derived from an earlier model for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in rats (Zeilmaker and van Eijkeren, 1997). Most compartments were perfusion-limited, and tissues modeled included blood, adipose (with diffusion limitation), slowly and richly perfused tissues, and liver. However, there was no separate

compartment for the lung. The liver compartment featured the AhR-dependent CYP450 induction mechanism and DNA adduct formation as a marker for formation of genotoxic benzo[a]pyrene metabolites. It was assumed that DNA adduct formation and the bulk benzo[a]pyrene metabolism were mediated by two different metabolic pathways. The model was experimentally calibrated in rats with the data for 7-ethoxyresorufin-O-deethylase (EROD) and formation of DNA adducts in the liver after i.v. administration of a single dose and per os administration of a single or repeated doses of benzo[a]pyrene (Zeilmaker et al., 1999a).

Zeilmaker et al. (1999b) assumed identical values for several parameters in rats and humans (i.e., benzo[a]pyrene tissue partition coefficients, AhR concentration in liver, rate constant for the decay of the benzo[a]pyrene-CYP450 complex, half-life of the CYP450 protein, fraction and rate of GI absorption of benzo[a]pyrene, and rates of formation and repair of DNA adducts in liver). The basal CYP450 activity in humans was assumed to be lower than that in rat liver. The mechanism of AhR-dependent induction of CYP450 dominated the simulated benzo[a]pyrene-DNA adduct formation in the liver. The results of PBPK model simulations indicated that the same dose of benzo[a]pyrene administered to rats or humans might produce one order of magnitude higher accumulation of DNA adducts in human liver when compared with the rat (Zeilmaker et al., 1999b).

Even though the model of Zeilmaker et al. (1999b) represents a major improvement in predictive modeling of benzo[a]pyrene toxicokinetics, the interspecies extrapolation introduces significant uncertainties. As emphasized by the authors, the conversion of benzo[a]pyrene to its mutagenic and carcinogenic metabolites could not be explicitly modeled in human liver because no suitable experimental data were available. According to the authors, improvement of the model would require direct measurements of basal activities of CYP1A1 and CYP1A2 and formation of benzo[a]pyrene-DNA adducts in human liver. Metabolic clearance of benzo[a]pyrene in the lungs was also not addressed. Additionally, the toxicokinetic modeling by Zeilmaker et al. (1999b) addressed only one pathway of benzo[a]pyrene metabolic activation, a single target organ (the liver), and one route of administration (oral). In order to model health outcomes of exposures to benzo[a]pyrene, the PBPK model needs to simulate rate of accumulation of benzo[a]pyrene-DNA adducts and/or the distribution and fate of benzo[a]pyrene metabolites (e.g., BPDE) that bind to DNA and other macromolecules. Alternatively, stable toxic metabolites (e.g., trans-anti-tetrol-benzo[a]pyrene) may be used as an internal dose surrogate. While the metabolic pattern of benzo[a]pyrene has been relatively well characterized qualitatively in animals, the quantitative kinetic relationships between the more complex metabolic reactions in potential target organs are not yet well defined.

D.2.1. Recommendations for the Use of PBPK Models in Toxicity Value Derivation

PBPK models for benzo[a]pyrene were evaluated to determine the capability to extrapolate from rats to humans, or between oral and inhalation exposure routes. Due to significant uncertainties with respect to the inter-species scaling of the metabolic parameters between rats

ED_006137A_00009570-00039

and humans, these models were not used for cross-species extrapolation. Furthermore, no complete mechanistic PBPK model for the inhalation route was identified, nor was there a model for humans that simulates the typical inhalation exposure to benzo[a]pyrene on poorly soluble carbonaceous particles. This precluded the model's use for cross-route extrapolation to the inhalation pathway.

D.3. HUMAN STUDIES

D.3.1. Noncancer Endpoints

Cardiovascular Endpoints

Burstyn et al. (2005) reported the association of death from cardiovascular disease with benzo[a]pyrene exposure in a cohort of 12,367 male European asphalt workers (Table D-1). These workers were first employed in asphalt paving between 1913 and 1999, and worked at least one season. Average duration of follow-up was 17 ± 9 years (mean ± standard deviation [SD]), encompassing 193,889 person-years of observation. Worker exposure to coal tar was estimated using industrial process and hygiene information and modeling (presented in a previous report), and coal tar exposure was found to be the strongest determinant of exposure to benzo[a]pyrene. Benzo[a]pyrene exposure was assessed quantitatively using measurement-driven mixed effects exposure models, using data collected from other asphalt industry workers, and this model was constructed and validated previously. Due to limited data availability, only information regarding the primary cause of death was collected, and this analysis was limited to diseases of the circulatory system (ICD codes 390–459), specifically ischemic heart disease (IHD: ICD codes 410–414). Diesel exhaust exposure was also assessed in this cohort, but varied little among the asphalt pavers, and was not associated with risk of death from cardiovascular disease. Of the initial cohort, 0.25% was lost to follow-up and 0.38% emigrated during the course of observation. Relative risks (RRs) and associated 95% confidence intervals (CIs) were estimated using Poisson regression, and all models included exposure index for agent of interest (coal tar or benzo[a]pyrene), age, calendar period of exit from cohort, total duration of employment, and country, using the category of lowest exposure as the reference. Confounding by tobacco smoke exposure was considered in relation to the strength of its association with cardiovascular disease and the smoking prevalence in the population. The RR attributed to cigarette smoking in former and current smokers was assumed to be 1.2 and 2, respectively, based upon literature reports. From analysis of smoking incidence in a subcohort, the following smoking distribution was proposed: in the lowest exposure group, 40% never-smokers, 30% former smokers, and 30% current smokers; and among the highest exposed, the proportion shifted to 20/30/50%, respectively.

Exposed subjects were stratified into quintiles based upon IHD mortality, with 83–86 deaths per exposure category, composing approximately 2/3 of the 660 cardiovascular disease-related deaths. Both cumulative and average exposure indices for benzo[a]pyrene were

ED_006137A_00009570-00040

positively associated with IHD mortality, with a RR of approximately 1.6 in the highest exposure quintile from both metrics, independent of total employment duration. Similar monotonic trends were observed for all cardiovascular diseases (combined), although a dose-response relationship was evident only for IHD and not hypertension or other individual heart disease categories. Similar trends were also observed for coal tar exposure and IHD. Adjusting the RR to account for possible confounding by smoking yields a RR of 1.39 under the assumptions mentioned above, and is still elevated (1.21) if the contribution of smoking to cardiovascular disease etiology was greater than the original assumptions. Furthermore, the RR for the high versus low exposure quintile is 1.24 even if the distribution of nonsmokers/former smokers/current smokers shifts to 0/30/70%, using the original assumptions of cigarette smoke casual potency.

Table D-1. Exposure to benzo[a]pyrene and mortality from cardiovascular diseases in a European cohort of asphalt paving workers

Effect measured	Cumulative exposure (ng/m^3-yrs)					*p*-value for trend
	0–189[a]	189–501	502–931	932–2,012	≥2,013	
Diseases of the circulatory system						
Deaths	137	145	118	132	128	
RR	1.00	1.08	1.06	1.24	1.42	0.09
95% CI		0.85–1.38	0.80–1.42	0.89–1.71	0.96–2.09	
IHD						
Deaths	83	83	84	83	85	
RR	1.00	0.99	1.22	1.24	1.58	0.06
95% CI		0.72–1.36	0.86–1.74	0.82–1.85	0.98–2.55	
Effect measured	**Average exposure (ng/m^3)**					***p*-value for trend**
	0–68[a]	**68–105**	**106–146**	**147–272**	**≥273**	
Diseases of the circulatory system						
Deaths	128	142	143	139	108	
RR	1.00	1.30	1.55	1.45	1.58	<0.001
95% CI		1.01–1.67	1.18–2.05	1.09–1.93	1.16–2.15	
IHD						
Deaths	83	83	83	86	83	
RR	1.00	1.13	1.33	1.20	1.64	0.02
95% CI		0.82–1.55	0.94–1.90	0.84–1.71	1.13–2.38	

[a]Reference category.

Source: Burstyn et al. (2005).

Friesen et al. (2010) examined the association between benzo[a]pyrene exposure and deaths from chronic nonmalignant disease in a cohort of 6,423 male and 603 female Canadian aluminum smelter workers (Table D-2). Inclusion criteria required at least 3 years of continuous

ED_006137A_00009570-00041

employment in either the smelter facility or power-generating station from 1954 to 1997, with worker history collected up through 1999. This cohort was probabilistically linked to the Canadian national mortality database for external comparison to the British Columbia population and calculation of standardized mortality ratios (SMRs), which were adjusted for age, sex, and time period. Ninety-five percent CIs were calculated for the SMRs assuming a Poisson distribution. Internal comparisons were also made during the analysis of IHD mortality in male workers, calculating hazard ratios (HRs) for IHD with or without acute myocardial infarction (AMI) after 1969, as AMI could not be differentiated from other IHD on death certificates issued previously. HRs were calculated using Cox regression models, with age as a metamarker of time, also including smoking status, time since first employed and work location status. Smoking information for 77% of this updated cohort was collected by questionnaire, and workers were categorized as 75% ever-smokers and 25% never-smokers. Quantitative exposure to coal tar pitch volatiles were estimated by benzo[a]pyrene measurements, calculated by a job classification and time-based exposure matrix, as described in a previous report; annual arithmetic mean values were calculated for exposures from 1977 to 2000, while pre-1977 levels were backwards-extrapolated from 1977 values, incorporating major technological changes in time periods as appropriate.

Cumulative exposure metrics were highly skewed. Cumulative benzo[a]pyrene with a 5-year lag (past benzo[a]pyrene exposure) and cumulative benzo[a]pyrene in the most recent 5 years (recent benzo[a]pyrene exposure) were only slightly positively correlated ($r = 0.10$, $p < 0.001$). Current benzo[a]pyrene exposure was highly correlated with cumulative exposure for the most recent 5 years of exposure ($r = 0.86$, $p < 0.001$), but not with 5-year lagged cumulative exposure ($r = 0.03$, $p < 0.001$). Lagged cumulative exposure metrics (0–10 years) were all highly correlated with each other ($r = 0.96$, all p-values <0.001); lagged metrics for cumulative exposure were used to distinguish between effects of current versus long-term exposure.

When exposed workers were pooled and compared externally to non-exposed referents, the IHD and AMI SMRs were all ≤1.00 for males, and the only significant association in females was an SMR of 1.27 for AMI. For internal comparisons, exposed males were stratified into quintiles based upon IHD mortality, with approximately 56 deaths per exposure category. Five-year lagged cumulative benzo[a]pyrene exposure was significantly associated with elevated risk of IHD mortality, HR = 1.62 (95% CI 1.06–2.46) in the highest exposure quintile, while no association was observed between most recent (5 years) exposure and mortality. Restricting IHD events to only AMI (1969 onward) resulted in similar monotonic trends, albeit of lower statistical significance. No association was observed between benzo[a]pyrene exposure and non-AMI IHD. While there was little difference in the exposure-response association among 0-, 2-, and 5-year lagged data, 10-year lagged data resulted in a weaker association. All risk estimates were strengthened by the incorporation of work status and time-since-hire to account for the healthy worker effect, as evidenced by the SMR of 0.87 (95% CI 0.82–0.92) for all chronic nonmalignant diseases combined in male exposed workers versus external referents. Using a continuous variable, the authors

calculated the risk of death from IHD as 1.002 (95% CI 1.000–1.005) per μg/m³ from cumulative benzo[a]pyrene exposure; however, visual inspection of the categorical relationships indicated that the association is nonlinear, suggesting that this value may be an underestimate. Restricting the cohort to only members who died within 30 days of active employment at the worksite, cumulative benzo[a]pyrene exposure was not significantly associated with IHD or AMI, although the HR for the highest exposure group was 2.39 (95% CI 0.95–6.05). Exposure-response relationships were similarly examined in male smelter workers for chronic obstructive pulmonary disease and cerebrovascular disease, but neither was significantly associated with cumulative benzo[a]pyrene exposure in either internal or external comparisons.

Table D-2. Exposure to benzo[a]pyrene and mortality from cardiovascular diseases in a Canadian cohort of male aluminum smelter workers

Effect measured	Categorical cumulative exposure with a 5-yr lag (μg/m³-yr)					*p*-value for trend[a]	Continuous[b]
	0	0–7.79	7.79–24.3	24.3–66.7	≥66.7		
All IHD (1957 onward)							
Deaths	56	56	57	56	56		281
Person-years of follow-up	33,111	37,581	34,838	31,533	13,688	0.053	150,751
HR	1	1.11	1.48	1.28	1.62		1.002
95% CI	referent	0.76–1.62	1.01–2.17	0.86–1.91	1.06–2.46		1.000–1.005
AMI (1969 onward)							
	0	**0–7.51**	**7.51–27.7**	**27.7–67.4**	**≥67.4**		
Deaths	35	37	37	38	37		184
Person-years of follow-up	25,071	30,454	34,621	24,081	13,261	0.19	127,488
HR	1	1.14	1.21	1.36	1.46		1.001
95% CI	referent	0.71–1.82	0.75–1.96	0.84–2.45	0.87–2.45		0.997–1.005

[a]Two-sided test for trend using the person-year-weighted mean value for each category as a linear, continuous variable.
[b]Exposure variable was entered as a continuous, linear variable in the model.

Source: Friesen et al. (2010).

Reproductive and Developmental Endpoints

Wu et al. (2010) conducted a study of benzo[a]pyrene-DNA adduct levels in relation to risk of fetal death in Tianjin, China. This case-control study included women who experienced a delayed miscarriage before 14 weeks gestational age (i.e., a fetal death that remained in utero and therefore required surgical intervention). Cases were matched by age and gravidity to controls (women undergoing induced abortion due to an unplanned or unwanted pregnancy). The study excluded women who smoked, women with chronic disease and pregnancy complications, and women with occupational exposures to PAHs. Residency within Tianjin for at least 1 year was also an eligibility

ED_006137A_00009570-00043

criterion. The participation rate was high: 81/84 eligible cases participated and 81/89 eligible controls participated. Data pertaining to demographic characteristics, reproductive history, and factors relating to potential PAH exposure were collected using a structured interview, and samples from the aborted tissue were obtained. In two of the four hospitals used in the study, blood samples from the women (n = 51 cases and 51 controls) were also collected. The presence of benzo[a]pyrene-BPDE adducts was assessed in the blood and tissue samples using high-performance liquid chromatography (HPLC). There was no correlation between blood and aborted tissue levels of benzo[a]pyrene adducts (r = −0.12 for the 102 blood-tissue pairs, r = −0.02 for the 51 case pairs, and r = −0.21 for the 51 control pairs). (The authors noted that there was little difference between women with and without blood samples in terms of the interview-based measures collected or in terms of the DNA-adduct levels in aborted tissue.) Benzo[a]pyrene-adduct levels were similar but slightly lower in the aborted tissue of cases compared with controls (mean ± SD 4.8 ± 6.0 in cases and 6.0 ± 7.4 in controls, $p = 0.29$). In the blood samples, however, benzo[a]pyrene-adduct levels were higher in cases (6.0 ± 4.7 and 2.7 ± 2.2 in cases and controls, respectively, $p < 0.001$). In logistic regression analyses using a continuous adduct measure, the odds ratio (OR) was 1.35 (95% CI 1.11–1.64) per adduct/10^8 nucleotide. These results were adjusted for education, household income, and gestational age, but were very similar to the unadjusted results. Categorizing exposure at the median value resulted in an adjusted OR of 4.27 (95% CI 1.41–12.99) in the high compared with low benzo[a]pyrene-adduct group. There was no relation between benzo[a]pyrene-adduct levels in the aborted tissue and miscarriage in the logistic regression analyses using either the continuous (adjusted OR 0.97, 95% CI 0.93–1.02) or dichotomous exposure measure (adjusted OR 0.76, 95% CI 0.37–1.54). Associations between miscarriage and several interview-based measures of potential PAH exposure were also seen: adjusted ORs of 3.07 (95% CI 1.31–7.16) for traffic congestion near residence, 3.52 (95% CI 1.44–8.57) for commuting by walking, 3.78 (95% CI 1.11–12.87) for routinely cooked during pregnancy, and 3.21 (95% CI 0.98–10.48) for industrial site or stack near residence, but there was no association with other types of commuting (e.g., by bike, car, or bus).

Perera et al. (2005a) studied 329 nonsmoking pregnant women (30 ± 5 years old) possibly exposed to PAHs from fires at the World Trade Center (WTC) during the 4 weeks after 09/11/2001. Maternal and umbilical cord blood levels of benzo[a]pyrene (BPDE)-DNA adducts were highest in study participants who lived within 1 mile of the WTC, with an inverse correlation between cord blood levels and distance from the WTC. Neither cord blood adduct level nor environmental tobacco smoke (ETS) alone was positively correlated with adverse birth outcomes. However, the interaction between ETS exposure and cord blood adducts was significantly associated with reduced birth weight and head circumference. Among babies exposed to ETS in utero, a doubling of cord blood benzo[a]pyrene-DNA adducts was associated with an 8% decrease in birth weight ($p = 0.03$) and a 3% decrease in head circumference ($p = 0.04$).

ED_006137A_00009570-00044

Perera et al. (2005b), a reanalysis of Perera et al. (2004), compared various exposures—ETS, nutrition, pesticides, material hardship—with birth outcomes (length, head circumference, cognitive development). ETS exposure and intake of PAH-rich foods by pregnant women were determined by questionnaire. Levels of BPDE-DNA adducts were determined in umbilical cord blood collected at delivery. The study population consisted of Dominican or African-American nonsmoking pregnant women (n = 214; 24 ± 5 years old) free of diabetes, hypertension, HIV, and drug or alcohol abuse. Benzo[a]pyrene adducts, ETS, and dietary PAHs were not significantly correlated with each other. However, the interaction between benzo[a]pyrene-DNA adducts and ETS exposure was significantly associated with reduced birth weights (−6.8%; $p = 0.03$) and reduced head circumference (−2.9%; $p = 0.04$).

Tang et al. (2006) measured BPDE-DNA adducts in maternal and umbilical cord blood obtained at delivery from a cohort of 150 nonsmoking women and their newborns in China. Exposure assessment was related to the seasonal operation of a local, coal-fired power plant; however, airborne PAH concentrations were not measured. Dietary PAH intake was not included as a covariate because it did not significantly contribute to the final models, but ETS, sex, and maternal height and weight were considered as covariates. DNA adduct levels were compared to several birth outcomes and physical development parameters, such as gestational age at birth; infant sex, birth weight, length, head circumference, and malformations; maternal height and pregnancy weight total weight gain; complications of pregnancy and delivery; and medications used during pregnancy.

High cord blood adduct levels were significantly associated with reduced infant/child weight at 18 months ($\beta = -0.048$, $p = 0.03$), 24 months ($\beta = -0.041$, $p = 0.027$), and 30 months of age ($\beta = -0.040$, $p = 0.049$); decreased birth head circumference was marginally associated with DNA adduct levels ($\beta = -0.011$, $p = 0.057$). Maternal adduct levels were correlated neither with cord blood adduct levels nor with fetal and child growth. Among female infants, cord blood adduct levels were significantly associated with smaller birth head circumference ($p = 0.022$) and with lower weight at 18 months ($p = 0.014$), 24 months ($p = 0.012$), and 30 months of age ($p = 0.033$), and with decreased body length at 18 months of age ($p = 0.033$). Among male infants, the corresponding associations were also inverse, but were not statistically significant.

Considerable evidence of a deleterious effect of smoking on male and female fertility has accumulated from epidemiological studies of time to pregnancy, ovulatory disorders, semen quality, and spontaneous abortion (reviewed in Waylen et al., 2009; Cooper and Moley, 2008; Soares and Melo, 2008). In addition, the effect of smoking, particularly during the time of the perimenopausal transition, on acceleration of ovarian senescence (menopause) has also been established (Midgette and Baron, 1990). More limited data are available pertaining specifically to measures of benzo[a]pyrene and reproductive outcomes.

Neal et al. (2008) examined levels of benzo[a]pyrene and other PAHs in follicular fluid and serum sample from 36 women undergoing in vitro fertilization at a clinic in Toronto, and compared

ED_006137A_00009570-00045

the successful conception rate in relation to benzo[a]pyrene levels. The women were classified by smoking status, with 19 current cigarette smokers, 7 with passive or sidestream smoke exposure (i.e., nonsmoker with a partner who smoked), and 10 nonsmokers exposed. An early follicular phase blood sample and follicular fluid sample from the follicle at the time of ovum retrieval were collected and analyzed for the presence of benzo[a]pyrene, acenapthelene, phenanthrene, pyrene, and chrysene using gas chromatography/mass spectrometry (MS) (detection limit 5 pg/mL). The frequency of nondetectable levels of serum benzo[a]pyrene was highest in the nonsmoking group (60.0, 14.3, and 21.0% below the detection limit in nonsmoking, sidestream smoke, and active smoking groups, respectively). A similar pattern was seen with follicular fluid benzo[a]pyrene (30.0, 14.3, and 10.5% below the detection limit in nonsmoking, sidestream smoke, and active smoking groups, respectively). In the analyses comparing mean values across groups, an assigned value of 0 was used for nondetectable samples. Follicular fluid benzo[a]pyrene levels were higher in the active smoking group (mean ± standard error [SE], 1.32 ± 0.68 ng/mL) than in the sidestream (0.05 ± 0.01 ng/mL) or nonsmoking (0.03 ± 0.01 ng/mL) groups ($p = 0.04$). The between-group differences in serum benzo[a]pyrene levels were not statistically significant (0.22 ± 0.15, 0.98 ± 0.56, and 0.40 ± 0.13 ng/mL in nonsmoking, sidestream smoke, and active smoking groups, respectively), and there were no differences in relation to smoking status. Among active smokers, the number of cigarettes smoked per day was strongly correlated with follicular fluid benzo[a]pyrene levels ($r = 0.7$, $p < 0.01$). Follicular fluid benzo[a]pyrene levels were significantly higher among the women who did not conceive (1.79 ± 0.86 ng/mL) compared with women who did get pregnant (mean approximately 0.10 ng/mL, as estimated from graph) ($p < 0.001$), but serum levels of benzo[a]pyrene were not associated with successful conception.

A small case-control study conducted between August 2005 and February 2006 in Lucknow city (Uttar Pradesh), India examined PAH concentrations in placental tissues (Singh et al., 2008) in relation to risk of preterm birth. The study included 29 cases (delivery between 28 and <36 weeks of gestation) and 31 term delivery controls. Demographic data on smoking history, reproductive history, and other information were collected by interview, and a 10-g sample of placental tissue was collected from all participants. Concentration of specific PAHs in placental tissue was determined using HPLC. In addition to benzo[a]pyrene, the PAHs assayed were naphthalene, acenaphthylene, phenanthrene, fluorene, anthracene, benzo[a]anthracene, fluoranthene, pyrene, benzo[k]fluoranthene, benzo[b]fluoranthene, benzo[g,h,i]perylene, and dibenzo[a,h]anthracene. PAH exposure in this population was from environmental sources and from cooking. The age of study participants ranged from 20 to 35 years. There was little difference in birth weight between cases and controls (mean 2.77 and 2.75 kg in the case and control groups, respectively). Placental benzo[a]pyrene levels were lower than the levels of the other PAHs detected (mean 8.83 ppb in controls for benzo[a]pyrene compared with 25–30 ppb for anthracene, benzo[k]fluoranthene, benzo[b]fluoranthene, and dibenzo[a,h]anthracene, 59 ppb for acenaphthylene, and 200–380 ppm for naphthalene, phenanthrene, fluoranthene, and pyrene; nondetectable levels of fluorine,

ED_006137A_00009570-00046

benzo[a]anthracene, and benzo[g,h,i]perylene were found). There was little difference in benzo[a]pyrene levels between cases (mean ± SE 13.85 ± 7.06 ppb) and controls (8.83 ± 5.84 ppb), but elevated levels of fluoranthene (325.91 ± 45.14 and 208.6 ± 21.93 ppb in cases and controls, respectively, $p < 0.05$) and benzo[b]fluoranthene (61.91 ± 12.43 and 23.84 ± 7.01 ppb in cases and controls, respectively, $p < 0.05$) were seen.

Neurotoxicity

Niu et al. (2010) studied 176 Chinese coke-oven workers with elevated benzo[a]pyrene exposure and compared them against 48 referents (workers in a supply warehouse), matched by socioeconomic status, lifestyle, and health. Blood levels of monoamine, amino acid and chlorine neurotransmitters were measured, and the World Health Organization Neurobehavioral Core Test Battery was administered to assess emotional state, learning, memory, and hand-eye coordination. The authors self-designed a study questionnaire to gather information on worker education, vocational history, smoking and drinking habits, and personal habits, personal and family medical history, as well as any current symptoms and medications used in the previous several weeks. Workers were excluded from the study for any of the following criteria: if they reported feeling depressed at any point during the previous 6 months; if they had taken medicine in the previous 2 weeks that could affect nervous system function; or if they reported undertaking vigorous exercise less than 48 hours previously. "Smoking" was defined as ≥10 cigarettes/day during the past year. Similarly, "drinking" was defined as wine/beer/spirits consumed ≥3 times/week for the past 6 months. Workplace environmental sampling stations were established at each of the physical work locations, including the referent's warehouse, and dual automatic air sampling pumps collected samples at personal breathing zone height for 6 hours/day, over 3 consecutive days. Benzo[a]pyrene content was determined by HPLC, and relative exposure was compared to post-shift urine levels of a benzo[a]pyrene metabolite, 1-hydroxypyrene (1-OH-Py). Blood was collected in the morning before breakfast; monoamine (norepinephrine and dopamine) and amino acid (glutamate, aspartate, glycine, and gamma-aminobutyric acid [GABA]) neurotransmitter levels were determined by HPLC, acetylcholine levels determined by hydroxyamine chromometry, and acetylcholine esterase (AchE) levels measured in lysed red blood cells (RBCs) using activity kits.

Benzo[a]pyrene mean concentrations were 19.56 ± 13.2, 185.96 ± 38.6, and 1,623.56 ± 435.8 ng/m^3 at the bottom, side, and top of the coke oven, respectively, all of which were higher than the mean at the referents' warehouse (10.26 ± 7.6 ng/m^3). The authors did not report stratified analysis by different levels of benzo[a]pyrene exposure, and reported only comparisons between the referents and all exposed workers combined (Table D-3), or between workers grouped by urinary benzo[a]pyrene metabolite 1-OH-Py levels (Table D-4). There were no significant differences in age, education, or smoking or alcohol use between the coke oven and warehouse workers. Urinary 1-OH-Py levels were 32% higher in coke oven workers compared to the referent group, corresponding to the higher levels of benzo[a]pyrene detected in all coke oven workstation compared to the supply warehouse. Performance in two neurobehavioral function tests, digit span

ED_006137A_00009570-00047

and forward digit span, were significantly decreased in the exposed oven workers versus the control group; when stratified by urinary metabolite level, scores significantly decreased with increasing 1-OH-Py levels. Of the neurotransmitters assessed, norepinephrine, dopamine, aspartate, and GABA were significantly decreased in exposed versus control workers; norepinephrine and aspartate were also significantly and inversely related with 1-OH-Py levels. Dopamine levels appeared to decrease with increased urinary metabolite levels, although the relationship was not statistically significant. GABA levels were highly variable, and appeared to increase with increasing 1-OH-Py levels, although this relationship was not statistically significant. Acetylcholine levels were fourfold higher in coke oven workers compared to referents, and AchE activity was 30% lower; both acetylcholine and AchE were significantly associated with urinary benzo[a]pyrene metabolite levels, although acetylcholine increased and AchE activity decreased with increasing 1-OH-Py. The authors reported the results of correlation analysis, indicating that digit span scores correlated negatively with acetylcholine and positively with AchE (coefficients of −0.230, −0.276 and 0.120, 0.170, respectively), although no indication of statistical significance was given. No other associations were reported.

Table D-3. Exposure-related effects in Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace

Effect measured	Exposure group		*p*-value
	Controls (n = 48)	Exposed workers (n = 176)	
Background information (mean ± SD, incidence or percent)			
Age (yrs)	39.71 ± 7.51	37.86 ± 6.51	0.098
Education (junior/senior)	23/25	110/66	0.068
Smoking	77%	64%	0.093
Drinking	27%	39%	0.140
Urine benzo[a]pyrene metabolite (μmol/mol creatinine; mean ± SD)			
1-OH-Py	2.77 ± 1.45	3.66 ± 0.67	0.000
Neurobehavioral function tests (mean ± SD)			
Simple reaction time	413.88 ± 95.40	437.39 ± 88.44	0.109
Digit span	17.31 ± 4.54	15.47 ± 4.08	0.006
Forward digit span	10.65 ± 2.42	9.25 ± 2.64	0.001
Neurotransmitter concentrations (mean ± SD)			
Norepinephrine (ng/mL)	62.54 ± 58.07	40.62 ± 29.78	0.000
Dopamine (ng/mL)	1,566.28 ± 317.64	1,425.85 ± 422.66	0.029
Aspartate (μg/mL)	2.13 ± 1.66	1.58 ± 0.99	0.004
Glutamate (μg/mL)	11.21 ± 5.28	9.68 ± 5.72	0.074
GABA (μg/mL)	2.52 ± 5.16	1.01 ± 2.21	0.004
Acetylcholine (μg/mL	172.60 ± 67.19	704.00 ± 393.86	0.000
AchE activity (U/mg protein)	71.31 ± 46.18	50.27 ± 34.02	0.012

Source: Niu et al. (2010).

ED_006137A_00009570-00048

Table D-4. Exposure-related effects in Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace, stratified by urinary metabolite levels

Effect measured	Exposure group categorized by 1-OH-Py level			*p*-value
	0–3.09 μmol/mol creatinine	3.09–3.90 μmol/mol creatinine	3.90–5.53 μmol/mol creatinine	
Number of subjects	**33**	**72**	**36**	
Neurobehavioral function tests (mean ± SD)				
Digit span	18.24 ± 4.58	16.04 ± 4.24	15.78 ± 3.71	0.003
Forward digit span	10.85 ± 2.12	9.80 ± 2.86	9.58 ± 2.33	0.019
Backward digit span	7.20 ± 3.07	6.38 ± 2.55	6.20 ± 2.15	0.089
Right dotting	152.15 ± 35.43	153.80 ± 31.55	167.22 ± 59.21	0.094
Neurotransmitter concentrations (mean ± SD)				
Norepinephrine (ng/mL)	67.31 ± 67.45	36.97 ± 23.58	46.75 ± 35.88	0.002
Dopamine (ng/mL)	1,614.45 ± 683.57	1,482.30 ± 323.66	1,405.06 ± 332.23	0.134
Aspartate (μg/mL)	2.29 ± 2.13	1.61 ± 0.71	1.47 ± 0.58	0.001
Glutamate (μg/mL)	11.56 ± 8.92	9.93 ± 4.14	9.06 ± 3.30	0.070
GABA (μg/mL)	1.40 ± 3.59	1.42 ± 3.44	1.56 ± 3.24	0.964
Acetylcholine (μg/mL)	334.66 ± 83.75	483.71 ± 57.87	665.85 ± 94.34	0.030
AchE activity (U/mg protein)	68.17 ± 9.28	54.98 ± 4.23	52.64 ± 4.60	0.043

Source: Niu et al. (2010).

Immunotoxicity

Zhang et al. (2012) studied 129 Chinese coke-oven workers with elevated benzo[a]pyrene exposure and compared them against 37 referents (workers in a supply warehouse), matched by socioeconomic status, lifestyle, and health. Area benzo[a]pyrene levels were quantified in the various work areas, and the primary endpoint was the level of early and late apoptosis in peripheral blood mononuclear cells (PBMCs) isolated from each worker subgroup the morning following an overnight fast. The authors self-designed a study questionnaire to gather information on worker education, vocational history, smoking and drinking habits, personal habits, and personal and family medical history, as well as any current symptoms and medications used in the previous several weeks. "Smoking" was defined as ≥10 cigarettes/day during the past year, with "smoking index" defined as cigarettes/day × years smoking. Similarly, "drinking" was defined as wine/beer/spirits consumed ≥3 times/week for the past 6 months, and "drinking index" defined as grams of alcohol consumed/day × years drinking. Exposed workers were categorized by physical worksite location and expected differences in benzo[a]pyrene exposure: 34 oven bottom workers, 48 oven side workers, and 47 oven top workers. Workplace environmental sampling stations were established at each of the physical work locations, including the referent's warehouse, and dual

ED_006137A_00009570-00049

automatic air sampling pumps collected samples at personal breathing zone height for 6 hours/day, over 3 consecutive days. Benzo[a]pyrene content was determined by HPLC, and relative exposure was compared to post-shift urine levels of a benzo[a]pyrene metabolite, 1-OH-Py. Collected and purified PBMCs were incubated with Annexin-V and PI prior to analysis by flow cytometry; early apoptotic cells were considered to be Annexin V+/PI-, while late apoptotic cells were considered Annexin V+/PI+.

All apoptosis data were displayed graphically, and in all groupings, early:late apoptotic PBMCs occurred at an approximate 2:1 frequency. PBMC apoptosis was similar in each of the three coke oven worker groups, which were all statistically significantly higher than referents (approximately twofold) for both early and late apoptosis. While self-reported smoking incidence varied significantly among the worker groups, stratification by smoking years or smoking index did not reveal any significant association with PBMC apoptosis. Multiple linear stepwise regression analysis suggested that urine 1-OH-Py levels and years of coke oven operation were positively associated with increased early and late PBMC apoptosis (Table D-5), and that years of ethanol consumption was negatively associated with only early apoptosis. These associations were tested by stratifying workers into three groups by urinary 1-OH-Py levels or coke oven operation years, and in both cases, the groups with the highest urinary metabolite levels or longest oven operating experience had statistically significantly higher levels of both early and late apoptotic PBMCs versus the lowest or shortest duration groups, respectively. Likewise, when sorted into groups based upon years of ethanol consumption, the highest ethanol "years of consumption" group had statistically significantly lower early apoptosis rates when compared to the lowest ethanol consuming group.

Table D-5. Background information on Chinese coke oven workers or warehouse controls exposed to benzo[a]pyrene in the workplace

Effect measured	Exposure group (ng/m^3; mean ± SD)				*p*-value
	10.2 ± 7.6	**19.5 ± 13.2**	**185.9 ± 38.6**	**1,623.5 ± 435.8**	
Number of subjects	**37**	**34**	**48**	**47**	
Background information (mean ± SD or %)					
Age (yrs)	37.16 ± 6.00	39.09 ± 5.53	36.98 ± 6.40	37.34 ± 6.78	0.451
Working years	17.35 ± 7.19	18.58 ± 7.23	16.78 ± 6.90	17.26 ± 7.44	0.742
Smoking	62.2	64.7	83.3	53.2	0.017
Drinking	24.3	41.2	39.6	44.7	0.259
Urine benzo[a]pyrene metabolite (μmol/mol creatinine; mean ± SD)					
1-OH-Py	2.78 ± 1.04	3.22 ± 0.81*	3.51 ± 0.55*	3.66 ± 0.58*	0.000

*$p < 0.05$ significantly different from control mean.

Source: Zhang et al. (2012).

ED_006137A_00009570-00050

D.3.2. Cancer-related Endpoints

Benzo[a]pyrene-Induced Cytogenetic Damage

Many studies measure cytogenetic damage as biomarkers of early biological effects, which also reflect exposure to genotoxic chemicals. Standard cytogenetic endpoints include chromosomal aberration (CA), sister chromatid exchange (SCE), micronucleus (MN) formation, hypoxanthine guanine phosphoribosyl transferase (hprt) mutation frequency, and glycophorin A mutation frequency (Gyorffy et al., 2008). These biomarkers are often incorporated in multi-endpoint studies with other biomarkers of exposure. Because they indicate related but different endpoints, there is often a lack of correlation between the different categories of biomarkers.

Merlo et al. (1997) evaluated DNA adduct formation (measured by [^{32}P]-postlabelling) and MN in white blood cells (WBCs) of 94 traffic policemen versus 52 residents from the metropolitan area of Genoa, Italy. All study subjects wore personal air samplers for 5 hours of one work shift, and levels of benzo[a]pyrene and other PAHs were measured. Policemen were exposed to 4.55 ng benzo[a]pyrene/m^3 air, compared with urban residents who were exposed to 0.15 ng/m^3. DNA adduct levels in policemen were 35% higher than in urban residents (p = 0.007), but MN in urban residents were 20% higher than in policemen (p = 0.02). Linear regressions of DNA adducts and MN incidence, respectively, versus benzo[a]pyrene exposure levels did not reveal significant correlations.

Perera and coworkers assessed DNA damage in Finnish iron foundry workers in two separate studies and using three methodologies. Based on results from personal sampling and stationary monitoring in both studies, three levels of benzo[a]pyrene air concentrations were defined: low (<5 ng/m^3 benzo[a]pyrene), medium (5–12 ng/m^3), and high (>12 ng/m^3) (Perera et al., 1994; Perera et al., 1993). In the first study, involving 48 workers, several biomarkers were analyzed for dose-response and interindividual variability (Perera et al., 1993). PAH-DNA adducts were determined in WBCs using an immunoassay and enzyme-linked immunosorbent assay (ELISA) with fluorescence detection. Mutations at the hprt locus were also measured in WBC DNA. The latter assay is based on the fact that each cell contains only one copy of the hprt gene, which is located on the X-chromosome. While male cells have only one X-chromosome, female cells inactivate one of the two X-chromosomes at random. The gene is highly sensitive to mutations such that in the event of a crucial mutation in the gene, enzyme activity disappears completely from the cell. In addition, mutations at the glycophorin A gene locus were measured in RBCs. The glycophorin A mutation frequency was not correlated with either benzo[a]pyrene exposure or PAH-DNA adduct formation. However, both PAH-DNA adduct levels and hprt mutation frequency increased with increasing benzo[a]pyrene exposure. In addition, there was a highly significant correlation between incidence of hprt mutations and PAH-DNA adduct levels (p = 0.004).

ED_006137A_00009570-00051

In a second study, Perera et al. (1994) surveyed 64 iron foundry workers with assessments conducted in 2 successive years; 24 of the workers provided blood samples in both years. Exposure to benzo[a]pyrene, collected by personal and area sampling in the first year of the study, ranged from <5 to 60 ng/m^3 and was estimated to have decreased by 40% in the second year. The levels of PAH-DNA adducts were roughly 50% lower in the 2nd year, presumably reflecting decreased exposure. The longer-lived hprt mutations were not as strongly influenced by the decreasing exposure to benzo[a]pyrene. Study subjects who did not have detectable levels of DNA adducts were excluded from the study. As in the previous study, a strong correlation between DNA adduct levels and incidence of hprt mutations was observed (Perera et al., 1993).

Kalina et al. (1998) studied several cytogenetic markers in 64 coke oven workers and 34 controls employed at other locations within the same plant. Airborne benzo[a]pyrene and seven other carcinogenic PAHs were collected by personal air samplers, which showed ambient benzo[a]pyrene concentrations ranging widely from 0.002 to 50 μg/m^3 in coke oven workers and from 0.002 to 0.063 μg/m^3 in controls. CAs, SCEs, high-frequency cells (HFCs), and SCE heterogeneity index were all significantly increased with benzo[a]pyrene exposure. Except for increases in HFCs, no effect of smoking was observed. Consistent with studies of PAH-DNA adduct formation, reduced cytogenetic response at high exposure levels produced a nonlinear dose-response relationship. The authors also evaluated the potential influence of polymorphisms in enzymes involved in the metabolism of benzo[a]pyrene. GSTM1 and N-acetyl transferase-2 polymorphisms were studied and no evidence of the two gene polymorphisms having any influence on the incidence of cytogenetic damage was found.

Motykiewicz et al. (1998) conducted a similar study of genotoxicity associated with benzo[a]pyrene exposure in 67 female residents of a highly polluted industrial urban area of Upper Silesia, Poland, and compared the results to those obtained from 72 female residents of another urban but less polluted area in the same province of Poland. Urinary mutagenicity and 1-OH-Py levels, PAH-DNA adducts in oral mucosa cells (detected by immunoperoxidase staining), SCEs, HFCs, CAs, bleomycin sensitivity, and GSTM1 and CYP1A1 polymorphisms in blood lymphocytes were investigated. High volume air samplers and gas chromatography were used to quantify ambient benzo[a]pyrene levels, which were 3.7 ng/m^3 in the polluted area and 0.6 ng/m^3 in the control area during the summer. During winter, levels rose to 43.4 and 7.2 ng/m^3 in the two areas, respectively. The cytogenetic biomarkers (CA and SCE/HFC), urinary mutagenicity, and urinary 1-OH-Py excretion were significantly increased in females from the polluted area, and differences appeared to be more pronounced during winter time. PAH-DNA adduct levels were significantly increased in the study population, when compared to the controls, only in the winter season. No difference in sensitivity to bleomycin-induced lymphocyte chromatid breaks was seen between the two populations. As with the study by Kalina et al. (1998), genetic polymorphisms assumed to affect the metabolic transformation of benzo[a]pyrene were not associated with any difference in the incidence of DNA damage.

In a study of Thai school boys in urban (Bangkok) and rural areas, bulky (including but not limited to BPDE-type) DNA adduct levels were measured in lymphocytes along with DNA single-strand breaks (SSBs), using the comet assay, and DNA repair capacity (Tuntawiroon et al., 2007). Ambient air and personal breathing zone measurements indicated that Bangkok school children experienced significantly higher exposures to benzo[a]pyrene and total PAHs. A significantly higher level of SSBs (tail length 1.93 ± 0.09 versus 1.28 ± 0.12 μm, +51%; $p < 0.001$) was observed in Bangkok school children when compared with rural children, and this parameter was significantly associated with DNA adduct levels. A significantly reduced DNA repair capacity (0.45 ± 0.01 versus 0.26 ± 0.01 γ-radiation-induced deletions per metaphase, −42%; $p < 0.001$) was also observed in the city school children, again significantly associated with DNA adduct levels. It was not evident why higher environmental PAH exposure would be associated with lowered DNA repair capacity. However, because the personal breathing zone PAH levels and DNA adduct levels were not associated with each other, it is conceivable that the city school children had a priori lower DNA repair capacities that contributed significantly to the high adduct levels. The authors considered genetic differences between the two study populations as a possible reason for this observation.

D.3.3. Epidemiologic Findings in Humans

The association between human cancer and contact with PAH-containing substances, such as soot, coal tar, and pitch, has been widely recognized since the early 1900s (Boström et al., 2002). Although numerous epidemiology studies establish an unequivocal association between PAH exposure and human cancer, defining the causative role for benzo[a]pyrene and other specific PAHs remains a challenge. In essentially all reported studies, either the benzo[a]pyrene exposure and/or internal dose are not known, or the benzo[a]pyrene carcinogenic effect cannot be distinguished from the effects of other PAH and non-PAH carcinogens. Nevertheless, three types of investigations provide support for the involvement of benzo[a]pyrene in some human cancers: molecular epidemiology studies; population- and hospital-based, case-control studies; and occupational cohort studies. In some cohort studies, benzo[a]pyrene exposure concentrations were measured and thus provide a means to link exposure intensity with observed cancer rates. In case-control studies, by their nature, benzo[a]pyrene and total PAH doses can only be estimated.

Molecular Epidemiology and Case-Control Cancer Studies

Defective DNA repair capacity leading to genomic instability and, ultimately, increased cancer risk is well documented (Wu et al., 2007; Wu et al., 2005). Moreover, sensitivity to mutagen-induced DNA damage is highly heritable and thus represents an important factor that determines individual cancer susceptibility. Based on studies comparing monozygotic and dizygotic twins, the genetic contribution to BPDE mutagenic sensitivity was estimated to be 48.0% (Wu et al., 2007). BPDE has been used as an etiologically relevant mutagen in case-control studies to examine the association between elevated lung and bladder cancer risk and individual sensitivity to BPDE-

ED_006137A_00009570-00053

induced DNA damage. Mutagen sensitivity is determined by quantifying chromatid breaks or DNA adducts in phytohemagglutinin-stimulated peripheral blood lymphocytes as an indirect measure of DNA repair capacity.

In a hospital-based, case-control study involving 221 lung cancer cases and 229 healthy controls, DNA adducts were measured in stimulated peripheral blood lymphocytes after incubation with BPDE in vitro (Li et al., 2001). Lung cancer cases showed consistent statistically significant elevations in induced BPDE-DNA adducts in lymphocytes, compared with controls, regardless of subgroup by age, sex, ethnicity, smoking history, weight loss, or family history of cancer. The lymphocyte BPDE-induced DNA adduct levels, when grouped by quartile using the levels in controls as cutoff points, were significantly dose-related with lung cancer risk (ORs 1.11, 1.62, and 3.23; trend test, $p < 0.001$). In a related hospital-based, case-control study involving 155 lung cancer patients and 153 healthy controls, stimulated peripheral blood lymphocytes were exposed to BPDE in vitro (Wu et al., 2005). DNA damage/repair was evaluated in lymphocytes using the comet assay, and impacts on cell cycle checkpoints were measured using a fluorescence-activated cell-sorting method. The lung cancer cases exhibited significantly higher levels of BPDE-induced DNA damage than the controls ($p < 0.001$), with lung cancer risk positively associated with increasing levels of lymphocyte DNA damage when grouped in quartiles (trend test, $p < 0.001$). In addition, lung cancer patients demonstrated significantly shorter cell cycle delays in response to BPDE exposure to lymphocytes, which correlated with increased DNA damage.

Sensitivity to BPDE-induced DNA damage in bladder cancer patients supports the results observed in lung cancer cases. In a hospital-based, case-control study involving 203 bladder cancer patients and 198 healthy controls, BPDE-induced DNA damage was specifically evaluated at the chromosome 9p21 locus in stimulated peripheral blood lymphocytes (Gu et al., 2008). Deletions of 9p21, which includes critical components of cell cycle control pathways, are associated with a variety of cancers. After adjusting for age, sex, ethnicity, and smoking status, individuals with high BPDE-induced damage at 9p21 were significantly associated with increased bladder cancer risk (OR 5.28; 95% CI 3.26–8.59). Categorization of patients into tertiles for BPDE sensitivity relative to controls demonstrated a dose-related association between BPDE-induced 9p21 damage and bladder cancer risk. Collectively, the results of molecular epidemiology studies with lung and bladder cancer patients indicate that individuals with a defective ability to repair BPDE-DNA adducts are at increased risk for cancer and, moreover, that specific genes linked to tumorigenesis pathways may be molecular targets for benzo[a]pyrene and other carcinogens.

Due to the importance of the diet as a benzo[a]pyrene exposure source, several population- and hospital-based, case-control studies have investigated the implied association between dietary intake of benzo[a]pyrene and risk for several tumor types. In a study involving 193 pancreatic cancer cases and 674 controls (Anderson et al., 2005), another involving 626 pancreatic cancer cases and 530 controls (Li et al., 2007), and a third involving 146 colorectal adenoma cases and 228 controls (Sinha et al., 2005), dietary intake of benzo[a]pyrene was estimated using food

frequency questionnaires. In all studies, the primary focus was on estimated intake of benzo[a]pyrene (and other carcinogens) derived from cooked meat. Overall, cases when compared with controls, had higher intakes of benzo[a]pyrene and other food carcinogens, leading to the conclusion that benzo[a]pyrene plays a role in the etiology of these tumors in humans. In a supportive follow-up case-control study of colorectal adenomas, levels of leukocyte PAH-DNA adducts were significantly higher in cases when compared with controls ($p = 0.02$), using a method that recognizes BPDE and several other PAHs bound to DNA (Gunter et al., 2007).

Cohort Cancer Studies

Epidemiologic studies of workers in PAH-related occupations indicate increased human cancer risks associated with iron and steel production, roofing, carbon black production, and exposure to diesel exhaust (Bosetti et al., 2007). Exposure to benzo[a]pyrene is only one of numerous contributors to the cancer risk from complex PAH-containing mixtures that occur in the workplace. Although some occupational cohort studies report measured or estimated inhalation exposure concentrations for benzo[a]pyrene, none report biomarkers of internal benzo[a]pyrene dose in study subjects (reviewed in Bosetti et al., 2007; Armstrong et al., 2004). Several of these cohort studies (summarized below) demonstrate a positive exposure-response relationship with cumulative PAH exposure using benzo[a]pyrene—or a proxy such as benzene-soluble matter (BSM) that can be converted to benzo[a]pyrene—as an indicator substance. These studies provide insight and support for the causative role of benzo[a]pyrene in human cancer.

Cancer incidence in aluminum and electrode production plants

Exposure to benzo[a]pyrene and BSM in aluminum smelter workers is strongly associated with bladder cancer and weakly associated with lung cancer (Boffetta et al., 1997; Tremblay et al., 1995; Armstrong et al., 1994; Gibbs, 1985; Theriault et al., 1984). In an analysis of pooled data from nine cohorts of aluminum production workers, 688 respiratory tract cancer cases were observed versus 674.1 expected (pooled RR 1.03; CI 0.96–1.11) (Bosetti et al., 2007). A total of 196 bladder cancer cases were observed in eight of the cohorts, compared with 155.7 expected (pooled RR 1.29; CI 1.12–1.49). Based on estimated airborne benzo[a]pyrene exposures from a meta-analysis of eight cohort studies, the predicted lung cancer RR per 100 $\mu g/m^3$-years of cumulative benzo[a]pyrene exposure was 1.16 (95% CI 1.05–1.28) (Armstrong et al., 2004).

Spinelli et al. (2006) reported a 14-year update to a previously published historical cohort study (Spinelli et al., 1991) of Canadian aluminum reduction plant workers. The results confirmed and extended the findings from the earlier epidemiology study. The study surveyed a total of 6,423 workers with ≥3 years of employment at an aluminum reduction plant in British Columbia, Canada, between the years 1954 and 1997, and evaluated all types of cancers. The focus was on cumulative exposure to coal tar pitch volatiles, measured as BSM and as benzo[a]pyrene. Benzo[a]pyrene exposure categories were determined from the range of predicted exposures over time from statistical exposure models. There were 662 cancer cases, of which approximately 98%

ED_006137A_00009570-00055

had confirmed diagnoses. The overall cancer mortality rate (SMR 0.97; CI 0.87–1.08) and cancer incidence rate (standardized incidence ratio [SIR] 1.00; CI 0.92–1.08) were not different from that of the British Columbia general population. However, this study identified significantly increased incidence rates for cancers of the bladder (SIR 1.80; CI 1.45–2.21) and stomach (SIR 1.46; CI 1.01–2.04). The lung cancer incidence rate was only slightly higher than expected (SIR 1.10; CI 0.93–1.30). Significant dose-response associations with cumulative benzo[a]pyrene exposure were seen for bladder cancer ($p < 0.001$), stomach cancer ($p < 0.05$), lung cancer ($p < 0.001$), non-Hodgkin lymphoma ($p < 0.001$), and kidney cancer ($p < 0.01$), although the overall incidence rates for the latter three cancer types were not significantly elevated versus the general population. Similar cancer risk results were obtained using BSM as the exposure measure; the cumulative benzo[a]pyrene and BSM exposures were highly correlated (r = 0.94).

In several occupational cohort studies of workers in Norwegian aluminum production plants, personal and stationary airborne PAH measurements were performed.

In a study covering 11,103 workers and 272,554 person × years of PAH exposure, cancer incidence was evaluated in six Norwegian aluminum smelters (Romundstad et al., 2000a) and (Romundstad et al., 2000b). Reported estimates of PAH exposure concentrations reached a maximum of 3,400 μg/m^3 PAH (680 μg/m^3 benzo[a]pyrene). The overall number of cancers observed in this study did not differ significantly from control values (SIR 1.03; CI 1.0–1.1). The data from this study showed significantly increased incidences for cancer of the bladder (SIR 1.3; CI 1.1–1.5) and elevated, but not significant, SIRs for larynx (SIR 1.3; CI 0.8–1.9), thyroid (SIR 1.4; CI 0.7–2.5), and multiple myeloma (SIR 1.4; CI 0.9–1.9). Incidence rates for bladder, lung, pancreas, and kidney cancer (the latter three with SIRs close to unity) were subjected to a cumulative exposure-response analysis. The incidence rate for bladder cancer showed a trend with increasing cumulative exposure and with increasing lag times (up to 30 years) at the highest exposure level. The incidence of both lung and bladder cancers was greatly increased in smokers. The authors reported that using local county rates rather than national cancer incidence rates as controls increased the SIR for lung cancer (SIR 1.4; CI 1.2–1.6) to a statistically significant level.

Cancer incidence in coke oven, coal gasification, and iron and steel foundry workers

An increased risk of death from lung and bladder cancer is reported in some studies involving coke oven, coal gasification, and iron and steel foundry workers (Boström et al., 2002; Boffetta et al., 1997). An especially consistent risk of lung cancer across occupations is noted when cumulative exposure is taken into consideration (e.g., RR of 1.16 per 100 unity-years for aluminum smelter workers, 1.17 for coke oven workers, and 1.15 for coal gasification workers). In an analysis of pooled data from 10 cohorts of coke production workers, 762 lung cancer cases were observed versus 512.1 expected (pooled RR 1.58; CI 1.47–1.69) (Bosetti et al., 2007). Significant variations in risk estimates among the studies were reported, particularly in the large cohorts (RRs of 1.1, 1.2, 2.0, and 2.6). There was no evidence for increased bladder cancer risk in the coke production workers. Based on estimated airborne benzo[a]pyrene exposures from a meta-analysis of

ED_006137A_00009570-00056

10 cohort studies, the predicted lung cancer RR per 100 μg/m^3-years of cumulative benzo[a]pyrene exposure was 1.17 (95% CI 1.12–1.22) (Armstrong et al., 2004).

A meta-analysis of data from five cohorts of gasification workers reported 251 deaths from respiratory tract cancer, compared with 104.7 expected (pooled RR 2.58; 95% CI 2.28–2.92) (Bosetti et al., 2007). Pooled data from three of the cohorts indicated 18 deaths from urinary tract cancers, versus 6.0 expected (pooled RR 3.27; 95% CI 2.06–5.19). Based on estimated airborne benzo[a]pyrene exposures from a meta-analysis of four gas worker cohort studies, the predicted lung cancer RR per 100 μg/m^3-years of cumulative benzo[a]pyrene exposure was 1.15 (95% CI 1.11–1.20) (Armstrong et al., 2004).

Increased risks were reported in iron and steel foundry workers for cancers of the respiratory tract, bladder, and kidney. In an analysis of pooled data from 10 cohorts, 1,004 respiratory tract cancer cases were observed versus 726.0 expected (pooled RR 1.40; CI 1.31–1.49) (Bosetti et al., 2007). A total of 99 bladder cancer cases were observed in seven of the cohorts, compared with 83.0 expected (pooled RR 1.29; CI 1.06–1.57). For kidney cancer, 40 cases were observed compared with 31.0 expected based on four studies (pooled RR 1.30; 95% CI 0.95–1.77).

Xu et al. (1996) conducted a nested case-control study, surveying the cancer incidence among 196,993 active or retired workers from the Anshan Chinese iron and steel production complex. A large number of historical benzo[a]pyrene measurements (1956–1995) were available. The study included 610 cases of lung cancer and 292 cases of stomach cancer, with 959 age- and gender-matched controls from the workforce. After adjusting for nonoccupational risk factors such as smoking and diet, significantly elevated risks for lung cancer and stomach cancer were identified for subjects employed for ≥15 years, with ORs varying among job categories. For either type of cancer, highest risks were seen among coke oven workers: lung cancer, OR = 3.4 (CI 1.4–8.5) and stomach cancer, OR = 5.4 (CI 1.8–16.0).

There were significant trends for long-term, cumulative benzo[a]pyrene exposure versus lung cancer (p = 0.004) or stomach cancer (p = 0.016) incidence. For cumulative total benzo[a]pyrene exposures of <0.84, 0.85–1.96, 1.97–3.2, and ≥3.2 μg/m^3-year, the ORs for lung cancer were 1.1 (CI 0.8–1.7), 1.6 (CI 1.2–2.3), 1.6 (1.1–2.3), and 1.8 (CI 1.2–2.5), respectively. For cumulative total benzo[a]pyrene exposures of <0.84, 0.85–1.96, 1.97–3.2, and ≥3.2 μg/m^3-year, the ORs for stomach cancer were 0.9 (CI 0.5–1.5), 1.7 (CI 1.1–2.6), 1.3 (0.8–2.1), and 1.7 (CI 1.1–2.7), respectively. However, the investigators noted that additional workplace air contaminants were measured, which might have influenced the outcome. Of these, asbestos, silica, quartz, and iron oxide-containing dusts may have been confounders. For lung cancers, cumulative exposures to total dust and silica dust both showed significant dose-response trends (p = 0.001 and 0.007, respectively), while for stomach cancer, only cumulative total dust exposure showed a marginally significant trend (p = 0.061). For cumulative total dust exposures of <69, 69–279, 280–882, and ≥883 mg/m^3, the ORs for lung cancer were 1.4 (CI 1.2–1.9), 1.2 (CI 1.0–2.19), 1.4 (CI 1.0–2.0), and

1.9 (CI 1.3–2.5), respectively. For cumulative silica dust exposures of <3.7, 3.7–10.39, 10.4–27.71, and ≥27.72 mg/m^3, the ORs for lung cancer were 1.7 (CI 1.2–2.4), 1.5 (CI 1.0–2.1), 1.5 (CI 1.0–2.1), and 1.8 (CI 1.2–2.5), respectively. For cumulative total dust exposures of <69, 69–279, 280–882, and ≥883 mg/m^3, ORs for stomach cancer were 1.3 (CI 0.8–2.1), 14 (CI 0.9–2.2), 12 (CI 0.8–1.9), and 1.6 (CI 1.1–2.5), respectively.

Exposure-response data from studies of coke oven workers in the United States have often been used to derive quantitative risk estimates for PAH mixtures, and for benzo[a]pyrene as an indicator substance (Boström et al., 2002). However, there are numerous studies of coke oven worker cohorts that do not provide estimates of benzo[a]pyrene exposure. An overview of the results of these and other studies can be obtained from the review of Boffetta et al. (1997).

Cancer incidence in asphalt workers and roofers

These groups encompass different types of work (asphalt paving versus roofing) and also different types of historical exposure that have changed from using PAH-rich coal tar pitch to the use of bitumen or asphalt, both of which are rather low in PAHs due to their source (crude oil refinery) and a special purification process. Increased risks for lung cancer were reported in large cohorts of asphalt workers and roofers; evidence for increased bladder cancer risk is weak (Burstyn et al., 2007; Partanen and Boffetta, 1994; Chiazze et al., 1991; Hansen, 1991, 1989; Hammond et al., 1976). In an analysis of pooled data from two cohorts of asphalt workers, 822 lung cancer cases were observed versus 730.7 expected (pooled RR 1.14; 95% CI 1.07–1.22) (Bosetti et al., 2007). In two cohorts of roofers, analysis of pooled data indicated that 138 lung cancer cases were observed, compared with 91.9 expected (pooled RR 1.51; 95% CI 1.28–1.78) (Bosetti et al., 2007).

Epidemiology of patients treated with coal tar containing ointments

In addition to cohorts of workers occupationally exposed to PAH mixtures, another source of potential exposure to benzo[a]pyrene is through topical coal tar formulations used for the treatment of psoriasis, eczema, and dermatitis. Epidemiological studies examining skin cancer risk in relation to various types of topical coal tar exposure are summarized below (see Table D-6); case reports, reviews, and studies that did not include a measure of coal tar use (e.g., Alderson and Clarke, 1983) are not included.

Table D-6. Studies examining skin cancer risk in relation to therapeutic coal tar

Reference and study details	Results
General population studies	
Mitropoulos and Norman (2005) (United States, Arizona) Case-control study (Southeastern Arizona Health Study-2), population-based; n = 404 squamous cell skin cancer cases, 395 controls, 1992–1996, age ≥30 yrs; controls selected using random digit dialing (frequency matched by 5-yr age group and gender); limited to whites; details regarding participation rates not reported Exposure: Interview, focusing on occupational and other sources of sun exposure, chemical exposures, and coal tar/dandruff shampoo Outcome: Incident squamous cell cancer from regional skin cancer registry	Squamous cell carcinoma (SCC), coal tar/dandruff shampoo use: Cases n (%) / Controls n (%) / OR[a] (95% CI) / OR[b] (95% CI) 101 (25) / 73 (19) / 1.50 (1.05, 2.14) / 1.28 (0.85, 1.9) [a]Adjusted for age and gender. [b]Adjusted for age, gender, actinic keratosis, current number of arm freckles, and reaction of skin to prolonged sun.
Studies of patients with skin conditions	
Roelofzen et al. (2010) (Netherlands) Cohort (retrospective); total n = 13,200 (4,315 psoriasis 8,885 eczema patients), identified through hospital records (manual). Diagnosed 1960–1990 (≥3 visits to dermatologist); median age 28 yrs; follow-up through 2003 (median follow-up 21 yrs) Exposure: Coal tar treatment (pix lithantracis and/or liquor carbonis detergens): 8,062 (39%); duration of use obtained from 1,100 users (14%), median = 6 mo Outcome: Skin cancer diagnosis from national cancer registry (operating since 1989) and cause of death registries, with some supplemental questionnaire data from 61% of the cohort	Skin cancer (excluding basal cell carcinoma); includes melanoma and squamous cell [number of cases = 145] HR (95% CI) for use of coal tar; referent category = only used dermatocorticosteroids: Psoriasis 1.08 (0.43, 2.72) Eczema 1.06 (0.62, 1.83) Psoriasis or eczema 1.09 (0.69, 1.72) Proportional hazards models, adjusted for age (continuous), gender, severity (>10% of body area affected), interaction term of coal tar and severity, calendar period, psoralen + ultraviolet-A (PUVA) systemic therapy, and smoking (current and ever versus never). Also examined skin type, history of sun exposure, and alcohol consumption. Smoking data imputed for 58% of the cohort.
Torinuki and Tagami (1988) (Japan) Cohort (prospective); total n = 151 psoriasis patients including 43 treated with Goeckerman regimen without PUVA treatment, mean age 43 yrs; patients	No skin cancers observed

ED_006137A_00009570-00059

Reference and study details	Results
treated between 1976–1986; follow-up: 5/43 Goeckerman patients followed for >6 yrs Exposure: Goeckerman regimen without PUVA treatment; duration of use not reported Outcome: Skin cancer diagnosis from case records	
Maughan et al. (1980) (United States, Mayo Clinic) Cohort (retrospective); n = 426 atopic dermatitis or neurodermatitis patients, treated with Goeckerman regimen between 1950–1954; follow-up: 305 (72%) followed to approximately 1980 (25 yrs) Exposure: Goeckerman regimen (ultraviolet-B [UVB] + coal tar treatments) at hospital; follow-up questionnaire inquired about other treatment (including coal tar treatment) after hospitalization; coal tar use ranged from none to every day for 26 yrs Outcome: Skin cancer diagnosis by self-report (follow-up questionnaire) with confirmation through histology specimens; 9 of 11 nonmelanoma skin cancers confirmed	Eleven nonmelanoma skin cancer cases (observed) [8 basal cell, 1 squamous cell, 2 unknown] Expected rates from Third National Cancer Survey Observed/Expected — Expected Minneapolis-St Paul — 6.7 — 1.64 San Francisco-Oakland — 9.4 — 1.17 Iowa — 5.3 — 2.08 Dallas-Fort Worth — 18.8 — 0.59 No difference in duration of coal tar use after hospitalization in skin cancer patients compared to those who did not develop skin cancer.
Pittelkow et al. (1981) (United States, Mayo Clinic) Cohort (retrospective); n = 280 psoriasis patients, hospitalized 1950–1954 at Mayo Clinic; 260 (92%) followed to 1978 (25 yrs) Exposure: Goeckerman regimen (UVB + coal tar treatments) at hospital; other treatment (including coal tar treatment) recorded from clinical records. Median duration use approximately 15 d in 1951–1955 and 21 d in 1956–1960 Outcome: Skin cancer diagnosis by self-report (follow-up questionnaire) with confirmation through histology specimens; 20 of 22 confirmed	Among patients reporting coal tar therapy use: n = 19 nonmelanoma squamous cell or basal cell (or unknown) skin cancer cases (observed) Expected rates from Third National Cancer Survey Observed/Expected — Expected Minneapolis-St Paul — 18.7 — 1.01 San Francisco-Oakland — 23.1 — 0.82 Iowa — 15.5 — 1.22 Dallas-Fort Worth — 49.2 — 0.39

Reference and study details	Results
Coal tar use in studies with combined treatment of PUVA therapy	
(Stern et al. (1998); Stern and Laird (1994)) (United States, 16 centers) Cohort (prospective); total n = 1,380 psoriasis patients, enrolled between 1975 and 1976 in the PUVA cohort study; mean age 44 yrs; follow-up at 12–15-mo intervals through 1996 (approximately 20 years); 1,049 (91%) patients interviewed at final follow-up Exposure: Non-PUVA treatments (including topical coal tar, ultraviolet B, methotrexate, and ionizing radiation) were collected at start of PUVA treatment and during follow-up; coal tar use was noted to be highly correlated with UVB therapy and thus reported as a single parameter; 'high use' defined as >45 mo topical tar therapy or >300 UVB treatments Outcome: Skin cancer diagnosis reported at follow-up, confirmed by histopathology	From 1996 follow-up (limited to first occurrence 1986–1996): Cancer type — OR (95% CI) [n cases] Squamous — 1.4 (1.0, 2.0) [1,047] Basal cell — 1.5 (1.1, 2.0) [821] OR compares 'high' exposure to UVB/tar to 'low' exposure to UVB/tar, adjusted for age, sex, geographic area, anatomic site (head and neck, other), PUVA treatments through 1985 (five categories from <100 to >336), PUVA treatments after 1985 (≥50, <50), methotrexate (≥208 weeks, <208 weeks), and Grenz rays or x-rays for therapy (ever/never)
Stern et al. (1980) (United States, 16 centers) Nested case-control study based on a study following 1,373 PUVA-treated patients (34 incident cases, 24 prevalent cases; 126 controls); matched by age (within 5 yrs), sex, skin type, geographic area, and ionizing radiation; incident cases also matched for number of PUVA treatments; average follow-up 2.7 yrs Exposure: Exposure to coal tar therapy and/or ultraviolet radiation based on follow-up interview; includes exposures before PUVA trial began; coal tar use quantified as number of months in which crude coal tar preparations was used at least weekly; high coal tar exposure defined as > 90 mo of use; high ultraviolet radiation exposure defined as ≥300 sunlamp treatments. Assumption made that coal tar and ultraviolet radiation have the same quantitative effect on risk of skin cancer Outcome: Skin cancer, prevalent cases occurred before PUVA trial started; incident cases occurred during follow-up period	RR (95% CI) of skin cancer (skin cancer type not specified) among high exposure (≥90 mo of tar use or ≥300 sunlamp treatments) Matched analysis: All cases (n = 58) — 4.7 (2.2, 10.0) Incident cases (n = 34) — 5.6 (1.9, 16.2) Prevalent cases (n = 24) — 3.8 (1.2, 12.5)

ED_006137A_00009570-00061

Reference and study details	Results
Lindelöf and Sigurgeirsson (1993) (Sweden) Nested case-control study based on a study following 4,799 PUVA-treated patients (24 cases, 96 controls); matched by gender, age, diagnosis, PUVA dose, number of treatments, type of psoralen regimen, site of treatment, and skin type; clinic location matching utilized when possible; mean age 52 yrs Exposure: Non-PUVA treatments (including tar, topical corticosteroids, UVB, and anthralin) collected by questionnaire; exposure not quantified and duration not provided Outcome: Skin cancer diagnosis obtained from Swedish cancer registry	SCC with coal tar usage: Cases n (%) / Controls n (%) / OR (95% CI) 17 (70) / 62 (64) / 1.3 (0.5, 3.5) (Similar results were seen for UVB exposure [OR 1.3, 95% CI 0.5, 3.5], reflecting the high correlation between these treatments)

The U.S. Environmental Protection Agency (EPA) noted several limitations with respect to study design and analysis in this literature, precluding the ability to provide a foundation for evaluating the potential association between use of therapeutic coal tar treatment (particularly long-term treatment) and risk of skin cancer. A primary limitation concerns the quality of the exposure assessment. Only one population-based, case-control study was identified (Mitropoulos and Norman, 2005); this study examined self-reported use of coal tar/dandruff shampoo and incidence of squamous cell cancer in a population in Arizona (adjusted OR 1.28, 95% CI 0.85, 1.9). This exposure measure is likely to be highly susceptible to misclassification bias. EPA considered the likelihood of non-differential misclassification to be high; differential misclassification was also considered to be possible, but of lower likelihood. Non-differential misclassification would arise from lack of awareness of the content of shampoos, inability to recall use of individual shampoos, and the lack of specificity of this particular question. Differential misclassification would arise from differential reporting based on disease status. EPA noted similar concerns regarding exposure quality in the nested case-control study conducted among patients receiving psoralen plus ultraviolet-A (PUVA) treatment (in addition to a variety of other treatments, including coal tar treatments and ultraviolet –B [UVB]) by Lindelöf and Sigurgeirsson (1993). Use of coal tar was collected through a mailed questionnaire, with no information on duration of use and no verification with medical records. A large study of psoriasis and eczema patients (n = 13,200 patients) by Roelofzen et al. (2010) with a 21-year follow-up period obtained data on coal tar treatment through manual chart review; this chart review was conducted in 2003 on medical records going back to 1960. Duration of use (median 6 months) was available for only 14% of the patients who had an indication of use. Thus, considerable non-differential misclassification of exposure (coal tar use) is likely, and the limited exposure data did not allow examination of variation in exposure level. Misclassification of disease was also noted to be a limitation of this study in that Roelofzen et al. (2010) included melanoma, in addition to squamous cell skin cancer,

ED_006137A_00009570-00062

which introduces a lack of specificity of outcome into the analysis as melanoma is not thought to be associated with PAH exposure. Given these issues of exposure and disease misclassification, the RRs from these studies do not provide a sound basis for interpretation as no risk, and would be expected to diminish effect estimates.

A common regimen for treatment of psoriasis and other skin conditions combines coal tar treatment with UVB radiation (referred to as the Goeckerman regimen). One study of this regimen was very small (n = 43 patients) with only 5 of the patients followed for more than 6 years (Torinuki and Tagami, 1988). Two larger Goeckerman treatment studies (280–426 patients) had a longer follow-up period (25 years), but were limited in terms of the choice of referent rates and differences in disease ascertainment between cases and the reference population (Pittelkow et al., 1981; Maughan et al., 1980). Specifically, dermatology patients were seen at the Mayo Clinic in Rochester, Minnesota, but the reference rates for cancer were obtained from survey data from Minneapolis-St Paul, San Francisco-Oakland, Iowa, and Dallas-Fort Worth. Therefore, it is unclear whether the reference population appropriately represents the case population. In addition, this combination of UVB and coal tar makes it impossible to attribute risk to either individual component. This limitation effects the interpretation of the results of the PUVA trial studies (Stern et al., 1998; Stern and Laird, 1994; Stern et al., 1980), in which the analysis was conducted using a definition of "high" exposure as >4 months of topical tar therapy or >300 UVB treatments. Similarly, the study by (Lindelöf and Sigurgeirsson (1993)) reported similar prevalence and risk estimates for coal tar use and for UVB, reflecting the high correlation between these treatments.

In summary, the available studies examining therapeutic topical coal tar use and risk of skin cancer were limited by low-quality exposure data with high potential of exposure misclassification (e.g., Roelofzen et al., 2010; Mitropoulos and Norman, 2005; Lindelöf and Sigurgeirsson, 1993), small size and short duration of follow-up (e.g., Torinuki and Tagami, 1988), and choice of referent rates and differences in disease ascertainment between cases and the reference population (e.g., Pittelkow et al., 1981; Maughan et al., 1980). In addition, clinic-based studies focused on the commonly used regimen of coal tar in conjunction with UVB therapy cannot distinguish effects of coal tar from the carcinogenic effects of UVB (e.g., Stern et al., 1998; Stern and Laird, 1994; Lindelöf and Sigurgeirsson, 1993; Stern et al., 1980). Therefore, the available studies do not provide an adequate basis for examining the potential association between coal tar treated patients and skin cancer.

D.4. ANIMAL STUDIES

D.4.1. Oral Bioassays

Subchronic Studies

De Jong et al. (1999) treated male Wistar rats (eight/dose group) with benzo[a]pyrene (98.6% purity) dissolved in soybean oil by gavage 5 days/week for 35 days at doses of 0, 3, 10, 30,

ED_006137A_00009570-00063

or 90 mg/kg-day (adjusted doses: 0, 2.14, 7.14, 21.4, and 64.3 mg/kg-day). At the end of the exposure period, rats were necropsied, organ weights were determined, and major organs and tissues were prepared for histological examination (adrenals, brain, bone marrow, colon, caecum, jejunum, heart, kidney, liver, lung, lymph nodes, esophagus, pituitary, spleen, stomach, testis, and thymus). Blood was collected for examination of hematological endpoints, but there was no indication that serum biochemical parameters were analyzed. Immune parameters included determinations of serum immunoglobulin (Ig) levels (IgG, IgM, IgE, and IgA), relative spleen cell distribution, and spontaneous cytotoxicity of spleen cell populations determined in a natural-killer (NK) cell assay.

Body weight gain was decreased beginning at week 2 at the high dose of 90 mg/kg-day; there was no effect at lower doses (De Jong et al., 1999). Hematology revealed a dose-related decrease in RBC count, hemoglobin, and hematocrit at ≥10 mg/kg-day (Table D-7). A minimal but significant increase in mean cell volume and a decrease in mean cell hemoglobin concentration were noted at 90 mg/kg-day, and may indicate dose-related toxicity for the RBCs and/or RBC precursors in the bone marrow. A decrease in WBCs, attributed to a decrease in the number of lymphocytes (approximately 50%) and eosinophils (approximately 90%), was observed at 90 mg/kg-day; however, there was no effect on the number of neutrophils or monocytes. A decrease in the cell number in the bone marrow observed in the 90 mg/kg-day dose group was consistent with the observed decrease in the RBC and WBC counts at this dose level. In the 90 mg/kg-day dose group, brain, heart, kidney, and lymph node weights were decreased and liver weight was increased (Table D-7). Decreases in heart weight at 3 mg/kg-day and in kidney weight at 3 and 30 mg/kg-day were also observed, but these changes did not show dose-dependent responses. Dose-related decreases in thymus weight were statistically significant at ≥10 mg/kg-day (Table D-7).

Table D-7. Exposure-related effects in male Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 5 weeks

Effect	Dose (mg/kg-d)				
	0	3	10	30	90
Hematologic effects (mean ± SD; n = 7–8)					
WBCs (10^9/L)	14.96 ± 1.9	13.84 ± 3.0	13.69 ± 1.8	13.58 ± 2.9	8.53 ± 1.1*
RBCs (10^9/L)	8.7 ± 0.2	8.6 ± 0.2	8.3 ± 0.2*	7.8 ± 0.4*	7.1 ± 0.4*
Hemoglobin (mmol/L)	10.5 ± 0.2	10.4 ± 0.3	9.8 ± 0.2*	9.5 ± 0.4*	8.6 ± 0.6*
Hematocrit (L/L)	0.5 ± 0.01	0.5 ± 0.01	0.47 ± 0.01*	0.46 ± 0.02*	0.43 ± 0.02*
Serum Ig levels (mean ± SD; n = 7–8)					
IgM	100 ± 13	87 ± 16	86 ± 31	67 ± 16*	81 ± 26
IgG	100 ± 40	141 ± 106	104 ± 28	106 ± 19	99 ± 29
IgA	100 ± 28	73 ± 29	78 ± 67	72 ± 22	39 ± 19*

Effect	Dose (mg/kg-d)				
	0	3	10	30	90
IgE	100 ± 65	50 ± 20	228 ± 351	145 ± 176	75 ± 55
Cellularity (mean ± SD; n = 7–8)					
Spleen (cell number × 10^7)	59 ± 15	71 ± 14	59 ± 13	63 ± 10	41 ± 10*
Bone marrow (G/L)	31 ± 7	36 ± 5	31 ± 8	27 ± 8	19 ± 4*
Spleen cell distribution (%)					
B cells	39± 4	36 ± 2	34 ± 3*	32 ± 4*	23 ± 4*
T cells	40 ± 9	48 ± 12	40 ± 9	36 ± 2	44 ± 6
Th cells	23 ± 7	26 ± 7	24 ± 5	22 ± 4	26 ± 4
Ts cells	24 ± 5	26 ± 6	24 ± 7	19 ± 2	27 ± 5
Body (g) and organ (mg) weights (means; n = 7–8)					
Body weight	305	282*	300	293	250*
Brain	1,858	1,864	1,859	1,784	1,743*
Heart	1,030	934*	1,000	967	863*
Kidney	1,986	1,761*	1,899	1,790*	1,626*
Liver	10,565	9,567	11,250	11,118	12,107*
Thymus	517 ± 47	472 ± 90	438 ± 64*	388 ± 71*	198 ± 65*
Spleen	551	590	538	596	505
Mandibular lymph nodes	152	123	160	141	89*
Mesenteric lymph nodes	165	148	130*	158	107*
Popliteal lymph nodes	19	18	19	17	10*
Thymus cortex surface area *(% of total surface area of thymus; mean ± SD; n = 6–8)*	77.9 ± 3.8	74.4 ± 2.2	79.2 ± 5.9	75.8 ± 4.0	68.9 ± 5.2*

*Significantly ($p < 0.05$) different from control mean. For body weight and organ weight means, SDs were only reported for thymus weights.

Source: De Jong et al. (1999).

Statistically significant reductions were also observed in the relative cortex surface area of the thymus and thymic medullar weight at 90 mg/kg-day, but there was no difference in cell proliferation between treated and control animals using the proliferating cell nuclear antigen (PCNA) technique. Changes in the following immune parameters were noted: dose-related and statistically significant decrease in the relative number of B cells in the spleen at 10 (13%), 30 (18%), and 90 mg/kg-day (41%); significant decreases in absolute number of cells harvested in the spleen (31%), in the number of B cells in the spleen (61%), and NK cell activity in the spleen (E:T ratio was 40.9 ± 28.4% that of the controls) at 90 mg/kg-day; and a decrease in serum IgM (33%) and IgA (61%) in rats treated with 30 and 90 mg/kg-day, respectively. The decrease in the spleen cell count was attributed by the study authors to the decreased B cells and suggested a possible selective toxicity of benzo[a]pyrene to B cell precursors in the bone marrow. The study authors considered the decrease in IgA and IgM to be due to impaired production of antibodies,

ED_006137A_00009570-00065

suggesting a role of thymus toxicity in the decreased (T-cell dependent) antibody production. In addition to the effects on the thymus and spleen, histopathologic examination revealed treatment-related lesions only in the liver and forestomach at the two highest dose levels, but the incidence data for these lesions were not reported by De Jong et al. (1999). Increased incidence for forestomach basal cell hyperplasia ($p < 0.05$ by Fisher's exact test) was reported at 30 and 90 mg/kg-day, and increased incidence for oval cell hyperplasia in the liver was reported at 90 mg/kg-day ($p < 0.01$, Fisher's exact test). The results indicate that 3 mg/kg-day was a no-observed-adverse-effect level (NOAEL) for effects on hematological parameters (decreased RBC count, hemoglobin, and hematocrit) and immune parameters (decreased thymus weight and percent of B cells in the spleen) noted in Wistar rats at 10 mg/kg-day (the lowest-observed-adverse-effect level [LOAEL]) and above. Lesions of the liver (oval cell hyperplasia) and forestomach (basal cell hyperplasia) occurred at doses ≥30 mg/kg-day.

Knuckles et al. (2001) exposed male and female F344 rats (20/sex/dose group) to benzo[a]pyrene (98% purity) at doses of 0, 5, 50, or 100 mg/kg-day in the diet for 90 days. Food consumption and body weight were monitored, and the concentration of benzo[a]pyrene in the food was adjusted every 3–4 days to maintain the target dose. The authors indicated that the actual intake of benzo[a]pyrene by the rats was within 10% of the calculated intake, and the nominal doses were not corrected to actual doses. Hematology and serum chemistry parameters were evaluated. Urinalysis was also performed. Animals were examined for gross pathology, and histopathology was performed on selected organs (stomach, liver, kidney, testes, and ovaries). Statistically significant decreases in RBC counts and hematocrit level (decreases as much as 10 and 12%, respectively) were observed in males at doses ≥50 mg/kg-day and in females at 100 mg/kg-day. A maximum 12% decrease (statistically significant) in hemoglobin level was noted in both sexes at 100 mg/kg-day. Blood chemistry analysis showed a significant increase in blood urea nitrogen (BUN) only in high-dose (100 mg/kg-day) males. Histopathology examination revealed an apparent increase in the incidence of abnormal tubular casts in the kidney in males at 5 mg/kg-day (40%), 50 mg/kg-day (80%), and 100 mg/kg-day (100%), compared to 10% in the controls. Only 10% of the females showed significant kidney tubular changes at the two high-dose levels compared to zero animals in the female control group. The casts were described as molds of distal nephron lumen and were considered by the study authors to be indicative of renal dysfunction. From this study, male F344 rats appeared to be affected more severely by benzo[a]pyrene treatment than the female rats. However, the statistical significance of the kidney lesions is unclear. Several reporting gaps and inconsistencies regarding the reporting of kidney abnormalities in Knuckles et al. (2001) make interpretation of the results difficult. Results of histopathological kidney abnormalities (characterized primarily as kidney casts) were presented graphically and the data were not presented numerically in this report. No indication was given in the graph that any groups were statistically different than controls, although visual examination of the magnitude of response and error bars appears to indicate a fourfold increase in kidney casts in males compared

ED_006137A_00009570-00066

to the control group (40 compared to 10%). The figure legend reported the data as "percentage incidence of abnormal kidney tissues" and reported values as mean ± SD. However, the text under the materials and methods section stated that Fisher's exact test was used for histopathological data, which would involve the pairwise comparison of incidence and not means. There are additional internal inconsistencies in the data presented. The data appeared to indicate that incidences for males were as follows: control, 10%; 5 mg/kg-day, 40%; 50 mg/kg-day, 80%; and 100 mg/kg-day, 100%; however, these incidences are inconsistent with the size of the study groups, which were reported as 6–8 animals per group. The study authors were contacted, but did not respond to EPA's request for clarification of study design and/or results. Due to issues of data reporting, a LOAEL could not be established for the increased incidence of kidney lesions. Based on the statistically significant hematological effects including decreases in RBC counts, hematocrit, and BUN, the NOAEL in males was 5 mg/kg-day and the LOAEL was 50 mg/kg-day, based on in F344 rats. No exposure-related histological lesions were identified in the stomach, liver, testes, or ovaries in this study.

In a range-finding study, Wistar (specific pathogen-free Riv:TOX) rats (10/sex/dose group) were administered benzo[a]pyrene (97.7% purity) dissolved in soybean oil by gavage at dose levels of 0, 1.5, 5, 15, or 50 mg/kg body weight-day, 5 days/week for 5 weeks (Kroese et al., 2001). Behavior, clinical symptoms, body weight, and food and water consumption were monitored. None of the animals died during the treatment period. Animals were sacrificed 24 hours after the last dose. Urine and blood were collected for standard urinalysis and hematology and clinical chemistry evaluation. Liver enzyme induction was monitored based on EROD activity in plasma. Animals were subjected to macroscopic examination, and organ weights were recorded. The esophagus, stomach, duodenum, liver, kidneys, spleen, thymus, lung, and mammary gland (females only) from the highest-dose and control animals were evaluated for histopathology. Intermediate-dose groups were examined if abnormalities were observed in the higher-dose groups.

A significant, but not dose-dependent, increase in food consumption in males at ≥1.5 mg/kg-day and a decrease in food consumption in females at ≥5 mg/kg-day was observed (Kroese et al., 2001). Water consumption was statistically significantly altered in males only: a decrease at 1.5, 5, and 15 mg/kg-day and an increase at 50 mg/kg-day. Organ weights of lung, spleen, kidneys, adrenals, and ovaries were not affected by treatment. There was a dose-related, statistically significant decrease in thymus weight in males at 15 and 50 mg/kg-day (decreased by 28 and 33%, respectively) and a significant decrease in thymus weight in females at 50 mg/kg-day (decreased by 17%) (Table D-8). In both sexes, liver weight was statistically significantly increased only at 50 mg/kg-day by about 18% (Table D-8).

Table D-8. Exposure-related effects in Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 5 weeks

Organ	Dose (mg/kg-d)				
	0	1.5	5	15	50
Liver weight (g; mean ± SD)					
Males	6.10 ± 0.26	6.19 ± 0.19	6.13 ± 0.10	6.30 ± 0.14	7.20 ± 0.18*
Females	4.28 ± 0.11	4.40 ± 0.73	4.37 ± 0.11	4.67 ± 0.17	5.03 ± 0.15*
Thymus weight (mg; mean ± SD)					
Males	471 ± 19	434 ± 20	418 ± 26	342 ± 20*	317 ± 21*
Females	326 ± 12	367 ± 23	351 ± 25	317 ± 30	271 ± 16*
Basal cell hyperplasia of the forestomach (incidence with slight severity)					
Males	1/10	1/10	4/10	3/10	7/10
Females	0/10	1/10	1/10	3/10*	7/10*

*Significantly ($p < 0.05$) different from control mean; n = 10/sex/group.

Source: Kroese et al. (2001).

Hematological evaluation revealed only statistically nonsignificant, small, dose-related decreases in hemoglobin in both sexes and RBC counts in males. Clinical chemistry analysis showed a small, but statistically significant, increase in creatinine levels in males only at 1.5 mg/kg-day, but this effect was not dose-dependent. A dose-dependent induction of liver microsomal EROD activity was observed, with a 5-fold induction at 1.5 mg/kg-day compared to controls, reaching 36-fold in males at 50 mg/kg-day; the fold induction in females at the top dose was less than in males. At necropsy, significant, dose-dependent macroscopic findings were not observed.

Histopathology examination revealed a statistically significant increase in basal cell hyperplasia in the forestomach of females at doses ≥15 mg/kg-day (Kroese et al., 2001). The induction of liver microsomal EROD was not accompanied by any adverse histopathologic findings in the liver at the highest dose, 50 mg/kg-day, so the livers from intermediate-dose groups were, therefore, not examined. An increased incidence of brown pigmentation of red pulp (hemosiderin) in the thymus was observed in treated animals of both sexes. However, this tissue was not examined in intermediate-dose groups. This range-finding, 5-week study identified a NOAEL of 5 mg/kg-day and a LOAEL of 15 mg/kg-day, based on decreased thymus weight and forestomach hyperplasia in Wistar rats.

Kroese et al. (2001) exposed Wistar (Riv:TOX) rats (10/sex/dose group) to benzo[a]pyrene (98.6% purity, dissolved in soybean oil) by gavage at 0, 3, 10, or 30 mg/kg body weight-day, 5 days/week for 90 days. The rats were examined daily for behavior and clinical symptoms and by palpation. Food and water consumption, body weights, morbidity, and mortality were monitored.

ED_006137A_00009570-00068

At the end of the exposure period, rats were subjected to macroscopic examination and organ weights were recorded. Blood was collected for hematology and serum chemistry evaluation, and urine was collected for urinalysis. All gross abnormalities, particularly masses and lesions suspected of being tumors, were evaluated. The liver, stomach, esophagus, thymus, lung, spleen, and mesenteric lymph node were examined histopathologically. In addition, cell proliferation in forestomach epithelium was measured as the prevalence of S-phase epithelial cells displaying bromodeoxyuridine (BrdU) incorporation.

There were no obvious effects on behavior of the animals, and no difference was observed in survival or food consumption between exposed animals and controls (Kroese et al., 2001). Higher water consumption and slightly lower body weights than the controls were observed in males, but not females, at the high dose of 30 mg/kg-day. Hematological investigations showed only nonsignificant, small dose-related decreases in RBC count and hemoglobin level in both sexes. Clinical chemistry evaluation did not show any treatment-related group differences or dose-response relationships for alanine aminotransferase, serum aspartate transaminase (AST), lactate dehydrogenase (LDH), or creatinine, but a small dose-related decrease in γ-glutamyl transferase activity was observed in males only. Urinalysis revealed an increase in urine volume in males at 30 mg/kg-day, which was not dose related. At the highest dose, both sexes showed increased levels of urinary creatinine and a dose-related increase in urinary protein. However, no further investigation was conducted to determine the underlying mechanisms for these changes. At necropsy, reddish to brown/gray discoloration of the mandibular lymph nodes was consistently noted in most rats; occasional discoloration was also observed in other regional lymph nodes (axillary). Statistically significant increases in liver weight were observed at 10 and 30 mg/kg-day in males (15 and 29%) and at 30 mg/kg-day in females (17%). A decrease in thymus weight was seen in both sexes at 30 mg/kg-day (17 and 33% decrease in females and males, respectively, compared with controls) (Table D-9). At 10 mg/kg-day, thymus weight in males was decreased by 15%, but the decrease did not reach statistical significance.

Table D-9. Means ± SD[a] for liver and thymus weights in Wistar rats exposed to benzo[a]pyrene by gavage 5 days/week for 90 days

Organ	Dose (mg/kg-d)			
	0	3	10	30
Liver weight (g)				
Males	7.49 ± 0.97	8.00 ± 0.85	8.62 ± 1.30*	9.67 ± 1.17*
Females	5.54 ± 0.70	5.42 ± 0.76	5.76 ± 0.71	6.48 ± 0.78*
Thymus weight (mg)				
Males	380 ± 60	380 ± 110	330 ± 60	270 ± 40*
Females	320 ± 60	310 ± 50	300 ± 40	230 ± 30*

*Significantly ($p < 0.05$) different from control mean; student t-test (unpaired, two-tailed); n = 10/sex/group.
[a]Reported as SE, but judged to be SD (and confirmed by study authors).

Source: Kroese et al. (2001).

Histopathologic examination revealed what was characterized by Kroese et al. (2001) as basal cell disturbance in the epithelium of the forestomach in males ($p < 0.05$) and females ($p < 0.01$) at 30 mg/kg-day. The basal cell disturbance was characterized by increased number of basal cells, mitotic figures, and remnants of necrotic cells; occasional early nodule development; infiltration by inflammatory cells (mainly histiocytes); and capillary hyperemia, often in combination with the previous changes (Kroese et al., 2001). Incidences for these lesions (also described as "slight basal cell hyperplasia") in the 0, 3, 10, and 30-mg/kg-day groups were 0/10, 2/10, 3/10, and 7/10, respectively, in female rats and 2/10, 0/10, 6/10, and 7/10, respectively, in male rats. Nodular hyperplasia was noted in one animal of each sex at 30 mg/kg-day. A significant ($p < 0.05$) increase in proliferation of forestomach epithelial cells was detected at doses ≥10 mg/kg-day by morphometric of analysis of nuclei with BrdU incorporation. The mean numbers of BrdU-staining nuclei per unit surface area of the underlying lamina muscularis mucosa were increased by about two- and three–fourfold at 10 and 30 mg/kg-day, respectively, compared with controls. A reduction of thymus weight and increase in the incidence of thymus atrophy (the report described the atrophy as slight, but did not specify the full severity scale used in the pathology examination) was observed in males only at 30 mg/kg-day ($p < 0.01$ compared with controls). Respective incidences for thymus atrophy for the control through high-dose groups were 0/10, 0/10, 0/10, and 3/10 for females and 0/10, 2/10, 1/10, and 6/10 for males. No significant differences were observed in the lungs of control and treated animals. In the esophagus, degeneration and regeneration of muscle fibers and focal inflammation of the muscular wall were judged to be a result of the gavage dosing rather than of benzo[a]pyrene treatment.

The target organs of benzo[a]pyrene toxicity in this 90-day dietary study of Wistar rats were the forestomach, thymus, and liver. The LOAEL for forestomach hyperplasia, decreased thymus weight, and thymus atrophy was 30 mg/kg-day and the NOAEL was 10 mg/kg-day.

Chronic Studies and Cancer Bioassays

Kroese et al. (2001) exposed Wistar (Riv:TOX) rats (52/sex/dose group) to benzo[a]pyrene (98.6% purity) in soybean oil by gavage at nominal doses of 0, 3, 10, or 30 mg/kg-day, 5 days/week, for 104 weeks. Mean achieved dose levels were 0, 2.9, 9.6, and 29 mg/kg-day. Additional rats (6/sex/group) were sacrificed after 4 and 5 months of exposure for analysis of DNA adduct formation in blood and major organs and tissues. The rats were 6 weeks old at the start of exposure. The rats were examined daily for behavior and clinical symptoms and by palpation. Food and water consumption, body weights, morbidity, and mortality were monitored during the study. Complete necropsy was performed on all animals that died during the course of the study, that were found moribund, or at terminal sacrifice (organ weight measurement was not mentioned in the report by Kroese et al., 2001). The organs and tissues collected and prepared for microscopic examination included brain, pituitary, heart, thyroid, salivary glands, lungs, stomach, esophagus, duodenum, jejunum, ileum, caecum, colon, rectum, thymus, kidneys, urinary bladder, spleen, lymph nodes, liver pancreas, adrenals, sciatic nerve, nasal cavity, femur, skin including mammary tissue, ovaries/uterus, and testis/accessory sex glands. Some of these tissues were examined only when gross abnormalities were detected. All gross abnormalities, particularly masses and lesions that appeared to be tumors, were also examined.

At 104 weeks, survival in the control group was 65% (males) and 50% (females), whereas mortality in the 30 mg/kg-day dose group was 100% after about week 70. At 80 weeks, survival percentages were about 90, 85, and 75% in female rats in the 0, 3, and 10 mg/kg-day groups, respectively; in males, respective survival percentages were ~95, 90, and 85% at 80 weeks. Survival of 50% of animals occurred at 104, 104, ~90, and 60 weeks for control through high-dose females; for males, the respective times associated with 65% survival were 104, 104, 104, and ~60 weeks. The high mortality rate in high-dose rats was attributed to liver or forestomach tumor development, not to noncancer systemic effects. After 20 weeks, body weight was decreased (compared with controls by >10%) in 30-mg/kg-day males, but not in females. This decrease was accompanied by a decrease in food consumption. Body weights and food consumption were not adversely affected in the other dose groups compared to controls. In males, there was a dose-dependent increase in water consumption starting at week 13, but benzo[a]pyrene treatment had no significant effects on water consumption in females.

Tumors were detected at significantly elevated incidences at several tissue sites in female and male rats at doses ≥10 and ≥3 mg/kg-day, respectively (Table D-10) (Kroese et al., 2001). The tissue sites with the highest incidences of tumors were the liver (hepatocellular adenoma and carcinoma) and forestomach (squamous cell papilloma and carcinoma) in both sexes (Table D-10). The first liver tumors were detected in week 35 in high-dose male rats. Liver tumors were described as complex, with a considerable proportion (59/150 tumors) metastasizing to the lungs. At the highest dose level, 95% of rats with liver tumors had malignant carcinomas (95/100; Table D-10). Forestomach tumors were associated with the basal cell proliferation observed

(without diffuse hyperplasia) in the forestomach of rats in the preliminary range-finding and 90-day exposure studies. At the highest dose level, 59% of rats with forestomach tumors had malignant carcinomas (60/102; Table D-10). Other tissue sites with significantly elevated incidences of tumors in the 30 mg/kg-day dose group included the oral cavity (papilloma and squamous cell carcinoma [SCC]) in both sexes, and the jejunum (adenocarcinoma), kidney (cortical adenoma), and skin (basal cell adenoma and carcinoma) in male rats (Table D-10). In addition, auditory canal tumors (carcinoma or squamous cell papilloma originating from pilo-sebaceous units including the Zymbal's gland) were also detected in both sexes at 30 mg/kg-day, but auditory canal tissue was not histologically examined in the lower dose groups and the controls (Table D-10). Gross examination revealed auditory canal tumors only in the high-dose group.

Table D-10. Incidences of exposure-related neoplasms in Wistar rats treated by gavage with benzo[a]pyrene, 5 days/week, for 104 weeks

	Dose (mg/kg-d)			
	0	3	10	30[a]
Site	**Females[b]**			
Oral cavity				
Papilloma	0/19	0/21	0/9	9/31*
SCC	1/19	0/21	0/9	9/31*
Basal cell adenoma	0/19	0/21	1/9	4/31
Sebaceous cell carcinoma	0/19	0/21	0/9	1/31
Esophagus				
Sarcoma undifferentiated	0/52	0/52	2/52	0/52
Rhabdomyosarcoma	0/52	1/52	4/52	0/52
Fibrosarcoma	0/52	0/52	3/52	0/52
Forestomach				
Squamous cell papilloma	1/52	3/51	20/51*	25/52*
SCC	0/52	3/51	10/51*	25/52*
Liver				
Hepatocellular adenoma	0/52	2/52	7/52*	1/52
Hepatocellular carcinoma	0/52	0/52	32/52*	50/52*
Cholangiocarcinoma	0/52	0/52	1/52	0/52
Anaplastic carcinoma	0/52	0/52	1/52	0/52
Auditory canal				
Benign tumor	0/0	0/0	0/0	1/20
Squamous cell papilloma	0/0	0/1	0/0	1/20
Carcinoma	0/0	0/1	0/0	13/20*

ED_006137A_00009570-00072

	Dose (mg/kg-d)			
	0	3	10	30[a]
Site	**Males[b]**			
Oral cavity				
Papilloma	0/24	0/24	2/37	10/38*
SCC	1/24	0/24	5/37	11/38*
Basal cell adenoma	0/24	0/24	0/37	2/38
Sebaceous cell carcinoma	0/24	0/24	0/37	2/38
Forestomach				
Squamous cell papilloma	0/52	7/52*	18/52*	17/52*
SCC	0/52	1/52	25/52*	35/52*
Jejunum				
Adenocarcinoma	0/51	0/50	1/51	8/49*
Liver				
Hepatocellular adenoma	0/52	3/52	15/52*	4/52
Hepatocellular carcinoma	0/52	1/52	23/52*	45/52*
Cholangiocarcinoma	0/52	0/52	0/52	1/52
Kidney				
Cortical adenoma	0/52	0/52	7/52*	8/52*
Adenocarcinoma	0/52	0/52	2/52	0/52
Urothelial carcinoma	0/52	0/52	0/52	3/52
Auditory canal				
Benign	0/1	0/0	1/7	0/33
Squamous cell papilloma	0/1	0/0	0/7	4/33
Carcinoma	0/1	0/0	2/7	19/33*
Sebaceous cell adenoma	0/1	0/0	0/7	1/33
Skin and mammary				
Basal cell adenoma	2/52	0/52	1/52	10/51*
Basal cell carcinoma	1/52	1/52	0/52	4/51
SCC	0/52	1/52	1/52	5/51
Keratoacanthoma	1/52	0/52	1/52	4/51
Trichoepithelioma	0/52	1/52	2/52	8/51*
Fibrosarcoma	0/52	3/52	5/52	0/51
Fibrous histiocytoma (malignant)	0/52	0/52	1/52	1/52

*Statistically significant difference ($p \leq 0.01$), Fisher's exact test; analysis of auditory canal tumor incidence was based on assumption of n = 52 and no tumors in the controls.

[a]This group had significantly decreased survival.

[b]Incidences are for number of rats with tumors compared with number of tissues examined histologically. Auditory canal and oral cavity tissues were only examined histologically when abnormalities were observed upon macroscopic examination.

Source: Kroese et al. (2001).

Kroese et al. (2001) did not systematically investigate nonneoplastic lesions detected in rats sacrificed during the 2-year study because the focus was to identify and quantitate tumor

ED_006137A_00009570-00073

occurrence. However, incidences were reported for nonneoplastic lesions in tissues or organs in which tumors were detected (i.e., oral cavity, esophagus, forestomach, jejunum, liver, kidney, skin, mammary, and auditory canal). The reported nonneoplastic lesions associated with exposure were the forestomach basal cell hyperplasia and clear cell foci of cellular alteration in the liver. Incidences for forestomach basal cell hyperplasia in the control through high-dose groups were 1/52, 8/51, 13/51, and 2/52 for females and 2/50, 8/52, 8/52, and 0/52 for males. Incidences for hepatic clear cell foci of cellular alteration were 22/52, 33/52, 4/52, and 2/52 for females and 8/52, 22/52, 1/52, and 1/52 for males. These results indicate that the lowest dose group, 3 mg/kg-day, was a LOAEL for increased incidence of forestomach hyperplasia and hepatic histological changes in male and female Wistar rats exposed by gavage to benzo[a]pyrene for up to 104 weeks (see Table D-10). The lack of an increase in incidence of these nonneoplastic lesions in the forestomach and liver at the intermediate and high doses (compared with controls) was associated with increased incidences of forestomach and liver tumors at these dose levels. The authors of this study noted that nonneoplastic effects were not quantified in organs with tumors.

As an adjunct study to the 2-year gavage study with Wistar rats, Kroese et al. (2001) sacrificed additional rats (6/sex/group) after 4 and 5 months of exposure (0, 1, 3, 10, or 30 mg/kg-day) for analysis of DNA adduct formation in WBCs and major organs and tissues. Additional rats (6/sex/time period) were exposed to 0.1 mg/kg-day benzo[a]pyrene for 4 and 5 months for analysis of DNA adduct formation. Using the [^{32}P]-postlabeling technique, five benzo[a]pyrene-DNA adducts were identified in all of the examined tissues at 4 months (WBCs, liver, kidney, heart, lung, skin, forestomach, glandular stomach, brain). Only one of these adducts (adduct 2) was identified based on co-chromatography with a standard. This adduct, identified as 10β-(deoxyguanosin-N2-yl)-7β,8α,9α-trihydroxy-7,8,9,10 tetrahydro-benzo[a]pyrene, was the predominant adduct in all organs of female rats exposed to 10 mg/kg-day, except the liver and kidney, in which another adduct (unidentified adduct 4) was predominant. Levels of total adducts (number of benzo[a]pyrene-DNA adducts per 10^{10} nucleotides) in examined tissues (from the single 10 mg/kg-day female rat) showed the following order: liver > heart > kidney > lung > skin > forestomach ≈ WBCs > brain. Mean values for female levels of total benzo[a]pyrene-DNA adducts (number per 10^{10} nucleotides) in four organs showed the same order, regardless of exposure group: liver > lung > forestomach ≈ WBCs; comparable data for males were not reported. Mean total benzo[a]pyrene-DNA adduct levels in livers increased in both sexes from about 100 adducts per 10^{10} nucleotides at 0.1 mg/kg-day to about 70,000 adducts per 10^{10} nucleotides at 30 mg/kg-day. In summary, these results suggest that total benzo[a]pyrene-DNA adduct levels in tissues at 4 months were not independently associated with the carcinogenic responses noted after 2 years of exposure to benzo[a]pyrene. The liver showed the highest total DNA adduct levels and a carcinogenic response, but total DNA adduct levels in heart, kidney, and lung (in which no carcinogenic responses were detected) were higher than levels in forestomach and skin (in which carcinogenic responses were detected).

Groups of Sprague-Dawley rats (32/sex/dose) were fed diets delivering a daily dose of 0.15 mg benzo[a]pyrene/kg body weight every ninth day or 5 times/week (Brune et al., 1981). Other groups (32/sex/dose) were given gavage doses of 0.15 mg benzo[a]pyrene (in aqueous 1.5% caffeine solution)/kg every ninth day, every third day, or 5 times/week. The study included an untreated control group (to compare with the dietary exposed groups) and a gavage vehicle control group (each with 32 rats/sex). Rats were treated until moribundity or death occurred, with average annual doses reported in Table D-11 [mg/kg-year, calculated by Brune et al. (1981)]. The following tissues were prepared for histopathological examination: tongue, larynx, lung, heart, trachea, esophagus, stomach, small intestine, colon, rectum, spleen, liver, urinary bladder, kidney, adrenal gland, and any tissues showing tumors or other gross changes. Survival was similar among the groups, with the exception that the highest gavage-exposure group showed a decreased median time of survival (Table D-11). Significantly increased incidences of portal-of-entry tumors (forestomach, esophagus, and larynx) were observed in all of the gavage-exposed groups and in the highest dietary exposure group (Table D-11). Following dietary administration, all observed tumors were papillomas. Following gavage administration, two malignant forestomach tumors were found (one each in the mid- and high-dose groups) and the remaining tumors were benign. The data in Table D-11 show that the carcinogenic response to benzo[a]pyrene was stronger with the gavage protocol compared with dietary exposure, and that no distinct difference in response was apparent between the sexes. Tumors at distant sites (mammary gland, kidney, pancreas, lung, urinary bladder, testes, hematopoietic, and soft tissue) were not considered treatment-related as they were also observed at similar rates in the control group (data not provided). The study report did not address noncancer systemic effects.

ED_006137A_00009570-00075

Table D-11. Incidences of alimentary tract tumors in Sprague-Dawley rats chronically exposed to benzo[a]pyrene in the diet or by gavage in caffeine solution

Average annual dose (mg/kg-yr)	Estimated average daily dose[a] (mg/kg-d)	Forestomach tumors[b]	Total alimentary tract tumors[c] (larynx, esophagus, forestomach)	Median survival time (wks)
Benzo[a]pyrene by gavage in 1.5% caffeine solution				
0	0	3/64 (4.7%)	6/64 (9.4%)	102
6	0.016	12/64 (18.8%)*	13/64 (20.3%)	112
18	0.049	26/64 (40.1%)**	26/64 (40.6%)	113
39	0.107	14/64 (21.9%)**	14/64 (21.9%)	87
Benzo[a]pyrene in diet				
0	0	2/64 (3.1%)	3/64 (4.7%)	129
6	0.016	1/64 (1.6%)	3/64 (4.7%)	128
39	0.107	9/64 (14.1%)*	10/64 (15.6%)	131

*Significantly ($p < 0.1$) different from control using a modified χ^2 test that accounted for group differences in survival time.
**Significantly ($p < 0.05$) different from control using a modified χ^2 test that accounted for group differences in survival time.
[a]Average annual dose divided by 365 days.
[b]No sex-specific forestomach tumor incidence data were reported by Brune et al. (1981).
[c]Sex-specific incidences for total alimentary tract tumors were reported as follows:

Gavage (control, high dose):	Male:	6/32, 7/32, 15/32, 8/32
	Female:	0/32, 6/32, 11/32, 6/32
Diet (control, high dose):	Male:	3/32, 3/32, 8/32
	Female:	0/32, 0/32, 2/32

Source: Brune et al. (1981).

In the other modern cancer bioassay with benzo[a]pyrene, female B6C3F$_1$ mice (48/dose group) were administered benzo[a]pyrene (98.5% purity) at concentrations of 0 (acetone vehicle), 5, 25, or 100 ppm in the diet for 2 years (Beland and Culp, 1998; Culp et al., 1998). This study was designed to compare the carcinogenicity of coal tar mixtures with that of benzo[a]pyrene and it included groups of mice fed diets containing one of several concentrations of two coal tar mixtures. Benzo[a]pyrene was dissolved in acetone before mixing with the feed. Control mice received only acetone-treated feed. Female mice were chosen because they have a lower background incidence of lung tumors than male B6C3F$_1$ mice. Culp et al. (1998) reported that the average daily intakes of benzo[a]pyrene in the 25- and 100-ppm groups were 104 and 430 μg/day, but did not report the intake for the 5-ppm group. Based on the assumption that daily benzo[a]pyrene intake at 5 ppm was one-fifth of the 25-ppm intake (about 21 μg/day), average daily doses for the three

ED_006137A_00009570-00076

benzo[a]pyrene groups are estimated as 0.7, 3.3, and 16.5 mg/kg-day. Estimated doses were calculated using time-weighted average (TWA) body weights of 0.032 kg for the control, 5- and 25-ppm groups and 0.026 kg for the 100-ppm group (estimated from graphically presented data). Food consumption, body weights, morbidity, and mortality were monitored at intervals, and lung, kidneys, and liver were weighed at sacrifice. Necropsy was performed on all mice that died during the experiment or survived to the end of the study period. Limited histopathologic examinations (liver, lung, small intestine, stomach, tongue, esophagus) were performed on all control and high-dose mice and on all mice that died during the experimental period, regardless of treatment group. In addition, all gross lesions found in mice of the low- and mid-dose groups were examined histopathologically.

None of the mice administered 100 ppm benzo[a]pyrene survived to the end of the study, and morbidity/mortality was 100% by week 78. Decreased survival was also observed at 25 ppm with only 27% survival at 104 weeks, compared with 56 and 60%, in the 5-ppm and control groups, respectively. In the mid- and high-dose groups, 60% of mice were alive at about 90 and 60 weeks, respectively. Early deaths in exposed mice were attributed to tumor formation rather than other causes of systemic toxicity. Food consumption was not statistically different in benzo[a]pyrene-exposed and control mice. Body weights of mice fed 100 ppm were similar to those of the other treated and control groups up to week 46, and after approximately 52 weeks, body weights were reduced in 100-ppm mice compared with controls. Body weights for the 5- and 25-ppm groups were similar to controls throughout the treatment period. Compared with the control group, no differences in liver, kidney, or lung weights were evident in any of the treated groups (other organ weights were not measured).

Papillomas and/or carcinomas of the forestomach, esophagus, tongue, and larynx at elevated incidences occurred in groups of mice exposed to 25 or 100 ppm, but no exposure-related tumors occurred in the liver or lung (Beland and Culp, 1998; Culp et al., 1998). The forestomach was the most sensitive tissue, demonstrated the highest tumor incidence among the examined tissues, and was the only tissue with an elevated incidence of tumors at 25 ppm (Table D-12). In addition, most of the forestomach tumors in the exposed groups were carcinomas, as 1, 31, and 45 mice had forestomach carcinomas in the 5-, 25-, and 100-ppm groups, respectively. Nonneoplastic lesions were also found in the forestomach at significantly ($p < 0.05$) elevated incidences: hyperplasia at ≥25 ppm and hyperkeratosis at ≥25 ppm (Table D-12). The esophagus was the only other examined tissue showing elevated incidence of a nonneoplastic lesion (basal cell hyperplasia, see Table D-12). Tumors (papillomas and carcinomas) were also significantly elevated in the esophagus and tongue at 100 ppm (Table D-12). Esophageal carcinomas were detected in 1 mouse at 25 ppm and 11 mice at 100 ppm. Tongue carcinomas were detected in seven 100-ppm mice; the remaining tongue tumors were papillomas. Although incidences of tumors of the larynx were not significantly elevated in any of the exposed groups, a significant dose-related trend was apparent (Table D-12).

Table D-12. Incidence of nonneoplastic and neoplastic lesions in female B6C3F$_1$ mice fed benzo[a]pyrene in the diet for up to 2 years

Tissue and lesion	Incidence (%)			
	Benzo[a]pyrene concentration (ppm) in diet			
	0	5	25	100
	Average daily doses (mg/kg-d)			
	0	0.7	3.3	16.5
Liver (hepatocellular adenoma)	2/48 (2)	7/48 (15)	5/47 (11)	0/45 (0)
Lung (alveolar/bronchiolar adenoma and/or carcinoma)	5/48 (10)	0/48 (0)	4/45 (9)	0/48 (0)
Forestomach (papilloma and/or carcinoma)	1/48[a] (2)	3/47 (6)	36/46* (78)	46/47* (98)
Forestomach (hyperplasia)	13/48[a] (27)	23/47 (49)	33/46* (72)	37/47* (79)
Forestomach (hyperkeratosis)	13/48[a] (27)	22/47 (47)	33/46* (72)	38/47* (81)
Esophagus (papilloma and/or carcinoma)	0/48[a] (0)	0/48 (0)	2/45 (0)	27/46* (59)
Esophagus (basal cell hyperplasia)	1/48[a] (2)	0/48 (0)	5/45 (11)	30/46* (65)
Tongue (papilloma and/or carcinoma)	0/49[a] (0)	0/48 (0)	2/46 (4)	23/48* (48)
Larynx (papilloma and/or carcinoma)	0/35[a] (0)	0/35 (0)	3/34 (9)	5/38 (13)

*Significantly different from control incidence ($p < 0.05$); using a modified Bonferonni procedure for multiple comparisons to the same control.
[a]Significant ($p < 0.05$) dose-related trend calculated for incidences of these lesions.

Sources: Beland and Culp (1998); Culp et al. (1998).

Neal and Rigdon (1967) fed benzo[a]pyrene (purity not reported) at concentrations of 0, 1, 10, 20, 30, 40, 45, 50, 100, and 250 ppm to male and female CFW-Swiss mice in the diet. Corresponding doses (in mg/kg-day) were calculated[1] as 0, 0.2, 1.8, 3.6, 5.3, 7.1, 8, 8.9, 17.8, and 44.4 mg/kg-day. The age of the mice ranged from 17 to 180 days old and the treatment time was from 1 to 197 days; the size of the treated groups ranged from 9 to 73. There were 289 mice (number of mice/sex not stated) in the control group. No forestomach tumors were reported at 0, 0.2, or 1.8 mg/kg-day. The incidences of forestomach tumors at 20, 30, 40, 45, 50, 100, and 250 ppm dose groups (3.6, 5.3, 7.1, 8, 8.9, 17.8, and 44.4 mg/kg-day) were 1/23, 0/37, 1/40, 4/40, 23/34, 19/23, and 66/73, respectively.

[1]Calculation: mg/kg-day = (ppm in feed × kg food/day)/kg body weight. Reference food consumption rates of 0.0062 kg/day (males) and 0.0056 kg/day (females) and reference body weights of 0.0356 kg (males) and 0.0305 kg (females) were used (U.S. EPA, 1988) and resulting doses were averaged between males and females.

ED_006137A_00009570-00078

Other Oral Exposure Cancer Bioassays in Mice

Numerous other oral exposure cancer bioassays in mice have limitations that restrict their usefulness for characterizing dose-response relationships between chronic-duration oral exposure to benzo[a]pyrene and noncancer effects or cancer, but collectively, they provide strong evidence that oral exposure to benzo[a]pyrene can cause portal-of-entry site tumors (see Table D-13 for references).

Table D-13. Other oral exposure cancer bioassays in mice

Species/strain	Exposure	Results	Comments	Reference
Rat/Sprague-Dawley	Groups of rats (32/sex/dose) were fed diets delivering a daily dose of 0.15 mg benzo[a]pyrene/kg body weight every 9th d or 5 times/wk (Brune et al., 1981). Other groups (32/sex/dose) were given gavage doses of 0.15 mg benzo[a]pyrene (in aqueous 1.5% caffeine solution)/kg every 9th d, every 3rd d, or 5 times/wk.	Larynx, esophagus, and forestomach tumors Dose (gavage) 0 6/64 0.016 13/64 0.049 26/64 0.107 14/64 Dose (diet) 0 3/64 0.016 3/64 0.107 10/64	Doses are annual averages. Nonstandard treatment protocol involved animals being treated for ≤5 d/wk; relatively high control incidence compared to other gavage studies.	Brune et al. (1981)
Mouse/HaICR	Groups of 12–20 mice (10 wks old) were fed benzo[a]pyrene in the diet (0.1, 0.3, or 1.0 mg/g diet) for 12–20 wks. Estimated doses were 14.3, 42.0, or 192 mg/kg-d.	Incidence with forestomach tumors: Low, 11/20 (18 wks) Mid, 13/19 (20 wks) High, 12/12 (12 wks)	Less-than-lifetime exposure duration; only stomachs were examined for tumors; tumors found only in forestomach.	Wattenberg (1972)
Mouse/HaICR	Groups of nine mice (9 wks old) were fed benzo[a]pyrene in the diet (0, 0.2, or 0.3 mg/g diet) for 12 wks and sacrificed. Estimated doses were 0, 27.3, or 41 mg/kg-d.	Incidence with forestomach tumors: Control, 0/9 Low, 6/9 High, 9/9	Less-than-lifetime exposure duration; glandular stomach, lung, and livers from control and exposed mice showed no tumors.	Triolo et al. (1977)

Species/strain	Exposure	Results	Comments	Reference
Mouse/HaICR	20 mice (9 wks old) were given benzo[a]pyrene in the diet (0.3 mg benzo[a]pyrene/g diet) for 6 wks and sacrificed after 20 wks in the study.	8/20 exposed mice had forestomach tumors	Less-than-lifetime exposure duration; only stomachs were examined for tumors; tumors found only in forestomach; no nonexposed controls were mentioned.	Wattenberg (1974)
Mouse/CD-1	20 female mice (9 wks old) were given 1 mg benzo[a]pyrene by gavage 2 times/wk for 4 wks and observed for 19 wks. Estimated dose was 33 mg/kg-d, using an average body weight of 0.030 kg from reported data.	Incidence with forestomach tumors: Exposed, 17/20 (85%) Controls, 0/24	Less-than-lifetime exposure duration; only stomach were examined for tumors; tumors found only in forestomach.	El-Bayoumy (1985)
Mouse/BALB	25 mice (8 wks old) were given 0.5 mg benzo[a]pyrene 2 times/wk for 15 wks.	5/25 mice had squamous carcinomas of the forestomach; tumors were detected 28–65 wks after treatment	Less-than-lifetime exposure duration; the following details were not reported: inclusion of controls, methods for detecting tumors, and body weight data.	Biancifiori et al. (1967)
Mouse/C3H	19 mice (about 3 mo old) were given 0.3 mL of 0.5% benzo[a]pyrene in polyethylene glycol-400 by gavage, once/d for 3 d.	By 30 wks, 7/10 mice had papillomas; no carcinomas were evident	Less-than-lifetime exposure duration.	Berenblum and Haran (1955)

ED_006137A_00009570-00080

Species/strain	Exposure	Results	Comments	Reference
Mouse/albino	Groups of 17–18 mice were given single doses of benzo[a]pyrene and allowed to survive until terminal sacrifice at 569 d.	Incidence of mice (that survived at least to 60 d) with forestomach papillomas: Incidence (Experiment 1) Dose (µg) (Experiment 2) Control 0/17 0/18 12.5 3/17 2/18 50 0/17 1/17 200 8/17 Not evaluated	Less-than-lifetime exposure duration; GI tract examined for tumors with hand lens; body weight data not reported.	Field and Roe (1965)
Mouse/albino	Groups of about 160 female mice (70 d of age; strain unknown) were given 0 or 8 mg benzo[a]pyrene mixed in the diet over a period of 14 mo.	Gastric tumors were observed at the following incidence: Control, 0/158 8 mg benzo[a]pyrene total, 13/160	Close to lifetime exposure duration; daily dose levels and methods of detecting tumors were not clearly reported.	Chouroulinkov et al. (1967)
Mouse/CFW	Groups of mice (mixed sex) were fed benzo[a]pyrene in the diet (dissolved in benzene and mixed with diet) at 0, 1, 10, 20, 30, 40, 45, 50, 100, or 250 ppm in the diet.	ppm / Exposure (d) / Fore-stomach tumor incidence 1 110 0/25 10 110 0/24 20 110 1/23 30 110 0/37 40 110 1/40 45 110 4/40 50 152 24/34 100 110 19/23 250 118 66/73	Less-than-lifetime exposure duration; no vehicle control group; animals ranged from 3 wks to 6 mo old at the start of dosing; only alimentary tract was examined for tumors.	Neal and Rigdon (1967)
Mouse/Swiss albino	Groups of mice (9–14 wks old) were given single doses of 0 or 0.05 mg benzo[a]pyrene in polyethylene glycol-400 by gavage. Surviving mice were killed at 18 mo of age and examined for macroscopic tumors.	Forestomach tumor incidence: Dose (µg) / Carcinoma / papilloma 0 0/65 2/65 50 1/61 20/61	Less-than-lifetime duration of exposure; exposure-related tumors only found in forestomach.	Roe et al. (1970)

ED_006137A_00009570-00081

Species/strain	Exposure	Results	Comments	Reference
Mouse/ICR	Groups of 20 or 24 mice (71 d old) were given 1.5 mg benzo[a]pyrene by gavage 2 times/wk for 4 wks; terminal sacrifice was at 211 d of age. Estimated dose was about 50 mg benzo[a]pyrene/kg, using an average body weight of 0.03 kg during exposure from reported data.	Incidence of mice with forestomach neoplasms Experiment 1, 23/24 Experiment 2, 19/20	Less-than-lifetime duration of exposure; only stomachs were examined for tumors; tumors found only in forestomach; nonexposed controls were not mentioned.	Benjamin et al. (1988)
Mouse/white	Groups of 16–30 mice were given benzo[a]pyrene in triethylene glycol (0.001–10 mg) weekly for 10 wks and observed until 19 mo.	Tumors in stomach antrum Dose (mg) — Carcinoma papilloma 0.001 — 0/16 0/16 0.01 — 0/26 2/26 0.1 — 0/24 5/24 1.0 — 11/30 12/30 10 — 16/27 7/27	Less-than-lifetime exposure duration.	Fedorenko and Yansheva (1967); as cited in U.S. EPA (1991a)
Mouse/A/HeJ	12 female mice (9 wks old) were given standard diet for 25 d, and 3 mg benzo[a]pyrene by gastric intubation on d 7 and 21 of the study. Mice were killed at 31 wks of age and examined for lung tumors.	12/12 exposed mice had lung tumors	Less-than-lifetime exposure duration; only lungs examined for tumors; no nonexposed controls were mentioned.	Wattenberg (1974)
Mouse/A/J	Groups of female mice were fed benzo[a]pyrene in the diet at 0, 16, or 98 ppm for 260 d. Average intakes of benzo[a]pyrene were 0, 40.6, and 256.6 µg/mouse/d. Estimated doses were 0, 1.6, and 9.9 mg/kg-d using a chronic reference body weight value of 0.026 kg (U.S. EPA, 1988).	Incidence of mice surviving to 260 d: Lung tumors Control, 4/21 16 ppm, 9/25 98 ppm, 14/27 Forestomach tumors Control, 0/21 16 ppm, 5/25 98 ppm, 27/27	Close to lifetime exposure duration; A/J strain of mice particularly sensitive to chemically induced cancer; only lungs and stomachs were examined for tumors.	Weyand et al. (1995)

ED_006137A_00009570-00082

Species/strain	Exposure	Results	Comments	Reference
Mouse/A/J	Groups 40 female mice (8 wks old) were given 0 or 0.25 mg benzo[a]pyrene (in 2% emulphor) by gavage 3 times/wk for 8 wks. Mice were killed at 9 mo of age and examined for lung or forestomach tumors.	Incidence for mice surviving at 9 mo of age: Lung tumors Control, 11/38 Exposed, 22/36 Forestomach tumors Control, 0/38 Exposed, 33/36	Less-than-lifetime duration of exposure; only lungs and GI tract were examined for tumors.	Robinson et al. (1987)

D.4.2. Inhalation Studies

Short-Term and Subchronic Studies

Wolff et al. (1989) exposed groups of 40 male and 40 female F344/Crl rats, via nose only, to 7.5 mg benzo[a]pyrene/m^3 for 2 hours/day, 5 days/week for 4 weeks (corresponding to a TWA of 0.45 mg/m^3). Rats were 10–11 weeks old at the beginning of the experiment. Benzo[a]pyrene (>98% pure) aerosols were formed by heating and then condensing the vaporized benzo[a]pyrene. The particle mass median aerodynamic diameter (MMAD) was 0.21 μm. Subgroups of these animals (six/sex/dose) were exposed for 4 days or 6 months after the end of the 4-week exposure to radiolabeled aluminosilicate particles. Lung injury was assessed by analyzing clearance of radiolabeled aluminosilicate particles and via histopathologic evaluations. Body and lung weights, measured in subgroups from 1 day to 12 months after the exposure did not differ between controls and treated animals. Radiolabeled particle clearance did not differ between the control and treated groups, and there were no significant lung lesions. This study identified a NOAEL for lung effects of 0.45 mg/m^3 for a short-term exposure.

Chronic Studies and Cancer Bioassays

Thyssen et al. (1981) conducted an inhalation study in which male Syrian golden hamsters were exposed to benzo[a]pyrene for their natural lifetime. Groups of 24 animals (8 weeks old) were exposed by nose-only inhalation to NaCl aerosols (controls; 240 μg NaCl/m^3) or benzo[a]pyrene condensed onto NaCl aerosols at three target concentrations of 2, 10, or 50 mg benzo[a]pyrene/m^3 for 3–4.5 hours/day, 5 days/week for 1–41 weeks, followed by 3 hours/day, 7 days/week for the remainder of study (until hamsters died or became moribund). Thyssen et al. (1981) reported average measured benzo[a]pyrene concentrations to be 0, 2.2, 9.5, or 46.5 mg/m^3. More than 99% of the particles were between 0.2 and 0.5 μm in diameter, and over 80% had diameters between 0.2 and 0.3 μm. The particle analysis of the aerosols was not reported to modern standards (MMAD and geometric SD were not reported). Final overall group sizes were larger as animals dying during the first 12 months of the study were replaced.

Review of the individual animal data (including individual animal pathology reports, time-to-death data, and exposure chamber monitoring data) provided by Thyssen et al. to EPA (U.S. EPA, 1990) revealed several discrepancies in the reported exposure protocol. The actual exposure

ED_006137A_00009570-00083

protocol was as follows: 4.5 hours/day, 5 days/week on weeks 1–12; 3 hours/day, 5 days/week on weeks 13–29; 3.7 hours/day, 5 days/week on week 30; 3 hours/day, 5 days/week on weeks 31–41; and 3 hours/day, 7 days/week for the reminder of the experiment.

Analytical chamber monitoring data were generally recorded about once or twice per week, with some exceptions ranging from no measurements for a 3-week period to as many as five measurements in 1 week. Individual measurements (in mg/m^3) were 0.2–4.52, 1.16–19.2, and 0.96–118.6 in the 2, 10, and 50 mg/m^3 target concentration groups, respectively. Overall, weekly average exposure concentrations varied two- to fivefold from the overall average for each group over the course of the study, with no particular trends over time (data not shown). The 95% confidence limits for the average exposure level over time in each group varied within 4–7% of the averages. Because some animals were started at different times and the exposure protocol changed over time, each individual animal had an exposure history somewhat different than others in the same exposure group. In order to address this variability, U.S. EPA (1990) used the individual animal data and the chamber monitoring data to calculate a lifetime average continuous exposure for each individual hamster. Group averages of these individual TWA concentrations were 0, 0.25, 1.01, and 4.29 mg/m^3 for the control through high-exposure groups.

Statistical analysis of outcomes was not reported by Thyssen et al. (1981). Survival was similar in the control, low-, and mid-exposure groups, but was decreased about 40% in the high-exposure group. Average survival times in the control, low-, mid-, and high-exposure groups were 96.4 ± 27.6, 95.2 ± 29.1, 96.4 ± 27.8, and 59.5 ± 15.2 weeks, respectively. After the 60th week, body weights decreased and mortality increased steeply in the highest exposure group. Histologic examination of organs[2] revealed an exposure-related increase in the mid- and high-exposure groups of benign and malignant tumors of the upper respiratory tract, including the nasal cavity, larynx, and trachea, and of the upper digestive tract, including the pharynx, esophagus, and forestomach (Table D-13). No lung tumors were observed. Tumors were detected in other sites, but none of these appeared to be related to exposure.

[2]Thyssen et al. (1981) did not report a complete list of organs examined histologically. The individual animal pathology reports documented examination of brain, pituitary, eyes, salivary gland, larynx, pharynx, thyroid, trachea, esophagus, thymus, heart lung, stomach, liver, spleen, pancreas, duodenum, jejunum and ileum, cecum, colon and rectum, kidneys, adrenals, bladder, testicle, epididymides, prostate, submandibular and mesenterial lymph nodes, aorta, sternum, bone, and muscle.

ED_006137A_00009570-00084

Table D-14. Tumor incidence in the respiratory tract and upper digestive tract for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime—Thyssen et al. (1981)[a]

Target exposure concentration and (lifetime average continuous exposure)[b], mg/m^3	Papillomas, polyps, papillary polyps, or carcinomas (total malignant tumors)						
	Respiratory tract			Upper digestive tract			Incidence of pharynx or respiratory tract tumors[c]
	Larynx	Trachea	Nasal cavity	Pharynx	Esophagus	Forestomach	
0	0/23[d]	0/24	0/23	0/21	0/24	0/24	0/21[e]
2 (0.25)	0/19	0/20	0/20	0/18	0/20	0/20	0/18
10 (1.01)	11/23 (8)[f]	2/23 (0)	4/23 (1)	9/19 (7)	0/23 (0)	1/23 (1)	17/22 (11)[f]
50 (4.29)	11/23 (8)	3/23 (1)	1/23 (0)	18/22 (17)	2/23 (0)	2/23 (0)	18/22 (17)

[a]Histopathology incidence data from the raw data obtained from the Thyssen study (Clement Associates, 1990), adjusted to show animals only on study long enough to be at risk of tumor development: at least 1 year (0 2, or 10 mg/m^3 groups) or until the first tumor occurrence (week 40 in the 50 mg/m^3 group). See Table E-17 for a list of all animals with histopathology results.
[b]See text.
[c]Excludes animals with unexamined tissues, unless a tumor was diagnosed in the tissues that were examined.
[d]Fractions represent the number of animals diagnosed with at least one of the specified tumors, among the animals examined for each tissue.
[e]Statistically significant trends by Cochran-Armitage trend test, conducted by EPA: all tumors: $p < 0.0001$, malignant tumors only: $p < 0.0001$.
[f]Includes one animal with an in situ carcinoma in the larynx.

The tumor types observed in the upper respiratory and upper digestive tract were very similar, characterized as polyps, papillomas, papillary polyps, and squamous carcinomas, with the exceptions of one in situ carcinoma and one adenocarcinoma (both in the mid-exposure group), reflecting similar cell types. Consequently, evaluation of the overall cancer hazard included consideration of the joint incidence of these tumor types. The pharynx and larynx (including the epiglottis), clearly the main cancer targets, can be difficult to distinguish given their close proximity. There were a few instances of nasal cavity or trachea tumors among animals without larynx or pharynx tumors. Tumors of the upper digestive tract may have been a consequence of mucociliary particle clearance (Thyssen et al., 1981), but the tumors in the esophagus and forestomach observed in the mid- and high-exposure groups all occurred in animals that also had pharynx or respiratory tract tumors. Overall, there were increasing trends in tumor incidence with increasing exposure, both for the combined incidence of benign or malignant tumors, or for only malignant tumors (Table D-14), and earlier occurrence of tumors with increasing exposure levels. Several studies have investigated the carcinogenicity of benzo[a]pyrene in hamsters exposed by intratracheal instillation. Single-dose studies verified that benzo[a]pyrene is tumorigenic, but do

ED_006137A_00009570-00085

not provide data useful for characterizing dose-response relationships because of their design (Kobayashi, 1975; Renzik-Schüller and Mohr, 1974; Henry et al., 1973; Mohr, 1971; Saffiotti et al., 1968; Gross et al., 1965; Herrold and Dunham, 1962). One multiple-dose study, which utilized very low doses (0.005, 0.02, and 0.04 mg once every 2 weeks), failed to find any tumorigenic response (Kunstler, 1983). Tumorigenic responses (mostly in the respiratory tract) were found at higher dosage levels (0.25–2 mg benzo[a]pyrene once per week for 30–52 weeks) in four multiple-dose studies (Feron and Kruysse, 1978; Ketkar et al., 1978; Feron et al., 1973; Saffiotti et al., 1972). These studies identify the respiratory tract as a cancer target with exposure to benzo[a]pyrene by intratracheal instillation and provide supporting evidence for the carcinogenicity of benzo[a]pyrene at portal-of-entry sites.

D.4.3. Dermal studies

Skin-Tumor Initiation-Promotion Assays

Results from numerous studies indicate that acute dermal exposure to benzo[a]pyrene induces skin tumors in mice when followed by repeated exposure to a potent tumor promoter (Weyand et al., 1992; Cavalieri et al., 1991; Rice et al., 1985; El-Bayoumy et al., 1982; Lavoie et al., 1982; Raveh et al., 1982; Cavalieri et al., 1981; Slaga et al., 1980; Wood et al., 1980; Slaga et al., 1978; Hoffmann et al., 1972). The typical exposure protocol in these studies involved the application of a single dose of benzo[a]pyrene (typically ≥20 nmol per mouse) to dorsal skin of mice followed by repeated exposure to a potent tumor promoter, such as 12-O-tetradecanoylphorbol-13-acetate (TPA).

Carcinogenicity Bioassays

Repeated application of benzo[a]pyrene to skin (in the absence of exogenous promoters) has been variously demonstrated to induce skin tumors in mice, rats, rabbits, and guinea pigs (IARC, 2010; IPCS, 1998; ATSDR, 1995; IARC, 1983, 1973). Mice have been most extensively studied, presumably because of early evidence that they may be more sensitive than other animal species, but comprehensive comparison of species differences in sensitivity to lifetime dermal exposure are not available. Early studies of complete dermal carcinogenicity in other species (rats, hamsters, guinea pigs, and rabbits) have several limitations that make them not useful for dose-response analysis [see IARC (1973) for descriptions of studies]. The limitations in these studies include inadequate reporting of the amount of benzo[a]pyrene applied, use of the carcinogen benzene as a vehicle, and less-than-lifetime exposure duration.

This section discusses complete carcinogenicity bioassays in mice that provide the best available dose-response data for skin tumors caused by repeated dermal exposure to benzo[a]pyrene (Sivak et al., 1997; Higginbotham et al., 1993; Albert et al., 1991; Grimmer et al., 1984; Habs et al., 1984; Grimmer et al., 1983; Habs et al., 1980; Schmähl et al., 1977; Schmidt et al., 1973; Roe et al., 1970; Poel, 1963, 1959). Early studies of benzo[a]pyrene complete carcinogenicity

ED_006137A_00009570-00086

in mouse skin (Wynder and Hoffmann, 1959; Wynder et al., 1957) are not further described herein, because the investigators applied solutions of benzo[a]pyrene at varying concentrations on the skin, but did not report volumes applied. As such, applied doses in these studies cannot be determined. Other complete carcinogenicity mouse skin tumor bioassays with benzo[a]pyrene are available, but these are not described further in this review, because: (1) they only included one benzo[a]pyrene dose level (e.g., Emmett et al., 1981) or only dose levels inducing 90–100% incidence of mice with tumors (e.g., Wilson and Holland, 1988; Warshawsky and Barkley, 1987) and thus provide no information about the shape of the dose-response relationship; (2) they used a 1-time/week (e.g., Nesnow et al., 1983) or 1-time every 2 weeks (e.g., Levin et al., 1977) exposure protocol, which is less useful for extrapolating to daily human exposure; or (3) they used a vehicle demonstrated to interact with or enhance benzo[a]pyrene carcinogenicity (Bingham and Falk, 1969).

Poel (1959) applied benzo[a]pyrene in toluene to shaved interscapular skin of groups of 13–56 male C57L mice at doses of 0, 0.15, 0.38, 0.75, 3.8, 19, 94, 188, 376, or 752 μg, 3 times/week for up to 103 weeks or until the appearance of a tumor by gross examination (3 times weekly). Some organs (not further specified) and interscapular skin in sacrificed mice were examined histologically. With increasing dose level, the incidence of mice with skin tumors increased and the time of tumor appearance decreased (see Table D-15). Doses >3.8 μg were associated with 100% mortality after increasingly shorter exposure periods, none greater than 44 weeks. Poel (1959) did not mention the appearance of exposure-related tumors in tissues other than interscapular skin.

Table D-15. Skin tumor incidence and time of appearance in male C57L mice dermally exposed to benzo[a]pyrene for up to 103 weeks

Dose (μg)[a]	Incidence of mice with gross skin tumors	Time o first tumor appearance (wks)	Incidence of mice with epidermoid carcinoma[b]	Length of exposure period (wks)
0 (toluene)	0/33 (0%)	–	0/33 (0%)	92
0.15	5/55 (9%)	42–44[c]	0/55 (0%)	98
0.38	11/55 (20%)	24	2/55 (4%)	103
0.75	7/56 (13%)	36	4/56 (7%)	94
3.8	41/49 (84%)	21–25	32/49 (65%)	82
19	38/38 (100%)	11–21	37/38 (97%)	25–44[c]
94	35/35 (100%)	8–19	35/35 (100%)	22–43
188	12/14 (86%)	9–18	10/14 (71%)	20–35
376	14/14 (100%)	4–15	12/14 (86%)	19–35
752	13/13 (100%)	5–13	13/13 (100%)	19–30

[a]Indicated doses were applied to interscapular skin 3 times/week for up to 103 weeks or until time of appearance of a grossly detected skin tumor.
[b]Carcinomas were histologically confirmed.
[c]Ranges reflect differing information in Tables 4 and 6 of Poel (1959).

Source: Poel (1959).

Poel (1963) applied benzo[a]pyrene in a toluene vehicle to shaved interscapular skin of groups of 14–25 male SWR, C3HeB, or A/He mice 3 times/week at doses of 0, 0.15, 0.38, 0.75, 3.8, 19.0, 94.0, or 470 μg benzo[a]pyrene per application, until mice died or a skin tumor was observed. Time ranges for tumor observations were provided, but not times of death for mice without tumors, so it was not possible to evaluate differential mortality among all dose groups or the length of exposure for mice without tumors. With increasing dose level, the incidence of mice with skin tumors increased and the time of tumor appearance decreased (Table D-16). The lowest dose level did not induce an increased incidence of mice with skin tumors in any strain, but strain differences in susceptibility were evident at higher dose levels. SWR and C3HeB mice showed skin tumors at doses ≥0.38 μg benzo[a]pyrene, whereas AH/e mice showed tumors at doses ≥19 μg benzo[a]pyrene (Table D-16). Except for metastases of the skin tumors to lymph nodes and lung, Poel (1963) did not mention the appearance of exposure-related tumors in tissues other than interscapular skin.

ED_006137A_00009570-00088

Table D-16. Skin tumor incidence and time of appearance in male SWR, C3HeB, and A/He mice dermally exposed to benzo[a]pyrene for life or until a skin tumor was detected

	SWR Mice		C3HeB Mice		A/He Mice	
Dose (μg)[a]	Tumor incidence[b]	Time of tumor appearance (wks)	Tumor incidence[b]	Time of tumor appearance (wks)	Tumor incidence[b]	Time of tumor appearance (wks)
0 (toluene)	0/20 (0%)	–	0/17 (0%)	–	0/17 (0%)	–
0.15	0/25 (0%)	–	0/19 (0%)	–	0/18 (0%)	–
0.38	2/22 (9%)	55	3/17 (18%)	81–93	0/19 (0%)	–
0.75	15/18 (83%)	25–72	4/17 (24%)	51–93	0/17 (0%)	–
3.8	12/17 (70%)	25–51	11/18 (61%)	35–73	0/17 (0%)	–
19.0	16/16 (100%)	12–28	17/17 (100%)	13–32	21/23 (91%)	21–40
94.0	16/17 (94%)	9–17	18/18 (100%)	10–22	11/16 (69%)	14–31
470.0	14/14 (100%)	5–11	17/17 (100%)	4–19	17/17 (100%)	4–21

[a]Indicated doses were applied 3 times/week for life or until a skin tumor was detected. Mice were 10–14 weeks old at initial exposure.
[b]Incidence of mice exposed ≥10 weeks with a skin tumor.

Source: Poel (1963).

Roe et al. (1970) treated groups of 50 female Swiss mice with 0 (acetone vehicle), 0.1, 0.3, 1, 3, or 9 μg benzo[a]pyrene applied to the shaved dorsal skin 3 times/week for up to 93 weeks; all surviving mice were killed and examined for tumors during the following 3 weeks. The dorsal skin of an additional control group was shaved periodically but was not treated with the vehicle. Mice were examined every 2 weeks for the development of skin tumors at the site of application. Histologic examinations included: (1) all skin tumors thought to be possibly malignant; (2) lesions of other tissues thought to be neoplastic; and (3) limited nonneoplastic lesions in other tissues. As shown in Table D-17, markedly elevated incidences of mice with skin tumors were only found in the two highest dose groups (3 and 9 μg), compared with no skin tumors in the control groups. Malignant skin tumors (defined as tumors with invasion or penetration of the panniculus carnosus muscle) were detected in 4/41 and 31/40 mice in the 3- and 9-μg groups, respectively, surviving to at least 300 days. Malignant lymphomas were detected in all groups, but the numbers of cases were not elevated compared with expected numbers after adjustment for survival differences. Lung tumors were likewise detected in control and exposed groups at incidences that were not statistically different.

Table D-17. Tumor incidence in female Swiss mice dermally exposed to benzo[a]pyrene for up to 93 weeks

Dose (μg)[a]	Cumulative number of mice with skin tumor/survivors						Skin tumor incidence[b]	Malignant lymphoma incidence[c]	Lung tumor incidence[c]
	200 d	300 d	400 d	500 d	600 d	700 d			
No treatment	0/48	0/43	0/40	0/31	0/21	0/0	0/43 (0%)	19/44 (43%)	12/41 (29%)
Acetone	0/49	0/47	0/45	0/37	0/23	0/0	0/47 (0%)	12/47 (26%)	10/46 (22%)
0.1	0/45	1/42	1/35	1/31	1/22	1/0	1/42 (2%)	11/43 (26%)	10/40 (25%)
0.3	0/46	0/42	0/37	0/30	0/19	0/0	0/42 (0%)	10/43 (23%)	13/43 (30%)
1	0/48	0/43	0/37	1/30	1/18	1/0	1/43 (2%)	16/44 (36%)	15/43 (35%)
3	0/47	0/41	1/37	7/35	8/24	8/0	8/41 (20%)	23/42 (55%)	12/40 (30%)
9	0/46	4/40	21/32	28/21	33/8	34/0	34/46 (74%)	9/40 (23%)	5/40 (13%)

[a]Doses were applied 3 times/week for up to 93 weeks to shaved dorsal skin.
[b]Numerator: number of mice detected with a skin tumor. Denominator: number of mice surviving to 300 days for all groups except the highest dose group. For the highest dose group (in which skin tumors were first detected between 200 and 300 days), the number of mice surviving to 200 days was used as the denominator.
[c]Numerator: number of mice detected with specified tumor. Denominator: number of mice surviving to 300 days unless a tumor was detected earlier, in which case, the number dying before 300 days without a tumor was subtracted from the number of animals reported to have been examined.

Source: Roe et al. (1970).

Schmidt et al. (1973) dermally administered benzo[a]pyrene in acetone to female NMRI mice (100/group) and female Swiss mice. Benzo[a]pyrene was applied to the shaved dorsal skin twice weekly at doses of 0, 0.05, 0.2, 0.8, or 2 μg until spontaneous death occurred or until an advanced carcinoma was observed. Skin carcinomas were identified by the presence of crater-shaped ulcerations, infiltrative growth, and the beginning of physical wasting (i.e., cachexia). Necropsy was performed for all animals, and histopathological examination of the dermal site of application and any other tissues with gross abnormalities was conducted. Skin tumors were observed at the two highest doses in both strains of female mice (see Table D-18), with induction periods of 53.0 and 75.8 weeks for the 0.8 and 2.0 μg NMRI mice and 57.8 and 60.7 weeks for the Swiss mice, respectively. The authors indicated that the latency period for tumor formation was highly variable, and significant differences among exposure groups could not be identified, but no further timing information was available, including overall survival. Carcinoma was the primary tumor type seen after lifetime application of benzo[a]pyrene to mouse skin.

ED_006137A_00009570-00090

Table D-18. Skin tumor incidence in female NMRI and Swiss mice dermally exposed to benzo[a]pyrene

Dose (μg)[a]	Skin tumor incidence (all types)	Incidence of papilloma	Incidence of carcinoma
Female NMRI mice			
0 (acetone)	0/100 (0%)	0/100 (0%)	0/100 (0%)
0.05	0/100 (0%)	0/100 (0%)	0/100 (0%)
0.2	0/100 (0%)	0/100 (0%)	0/100 (0%)
0.8	2/100 (2%)	0/100 (0%)	2/100 (2%)
2	30/100 (30%)	2/100 (2%)	28/100 (28%)
Female Swiss mice			
0 (acetone)	0/80 (0%)	0/80 (0%)	0/80 (0%)
0.05	0/80 (0%)	0/80 (0%)	0/80 (0%)
0.2	0/80 (0%)	0/80 (0%)	0/80 (0%)
0.8	5/80 (6%)	0/80 (0%)	5/80 (6%)
2	45/80 (56%)	3/80 (4%)	42/80 (52%)

[a]Mice were exposed until natural death or until they developed a carcinoma at the site of application; indicated doses were applied 2 times/week to shaved skin of the back.

Source: Schmidt et al. (1973).

Schmähl et al. (1977) applied benzo[a]pyrene 2 times/week to the shaved dorsal skin of female NMRI mice (100/group) at doses of 0, 1, 1.7, or 3 μg in 20 μL acetone. The authors reported that animals were observed until natural death or until they developed a carcinoma at the site of application. The effective numbers of animals at risk was about 80% of the nominal group sizes, which the authors attributed to autolysis; no information was provided concerning when tumors appeared in the relevant groups, how long treatment lasted in each group, or any times of death. Necropsy was performed on all mice and the skin of the back, as well as any organs that exhibited macroscopic changes, were examined histopathologically. The incidence of all types of skin tumors was increased in a dose-related manner compared to controls (see Table D-19). Carcinoma was the primary tumor type observed following chronic dermal exposure to benzo[a]pyrene, and skin papillomas occurred infrequently. Dermal sarcoma was not observed.

ED_006137A_00009570-00091

Table D-19. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene

Dose (μg)[a]	Skin tumor incidence (all types)	Incidence of papilloma	Incidence of carcinoma
0	1/81 (1%)[b]	0/81 (0%)	0/81 (0%)
1	11/77 (14%)	1/77 (1%)	10/77 (13%)
1.7	25/88 (28%)	0/88 (0%)	25/88 (28%)
3	45/81 (56%)	2/81 (3%)	43/81 (53%)

[a]Mice were exposed until natural death or until they developed a carcinoma at the site of application; indicated doses were applied 2 times/week to shaved skin of the back.
[b]Sarcoma.

Source: Schmähl et al. (1977).

Habs et al. (1980) applied benzo[a]pyrene to the shaved interscapular skin of female NMRI mice (40/group) at doses of 0, 1.7, 2.8, or 4.6 μg in 20 μL acetone twice weekly, from 10 weeks of age until natural death or gross observation of infiltrative tumor growth. Latency of tumors, either as time of first appearance or as average time of appearance of tumors, was not reported. Necropsy was performed on all animals, and the dorsal skin, as well as any organs showing gross alterations at autopsy, was prepared for histopathological examination. Age-standardized mortality rates, using the total population of the experiment as the standard population, were used to adjust tumor incidence findings in the study. Benzo[a]pyrene application was associated with a statistically significant increase in the incidence of skin tumors at each dose level (see Table D-20).

Table D-20. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene

Dose (μg)[a]	Skin tumor incidence	Age-standardized tumor incidence[b]
0 (acetone)	0/35 (0%)	0%
1.7	8/34 (24%)	24.8%
2.8	24/35 (68%)	89.3%
4.6	22/36 (61%)	91.7%

[a]Mice were exposed until natural death or until they developed a carcinoma at the site of application; indicated doses were applied 2 times/week to shaved skin of the back.
[b]Mortality data of the total study population were used to derive the age-standardized tumor incidence.

Source: Habs et al. (1980).

Grimmer et al. (1984) and Grimmer et al. (1983) applied benzo[a]pyrene (in 0.1 mL of a 1:3 solution of acetone:dimethyl sulfoxide [DMSO]) to the interscapular skin of female CFLP mice

ED_006137A_00009570-00092

(65–80/group) 2 times/week for 104 weeks. Doses were 0, 3.9, 7.7, and 15.4 μg in the 1983 experiment, and 0, 3.4, 6.7, and 13.5 μg in the 1984 experiment. Mice were observed until spontaneous death, unless an advanced tumor was observed or if animals were found moribund. Survival information was not provided; incidences reflect the number of animals placed on study. Necropsy was performed on all mice. Histopathological examination of the skin and any other organ showing gross abnormalities was performed. Chronic dermal exposure to benzo[a]pyrene produced a dose-related increase in skin tumor incidence and a decrease in tumor latency (see Table D-21). Carcinoma was the primary tumor type observed and a dose-response relationship was evident for carcinoma formation and incidence of all types of skin tumors.

Table D-21. Skin tumor incidence and time of appearance in female CFLP mice dermally exposed to benzo[a]pyrene for 104 weeks

Dose (μg)[a]	Skin tumor incidence (all types)	Incidence of papilloma	Incidence of carcinoma	Tumor appearance (Wks)
Grimmer et al. (1983)				
0 (1:3 Solution of acetone:DMSO)	0/80 (0%)	0/80 (0%)	0/80 (0%)	–
3.9	22/65 (34%)	7/65 (11%)	15/65 (23%)	74.6 ± 16.78[b]
7.7	39/64 (61%)	5/64 (8%)	34/64 (53%)	60.9 ± 13.90
15.4	56/64 (88%)	2/64 (3%)	54/64 (84%)	44.1 ± 7.66
Grimmer et al. (1984)				
0 (1:3 Solution of acetone:DMSO)	0/65 (0%)	0/65 (0%)	0/65 (0%)	–
3.4	43/64 (67%)	6/64 (9%)	37/64 (58%)	61 (53–65)[c]
6.7	53/65 (82%)	8/65 (12%)	45/65 (69%)	47 (43–50)
13.5	57/65 (88%)	4/65 (6%)	53/65 (82%)	35 (32–36)

[a]Indicated doses were applied twice/week to shaved skin of the back.
[b]Mean ± SD.
[c]Median with 95% CI.

Sources: Grimmer et al. (1984) and Grimmer et al. (1983).

Habs et al. (1984) applied benzo[a]pyrene (in 0.01 mL acetone) to the shaved interscapular skin of female NMRI mice at doses of 0, 2, or 4 μg, 2 times/week for life. Animals were observed twice daily until spontaneous death, unless an invasive tumor was observed. All animals were necropsied and histopathological examination was performed on the dorsal skin and any other organ with gross abnormalities. Chronic dermal exposure to benzo[a]pyrene did not affect body weight gain, but appeared to reduce survival at the highest dose with mean survival times of 691, 648, and 528 days for the 0, 2, and 4 μg/day groups, respectively. The total length of exposure for

ED_006137A_00009570-00093

each group was not reported, but can be inferred from the survival data. Latency also was not reported. Benzo[a]pyrene application resulted in a dose-related increase the incidence of total skin tumors and skin carcinomas (see Table D-22). Hematopoietic tumors (at 6/20, 3/20, and 3/20) and lung adenomas (at 2/20, 1/20, and 0/20) were observed in the controls and in the benzo[a]pyrene treatment groups, but did not appear to be treatment related according to the study authors.

Table D-22. Skin tumor incidence in female NMRI mice dermally exposed to benzo[a]pyrene for life

Dose (μg)[a]	Skin tumor incidence (all types)	Incidence of papilloma	Incidence of carcinoma	Mean survival time, days (95% CI)
0 (Acetone)	0/20 (0%)	0/20 (0%)	0/20 (0%)	691 (600–763)
2	9/20 (45%)	2/20 (10%)	7/20 (35%)	648 (440–729)
4	17/20 (85%)	0/20 (0%)	17/20 (85%)	528 (480–555)

[a]Mice were exposed until natural death or until they developed an invasive tumor at the site of application; indicated doses were applied 2 times/week to shaved interscapular skin.

Source: Habs et al. (1984).

Groups of 23–27 female Ah-receptor-responsive Swiss mice were treated on a shaved area of dorsal skin with 0, 1, 4, or 8 nmol (0, 0.25, 1, or 2 μg/treatment) benzo[a]pyrene (>99% pure) in acetone 2 times weekly for 40 weeks (Higginbotham et al., 1993). Surviving animals were sacrificed 8 weeks later. Complete necropsies were performed, and tissues from the treated area, lung, liver, kidney, spleen, urinary bladder, ovary, and uterus were harvested for histopathologic examination. Histopathologic examination was performed on tissues from the treated area, lungs, liver, kidneys, spleen, urinary bladder, uterus, and ovaries, as well as any other grossly abnormal tissue. Lung adenomas occurred in each group (1/27, 2/24, 1/23, 1/23), and other tumors were noted in isolated mice (i.e., malignant lymphoma [spleen] in one low-dose and one mid-dose mouse; malignant lymphoma with middle organ involvement in one high-dose mouse; and hemangioma [liver] in one mid-dose mouse) and were not considered dose related. In addition, benzo[a]pyrene showed no skin tumors under the conditions of this bioassay.

Sivak et al. (1997) designed a study to compare the carcinogenicity of condensed asphalt fumes (including benzo[a]pyrene and other PAHs) with several doses of benzo[a]pyrene alone. For the purposes of this assessment, the exposure groups exposed to PAH mixtures are not discussed. Groups of 30 male C3H/HeJ mice were treated dermally twice/week to 0, 0.0001, 0.001, or 0.01% (0, 0.05, 0.5, or 5 μg) benzo[a]pyrene in a 50 μL volume of cyclohexanone/acetone (1:1) for 104 weeks beginning at 8 weeks of age. Mice dying during the exposure period or sacrificed at the 24-month termination were necropsied; mice with skin tumors that persisted for 4 consecutive

weeks with diameters >3 cm were sacrificed before the study termination and also necropsied. Skin samples and any grossly observed lesions were subjected to histopathological examination. Carcinomas and sarcomas were referred to as carcinomas, whereas papillomas, keratoacanthomas, and fibromas were referred to as papillomas. The incidences of mice with skin tumors and mean survival times for each group are shown in Table D-23. All high-dose mice died before the final sacrifice, and 80% showed scabs and sores at the site of application. The time of first tumor appearance was not reported for the tumor-inducing groups, but from a plot of the tumor incidence in the high-dose group versus treatment days, an estimate of ~320 days (~43 weeks) is obtained for this group. The extent of deaths prior to 1 year in each group was not provided, so the reported incidence may underestimate the tumor rate of animals exposed long enough to develop tumors. However, the crude skin tumor rates show an increasing trend in incidence.

Table D-23. Skin tumor incidence in male C3H/HeJ mice dermally exposed to benzo[a]pyrene for 24 months

Dose (μg)[a]	Skin tumor incidence (all types)[b]	Number of mice that died before final sacrifice	Mean survival time (days)
0 cyclohexanone/acetone (1:1)	0/30 (0%)	19	607
0.05	0/30 (0%)	15	630
0.5	5/30 (20%)	15	666
5.0	27/30 (90%)	30	449

[a]Indicated doses were applied twice/week to shaved dorsal skin.
[b]Number of skin tumor-bearing mice. In the high-dose group, 1 papilloma and 28 carcinomas were detected; in the 0.5 μg group, 2 papillomas and 3 carcinomas were detected.

Source: Sivak et al. (1997).

To examine dose-response relationships and the time course of benzo[a]pyrene-induced skin damage, DNA adduct formation, and tumor formation, groups of 43–85 female Harlan mice were treated dermally with 0, 16, 32, or 64 μg of benzo[a]pyrene in 50 μL of acetone once per week for 29 weeks (Albert et al., 1991). Interscapular skin of each mouse was clipped 3 days before the first application and every 2 weeks thereafter. Additional groups of mice were treated for 9 weeks with 0, 8, 16, 32, or 64 μg radiolabeled benzo[a]pyrene to determine BPDE-DNA adduct formation in the epidermis at several time points (1, 2, 4, and 9 weeks). Tumor formation was monitored only in the skin.

No tumors were present in vehicle-treated or untreated control mice. In exposed groups, incidences of mice with skin tumors were not reported, but time-course data for cumulative number of tumors per mouse, corrected for deaths from nontumor causes, were reported. Tumors began appearing after 12–14 weeks of exposure for the mid- and high-dose groups and at 18 weeks

ED_006137A_00009570-00095

for the low-dose group. At study termination (35 weeks after start of exposure), the mean number of tumors per mouse was approximately one per mouse in the low- and mid-dose groups and eight per mouse in the high-dose group, indicating that most, if not all, mice in each exposure group developed skin tumors and that the tumorigenic response was greatest in the highest dose group. The majority of tumors were initially benign, with an average time of 8 weeks for progression from benign papillomas to malignant carcinomas. Epidermal damage occurred in a dose-related manner (more severe in the high-dose group than in the low- and mid-dose groups) and included statistically significant increases (compared with controls) in: [^{3}H]-thymidine labeling and mitotic indices; incidence of pyknotic and dark cells (signs of apoptosis); and epidermal thickness. Only a minor expansion of the epidermal cell population was observed. In the high-dose group, indices of epidermal damage increased to a plateau by 2 weeks of exposure. The early time course of epidermal damage indices was not described in the low- or mid-dose groups, since data for these endpoints were only collected at 20, 24, and 30 weeks of exposure. An increased level of BPDE-DNA adducts, compared with controls, was apparent in all exposed groups after 4 weeks of exposure in the following order: 64 > 32 > 16 > 8 μg/week. The time-course data indicate that benzo[a]pyrene-induced increases in epidermal damage indices and BPDE-DNA adducts preceded the appearance of skin tumors.

D.4.4. Reproductive and Developmental Toxicity Studies

Oral

In a study evaluating the combined effects of dibutyl phthalate and benzo[a]pyrene on the male reproductive tract, Chen et al. (2011) administered benzo[a]pyrene alone in corn oil via daily gavage at 5 mg/kg-day to 30 male Sprague-Dawley rats (28–30 days old); a group of 30 rats received only vehicle. Body weight was measured weekly. Groups of 10 rats per group were sacrificed after 4, 8, and 12 weeks of exposure. At sacrifice, blood was collected for analysis of serum testosterone levels by radioimmunoassay. The testes and epididymides were weighed, and the right testis and epididymis were examined microscopically. The left epididymis was used for evaluation of sperm parameters (sperm count and morphology). Oxidative stress, as measured by superoxide dismutase (SOD), glutathione peroxidase, and catalase activity and malondialdehyde levels, was evaluated in the left testis of each rat. Exposure to benzo[a]pyrene did not affect body weight, and no signs of toxicity were seen. Testes and epididymides weights of exposed rats were similar to controls at all time points. Sperm counts and percent abnormal sperm were also similar to controls at 4 and 8 weeks of exposure, but were significantly ($p < 0.05$) different from controls after 12 weeks of exposure to benzo[a]pyrene (29% decrease in sperm count and 54% increase in percent abnormal sperm). Serum testosterone levels were significantly increased relative to controls after 4 weeks (>2-fold higher) and 8 weeks (~1.5-fold higher) of benzo[a]pyrene exposure, but were comparable to controls after 12 weeks. Histopathology evaluation of the testes revealed irregular and disordered arrangement of germ cells in the seminiferous tubules of treated rats; the

authors did not report incidence or severity of these changes. Among measures of testicular oxidative stress, only catalase activity was significantly affected by benzo[a]pyrene exposure, showing an increase of ~50% after 12 weeks of exposure. These data suggest a LOAEL of 5 mg/kg-day (the only dose tested) for decreased sperm count, increased percentage of abnormal sperm, altered testosterone levels, and histopathology changes in the testes following 13 weeks of exposure.

Chung et al. (2011) evaluated the effects of low-dose benzo[a]pyrene exposure on spermatogenesis and the role of altered steroidogenesis on the sperm effects. Groups of 20–25 male Sprague-Dawley rats (8 weeks old) were given daily gavage doses of 0, 0.001, 0.01, or 0.1 mg/kg-day benzo[a]pyrene in DMSO for 90 consecutive days. At the end of exposure, the animals were sacrificed for removal of the pituitary, testes, and epididymides, and collection of serum and testicular interstitial fluid. Subgroups of each exposure group were used for various analyses. Serum levels of testosterone and luteinizing hormone (LH) were measured, as was testosterone concentration in the interstitial fluid (ELISA). Body and testes weights were recorded. Sections of the testis were analyzed for apoptotic germ cells using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Evaluation of the epididymis included histopathology as well as measurement of caput and caudal epididymal tubule diameters. In addition, sperm were isolated from the cauda epididymis for analysis of sperm number and motility, acrosomal integrity, and immunocytochemistry for ADAM3 (a disintegrin and metallopeptidase domain 3; a sperm surface protein associated with fertilization).

Leydig cells were isolated from the right testis of animals from each dose group and cultured with or without human chorionic gonadotropin (hCG) or dibutyl cyclic adenosine monophosphate (dbcAMP) to evaluate testosterone production (Chung et al., 2011). Cultured Leydig cells were also subjected to western blot and immunocytochemistry analyses to evaluate changes in the expression of genes involved in steroidogenesis (steroidogenic acute regulatory protein, p450 side-chain cleavage, and 3β-hydroxysteroid dehydrogenase isomerase). Finally, pituitary gland extracts were evaluated for LH protein content using immunohistochemistry. Data were reported graphically and analyzed by analysis of variance (ANOVA) followed by Duncan's post hoc test, using a p-value cutoff of 0.05 for significant difference.

At termination of exposure, body weights of treated animals were similar to controls, as were absolute testes weights (Chung et al., 2011). Testosterone concentrations in both serum and testicular interstitial fluid were significantly reduced at the high dose of benzo[a]pyrene (0.1 mg/kg-day); based on visual inspection of the data, the mean serum concentration in this group was ~20% of the control and the mean interstitial fluid concentration was ~60% of the control (n = 9 animals/dose for these evaluations). In addition, baseline production of testosterone by cultured Leydig cells was significantly decreased (~50% based on data shown graphically) at 0.1 mg/kg-day. Both hCG- and dbcAMP-stimulated testosterone production measurements were lower (~60% lower than controls) in Leydig cells from rats exposed to either 0.01 or 0.1

mg/kg-day. Serum LH was significantly increased at both 0.01 and 0.1 mg/kg-day (~65–75% higher than controls based on visual inspection of graphs); concordant increases in the intensity of LH immunoreactivity were evident in pituitary extracts from exposed rats.

Dose-related increases in the number of apoptotic germ cells, primarily spermatogonia, were demonstrated both via TUNEL assay and caspase-3 staining; the number per tubule was significantly increased over control at all doses (Chung et al., 2011). Numbers of sperm were lower in the treatment groups, but did not differ significantly from the control group. However, sperm motility was significantly reduced in exposed groups compared with controls. The authors did not report sperm motility for all dose groups, but showed only the significant decrease in the 0.01 mg/kg-day mid-dose group (~30% lower than controls based on visual inspection of graph). Acrosomal integrity (measured by LysoTracker staining) was diminished in sperm heads from exposed rats; likewise, the expression of ADAM3 protein was downregulated by exposure to benzo[a]pyrene; the authors reported a significant decrease in the 0.01 mg/kg-day group, but did not provide details of the analysis of other exposure groups. Histopathology examination of the caput and cauda epididymides revealed dose-related decreases in both cauda and caput tubule diameters that were statistically significantly lower than controls at all doses (~10–30% smaller mean diameter than control based on measurements of 175 tubules collected from five samples in each group; data reported graphically).

Statistically significant effects observed at the lowest dose (0.001 mg/kg-day) of benzo[a]pyrene in this study included decreased caput and cauda epididymal tubule diameters (~10–15% lower than controls) and increased numbers of apoptotic germ cells (~twofold higher than controls) by TUNEL assay (Chung et al., 2011). The authors reported that "sperm motility was significantly reduced in the benzo[a]pyrene-exposed groups in comparison to that of the control" but provided quantitative data only for the middle dose group, which exhibited a ~30% decrease in percent motile sperm. No statistically significant decrease in sperm count was reported at any dose. The middle dose (0.01 mg/kg-day) is considered to be a LOAEL based on reduced sperm motility.

Gao et al. (2011) examined effects of benzo[a]pyrene exposure via on cervical cell morphology. Female ICR mice (18–22 g) were exposed to doses of 0, 2.5, 5, or 10 mg/kg twice per week for 14 weeks, either by gavage or by intraperitoneal (i.p.) injection (for this review, only oral results are reported). After adjustment for equivalent continuous dosing (2/7 days/week), the equivalent daily doses are estimated to be 0.7, 1.4, and 2.9 mg/kg-day. Both vehicle (sesame oil) and untreated control groups were maintained. Body weights were determined weekly. Groups of 26 mice per dose per exposure route were sacrificed at the end of exposure for evaluation of cervical weight and histopathology. Additional groups of 10 mice were exposed for 14 weeks and used for determination of lipid peroxidation (malondialdehyde and glutathione-S-transferase levels) and CYP1A1 activity (EROD) in both liver and cervix, as well as creatine kinase activity, AST activity, and IL-6 levels in cervix and serum.

ED_006137A_00009570-00098

Mortality was observed in all exposure groups with the exception of the low-dose oral exposure group; the authors did not indicate the timing or causes of death (Gao et al., 2011). There were no control deaths. Mortality incidences in the oral exposure groups (low to high dose) were 0/26 (untreated control), 0/26 (vehicle control), 0/26, 1/36, and 2/26. Benzo[a]pyrene treatment resulted in dose-dependent decreases in body weight gain. In the high-dose group of both treatments, body weight began to decline after ~7 weeks of exposure. Based on visual examination of data presented graphically, mean terminal body weights in the low-, mid-, and high-dose oral exposure groups were ~10, 15, and 30% lower (respectively) than the vehicle control mean. The untreated control mean body weight for the oral exposure group was similar to the vehicle control mean body weight. Cervical weight as a function of body weight was not affected by oral benzo[a]pyrene exposure. Microscopic examination of the cervix revealed increased incidences of epithelial hyperplasia and inflammatory cells in the cervix of all groups of exposed mice, and atypical hyperplasia of the cervix in mice exposed to 1.4 or 2.9 mg/kg -day benzo[a]pyrene. Statistical analysis of the findings was conducted, but was poorly reported in the publication. Table D-24 shows the incidences in the oral exposure groups, along with the results of Fisher's exact tests performed for this review.

Table D-24. Mortality and cervical histopathology incidences in female ICR mice exposed to benzo[a]pyrene via gavage for 14 weeks

Endpoint	Dose (mg/kg-d)				
	Untreated control	Vehicle control	0.7	1.4	2.9
Mortality	0/26	0/26	0/26	1/26	2/26
Cervical epithelial hyperplasia	0/26	0/26	4/26	6/25*	7/24*
Atypical hyperplasia of cervix	0/26	0/26	0/26	2/25	4/24*
Inflammatory cells in cervix	2/26	3/26	10/26*	12/25*	18/24*

*Significantly different from vehicle control by Fisher's exact test performed for this review (one-sided $p < 0.05$).

Source: Gao et al. (2011).

Levels of malondialdehyde in both the cervix and liver were significantly higher than controls in all dose groups of animals treated by either oral (1.5–2-fold higher in the cervix and ~3–7-fold higher in the liver after oral exposure, $p < 0.05$) or i.p. exposure. Concomitant decreases in GST activity (~15–50% lower than controls in the cervix and ~30–60% lower in the liver after oral exposure, $p < 0.05$) were also observed at all doses and in both organs and both treatments. EROD activity was increased in the cervix (~4–~12-fold) and liver (~12–~35-fold) of all exposure groups. Measurement of creatine kinase and AST activity in the cervix and serum also showed significant increases at all doses and after both exposures (~1.5–2-fold in the cervix, and ~20–50%

ED_006137A_00009570-00099

higher than controls in the liver after oral exposure). Finally, levels of the inflammatory cytokine IL-6 were significantly ($p < 0.05$) increased in the cervix of all treated mice, and were markedly increased (from more than twofold higher than untreated or vehicle controls at the low dose, to ~sixfold higher at the high dose) in the serum of treated mice.

Based on the observations of decreased body weight and increased cervical epithelial inflammation and hyperplasia, a LOAEL of 0.7 mg/kg-day (the lowest dose tested) is identified for this study.

Mohamed et al. (2010) investigated multi-generational effects in male mice following exposure of 6-week-old C57BL/6 mice (10/group) to 0 (corn oil), 1, or 10 mg/kg-day benzo[a]pyrene for 6 weeks by gavage. Following final treatment, male mice were allowed to stabilize for 1 week prior to being mated with two untreated female mice to produce an F1 generation. Male mice were sacrificed 1 week after mating. F1 males were also mated with untreated female mice, as were F2 males. The mice of the F1, F2, and F3 generations were not exposed to benzo[a]pyrene. The F0, F1, F2, and F3 mice were all sacrificed at the same age (14 weeks) and endpoints including testis histology, sperm count, sperm motility, and in vitro sperm penetration (of hamster oocytes) were evaluated. These endpoints were analyzed statistically using ANOVA and Tukey's honest significance test and results were reported graphically as means ± SD.

Testicular atrophy was observed in the benzo[a]pyrene treatment groups, but was not statistically different than controls. Statistically significant reductions were observed in epididymal sperm counts of F0 and F1 generations treated with the high or low dose of benzo[a]pyrene. For F0 and F1 generations, epididymal sperm counts were reduced approximately 50 and 70%, respectively, in the low- and high-dose groups. Additionally, sperm motility was statistically significantly decreased at the high dose in the F0 and F1 generations. Sperm parameters of the F3 generation were not statistically different from controls. An in vitro sperm penetration assay revealed statistically significantly reduced fertilization in F0 and F1 generations of the low- and high-dose groups. However, the value of this in vitro test is limited as it bypasses essential components of the intact animal system (U.S. EPA, 1996). Based on decreased epididymal sperm counts of F0 and F1 generations, a LOAEL of 1 mg/kg-day was established from this study (no NOAEL was identified).

Arafa et al. (2009) exposed groups of 12 male Swiss albino rats to benzo[a]pyrene in olive oil (0 or 50 mg/kg-day via gavage) for 10 consecutive days, either alone or after similar treatment with 200 mg/kg-day of the flavonoid hesperidin, which has been shown to exert anti-inflammatory, antioxidant, and anticarcinogenic activity. One day after the final dose, the animals were sacrificed for removal of the cauda epididymides and testes. Epididymal sperm count and motility were assessed, as was daily sperm production in the testes. The study authors also investigated the testicular activity of LDH, SOD, and GST, as well as GSH, malondialdehyde, and protein content. The testes were examined under light microscope.

Relative testes weights (normalized to body weight) of benzo[a]pyrene exposed-animals were significantly decreased compared with controls (35% lower, $p < 0.05$) (Arafa et al., 2009). In addition, exposure to benzo[a]pyrene alone resulted in significantly decreased sperm count, numbers of motile sperm, and daily sperm production (~40% decrease from control in each parameter, $p < 0.05$). Effects on sperm count and production were abolished by hesperidin pretreatment, but the number of motile sperm remained significantly depressed (compared with the control group) in the group exposed to both benzo[a]pyrene and hesperidin. Measures of antioxidant enzymes and lipid peroxidation showed statistically significant induction of oxidative stress in the testes of benzo[a]pyrene-exposed rats. With the exception of the decrease in testicular GSH content (which was partially mitigated), pretreatment with hesperidin eliminated the effects of benzo[a]pyrene on lipid peroxidation and antioxidant enzymes.

Xu et al. (2010) treated female Sprague-Dawley rats (6/group) to 0 (corn oil only), 5, or 10 mg/kg-day benzo[a]pyrene by gavage every other day for a duration of 60 days. This resulted in TWA doses of 0, 2.5, and 5 mg/kg-day over the study period of 60 days. Endpoints examined included ovary weight, estrous cycle, 17B-estradiol blood level, and ovarian follicle populations (including primordial, primary, secondary, atretic, and corpora lutea). Animals were observed daily for any clinical signs of toxicity and following sacrifice, gross pathological examinations were made and any findings were recorded. All animals survived to necropsy. A difference in clinical signs was not observed for the treated groups and body weights were not statistically different in treated animals (although they appear to be depressed 6% at the high dose). Absolute ovary weight was statistically significantly reduced in both the low- and high-dose groups (11 and 15%, respectively) (see Table D-25). Animals treated with the high dose were noted to have a statistically significantly prolonged duration of the estrous cycle and nonestrus phase compared to controls. Animals in the high-dose group also had statistically significantly depressed levels of estradiol (by approximately 25%) and decreased numbers of primordial follicles (by approximately 20%). This study also indicated a strong apoptotic response of ovarian granulosa cells as visualized through TUNEL labeling; however, the strongest response was seen at the low dose; decreased apoptosis was also observed at the high dose. Based on decreased ovary weight following a 60-day oral exposure to benzo[a]pyrene, a LOAEL of 2.5 mg/kg-day was established from this study (no NOAEL was identified).

ED_006137A_00009570-00101

Table D-25. Means ± SD for ovary weight in female Sprague-Dawley rats

	Dose (mg/kg-d)[a]		
	0	**2.5**	**5**
Ovary weight (g)	0.160 ± 0.0146	0.143 ± 0.0098*	0.136 ± 0.0098*
Body weight (g)	261.67 ± 12.0	249.17 ± 11.2	247.25 ± 11.2

*Statistically different from controls ($p < 0.05$) using one-way ANOVA.
[a]TWA doses over the 60-day study period.

Source: Xu et al. (2010).

Zheng et al. (2010) treated male Sprague-Dawley rats to 0 (corn oil only), 1, or 5 mg/kg-day benzo[a]pyrene by daily gavage for a duration of 30 (8/group) or 90 days (8/group). At necropsy, the left testis of each animal was collected and weighed. Testes testosterone concentrations were determined by radioimmunoassay and results were expressed as ng/g testis and reported graphically. Testicular testosterone was statistically significantly decreased in the high-dose group approximately 15% following 90 days of exposure. The low-dose group also appeared to have a similar average depression of testosterone levels; however, the change did not reach statistical significance. Testosterone levels measured in animals sacrificed following 30 days of benzo[a]pyrene exposure were not statistically different than controls. Based on decreased testicular testosterone levels following a 90-day oral exposure to benzo[a]pyrene, a LOAEL of 5 mg/kg-day and a NOAEL of 1 mg/kg-day were identified.

McCallister et al. (2008) administered 0 or 300 μg/kg-day benzo[a]pyrene by gavage in peanut oil to pregnant Long-Evans rats (n = 5 or 6) on gestational days (GDs) 14–17. At this exposure level, no significant changes were see in number of pups per litter, pup growth, or liver to body weight ratios in control compared to benzo[a]pyrene exposed offspring. Treatment-related differences in brain to body weight ratios were observed only on postnatal days (PNDs) 15 and 30. Decreases in cerebrocortical messenger ribonucleic acid (mRNA) expression of the glutamatergic N-methyl-D-aspartate (NMDA) receptor subunit was significantly reduced (50%) in treated offspring compared to controls. In addition, in utero exposed offspring exhibited decreased evoked cortical neuronal activity in the barrel field cortex when tested at PNDs 90–120.

Rigdon and Neal (1965) administered diets containing 1,000 ppm benzo[a]pyrene to pregnant mice (nine/group) on GDs 10–21 or 5–21. The pups were reported as appearing generally normal at birth, but cannibalism was elevated in the exposed groups. These results are in contrast with an earlier study (Rigdon and Rennels, 1964) in which rats (strain not specified) were fed diets containing benzo[a]pyrene at 1,000 ppm for approximately 28 days prior to mating and during gestation. In the earlier study, five of eight treated females mated with untreated males became pregnant, but only one delivered live young. The treated dam that delivered had two live and two stillborn pups; one dead pup was grossly malformed. In the remaining treated females,

vaginal bleeding was observed on GDs 23 or 24. In the inverse experimental design, three of six controls mated to benzo[a]pyrene-treated males became pregnant and delivered live young. Visceral and skeletal examinations of the pups were not conducted. These studies were limited by the small numbers of animals, minimal evaluation of the pups, lack of details on days of treatment (food consumption, weight gain), and occurrence of cannibalism.

Reproductive Effects of In Utero Exposure Via Oral Route

Mackenzie and Angevine (1981) conducted a two-generation reproductive and developmental toxicity study for benzo[a]pyrene in CD-1 mice. Benzo[a]pyrene was administered by gavage in 0.2 mL of corn oil to groups of 30 or 60 pregnant (the F0 generation) mice at doses of 0, 10, 40, or 160 mg/kg-day on GDs 7–16 only. Therefore, unlike the standard two-generation study, F1 animals were exposed only in utero. F1 offspring were evaluated for postnatal development and reproductive function as follows. F1 pups (four/sex when possible) were allowed to remain with their mothers until weaning on PND 20. Crossover mating studies were then conducted. Beginning at 7 weeks of age, each F1 male mouse (n = 20–45/group) was allowed to mate with two untreated virgin females for 5-day periods for 25 days (for a total exposure of 10 untreated females/F1 male), after which time the males were separated from the females. Fourteen days after separation from the males (i.e., on days 14–19 of gestation), the females were sacrificed and the numbers of implants, fetuses, and resorptions were recorded. The F2 fetuses were then examined for gross abnormalities. Similarly, each F1 female mouse (n = 20–55/group), beginning at 6 weeks of age, was paired with an untreated male for a period of 6 months. Males were replaced if the females failed to produce a litter during the first 30-day period. All F2 young were examined for gross abnormalities on day 1 of life and their weights were recorded on day 4. This F2 group was sacrificed on day 20 postpartum, while the F1 female was left with a male until the conclusion of the study. At 6 weeks of age, gonads of groups of 10 male and 10 female F1 mice exposed to 0, 10, or 40 mg/kg-day benzo[a]pyrene in utero were subjected to gross pathology and histologic examinations.

No maternal toxicity was observed. The number of F0 females with viable litters at parturition at the highest dose was statistically significantly reduced by about 35% (Table D-26), but progeny were normal by gross observation. Parturition rates of the low- and mid-dose groups were unaffected by treatment, and litter sizes of all treated groups were similar to the control group throughout lactation. However, body weights of the F1 pups in the mid- and high-dose groups were statistically significantly decreased on PND 20, by 7 and 13%, respectively, and in all treated pups on PND 42, 6, 6, and 10% for the low, mid, and high dose, respectively (Table D-26). The number of F1 pups surviving to PNDs 20 and 42 was significantly reduced at the high dose ($p < 0.01$), by 8 and 16%, respectively. When F1 males were bred to untreated females and F1 females were mated with untreated males, a marked dose-related decrease in fertility of >30% was observed in both sexes, starting at the lowest exposure. There were no treatment-associated gross abnormalities or differences in body weights in the F2 offspring.

Table D-26. Reproductive effects in male and female CD-1 F1 mice exposed in utero to benzo[a]pyrene

Effect	Dose (mg/kg-d)[a]			
	0	10	40	160
F0 mice with viable litters at parturition	46/60 (77%)	21/30 (70%)	44/60 (73%)	13/30 (43%)*
Mean ± SEM pup weight (g) at PND 20	11.2 ± 0.1	11.6 ± 0.1	10.4 ± 0.1*	9.7 ± 0.2*
Mean ± SEM pup weight (g) at PND 42	29.9 ± 0.2	28.2 ± 0.3*	28.0 ± 0.2*	26.8 ± 0.4*
F1 male fertility index[b]	80.4	52.0*	4.7*	0.0*
F1 female fertility index[c]	100.0	65.7*	0.0*	0.0*

*Significantly ($p < 0.05$) different from control by unspecified tests.
[a]Pregnant F0 mice were administered daily doses of benzo[a]pyrene in corn oil on GDs 7–16.
[b]Beginning at 7 weeks of age, each F1 male mouse (20–45/group) was exposed to 10 untreated females over a period of 25 days. Index = (females pregnant/females exposed to males) × 100.
[c]Beginning at 6 weeks of age, each F1 female mouse (20–55/group) was cohabitated with an untreated male for a period of 6 months.

SEM = standard error of the mean.

Source: Mackenzie and Angevine (1981).

Exposure to benzo[a]pyrene caused a marked dose-related decrease in the size of the gonads. In F1 males, testes weights were statistically significantly reduced. Testes from animals exposed in utero to 10 and 40 mg/kg-day weighed approximately 42 and 82%, respectively, of the weight of testes from the control animals (no F2 offspring were produced in the high-dose group). This was confirmed by histopathologic observation of atrophic seminiferous tubules in the 40 mg/kg-day group that were smaller than those of controls and were empty except for a basal layer of cells. The number of interstitial cells in the testes was also increased in this group. Males from the 10 mg/kg-day group showed limited testicular damage; although all exhibited evidence of tubular injury, each animal had some seminiferous tubules that displayed active spermatogenesis. Ovarian tissue was absent or reduced in F1 females such that organ weights were not possible to obtain. Examination of available tissue in these females revealed hypoplastic ovaries with few follicles and corpora lutea (10 mg/kg-day) or with no evidence of folliculogenesis (40 mg/kg-day). Ovarian tissue was not examined in highest-dose females.

The LOAEL in this study was 10 mg/kg-day based on decreases in mean pup weight (<5%) at PND 42 of F1 offspring of dams treated with 10, 40, or 160 mg/kg-day benzo[a]pyrene, marked decreases in the reproductive capacity (as measured by fertility index) of both male and female F1 offspring exposed at all three treatment levels of benzo[a]pyrene (by approximately 30% in males and females), decreased litter size (by about 20%) in offspring of F1 dams, and the dramatic

decrease in size and alteration in anatomy of the gonads of both male and female F1 mice exposed to 10 and 40 mg/kg-day benzo[a]pyrene in utero. A NOAEL was not identified.

In another reproductive and developmental toxicity study, benzo[a]pyrene was administered by gavage in corn oil to nine female NMRI mice at a dose of 10 mg/kg-day on GDs 7–16; a group of nine controls received corn oil (Kristensen et al., 1995). Body weights were monitored. F0 females were kept with their offspring until after weaning (21 days after delivery). At 6 weeks of age, one F1 female from each litter (n = 9) was caged with an untreated male. The F2 offspring were inspected for gross deformities at birth, weight and sex were recorded 2 days after birth, and the pups were sacrificed. The F1 females were sacrificed after 6 months of continuous breeding. The effects of benzo[a]pyrene treatment on fertility, ovary weights, follicles, and corpora lutea were evaluated. F0 females showed no signs of general toxicity, and there was no effect on fertility. F1 females had statistically significantly lower median numbers of offspring, number of litters, and litter sizes and a statistically significantly greater median number of days between litters as compared with the controls (Table D-27). At necropsy, the F1 females from treated F0 females had statistically significantly reduced ovary weights; histologic examination of the ovaries revealed decreased numbers of small, medium, or large follicles and corpora lutea (Table D-27). Only one dose group was used in this study, with decreased F1 female fertility observed following in utero exposure at the LOAEL of 10 mg/kg-day; no NOAEL was identified.

Table D-27. Effect of prenatal exposure to benzo[a]pyrene on indices of reproductive performance in F1 female NMRI mice

Endpoint (median with range in parentheses)	Control[a]	Benzo[a]pyrene exposed[a] (10 mg/kg-d)
Number of F2 offspring	92 (26–121)	22* (0–86)
Number of F2 litters	8 (3–8)	3* (0–8)
F2 litter size (number of pups per litter)	11.5 (6–15)	8* (3–11)
Number of d between F2 litters	20.5 (20–21)	21* (20–23)
F1 ovary weight (mg)	13 (13–20)	9* (7–13)
Number of small follicles	44 (1–137)	0* (0–68)
Number of medium follicles	9 (5–25)	0* (0–57)
Number of large follicles	14 (6–23)	0* (0–19)
Number of corpora lutea	16 (6–35)	0* (0–14)

*Significantly ($p < 0.05$) different from control group by Wilcoxon rank sum test or Kruskall-Wallis two-tailed test.
[a]Groups of nine female NMRI F0 mice were administered 0 or 10 mg benzo[a]pyrene/kg-day by gavage in corn oil on GDs 7–16. One F1 female from each litter was continuously bred with an untreated male for 6 months.

Source: Kristensen et al. (1995).

Chen et al. (2012) treated male and female neonatal Sprague-Dawley rats (10/sex/group) with benzo[a]pyrene (unspecified purity) dissolved in peanut oil by gavage daily on PNDs 5–11, at doses of 0.02, 0.2, or 2 mg/kg in 3 mL vehicle/kg body weight, determined individually based upon daily measurements. This time period was described as representing the brain growth spurt in rodents, analogous to brain developmental occurring from the third trimester to 2 years of age in human infants. Breeding was performed by pairs of 9-week-old rats, with delivery designated as PND 0. Litters were culled to eight pups/dam (four males and four females, when possible) and randomly redistributed at PND 1 among the nursing dams; dams themselves were rotated every 2–3 days to control for caretaking differences, and cage-side observations of maternal behavior were made daily. One male and female from each litter were assigned per treatment group, and the following physical maturation landmarks were assessed daily in all treatment groups until weaning at PND 21: incisor eruption, eye opening, development of fur, testis decent, and vaginal opening.

Neonatal sensory and motor developmental tests were administered to pups during the preweaning period at PNDs 12, 14, 16, and 18, and were behavioral tests administered to rats as adolescents (PNDs 35 and 36) or as adults (PNDs 70 and 71): each rat was only tested during one developmental period. All dosing was performed from 1300 to 1600 hours, and behavioral testing was during the "dark" period from 1900 to 2300 hours, although tests were performed in a lighted environment. Pups were observed individually and weighed daily, the order of testing litters was randomized each day, and all observations were recorded by investigators blinded to group treatment.

Sensory and motor developmental tests, including the surface righting reflex test, negative geotaxis test, and cliff aversion test, were performed only once, while the forelimb grip strength test was assessed during three 60-second trials on PND 12. Rat movements during the open-field test were recorded by camera, and two blinded investigators scored movement and rearing separately during a 5-minute evaluation period. Blinded investigators directly observed video monitoring of rat movements during the elevated plus maze, and after a 5-minute free exploration period, recorded number of entries into the closed and open arms, time spent in the open arms, and latency to the first arm entry. Assessment of the Morris water maze was slightly different, in that the rats were habituated to the testing pool by a 60-second swim without a platform on the day prior to testing. The rats were then tested during a 60-second swim with a hidden platform present at a constant position each day for 4 days; on the 5th day, the rats were evaluated during a 60-second probe swim without a platform. The number of times each animal crossed the original platform location and the duration of time spent in the platform quadrant were recorded during this final evaluation. One pup/sex/litter were assigned for behavioral testing to each of four tracks: Track 1, surface righting reflex test, cliff aversion test, and open-field test (PNDs 12–18); Track 2, negative geotaxis test, forelimb grip strength test, and open-field test (PNDs 12–20); Track 3, elevated plus maze, Morris water maze, and open-field test (PNDs 34–36); and Track 4, elevated plus maze,

Morris water maze, and open-field test (PNDs 69–71). All results were presented in graphic form only.

No significant effects on pup body weight were observed during the 7-day treatment period (PNDs 5–11). Three-way ANOVA (time × benzo[a]pyrene treatment × sex) indicated that effects of benzo[a]pyrene were not sex-dependent throughout the 71-day experiment, so both sexes were pooled together. From this pooled analysis, pups in the 2 mg/kg-day treatment group gained significantly less weight at both PND 36 and 71. There were no differences among treatment groups in incisor eruption, eye opening, development of fur, testis decent, or vaginal opening.

For all measurements of neonatal sensory and motor development, results from both sexes were analyzed together since benzo[a]pyrene was reported to have no significant interaction with sex by 3-way ANOVA. No significant differences were observed in either the cliff aversion or forelimb grip strength tests. In the surface righting reflex test, latency was increased in the 0.2 mg/kg-day group at PND 12, in the 0.02 and 2 mg/kg-day groups at PND 14, and in only the high-dose group at PND 16; latency was not significantly different in any group at PND 18. At PND 12, there was a dose-related increase in negative geotaxis latency associated with 0.02, 2, and 2 mg/kg-day benzo[a]pyrene, which was also present in the 2 mg/kg-day group at PND 14, but returned to control levels at PND 16 and 18. In the open field test, there were no significant differences in either locomotion or rearing activity at PND 18 or 20. At PND 34, the 2 mg/kg-day group exhibited significantly increased movement, but increases in rearing were not significant. At PND 69, increased locomotion was observed in both the 0.2 and 2 mg/kg-day groups, while rearing was significantly increased in only the 2 mg/kg-day treatment group.

The elevated plus maze performance was only evaluated in adolescent and adult rats. Unlike the previous tests, 3-way ANOVA revealed a statistically significant interaction between neonatal benzo[a]pyrene treatment and sex, so male and female performance was analyzed independently. No significant differences in PND 35 males were observed, and the only significant observation in PND 35 females was increased time spent in the open maze arms by the 2 mg/kg-day treatment group. Significantly decreased latency time to first open arm entry was observed in PND 70 males and females in both 0.2 and 2 mg/kg-day treatment groups; these groups also spent significantly more time in open maze arms, along with the 0.02 mg/kg-day female group. At PND 70, the 2 mg/kg-day males, along with the 0.2 and 2 mg/kg-day females, entered more frequently into open arms and less frequently into closed arms than the vehicle controls. In the Morris water maze, escape latency (time to reach the platform during each of the four testing days) was consistently increased in the 2 mg/kg-day treatment group of both sexes, in both adolescent and adult animals. These increases were statistically significant in both males and females treated with 2 mg/kg-day benzo[a]pyrene at both PNDs 39 and 74, and were also significantly elevated in 0.2 mg/kg-day animals of both sexes at PND 74. Likewise, performance during the 5th test day, in the absence of the escape platform, was significantly adversely affected by both metrics (decreased time spent in the target quadrant and decreased number of attempts to cross the platform location)

in 2 mg/kg-day rats of both sexes at both PNDs 40 and 75. PND 75 females treated with 0.2 mg/kg-day benzo[a]pyrene also showed significant decreases in both performance metrics, while PND 75 0.2 mg/kg-day males only demonstrated significant differences in "time spent in target quadrant." Swim speed was also assessed, but there were no differences among any treatment group at either age evaluated.

Jules et al. (2012) treated pregnant Long-Evans Hooded rats with benzo[a]pyrene (unspecified purity) dissolved in 0.875 mL peanut oil by gavage daily on GDs 14–17, at doses of 150, 300, 600, and 1,200 μg benzo[a]pyrene/kg body weight, with animals weighed daily. Cage-side observations were performed until pup weaning, and litter size was evaluated for each treatment group. Pups from four to five individual litters were analyzed for each endpoint, which was independently repeated for a total of three replicates. Delivery was designated PND 0, and pups were harvested on PNDs 0–15 for benzo[a]pyrene metabolite identification, or for other endpoints as young adults at PND 53. Systolic/diastolic blood pressure and heart rate was recorded by a volume pressure recording sensor and occlusion tail-cuff applied to conscious, non-anesthetized animals. Animals were preconditioned to the restraint device and tail-cuff by daily acclimatization sessions during PNDs 46–50, to minimize stress effects during data collection. Cardiac function values were averaged from 15 readings each collected over a 1-minute interval every other minute for 30 minutes on PND 53.

No significant differences in litter size or pup weight gain from PND 0 to 15 were reported in any treatment group, and no convulsions, tremors, or abnormal movements were reproducibly observed. Most analytical data were reported graphically, as mean ± standard error of the mean (SEM) of three replicates of 3–5 offspring measured/group. Plasma and heart tissue total benzo[a]pyrene metabolite levels were maximal at PND 0 (the first time point sampled) and progressively decreased from PNDs 0 to 13. Compared to the low-dose group (150 μg/kg), plasma metabolite levels were significantly elevated in the 600 and 1,200 μg/kg-day benzo[a]pyrene groups through PND 13, while heart metabolite levels were significantly increased through PND 11. Metabolites in mid-dose group, 300 μg/kg-day, trended between the 150 and 600 μg/kg-day group levels from PND 0 to 7, while not achieving statistically significant differences in pair-wise comparisons. Three principal groups of benzo[a]pyrene metabolites were identified. More than 70% of the total heart metabolite burden was composed of diol metabolites through PND 13, while the more reactive hydroxyl metabolites increased in relative composition from PND 9 to 13, and the dione population remained constant at ≤5%.

Cardiovascular function was evaluated in pups exposed in utero to 600 or 1,200 μg/kg-day benzo[a]pyrene versus controls (see Table D-28). A dose-related and statistically significant increase in both systolic (20, 50%) and diastolic pressure (30, 80%) was observed in mid- and high-dose pups, respectively. Heart rate was also significantly altered; a 10% increased heart rate was reported in the 600 μg/kg-day benzo[a]pyrene group, while the average heart rate of the 1,200 μg/kg-day benzo[a]pyrene groups decreased 8%.

Table D-28. Exposure-related effects in Long-Evans Hooded rats exposed to benzo[a]pyrene by gavage daily in utero from GD 14 to 17

Effect measured	Dose (mg/kg-d)		
	0	0.600	1.20
Heart rate (bpm; mean ± SEM)	504.6 ± 15.7	554.6 ± 26.2*	466.3 ± 16.9*
Blood pressure measured by tail cuff (mmHg; mean ± SEM)			
Systolic pressure	131.6 ± 1.2	151.6 ± 45*	200.4 ± 2.4*
Diastolic pressure	85.0 ± 4.2	113.0 ± 3.3*	155.6 ± 3.2*

*Significantly ($p < 0.05$) different from control mean; n = 4–5/replicate, 3 replicates performed.

Source: Jules et al. (2012).

Bouayed et al. (2009a) treated nursing female Swiss Albino OF1 mice (5/dose group) with benzo[a]pyrene (unspecified purity) dissolved in avocado oil by gavage daily while nursing pups from PND 1 to 14 at 0, 2, or 20 mg/kg-day in 10 mL/kg body weight, individually determined each day. Prior to benzo[a]pyrene treatment, litters were culled to 10 pups (5/sex when possible), and nurturing females were assigned to litters that were stratified randomly to achieve equivalent mean pup litter body weights across the designated treatment groups. As the effects of benzo[a]pyrene on maternal nurturing behavior was unknown, dam behavior was visually monitored daily until weaning. Furthermore, maternal nurturing performance from PND 0 to 21 was assessed by two methods: a nest-building test administered twice a day where nest quality/ complexity was scored 15 minutes after cotton material was supplied; and pup retrieval, in which latency to return the displaced pup to the nest was measured twice and averaged, was evaluated once daily At the indicated times, two mice/sex/litter were randomly selected and weighed, and their brains were resected for later mRNA expression analysis (n = 20/group).

Pup neuromotor maturation and behavior was assessed during pre-weaning by four standard methods (administered between 10 am and 1 pm on testing days, and in temporal order as indicated): (1) *righting reflex test*, maximum duration of 120 seconds, administered on PNDs 3, 5, 7, and 9; (2) *negative geotaxis test*, maximum duration of 120 seconds, administered on PNDs 5, 7, 9, and 11; (3) *forelimb grip test*, duration until failure, administered on PNDs 9 and 11; and (4) *open field test*, 6-minute evaluation of locomotor activity and rearing following a 1-minute habituation period, administered on PND 15. Adolescent function was evaluated by three methods: *water escape pole climbing (WESPOC) test*, administered at PND 20, in which the time to find the pole, time to climb the pole, and the time to reach the safety platform were reported; *elevated plus maze*, administered at PND 32 for 5 minutes, in which the latency time to first open arm entry, number of entries into open arms, total number of entries, percent of time spent in open arms, and percent of entries into open arms was determined; and *Y-maze spontaneous alternation test*, administered at

ED_006137A_00009570-00109

PND 40 for 5 minutes, in which the percentage of spontaneous alternation was calculated by: [(the number of successful overlapping triplets)/(total number of arm entries − 2) × 100%].

Benzo[a]pyrene treatment did not significantly affect the body weight of nursing mothers during the 2-week treatment period. Since 3-way ANOVA indicated that changes in pup weight as a result of benzo[a]pyrene treatment were not sex-dependent, data from male and female pups were combined. Benzo[a]pyrene treatment of nursing mothers was associated with a 8–9% weight gain in pups nursing from the 2 mg/kg-day group and a 10–12% weight gain in pups from the 20 mg/kg-day group at PNDs 12–20 (see Table D-29). While not significantly different from PND 26 to 40, pup weight in the 20 mg/kg-day group was continuously higher than either the 2 mg/kg-day group or vehicle-treated controls. There were no significant differences in pup brain weight or eye opening observed. Likewise, benzo[a]pyrene treatment of nursing mothers did not affect nest-building interest or quality, and while not significantly impacting pup retrieval time, the retrieval latency period was observed to increase with increasing treatment duration in both benzo[a]pyrene groups versus controls.

Table D-29. Exposure-related pup body weight effects in Swiss Albino OF1 mice exposed as pups to benzo[a]pyrene in breast milk from dams treated by gavage daily from PND 1 to 14

Pup body weight (g; mean ± SEM, n = 20)	Dose (mg/kg-d)		
	0	2	20
PND 0	1.70 ± 0.02	1.73 ± 0.02	1.74 ± 0.02
PND 4	3.01 ± 0.08	3.08 ± 0.06	3.16 ± 0.04
PND 8	5.08 ± 0.1	5.26 ± 0.09	5.30 ± 0.08
PND 12	6.57 ± 0.12	7.16 ± 0.06*	7.39 ± 0.05*
PND 20	12.51 ± 0.24	13.55 ± 0.25**	13.79 ± 0.14*
PND 26	17.71 ± 0.49	18.60 ± 0.36	18.35 ± 0.34
PND 32	24.47 ± 0.55	25.59 ± 0.57	25.38 ± 0.54
PND 40	30.55 ± 0.94	30.90 ± 0.93	31.78 ± 0.97

*$p < 0.001$ significantly different from control mean.
**$p < 0.01$.

Source: Bouayed et al. (2009a).

Behavioral test data was reported graphically, as mean ± SEM of n = 20/group. For the pre-weaning neuromotor developmental tests, benzo[a]pyrene treatment was found to not depend on sex; therefore, data from male and female pups were combined. Pups nursing from mothers administered 2 or 20 mg/kg-day benzo[a]pyrene had significantly elevated righting reflex times at PNDs 3–5, which decreased to control times at PNDs 7–9. Only pups from the 20 mg/kg-day

ED_006137A_00009570-00110

treatment group demonstrated significantly increased negative geotaxis latency, which was twofold greater than controls at PNDs 5, 7, and 9, but returned to control levels at PND 11. Interestingly, mice in the 20 mg/kg-day group had increased forelimb grip strength, which was significantly greater than control mice at PNDs 9 and 11, corresponding to increased body weight in the benzo[a]pyrene-treated mice versus controls. Mice in the 2 mg/kg-day group also performed better than controls at PND 9, but were equivalent at PND 11. No treatment or sex-related effects were reported on locomotion or rearing activity during the open field test. Sex-dependency on test performance became evident during the analysis of the WESPOC test data: female pups were not significantly affected using any metric, while males in the 20 mg/kg-day group demonstrated a statistically significantly longer pole-grasping latency (threefold), and took 13 times longer to escape the pole and board the safety platform versus vehicle controls. While performance of male pups from the 2 mg/kg-day group was not statistically significantly worse than vehicle controls by pair-wise comparison, latency for both pole-grasping and escape in this treatment group contributed to a significant trend for treatment dose and these effects. In the evaluation of the elevated plus maze, treatment effects did not appear to depend upon sex, so both male and female performance was analyzed together. Mice in both benzo[a]pyrene treatment groups demonstrated decreased latency time to first entering an open arm (30–50%), as well as entered open arms 2 times more frequently and spent twice as much time there versus vehicle controls. While mice in the 2 mg/kg-day treatment group entered into closed arms 20% less frequently than controls, mice in the 20 mg/kg-day group were not significantly different. Likewise, mice nursing from mothers treated with 2 mg/kg-day benzo[a]pyrene performed 15% more spontaneous alternations in the Y-maze spontaneous alternation test compared to controls, while mice in the high-dose group were not significantly different. The brains of pups nursing from the 20 mg/kg-day group expressed approximately 50% lower levels of 5-hydroxytryptamine (serotonin) 1A (5HT1A), and mu 1-opioid (MOR1) mRNA, and a trend was observed in the low-dose group as well. No significant changes in alpha-1D adrenergic or GABA-A mRNA levels were detected.

Reproductive Effects in Adults and Repeated Oral Exposure

Rigdon and Neal (1965) conducted a series of experiments to assess the reproductive effects of orally administered benzo[a]pyrene to Ah-responsive white Swiss mice. Female animals (number not stated) were administered benzo[a]pyrene at 250, 500, or 1,000 ppm in the feed before or during a 5-day mating period. Based on the initial body weight, the doses can be estimated as 32, 56, and 122 mg/kg-day, respectively. No effect on fertility was observed at any treatment dose, even when animals were fed 1,000 ppm benzo[a]pyrene for 20 days prior to mating, but interpretation of this finding was marred by large variability in numbers of pregnant females and litter sizes for both treated and control mice. In separate experiments, the fertility of five male mice/group was not affected by exposure to 1,000 ppm in food for up to 30 days prior to mating with untreated females. Histologic examinations showed that male mice fed 500 ppm benzo[a]pyrene for 30 days had spermatozoa present in their testes; further details were not

ED_006137A_00009570-00111

provided. The only treatment-related effect was a lack of weight gain related to feed unpalatability. While this study suggests that premating exposure of male or female mice to doses up to 122 mg/kg-day for 20 days may not affect fertility, the sample sizes were too small and the study designs were too inconsistent to provide reliable NOAELs and LOAELs for reproductive/ developmental toxicity.

In an earlier study (Rigdon and Rennels, 1964), rats (strain not specified) were fed diets containing benzo[a]pyrene at 1,000 ppm for approximately 28 days prior to mating and during gestation. In this study, five of eight treated females mated with untreated males became pregnant, but only one delivered live young. The treated dam that delivered had two live and two stillborn pups; one dead pup was grossly malformed. In the remaining treated females, vaginal bleeding was observed on GDs 23 or 24. In the inverse experimental design, three of six controls mated to benzo[a]pyrene-treated males became pregnant and delivered live young. Visceral and skeletal examinations of the pups were not conducted. These studies are insufficiently reported and of insufficient design (e.g., inadequate numbers of animals for statistical analysis) to provide reliable NOAELs or LOAELs for reproductive effects from repeated oral exposure to benzo[a]pyrene.

D.4.5. Inhalation

Reproductive Toxicity and In Utero Exposure via Inhalation

Archibong et al. (2002) evaluated the effect of exposure to inhaled benzo[a]pyrene on fetal survival and luteal maintenance in timed-pregnant F344 rats. Prior to exposure on GD 8, laparotomy was performed to determine the number of implantation sites, and confirmed pregnant rats were divided into three groups, consisting of rats that had four to six, seven to nine, or more than nine conceptuses in utero. Rats in these groups were then assigned randomly to the treatment groups or control groups to ensure a similar distribution of litter sizes. Animals (10/group) were exposed to benzo[a]pyrene:carbon black aerosols at concentrations of 25, 75, or 100 μg/m^3 via nose-only inhalation, 4 hours/day on GDs 11–20. Control animals were either sham-exposed to carbon black or remained entirely unexposed. Results of particle size analysis of generated aerosols were reported by several other reports from this laboratory (Inyang et al., 2003; Ramesh et al., 2001a; Hood et al., 2000). Aerosols showed a trimodal distribution (average of cumulative mass, diameter) <95%, 15.85 μm; 89%, <10 μm; 55%, <2.5 μm; and 38%, <1 μm (Inyang et al., 2003). Ramesh et al. (2001a) reported that the MMAD (± geometric SD) for the 55% mass fraction with diameters <2.5 μm was 1.7 ± 0.085. Progesterone, estradiol-17β, and prolactin concentrations were determined in plasma collected on GDs 15 and 17. Fetal survival was calculated as the total number of pups divided by the number of all implantation sites determined on GD 8. Individual pup weights and crown-rump length per litter per treatment were determined on PND 4 (PND 0 = day of parturition).

Archibong et al. (2001) reported that exposure of rats to benzo[a]pyrene caused biologically and statistically significant ($p \leq 0.05$) reductions in fetal survival compared with the

two control groups; fetal survival rates were 78.3, 38.0, and 33.8% per litter at 25, 75, and 100 μg/m³, respectively, and 96.7% with carbon black or 98.8% per litter in untreated controls (see Table D-30). Consequently, the number of pups per litter was also decreased in a concentration-dependent manner. The decrease was ~50% at 75 μg/m³ and ~65% at 100 μg/m³, compared with sham-exposed and unexposed control groups. No effects on hormone levels were observed on GDs 15 or 17 at the low dose. Biologically significant decreases in mean pup weights (expressed as g per litter) of >5% were observed at doses ≥75 μg/m³ (14 and 16% decreases at 75 and 100 μg/m³, respectively, $p < 0.05$). Exposure to benzo[a]pyrene did not affect crown-rump length (see Table D-30).

Table D-30. Pregnancy outcomes in female F344 rats treated with benzo[a]pyrene on GDs 11–21 by inhalation

	Administered concentration of benzo[a]pyrene (μg/m³)				
Parameter[a]	0 (unexposed control)	0 (carbon black)	25	75	100
Implantation sites	8.6 ± 0.2	8.8 ± 0.1	8.8 ± 0.5	9.0 ± 0.2	8.8 ± 0.1
Pups per litter	8.5 ± 0.2	8.7 ± 0.2	7.4 ± 0.5*	4.2 ± 0.1*	3.0 ± 0.2*
Survival (litter %)	98.9 ± 1.1	96.7 ± 1.7	78.3 ± 4.1*	38.0 ± 2.1*	33.8 ± 1.3*
Pup weight (g/litter)	10.6 ± 0.1	8.8 ± 0.1	10.5 ± 0.2	9.1 ± 0.2*	8.9 ± 0.1*
Crown-rump length (mm/litter)	29.4 ± 0.6	29.3 ± 0.5	28.0 ± 0.6	27.3 ± 0.7	27.9 ± 0.7

*Significantly different from controls at $p < 0.05$ by one-tailed post-hoc t-testing following ANOVA.
[a]Values presented as means ± SEM.

Source: Archibong et al. (2002).

Benzo[a]pyrene exposure at 75 μg/m³ caused a statistically significant decrease in plasma progesterone, estradiol, and prolactin on GD 17; these levels were not determined in the rats exposed to 100 μg/m³ (Archibong et al., 2002). Plasma prolactin is an indirect measure of the activity of decidual luteotropin, a prolactin-like hormone whose activity is necessary for luteal maintenance during pregnancy in rats. Control levels of prolactin increased from GD 15 to 17, but this increase did not occur in the rats exposed to 75 μg/m³. Although the progesterone concentration at 75 μg/m³ was significantly lower than in controls on GD 17, the authors thought that the circulating levels should have been sufficient to maintain pregnancy; thus, the increased loss of fetuses was thought to be caused by the lower prolactin levels rather than progesterone deficiency. The reduced circulating levels of progesterone and estradiol-17β among benzo[a]pyrene-treated rats were thought to be a result of limited decidual luteotropic support for the corpora lutea. The authors proposed the following mechanism for the effects of benzo[a]pyrene

ED_006137A_00009570-00113

on fertility: benzo[a]pyrene or its metabolites decreased prolactin and decidual luteotropin levels, compromising the luteotropic support for the corpora lutea and thereby decreasing the plasma levels of progesterone and estradiol-17β. The low estradiol-17β may decrease uterine levels of progesterone receptors, thereby resulting in fetal mortality. Based on biologically and statistically significant decreases in pups/litter and percent fetal survival/per litter, the LOAEL was 25 μg/m^3; no NOAEL was identified.

Neurotoxicity and In Utero Exposure via Inhalation

To evaluate the effects of benzo[a]pyrene on the developing central nervous system, Wormley et al. (2004) exposed timed-pregnant F344 rats (10/group) to benzo[a]pyrene:carbon black aerosols by nose-only inhalation on GDs 11–21 for 4 hours/day at a concentration of 100 μg/m^3. Results of particle size analysis of generated aerosols were reported by other reports from this laboratory (Ramesh et al., 2001a; Hood et al., 2000). Particle size analysis of a 100-μg/m^3 aerosol showed a trimodal distribution (average of cumulative mass, diameter): <95%, 15.85 μm; 90%, <10 μm; 67.5%, <2.5 μm; and 66.2%, <1 μm; the MMAD ± geometric SD for the latter fraction was 0.4 ± 0.02 μm (Hood et al., 2000). Dams were maintained to term and pups were weaned on PND 30. Benzo[a]pyrene reduced the number of live pups to one-third of control values without affecting the number of implantation sites. During PNDs 60–70, electrical stimulation and evoked field potential responses were recorded via electrodes implanted into the brains of the animals. Direct stimulation of perforant paths in the entorhinal region revealed a diminution in long-term potentiation of population spikes across the perforant path-granular cell synapses in the dentate gyrus of the hippocampus of F1 generation benzo[a]pyrene-exposed animals; responses in exposed offspring were about 25% weaker than in control offspring. Additionally, NMDA receptor subunit 1 protein (important for synaptic functioning) was down-regulated in the hippocampus of benzo[a]pyrene-exposed F1 pups. The authors interpreted their results as suggesting that gestational exposure to benzo[a]pyrene inhalation attenuates the capacity for long-term potentiation (a cellular correlate of learning and memory) in the F1 generation.

In another study by this same group of investigators, Wu et al. (2003a) evaluated the generation of benzo[a]pyrene metabolites in F1 generation pups, as well as the developmental profile for AhR and mRNA. In this study, confirmed-pregnant F344 rats were exposed to benzo[a]pyrene:carbon black aerosols at 25, 75, or 100 μg/m^3 via nose-only inhalation, 4 hours/day, for 10 days (GDs 11–21). Control animals either were exposed to carbon black (sham) to control for inert carrier effects or remained untreated. Each benzo[a]pyrene concentration had its own set of controls (carbon black and untreated). Two randomly selected pups were sacrificed on each of PNDs 0, 3, 5, 10, 15, 20, and 30. Body, brain, and liver weights were recorded. Benzo[a]pyrene metabolites were analyzed in the cerebral cortex, hippocampus, liver, and plasma. A dose-related increase in plasma and cortex benzo[a]pyrene metabolite concentrations in pups was observed. Dihydrodiols (4,5-; 7,8-; 9,10-) dominated the metabolite distribution profile up to PND 15 and the hydroxy (3-OH-benzo[a]pyrene; 9-OH-benzo[a]pyrene)

ED_006137A_00009570-00114

metabolites after PND 15 at 100 μg/m³ (the only exposure concentration reported). Results indicated a dose-related decrease in the ratio of the total number of pups born per litter to the total number of implantation sites per litter. The number of resorptions at 75 and 100 μg/m³, but not at 25 μg/m³, was statistically significantly increased compared with controls.

Adult Male Reproductive Effects and Repeated Inhalation Exposure

Inyang et al. (2003) evaluated the effect of subacute exposure to inhaled benzo[a]pyrene on testicular steroidogenesis and epididymal function in rats. Male F344 rats (10/group), 13 weeks of age, were exposed to benzo[a]pyrene:carbon black aerosols at 25, 75, or 100 μg/m³ via nose-only inhalation, 4 hours/day for 10 days. Control animals either were exposed to carbon black (sham) to control for exposure to the inert carrier or remained untreated. Each benzo[a]pyrene concentration had its own set of controls (carbon black and untreated). Aerosols showed a trimodal distribution (average of cumulative mass, diameter): 95%, <15.85 μm; 89%, <10 μm; 55%, <2.5 μm; and 38%, <1 μm (Inyang et al., 2003); an earlier report from this laboratory indicated that the 55% mass fraction had a MMAD ± geometric SD of 1.7 ± 0.085 (Ramesh et al., 2001a). Blood samples were collected at 0, 24, 48, and 72 hours after cessation of exposure to assess the effect of benzo[a]pyrene on systemic concentrations of testosterone and LH, hormones that regulate testosterone synthesis. Reproductive endpoints such as testis weight and motility and density of stored (epididymal) sperm were evaluated.

Regardless of the exposure concentration, inhaled benzo[a]pyrene did not affect testis weight or the density of stored sperm compared with controls. However, inhaled benzo[a]pyrene caused a concentration-dependent reduction in the progressive motility of stored sperm. Progressive motility was similar at 75 and 100 μg/m³, but these values were significantly lower ($p < 0.05$) than in any other group. The reduction in sperm motility postcessation of exposure was thought to be the result of benzo[a]pyrene limiting epididymal function. Benzo[a]pyrene exposure to 75 μg/m³ caused a decrease in circulating concentrations of testosterone compared with controls from the time of cessation of exposure (time 0) to 48 hours posttermination of exposure ($p < 0.05$). However, the decrease was followed by a compensatory increase in testosterone concentration at 72 hours postcessation of exposure. Exposure to 75 μg/m³ caused a nonsignificant increase in plasma LH concentrations at the end of exposure compared with controls, which increased further and turned significant ($p < 0.05$) for the remaining time of the study period. The decreased plasma concentration of testosterone, accompanied by an increased plasma LH level, was thought to indicate that benzo[a]pyrene did not have a direct effect on LH. The authors also noted that the decreased circulating testosterone may have been secondary to induction of liver CYP450 enzymes by benzo[a]pyrene. The authors concluded that subacute exposure to benzo[a]pyrene contributed to impaired testicular endocrine function that ultimately impaired epididymal function. For this study, the NOAEL was 25 μg/m³ and the LOAEL was 75 μg/m³, based on a statistically significant reduction in the progressive motility of stored sperm and impairment of testicular function with 10 days of exposure at 75 μg/m³.

In a follow-up study with longer exposure duration, adult male F344 rats (10 per group) were exposed to benzo[a]pyrene:carbon black aerosols at 75 μg/m³ via nose-only inhalation, 4 hours/day for 60 days (Archibong et al., 2008; Ramesh et al., 2008). Rats in the control group were subjected to the nose-only restraint, but were not exposed to the carbon black carrier. Blood samples were collected at 0, 24, 48, and 72 hours after exposure terminated, and the animals were sacrificed for tissue analyses following the last blood sampling. Data were analyzed statistically for benzo[a]pyrene effects on weekly body weights, total plasma testosterone and LH concentrations, testis weights, density of stored spermatozoa, sperm morphological forms and motility, benzo[a]pyrene metabolite concentrations and aryl hydrocarbon hydroxylase (AHH) activity, and morphometric assessments of testicular histologies. Relative to controls, the results indicated 34% reduced testis weight ($p < 0.025$), reduced daily sperm production ($p < 0.025$), and reduced intratesticular testosterone concentrations ($p < 0.025$). Plasma testosterone concentrations were reduced to about one-third of the level in controls on the last day of exposure (day 60) and at 24, 48, and 72 hours later ($p < 0.05$). However, plasma LH concentrations in benzo[a]pyrene-exposed rats were elevated throughout the blood sampling time periods compared with controls ($p < 0.05$). In testis, lung, and liver, AHH activity and benzo[a]pyrene-7,8-dihydrodiol (precursor to the DNA-reactive BPDE) and benzo[a]pyrene-3,6-dione metabolites were significantly ($p < 0.05$) elevated relative to controls. Progressive motility and mean density of stored spermatozoa were significantly reduced ($p < 0.05$). Weekly body weight gains were not affected by benzo[a]pyrene exposure. These results indicate that a 60-day exposure of adult male rats to benzo[a]pyrene: carbon black aerosols at 75 μg/m³ produced decreased testis weight; decreased intratesticular and plasma testosterone concentrations; and decreased sperm production, motility, and density.

D.5. OTHER PERTINENT TOXICITY INFORMATION

D.5.1. Genotoxicity Information

Information regarding the genotoxicity of benzo[a]pyrene in in vitro and in vivo systems is presented in Tables D-31, D-32, and D-33.

Table D-31. In vitro genotoxicity studies of benzo[a]pyrene in non-mammalian cells

	Result		Reference
	+S9	−S9	
Endpoint/test system: *prokaryotic cells*			
Forward mutation			
Salmonella typhimurium TM677	+	−	Rastetter et al. (1982)
S. typhimurium TM677	+	ND	Babson et al. (1986)
Reverse mutation			

ED_006137A_00009570-00116

	Result		Reference
	+S9	−S9	
S. typhimurium TA98, TA1538	+	ND	Ames et al. (1975)
S. typhimurium TA98, TA100, TA1538	+	ND	Mccann et al. (1975)
S. typhimurium TA1538, TA98	+	−	Wood et al. (1976)
S. typhimurium TA98, TA100, TA1537	+	−	Epler et al. (1977)
S. typhimurium TA98, TA100	+	−	Obermeier and Frohberg (1977)
S. typhimurium TA98	+	−	Pitts et al. (1978)
S. typhimurium TA98, TA100	+	ND	Lavoie et al. (1979)
S. typhimurium TA98, TA100	+	−	Simmon (1979a)
S. typhimurium TA98	+	ND	Hermann (1981)
S. typhimurium TA98, TA100	+	ND	Alfheim and Ramdahl (1984)
S. typhimurium TA98, TA100, TA1538	ND	−	Glatt et al. (1985)
S. typhimurium TA97, TA98, TA100	+	−	Sakai et al. (1985)
S. typhimurium TA97, TA98, TA100, TA1537	+	−	Glatt et al. (1987)
S. typhimurium TA97, TA98, TA100	+	ND	Marino (1987)
S. typhimurium TA98	+	−	Alzieu et al. (1987)
S. typhimurium TA98, TA100	+	−	Prasanna et al. (1987)
S. typhimurium TA98	+	ND	Ampy et al. (1988)
S. typhimurium TA98, TA100	+	ND	Bos et al. (1988)
S. typhimurium TA98	+	ND	Lee and Lin (1988)
S. typhimurium TA98	+	ND	Antignac et al. (1990)
S. typhimurium TA98	−	ND	Gao et al. (1991)
S. typhimurium TA98	+	ND	Balansky et al. (1994)
S. typhimurium TA100	+	ND	Norpoth et al. (1984)
S. typhimurium TA100	+	−	Carver et al. (1986)
S. typhimurium TA100	+	ND	Pahlman and Pelkonen (1987)
S. typhimurium TA100	+	ND	Tang and Friedman (1977)
S. typhimurium TA100	+	ND	Bruce and Heddle (1979)
S. typhimurium TA100	+	ND	Phillipson and Ioannides (1989)
S. typhimurium TA100	−	ND	Balansky et al. (1994)
S. typhimurium TA1537, TA1538	+	−	Ames et al. (1973)
S. typhimurium TA1537, TA1538	+	−	Glatt et al. (1975)
S. typhimurium TA1537	+	ND	Oesch et al. (1976)

	Result		Reference
	+S9	−S9	
S. typhimurium TA1538	+	ND	Egert and Greim (1976)
S. typhimurium TA1538	+	−	Rosenkranz and Poirier (1979)
S. typhimurium TA1535	−	−	Ames et al. (1973)
S. typhimurium TA 1535	−	−	Glatt et al. (1975)
S. typhimurium TA 1535	−	ND	Mccann et al. (1975)
S. typhimurium TA1535	−	−	Epler et al. (1977)
DNA damage			
Escherichia coli/pol A	+	−	Rosenkranz and Poirier (1979)
E. coli/differential killing test	+	−	Tweats (1981)
E. coli WP2-WP100/rec-assay	+	ND	Mamber et al. (1983)
E. coli/SOS chromotest Pq37	+	−	Mersch-Sundermann et al. (1992)
Endpoint/test system: *nonmammalian eukaryotes*			
Mitotic recombination			
Saccharomyces cerevisiae D4-RDII	ND	−	Siebert et al. (1981)
S. cerevisiae D3	−	−	Simmon (1979b)

+ = positive; − = negative; ND = not determined.

Table D-32. In vitro genotoxicity studies of benzo[a]pyrene in mammalian cells

Assay/test system	Result		Reference
	+S9	−S9	
Forward mutation			
Human AHH-1 lymphoblastoid cells	ND	+	Danheiser et al. (1989)
Human lymphoblast (AHH-1) cells (*hprt*)	ND	+	Crespi et al. (1985)
Human lymphoblastoid (AHH-1) cell line	ND	+	Chen et al. (1996)
Human fibroblast (MRC5CV1) cell line (*hprt*)	−	ND	Hanelt et al. (1997)
Human lymphoblast (TK) cells	ND	+	Barfknecht et al. (1982)
Human lymphoblast (TK6) cells	+	ND	Crespi et al. (1985)
Human embryonic epithelial (EUE) cells	ND	+	Rocchi et al. (1980)
Human HSC172 lung fibroblasts	+	−	Gupta and Goldstein (1981)
Human Q3-wp normal lung keratinocytes	+	ND	Allen-Hoffmann and Rheinwald (1984)
Human SCC-13Y lung keratinocytes	ND	+	Allen-Hoffmann and Rheinwald (1984)

ED_006137A_00009570-00118

Assay/test system	Result		Reference
	+S9	−S9	
Mouse *lacZ* transgenic Muta™Mouse primary hepatocytes	ND	+	Chen et al. (2010)
Mouse L5178Y/HGPRT	+	−	Clive et al. (1979)
Mouse lymphoma (L5178Y/TK+/-) cells	+	−	Clive et al. (1979)
Mouse lymphoma (L5178Y/TK+/-) cells	+	ND	(Amacher et al. (1980); Amacher and Turner (1980))
Mouse lymphoma (L5178Y/TK+/-) cells	+	−	Amacher and Paillet (1983)
Mouse lymphoma (L5178Y/TK+/-) cells	+	ND	Arce et al. (1987)
Chinese hamster ovary (CHO) cells (*aprt*)	+	ND	Yang et al. (1999)
CHO cells (5 marker loci)	+	+	Gupta and Singh (1982)
Chinese hamster V79 cells (co-cultured with irradiated HepG2 cells)	+	ND	Diamond et al. (1980)
Chinese hamster V79 lung epithelial cells	+	ND	Huberman et al. (1976)
Chinese hamster V79 lung epithelial cells	+	ND	Arce et al. (1987)
Chinese hamster V79 lung epithelial cells	+	ND	O'Donovan (1990)
Rat/Fischer, embryo cells/OuaR	ND	+	Mishra et al. (1978)
DNA damage			
DNA adducts			
Human peripheral blood lymphocytes	ND	+	Wiencke et al. (1990)
Human peripheral blood lymphocytes	ND	+	Li et al. (2001)
Human peripheral blood lymphocytes	ND	+	Wu et al. (2005)
Human peripheral blood lymphocytes	ND	+	Gu et al. (2008)
Human fibroblast (MRC5CV1) cell line	+	ND	Hanelt et al. (1997)
Human hepatoma (HepG2) cell line	ND	+	Tarantini et al. (2009)
Hamster tracheal cells	ND	+	Roggeband et al. (1994)
Chinese hamster V79 lung epithelial cells	+	ND	Arce et al. (1987)
Virus transformed SHE and mouse C3H10T1/2 cells	ND	+	Arce et al. (1987)
Mouse lymphoma (L5178Y/TK+/-) cells	+	ND	Arce et al. (1987)
Rat tracheal cells	ND	+	Roggeband et al. (1994)
Unscheduled DNA synthesis			
HeLa cells	+	ND	Martin et al. (1978)
Human fibroblasts	+	ND	Agrelo and Amos (1981)
Human fibroblasts	+	−	Robinson and Mitchell (1981)
Human HepG2	ND	+	Valentin-Severin et al. (2004)
Hamster primary embryo cells	ND	+	Casto et al. (1976)
Hamster tracheal cells	ND	+	Roggeband et al. (1994)

Assay/test system	Result		Reference
	+S9	−S9	
Rat hepatocytes	ND	+	Michalopoulos et al. (1978)
Rat tracheal cells	ND	–	Roggeband et al. (1994)
DNA repair			
Human mammary epithelial cells	ND	+	Leadon et al. (1988)
Human skin fibroblasts	ND	+	Milo et al. (1978)
Baby hamster kidney (BHK21/c13) cells	ND	+	Feldman et al. (1978)
secondary mouse embryo fibroblasts (C57BL/6) and human lymphocytes	ND	+	Shinohara and Cerutti (1977)
Rat/F344 hepatocytes	ND	+	Williams et al. (1982)
Cytogenetic damage			
CAs			
Human blood cells	ND	+	Salama et al. (2001)
Human WI38 fibroblasts	+	–	Weinstein et al. (1977)
Chinese hamster lung cells	+	–	Matsuoka et al. (1979)
Chinese hamster V79-4 lung epithelial cells	–	–	Popescu et al. (1977)
Mouse lymphoma (L5178Y/TK+/-) cells	+	ND	Arce et al. (1987)
Rat Liver RL1 cells	+	ND	Dean (1981)
MN			
Human AHH-1 lymphoblastoid cells	ND	+	Crofton-Sleigh et al. (1993)
Human HepG2 liver cells	ND	+	Wu et al. (2003a)
Human lymphoblastoid (TK) cells	ND	+	Fowler et al. (2010)
Human MCL-5 lymphoblastoid cells	ND	+	Crofton-Sleigh et al. (1993)
Human peripheral blood lymphocytes	+	ND	Lo Jacono et al. (1992)
Chinese hamster V79 cells	ND	+	Whitwell et al. (2010)
Chinese hamster V79-MZ cells	ND	+	Matsuoka et al. (1999)
DNA strand breaks			
Human sperm	+	+	Sipinen et al. (2010)
Human peripheral blood lymphocytes	+	+	Rodriguez-Romero et al. (2012)
Human fibroblast (MRC5CV1) cell line	+	ND	Hanelt et al. (1997)
Human hepatoma (HepG2) cell line	ND	+	Tarantini et al. (2009)
Human prostrate carcinoma (DU145) cell line	ND	+	Nwagbara et al. (2007)
Mouse embryo fibroblast (C3H/10T1/2 CL 8) cells	ND	+	Lubet et al. (1983)
Rat C18 trachea epithelial cells	ND	+	(Cosma and Marchok (1988); Cosma et al. (1988))
Rat lymphocytes	ND	+	(Gao et al., 1991)
SCEs			

ED_006137A_00009570-00120

Assay/test system	Result		Reference
	+S9	−S9	
Human C-HC-4 and C-HC-20 hepatoma cells	ND	+	(Abe et al. (1983a), 1983b))
Human diploid fibroblast (TIG-II) cell line	+	+	Huh et al. (1982)
Human fibroblasts	ND	+	Juhl et al. (1978)
Human blood cells	ND	+	Salama et al. (2001)
Human peripheral blood lymphocytes	ND	+	Rudiger et al. (1976)
Human peripheral blood lymphocytes	ND	+	Craig-Holmes and Shaw (1977)
Human peripheral blood lymphocytes	ND	+	Schonwald et al. (1977)
Human peripheral blood lymphocytes	ND	+	Wiencke et al. (1990)
Human peripheral blood lymphocytes	+	−	Tohda et al. (1980)
Human peripheral blood lymphocytes	+	ND	Lo Jacono et al. (1992)
Chinese hamster Don-6 cells	ND	+	(Abe et al. (1983a), 1983b))
Chinese hamster V79 lung epithelial cells	+	−	Popescu et al. (1977)
Chinese hamster V79 lung epithelial cells	+	ND	Mane et al. (1990)
Chinese hamster V79 lung epithelial cells	+	ND	Wojciechowski et al. (1981)
Chinese hamster V79 lung epithelial cells	+	ND	Arce et al. (1987)
Chinese hamster V79 lung epithelial cells	ND	+	Kulka et al. (1993a)
CHO cells	+	−	de Raat (1979)
CHO cells	+	−	Husgafvel-Pursiainen et al. (1986)
CHO cells	ND	+	Wolff and Takehisa (1977)
CHO cells	ND	+	Pal et al. (1978)
Chinese hamster lung cells	ND	+	Shimizu et al. (1984)
Rabbit peripheral blood lymphocytes	ND	+	Takehisa and Wolff (1978)
Rat ascites hepatoma AH66-B	ND	+	(Abe et al. (1983a), 1983b))
Rat esophageal tumor R1	ND	+	(Abe et al. (1983a), 1983b))
Rat hepatocyte (immortalized) cell lines (NRL cl-B, NRL cl-C, and ARL)	+	ND	Kulka et al. (1993b)
Rat hepatoma (Reuber H4-II-E) cells	ND	+	Dean et al. (1983)
Rat liver cell line ARL18	ND	+	Tong et al. (1981)
Rat pleural mesothelial cells	ND	+	Achard et al. (1987)
Aneuploidy			
Chinese hamster V79-MZ cells	ND	+	Matsuoka et al. (1998)
Cell transformation			
Human BEAS-2B lung cells	ND	+	van Agen et al. (1997)
Human breast epithelial (MCF-10F, MCF-7, T24) cell lines	ND	+	Calaf and Russo (1993)
Baby hamster kidney (BHK21/c13) cells	+	ND	Greb et al. (1980)

ED_006137A_00009570-00121

Assay/test system	Result		Reference
	+S9	−S9	
Golden hamster embryo cells	+	ND	Mager et al. (1977)
Syrian hamster embryo (SHE) cells	ND	+	(Dipaolo et al. (1971); Dipaolo et al. (1969))
SHE cells	ND	+	Dunkel et al. (1981)
SHE cells	ND	+	Leboeuf et al. (1990)
SHE cells/focus assay	ND	+	Casto et al. (1977)
Fetal Syrian hamster lung cells	ND	+	(Emura et al. (1987); Emura et al. (1980))
Virus infected rat embryo RLV/RE and RAT cells; mouse embryo AKR/Me cells; Syrian hamster embryo cells	ND	+	Heidelberger et al. (1983)
Virus transformed SHE and mouse C3H10T1/2 cells	ND	+	Arce et al. (1987)
Mouse C3H/10T1/2 embryo fibroblasts	ND	+	(Nesnow et al. (2002); Nesnow et al. (1997))
Mouse embryo fibroblast (C3H/10T1/2 CL 8) cells	ND	+	Peterson et al. (1981)
Mouse embryo fibroblast (C3H/10T1/2 CL 8) cells	ND	+	Lubet et al. (1983)
Mouse SHE cells; BALB/c-3t3 cells; C3H/10T1/2 cells; prostate cells	ND	+	Heidelberger et al. (1983)
Mouse BALB/c-3T3 cells	ND	+	Dunkel et al. (1981)
Mouse BALB/c-3T3 cells	ND	+	Matthews (1993)
Mouse BALB/c-3T3 clone A31-1-1	ND	+	Little and Vetrovs (1988)
Rat/Fischer, embryo cells (leukemia virus transformed)	ND	+	Dunkel et al. (1981)
Rat/Fischer, embryo cells/Oua^{R}	ND	+	Mishra et al. (1978)

+ = positive; − = negative; CHO = Chinese hamster ovary; ND = not determined; SHE = Syrian hamster embryo; TK = thymidine kinase.

ED_006137A_00009570-00122

1 **Table D-33. In vivo genotoxicity studies of benzo[a]pyrene**

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutation	Human, blood T lymphocytes (smokers and nonsmokers); hprt locus mutation assay	T-cells of lung cancer patients (smokers and nonsmokers from lung cancer patients and population controls with known smoking status) analyzed for hprt locus mutations.	+	Smokers and nonsmokers	Splicing mutations, base-pair substitutions, frameshift, and deletion mutations observed. Smokers and nonsmokers had GC→TA transversions (13 and 6%, respectively) and GC→AT transitions (24 and 35%, respectively) in hprt gene consistent with in vitro mutagenicity of benzo[a]pyrene.	Hackman et al. (2000)
Mutation, germline	Mouse, T-stock, (SEC × C57BL)F1, (C3H × 101)F1, or (C3H × C57BL)F1 for females; (101 × C3H)F1 or (C3H × 101)F1 for males; dominant-lethal mutation assay	12-wk-old males dosed with benzo[a]pyrene i.p. and mated 3.5–6.5 d posttreatment with 12-wk-old females from different stocks; sacrificed on d 12–15 after vaginal plug was observed; females kept in a 5-hr dark phase to synchronize ovulation 5 wks before the start of the experiment; fertilized eggs collected 9–11 hrs after mating and first-cleavage metaphase chromosomes prepared 20 hrs after mating.	+	500 mg/kg	The percent of dominant lethal mutations were in the order of T-stock = (C3H × 101)F1 > (SEC × C57BL)F1 > (C3H × C57BL)F1.	Generoso et al. (1979)
Mutation, germline	Mouse, male stocks: (101 × C3H)F1; female stocks (A): (101 × C3H)F1, (B): (C3H × 101)F1, (C): (C3H × C57BL)F1, (D):(SEC × C57BL)F1, (E):T-stock females; dominant lethal mutations	In dominant lethal assay, 12-wk-old males dosed i.p. with benzo[a]pyrene and mated with 10–12-wk-old (#1) stock A females; or (#2) stock B females on the day of dosing; or with (#3a) with stocks B, C, and D females 3.5–7.5 d postdosing, or with (#3b) with stocks B, C, D, and E females 3.5–6.5 d postdosing. Control group mated at time corresponding to 1.5–4.5 d posttreatment in the test groups.	+	500 mg/kg	Dominant lethal effects were observed in early to middle (4.5–5.5 and 6.5–7.5 d posttreatment, respectively) spermatozoa and in preleptotene spermatocytes (32.5–33.5 and 34.5–35.5 d posttreatment).	Generoso et al. (1982)

ED_006137A_00009570-00123

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutation, germline	Mouse, male stocks: (101 × C3H)F1; female stocks (A): (101 × C3H)F1, (B): (C3H × 101)F1, (C): (C3H × C57BL)F1, (D): (SEC × C57BL)F1, (E): T-stock females; heritable translocations	For heritable translocation assay, males were mated with stocks B and D females 3.5–7.7 d post-benzo[a]pyrene treatment and male progeny screened for translocation heterozygosity.	–	500 mg/kg	No significant differences were observed between treated and control progeny.	Generoso et al. (1982)
Mutations and BPDE-DNA adducts, germline	Mouse, C57BL/6, *cII* transgenic (Big Blue®)	Benzo[a]pyrene administered i.p. in corn oil on d 0, 1, and 2; sacrificed at d 4, 16, 30, 44, or 119. Caput and cauda epididymal spermatozoa analyzed for *cII* mutation frequency, and DNA adducts analyzed in testis by liquid chromatography-MS/MS selected reaction monitoring with ^{15}N-deoxyguanosine labeling.	+	50 mg/kg	Exposed spermatocytes acquired persistent BPDE-DNA adducts; exposed spermatogonia gave rise to spermatocytes with mutations consistent with a benzo[a]pyrene spectrum (GC>TA transversions).	Olsen et al. (2010)
Mutations and BPDE-DNA adducts, germline	Mouse, C57BL/6 males, WT and Xpc$^{-/-}$ with pUR288 *lacZ* reporter gene	Benzo[a]pyrene given via gavage in sunflower oil 3 times/wk for 1, 4, or 6 wks (Xpc$^{-/-}$) or 6 wks (WT). Spleen, testis, and sperm cells analyzed for *lacZ* mutation frequency, and DNA adducts analyzed in testis by [^{32}P]-postlabeling.	+	13 mg/kg	Statistically significant increases in lacZ mutation frequencies in Xpc$^{-/-}$ spleen at 4 and 6 wks (dose dependent) and in WT spleen and sperm at 6 wks; DNA adducts were statistically significant in testis in all exposed groups.	Verhofstad et al. (2011)

ED_006137A_00009570-00124

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutations and BPDE-DNA adducts	Mouse, C57BL/6 *lacZ* transgenic	Mice dosed with single i.p. injection of benzo[a]pyrene in DMSO; sacrificed 1, 3, 5, 7, 14, 21, and 28 d posttreatment; spleen, lung, liver, kidney, and brain collected, DNA isolated and analyzed for mutations in *lacZ* reporter gene in *E. coli* and adducts by [^{32}P]-postlabeling assay.	+	50 mg/kg	BPDE-dG adduct levels peaked between 5 and 7 d posttreatment, followed by gradual decline; rate of removal highest in lung, liver, and spleen and lowest in kidney and brain; mutant frequencies peaked between 7 and 14 d in lung, spleen, liver, and kidney; brain was not significant at any time point.	Boerrigter (1999)
Mutation	Mouse, C57BL female × T-strain male; somatic mutation assay	Mice mated for a 5-d period; 10.25 d post-appearance of vaginal plug, females injected i.p. with benzo[a]pyrene or vehicle; offspring (pups) scored for survival, morphology, and presence of white near-midline ventral spots and recessive spots.	+	100 or 500 mg/kg	Induced coat color mosaics represent genetic changes (e.g., point mutations) in somatic cells. White near-midline ventral spots and recessive spots represent melanocyte cell killing and mutagenicity, respectively. Benzo[a]pyrene caused high incidence of recessive spots but did not correlate with white near-midline ventral spots.	Russell (1977)
Mutation	Mouse, *lacZ* transgenic (Muta™Mouse)	Benzo[a]pyrene given via gavage in olive oil daily for 28 consecutive d; sacrificed 3 d after last dosing; four organs analyzed for *lacZ* mutation frequency.	+	25, 50, and 75 mg/kg-d	Highest *lacZ* mutation frequency observed in small intestine, followed by bone marrow, glandular stomach, and liver.	Lemieux et al. (2011)
Mutation	Mouse, *lacZ* transgenic (Muta™Mouse)	Benzo[a]pyrene given orally in corn oil for 5 consecutive d; sacrificed 14 d after last dosing; 11 organs analyzed for *lacZ* mutation frequency.	+	125 mg/kg-d	Highest mutation frequency observed in colon followed by ileum > forestomach > bone marrow = spleen > glandular stomach > liver = lung > kidney = heart.	Hakura et al. (1998)

ED_006137A_00009570-00125

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutation	Mouse, C57BL/6J *Dlb-1* congenic; *Dlb-1* locus assay	Animals dosed: (1) i.p. with vehicle or benzo[a]pyrene two, four, or six doses at 96-hr intervals; or (2) single dose of benzo[a]pyrene given i.p. or orally alone or 96 hrs following a single i.p. dosing with 10 µg/kg TCDD.	+	40 mg/kg	Benzo[a]pyrene caused a dose-dependent increase in mutant frequency; i.p. route showed higher mutant frequency than oral route; induction of mutations were associated with Ah-responsiveness.	Brooks et al. (1999)
Mutation	Mouse, C57BL/6 (*lacZ* negative and $XPA^{+/+}$ and $XPA^{-/-}$); hprt mutations in T lymphocytes	Gavage in corn oil 3 times/wk for 0, 1, 5, 9, or 13 wks; sacrificed 7 wks after last treatment.	+	13 mg/kg	Mutation sensitivity: $XPA^{-/-} > XPA^{+/+}$.	Bol et al. (1998)
Mutation	Mouse, Cockayne syndrome-deficient ($Csb^{-/-}$); heterozygous ($Csb^{+/-}$) and WT controls ($Csb^{+/+}$); hprt mutation frequency assay	$Csb^{-/-}/lacZ^{+/-}$ and $Csb^{+/-}/lacZ^{+/-}$ mice were dosed i.p. with benzo[a]pyrene 3 times/wk for 5, 9, or 13 wks; for hprt mutation frequency analysis mice were sacrificed 3 wks after last treatment; splenocytes collected; for *lacZ* mutation frequency analysis, mice were sacrificed 3 d after last treatment and liver, lung, and spleen were collected.	+	13 mg/kg	*lacZ* mutation frequency detected in all tissues but no differences between WT and $Csb^{-/-}$ mice; hprt mutations significantly higher in $Csb^{-/-}$ mice than control mice. BPDE-dGuo adducts in hprt gene are preferentially removed in WT mice than $Csb^{-/-}$ mice.	Wijnhoven et al. (2000)
Mutation	Mouse, $B6C3F_1$, forestomach H-*ras*, K-*ras*, and *p53* mutations	Benzo[a]pyrene given in feed in a 2-yr chronic feeding study.	+	5, 25, or 100 ppm	68% K-*ras* (codons 12, 13), 10% H-*ras* (codon 13), 10% *p53* mutations; all G→T transversions.	Culp et al. (2000)
Mutation	Mouse, *lacZ/galE* (Muta™ Mouse); skin painting study	Mice topically treated with a single dose or in five divided doses daily; sacrificed 7 or 21 d after the single or final treatment; DNA from skin, liver, and lung analyzed for mutations.	$+^{Sk}$ or $-^{Li,Lu}$	1.25 or 2.5 mg/kg (25 or 50 µg/mouse)	Skin showed significant dose- and time-dependent increase in mutation frequency; liver and lung showed no mutations; mutation frequency for single- or multiple-dose regimens was similar.	Dean et al. (1998)

ED_006137A_00009570-00126

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutation	Mouse, T-strain	Benzo[a]pyrene given to pregnant mice by gavage in 0.5 mL corn oil on GDs 5–10.	+	10 mg/mouse (5 × 2 mg)		Davidson and Dawson (1976)
Mutation	Mouse, 129/Ola (WT); hprt mutations in splenic T lymphocytes	Single i.p. injection followed by sacrifice 7 wks posttreatment.	+	0, 50, 100, 200, or 400 mg/kg	Dose-dependent increase in hprt mutation frequency.	Bol et al. (1998)
Mutation	Mouse, A/J, male	Single i.p. injection followed by sacrifice 28 days posttreatment.	+	0, 0.05, 0.5, 5, or 50 mg/kg	Dose-dependent increase in lung tissue K-*ras* codon 12 G→T mutation frequency.	Meng et al. (2010)
Mutation	Mouse, CD-1; skin papillomas (Ha-*ras* mutations)	Female mice were initiated topically with a single dose of benzo[a]pyrene and 1 wk after initiation promoted twice weekly with 5 nmol TPA for 14 wks. One month after stopping TPA application, papillomas were collected and DNA from 10 individual papillomas was analyzed for Ha-*ras* mutations by polymerase chain reaction and direct sequencing.	+	600 nmol/mouse	About 90% of papillomas contained Ha-*ras* mutations, all of them being transversions at codons 12 (20% GGA→GTA), 13 (50% GGC→GTC), and 61 (20% CAA→CTA).	Colapietro et al. (1993)
Mutation	Rat, Wistar	Single dose by gavage; urine and feces collected 0–24, 24–48, and 48–72 hrs posttreatment; urine and extracts of feces tested in *S. typhimurium* TA100 strain with or without S9 mix and β-glucuronidase.	+	0, 1, 5, 10, or 100 mg/kg	Fecal extracts and urine showed mutagenicity ≥1 and 10 mg/kg body weight benzo[a]pyrene, respectively. Highest mutagenic activity observed for 0–24 hrs posttreatment for feces and 24–48 hrs posttreatment for urine with β-glucuronidase ± S9 mix.	Willems et al. (1991)

ED_006137A_00009570-00127

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
BPDE-DNA adducts	Human, WBCs	96 people occupationally or medically exposed to PAH mixtures (psoriatic patients, coke oven workers, chimney sweeps, and aluminum anode plant workers); adducts measured by HPLC/fluorescence analysis.	+		Percentages of subjects with adduct levels greater than the 95th percentile control value were 47% (7/15), 21% (4/19), and 3% (1/34) in coke oven workers, chimney sweeps, and controls, respectively.	Pavanello et al. (1999)
BPDE-DNA adducts	Human, WBCs	67 highly exposed coke oven workers were tested for genetic factors that can modulate individual responses to carcinogenic PAHs; adducts measured by HPLC/fluorescence analysis.	+		Levels of BPDE-DNA adducts were significantly associated with workplace PAH exposure (as correlated with urinary excretion of 1-pyrenol), lack of GSTM1 activity, and low nucleotide excision repair capacity.	Pavanello et al. (2005)
BPDE-DNA adducts	Human, peripheral lymphocytes	585 Caucasian municipal workers (52% males, 20–62 years old) from northeast Italy environmentally exposed to PAH mixtures were screened for adducts measured by HPLC/fluorescence analysis.	+		Forty-two percent of the participants had elevated anti-BPDE-DNA adduct levels, defined as >0.5 adducts/ 108 nucleotides (mean, 1.28 ± 2.80 adducts/ 108 nucleotides). Comparison of adduct levels with questionnaire responses indicated that smoking, frequent consumption of PAH-rich meals (>52 versus <52 times/yr), and long time periods spent outdoors (>4 versus <4 hrs/d) were risk factors as all increased BPDE-DNA adduct levels significantly.	Pavanello et al. (2006)

ED_006137A_00009570-00128

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
BPDE-DNA adducts	Human, maternal and umbilical cord blood	Maternal and umbilical cord blood obtained following normal delivery from 329 nonsmoking pregnant women exposed to emissions from fires during the 4 wks following the collapse of the WTC building in New York City on 09/11/2001.	+		BPDE-DNA adduct levels in cord and maternal blood were highest in study participants who lived within 1 mile of the WTC, with inverse correlation between cord blood levels and distance from WTC.	Perera et al. (2005b)
BPDE-DNA adducts	Human, WBCs	Workers were exposed for 6–8 hrs/d for at least 4–6 mo before blood collection; leukocyte DNA isolated and digested, and benzo[a]pyrene tetrols analyzed by HPLC with fluorescent detection. Low, medium, and high exposure groups correspond to <0.15, 0.15–4, and >4 mg/m^3 of benzo[a]pyrene, respectively.	+	<0.15, 0.15–4, or >4 μg/m^3 of benzo[a]pyrene	PAH exposure, CYP1A1 status and smoking significantly affected DNA adduct levels, i.e., *CYP1A1*(**1/*2* or **2A/*2*a) > *CYP1A1*1/*1*; occupational > environmental exposure; smokers > nonsmokers; adducts increased with dose and duration of smoking.	Rojas et al. (2000)
BPDE-DNA adducts	Human, WBCs	Coke oven workers were exposed to PAHs and benzo[a]pyrene-WBC DNA analyzed by HPLC-fluorescence detection for BPDE-DNA adducts.	±	0.14 μg/m^3	Median detectable BPDE-DNA adducts in workers versus controls not significant due to low number of subjects (9 workers, 26 controls); 4/9 workers had adducts substantially higher than all controls. No significant difference between smokers and nonsmokers; no correlation with air benzo[a]pyrene levels and adduct levels.	Mensing et al. (2005)
BPDE-DNA adducts	Mouse, *lacZ* transgenic (Muta™Mouse)	Benzo[a]pyrene given via gavage in olive oil daily for 28 consecutive d; sacrificed 3 d after last dosing; four organs analyzed for DNA adducts using [^{32}P]-postlabeling with nuclease P1 digestion enrichment.	+	25, 50, and 75 mg/kg-day	Highest adduct levels observed in liver, followed by glandular stomach, small intestine, and bone marrow.	Lemieux et al. (2011)

ED_006137A_00009570-00129

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
BPDE-DNA adducts	Mouse, (*Ahr*$^{+/+}$, *Ahr*$^{+/-}$, *Ahr*$^{-/-}$)	Gavage; sacrificed 24 hrs posttreatment.	+	100 mg/kg	No induction of CYP in *Ahr*$^{-/-}$, but all alleles positive for adduct formation.	Sagredo et al. (2006)
BPDE-DNA adducts	Mouse, C57BL/6J *Cyp1a1*(+/-) and *Cyp1a1* (-/-)	Single i.p. injection; sacrificed 24 hrs posttreatment; liver DNA analyzed by [^{32}P]-postlabeling assay.	+	500 mg/kg	BPDE-DNA adduct levels fourfold higher in *Cyp1a1*(-/-) mice than *Cyp1a1*(+/-) mice.	Uno et al. (2001)
BPDE-DNA adducts	Mouse, B6C3F$_1$	Benzo[a]pyrene fed in diet for 4 wks (100 ppm) or for 1, 2, 8, 16, and 32 wks (5 ppm); sacrificed and liver, lungs, forestomach, and small intestine collected; DNA analyzed by [^{32}P]-postlabeling assay.	+	5 ppm (32 wks) and 100 ppm (4 wks)	Linear dose-response in 4-wk study; the 5 ppm groups showed a plateau after 4 wks of feeding.	Culp et al. (2000)
BPDE-DNA adducts	Mouse, BALB/c	Single i.p. injection; sacrificed 12 hrs postinjection; liver and forestomach collected; DNA binding of [^{3}H]-benzo[a]-pyrene analyzed by scintillation counting.	+	140 µCi/100 g body weight	Liver DNA had threefold higher binding of benzo[a]pyrene than that of forestomach.	Gangar et al. (2006)
BPDE-DNA adducts	Mouse, BALB/cAnN (BALB), CBA/JN (CBA); [^{32}P]-postlabeling assay	Animals dosed i.p. with or without 24-hr pretreatment with TCDD.	+	50 and 200 mg/kg	Adduct levels similar in both strains dosed with benzo[a]pyrene alone. TCDD pretreatment had a greater suppressive effect on adduct formation in BALB relative to CBA mice at low dose but resulted in no significant difference in adduct levels at high dose.	Wu et al. (2008)
BPDE-DNA adducts	Mouse, BALB/c, skin	Four doses of benzo[a]pyrene topically applied to the shaved backs of animals at 0, 6, 30, and 54 hrs; sacrificed 1 d after last treatment; DNA analyzed by [^{32}P]-postlabeling assay.	+	4 × 1.2 µmol/ animal	Five adducts spots detected.	Reddy et al. (1984)

ED_006137A_00009570-00130

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
BPDE-DNA adducts	Mouse, Swiss, epidermal and dermal skin	Single topical application on shaved backs; sacrificed 1, 3, and 7 d posttreatment; epidermal and dermal cells separated; DNA isolated, digested with DNAseI, and estimated DNA binding; adducts separated by HPLC.	+	250 nmol in 150 µL acetone	Both cells positive for benzo[a]pyrene adducts; epidermis > dermis; adducts persisted up to 7 d with a gradual decline in levels.	Oueslati et al. (1992)
BPDE-DNA adducts	Rat, CD, peripheral blood lymphocytes, lungs, and liver	Single i.p. injection; sacrificed 3 d posttreatment; DNA analyzed by Nuclease P1-enhanced [^{32}P]-postlabeling assay.	+	2.5 mg/animal	BPDE-dG as major adducts and several minor adducts detected in all tissues.	Ross et al. (1991)
BPDE-DNA adducts	Rat, Sprague-Dawley, liver	Single i.p. injection followed by sacrifice at 4 hrs posttreatment; liver DNA isolated and analyzed by [^{32}P]-postlabeling assay.	+	100 mg/kg	Two adduct spots detected.	Reddy et al. (1984)
BPDE-DNA adducts	Rat, Lewis, lung and liver	Animals received a single oral dose of benzo[a]pyrene in tricaprylin; sacrificed 1, 2, 4, 11, and 21 d postdosing; analyzed liver and lung DNA for BP-DNA adducts by [^{32}P]-postlabeling assay and urine for 8-oxo-7,8-dihydro-2'-deoxyguanosine adducts by HPLC-electrochemical detection.	+	10 mg/kg	BPDE-dG levels peaked 2 d after exposure in both tissues, higher in lungs than liver at all time points, decline faster in liver than lung; Increased 8-oxo-7,8-dihydro-2'-deoxyguanosine levels in urine and decreased levels in liver and lung.	Briedé et al. (2004)
BPDE-DNA adducts	Rat, F344; [^{32}P]-postlabeling assay	Benzo[a]pyrene given in the diet for 30, 60, or 90 d; animals sacrificed and liver and lung isolated and DNA extracted and analyzed for adducts.	+	0, 5, 50, or 100 mg/kg	Adduct levels linear at low and intermediate doses, nonlinear at high dose.	Ramesh and Knuckles (2006)
BPDE-DNA adducts	Rat, Wistar; liver and peripheral blood lymphocyte adducts	Single dose by gavage; sacrificed 24 hrs postdosing; peripheral blood lymphocytes and liver DNA analyzed by [^{32}P]-postlabeling for BPDE-DNA adducts.	+	0, 10, or 100 mg/kg	At 100 mg/kg dose, total adduct levels in peripheral blood lymphocytes were twofold higher than the levels in liver; adduct profiles differed between peripheral blood lymphocytes and liver.	Willems et al. (1991)

ED_006137A_00009570-00131

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
CAs	Mouse, C57 (high AHH inducible) and DBA (low AHH inducible) strains; 11-d-old embryos; adult bone marrows	Study used four matings (female × male): C57 × C57; DBA × DBA; C57 × DBA; and DBA × C57; pregnant mice treated orally on GD 11 with benzo[a]pyrene; sacrificed 15 hrs posttreatment; material liver, bone marrow and placenta and embryos collected; male mice dosed similarly and bone marrows collected; individual embryo cell suspensions and bone marrow preparations scored for CAs. Tissue AHH activity measured.	+	150 mg/kg	Levels of CAs: hybrid embryos > homozygous DBA embryos > homozygous C57 embryos; tissue AHH activity: C57 mothers and their embryos > DBA females and their homozygous embryos. No quantitative correlation between benzo[a]pyrene-induced CAs and AHH inducibility. No differences in bone marrow mitotic index of males of different strains between control and treatment groups.	Adler et al. (1989)
CAs	Mouse, 1C3F1 hybrid (101/E1 × C31 × E1)F1; CAs in bone marrow	Single dose by gavage; sacrificed 30 hrs postdosing; bone marrow from femur isolated and analyzed for CAs.	+	63 mg/kg	Significant increase in CAs in benzo[a]pyrene-treated animals compared to controls.	Adler and Ingwersen (1989)
CAs	Rat, Wistar; peripheral blood lymphocytes	Single dose by gavage; sacrificed 6, 24, and 48 hrs posttreatment; blood from abdominal aorta collected, whole blood cultures set up, CAs scored in 100 first-division peripheral blood lymphocytes per animal.	–	0, 10, 100, or 200 mg/kg	No difference between control and treatment groups at any dose or at any sampling time observed.	Willems et al. (1991)
CAs	Hamster; bone marrow	Single, i.p. injection of benzo[a]pyrene dissolved in tricapryline; animals sacrificed 24 hrs post-exposure.	+	25, 50, or 100 mg/kg	Benzo[a]pyrene induced CAs at 50 mg/kg body weight only, with negative responses at the low and high dose.	Bayer (1978)
MN	Mouse, *lacZ* transgenic (Muta™Mouse)	Benzo[a]pyrene given via gavage in olive oil daily for 28 consecutive d; blood samples were collected 48 h after last dose; percent of PCEs and NCEs reported.	+	25, 50, and 75 mg/kg-d	Statistically significant, dose-dependent increases in percent of PCEs and NCEs at all doses.	Lemieux et al. (2011)

ED_006137A_00009570-00132

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
MN	Mouse, CD-1 and BDF1; bone marrow	Dosed orally once, twice, or thrice at 24-hr intervals; sacrificed 24 hrs after last treatment.	+	250, 500, 1,000, or 2,000 mg/kg	Significant increase at all doses; no dose-response; double dosing at 500 mg/kg dose gave best response.	Shimada et al. (1990)
MN	Mouse, CD-1 and BDF1, peripheral blood reticulocytes	Given single i.p injection; tail blood collected at 24-hr intervals from 0 to 72 hrs.	+	62.5, 125, 250, or 500 mg/kg	Maximum response seen at 48 hrs posttreatment.	Shimada et al. (1992)
MN	Mouse, ICR [Hsd: (ICR)Br]	Benzo[a]pyrene was heated in olive oil and given orally as a single dose; males, females, and pregnant mothers used; pregnant mice dosed on GDs 16–17 and sacrificed on GDs 17–18; micronuclei evaluated in adult bone marrow and fetal liver.	+	150 mg/kg	All groups significantly higher than controls for MN; fetal liver more sensitive than any other group.	Harper et al. (1989)
MN	Mouse, Swiss albino; bone marrow	Given orally in corn oil; sacrificed 24 hrs post-exposure.	+	75 mg/kg		Koratkar et al. (1993)
MN	Mouse, Swiss; bone marrow polychromatic erythrocytes	Given by gavage and sacrificed 36 hrs posttreatment.	+	75 mg/kg		Rao and Nandan (1990)
MN	Mouse, CD-1 and MS/Ae strains	i.p. and oral administration.	+	62.5, 125, 250, or 500 mg/kg	Good dose-response by both routes, strains; i.p. better than oral; MS/Ae strain more sensitive than CD-1 strain.	Awogi and Sato (1989)
MN	Mouse, BDF1, bone marrow	Male and female mice aged 12–15 wks given single i.p. injection of benzo[a]pyrene or corn oil; sacrificed 24, 48, and 72 hrs posttreatment; bone marrow smears prepared, stained with May-Grunwald-Giemsa technique and scored for MN PCEs.	+	0, 25, 50, or 60 mg/kg	Positive at all doses, time points, and sexes tested. Dose-dependent increase in MN observed in both sexes; males responded better than females; highest positive response observed at 72 hrs postinjection.	Balansky et al. (1994)

ED_006137A_00009570-00133

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
MN	Mouse, HRA/Skh hairless, keratinocytes	Single topical application.	+	0.5, 5, 50, 100, or 500 mg/mouse		He and Baker (1991)
MN	Mouse, HOS:HR-1, hairless; skin micronuclei	Topical application once daily for 3 d; sacrificed 24 hrs after last treatment.	+	0.4, 1, 2, or 4 mg		Nishikawa et al. (2005)
MN	Mouse, HR-1 hairless, skin (benzo[a]pyrene with slight radiation)		+		Exposure to sunlight simulator to evaluate photogenotoxicity and chemical exposure.	Hara et al. (2007)
MN	Rat, Sprague-Dawley, peripheral blood reticulocytes	Given single i.p injection; tail blood collected at 24-hr intervals from 0 to 96 hrs.	+	62.5, 125, 250, 500, or 1,000 mg/kg	Maximum response seen at 72 hrs posttreatment.	Shimada et al. (1992)
MN	Rat, Sprague-Dawley, pulmonary alveolar macrophages	Intratracheal instillation, once/day for 3 d.	+	25 mg/kg		De Flora et al. (1991)
MN	Rat, Sprague-Dawley, bone marrow cells	Intratracheal instillation, once/day for 3 d.	–	25 mg/kg		De Flora et al. (1991)
MN	Hamster; bone marrow	Single, i.p. injection of benzo[a]pyrene dissolved in tricaprylin; animals sacrificed 30 hrs post-exposure.	–	100, 300, or 500 mg/kg		Bayer (1978)
MN	Fish (carp, rainbow trout, clams); blood and hemolymph		+	0.05, 0.25, 0.5, or1 ppm		Kim and Hyun (2006)

ED_006137A_00009570-00134

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
DNA strand breaks	Rat, Sprague-Dawley; comet assay	Instilled intratracheally with: (1) single dose of benzo[a]pyrene in aqueous suspension; sacrificed at 3, 24, and 48 hrs posttreatment; alveolar macrophages, lung cells, lymphocytes, and hepatocytes collected or (2) dose-response study and sacrificed at 24 hrs posttreatment; lungs collected; controls received normal saline instillation; all cells analyzed by comet assay.	+	Experiment #1: 3 mg of benzo[a]pyrene; Experiment #2: dose-response study with 0.75, 1.5, or 3 mg benzo[a]pyrene	All time points showed significant increase in SSBs (Experiment #1); a dose-response in SSBs was observed (Experiment #2).	(Garry et al. (2003a), 2003b))
DNA strand breaks	Aquatic organisms: carp (*Cyprinus carpio*), rainbow trout (*Oncorhynchus mykiss*), and clams (*Spisula sachalinensis*); Comet assay	All organisms acclimatized in tanks for 2 d, water changed every 24 hrs; exposed to benzo[a]pyrene in DMSO in a tank; one-third volume of tank contents changed every 12 hrs; organisms sacrificed at 24, 48, 72, and 96 hrs posttreatment; cell suspensions prepared from liver (carp and trout) or digestive gland (clam) for comet assay.	+	0.05, 0.25, 0.5, and 1 ppm	Significant dose-response for strand breaks observed; carp and trout liver showed highest response at 48 hrs and clam digestive gland showed time-dependent increase at highest concentration.	Kim and Hyun (2006)
DNA strand breaks	Rat, Brown Norway	UDS determined after 5 and 18 hrs of a single intragastric dosing.	–	62.5 mg/kg	Negative at both time points.	Mullaart et al. (1989)
UDS	Rat, F344	Single i.p. injection of benzo[a]pyrene or DMSO; sacrificed at 2 or 12 hrs post-exposure; liver isolated, hepatocyte cultures were set up and incubated with 10 mCi/mL [^{3}H]-thymidine for 4 hrs; washed and autoradiography performed.	–	100 mg/kg	Benzo[a]pyrene was negative at both time points.	Mirsalis et al. (1982)

ED_006137A_00009570-00135

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
UDS	Mouse, HOS:HR-1 hairless; skin	Single topical application on two spots on the backs after stripping stratum corneum with adhesive tape to enhance penetration; sacrificed 24 hrs posttreatment, skin isolated [^{3}H]-thymidine; cultured; epidermal UDS measured.	+	0, 0.25, 0.5, and 1% (w/v) in acetone	UDS index showed a dose-dependent increase up to 0.5% benzo[a]pyrene dose and then plateaued.	Mori et al. (1999)
UDS	Rat, Brown Norway; liver	Single intragastric injection; sacrificed at 5 and 18 hrs post-injection.	–	62.5 mg/kg	Benzo[a]pyrene was negative at both time points.	Mullaart et al. (1989)
UDS	Mouse, (C3Hf × 101)F1 hybrid, germ cells	i.p. injection of benzo[a]pyrene; [^{3}H]-thymidine injection later.	–	0.3 mL	Concentration not specified.	Sega (1979)
UDS	Mouse, early spermatid	i.p. injection.	–	250–500 mg/kg	Reviewed by Sotomayor and Sega (2000).	Sega (1982)
SCEs	Hamster; SCEs in bone marrow	8–12-wk-old animals dosed with two i.p. injections of benzo[a]pyrene given 24 hrs apart; animals sacrificed 24 hrs after last treatment; bone marrow from femur isolated and metaphases analyzed.	+	450 mg/kg	Significant increase in metaphase SCEs in benzo[a]pyrene-treated animals compared to vehicle-treated controls.	Roszinsky-Köcher et al. (1979)
SCEs	Hamster	Animals implanted subcutaneously (s.c.) with BrdU tablet; 2 hrs later given phorone (125 or 250 mg/kg) i.p.; another 2 hrs later dosed i.p. with benzo[a]pyrene; 24 hrs post-BrdU dosing, animals injected with colchicine 10 mg/kg body weight, sacrificed 2 hrs later; bone marrow from femur prepared for SCE assay.	+	50 or 100 mg/kg	SCEs increased with low dose of phorone significantly.	Bayer et al. (1981)
SCEs	Hamster; fetal liver	i.p. injection to pregnant animals on GDs 11, 13, or 15; fetal liver SCEs were analyzed.	+	50 and 125 mg/kg	Produced doubling of SCE frequency.	Pereira et al. (1982)
SCEs	Hamster; bone marrow	Not available	+	2.5, 25, 40, 50, 75, or 100 mg/kg	Frequency of SCEs increased ≥40 mg/kg body weight.	Bayer (1978)

ED_006137A_00009570-00136

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
SCEs	Mouse, DBA/2 and C57BL/6, bone marrow cells	Two intragastric injections given; mice implanted with BrdU tablets, sacrificed on d 5, SCEs estimated.	+	10 or 100 mg/kg	SCEs and benzo[a]pyrene-DNA adducts in the order of C57Bl/6 (AHH-inducible) < DBA/2 (AHH-noninducible).	Wielgosz et al. (1991)
SCEs	Mouse, DBA/2 and C57BL/6, splenic lymphocytes	Two intragastric injections given; mice killed on 5th day and cells cultured for 48 hrs with BrdU.	+	10 or 100 mg/kg	SCEs and benzo[a]pyrene-DNA adducts in the order of C57Bl/6 (AHH-inducible) < DBA/2 (AHH-noninducible).	Wielgosz et al. (1991)
SCEs	Rat, Wistar; peripheral blood lymphocytes	Single dose by gavage; sacrificed 6, 24, and 48 hrs posttreatment; blood from abdominal aorta collected, whole blood cultures set up, SCEs scored in 50 second-division metaphases in peripheral blood lymphocytes per animal.	+	0, 10, 100, or 200 mg/kg	Linear dose-response at any sampling time; however, significant at the highest dose only; no interaction between dose and sampling time.	Willems et al. (1991)
Mutation	*Drosophila melanogaster*, sex-linked recessive lethal test	*Basc* males exposed to benzo[a]pyrene were mated with virgin females of Berlin K or *mei-9*^{L1} strains.	±	10 mM	Data inconclusive due to low fertility rates of *mei-9*^{L1} females.	Vogel et al. (1983)
Mutation	*D. melanogaster*, sex-linked recessive lethal test	Adult Berlin males treated orally with benzo[a]pyrene.	+	5 or 7.5 mM	Low mutagenic activity.	Vogel et al. (1983)
Mutation	*D. melanogaster*, Berlin-K and Oregon-K strains; sex-linked recessive lethal test	Benzo[a]pyrene dissolved in special fat and injected into the abdomen of flies.	–	2 or 5 mM	Negative at both doses.	Zijlstra and Vogel (1984)
Mutation	*D. melanogaster*, sex-linked recessive lethal test	Male Berlin K larvae treated with benzo[a]pyrene for 9–11 d.	+	0.1–4 mM	Threefold enhancement in lethals in treated versus controls.	Vogel et al. (1983)

ED_006137A_00009570-00137

Endpoint	Test system	Test conditions	Results	Dose	Comment	Reference
Mutation	*D. melanogaster*, Canton-S (WT) males, FM6 (homozygous for an X-chromosome) females; sex-linked recessive lethal test	Adult male flies were fed on filters soaked in benzo[a]pyrene for 48 or 72 hrs; treated and control males mated with FM6[a] females, males transferred to new groups of females at intervals of 3, 2, 2, and 3 d; four broods obtained; a group of 100 daughters of each male were mated again; scored for percent lethal.	–	250 or 500 ppm	Authors report incomplete dissolution of benzo[a]pyrene in DMSO as a possible cause of negative result.	Valencia and Houtchens (1981)
Mutation	*D. melanogaster;* somatic mutation, eye color mosaicism	Fifty females and 20 females were mated in a culture bottle for 48 hrs allowing females to oviposit; adults were then discarded and the eggs were allowed to hatch; larvae fed on benzo[a]pyrene deposited on food surface and the emerging adult males were scored for mosaic eye sectors.	+	1, 2, or 3 mM	Benzo[a]pyrene was effective as a mutagen; no dose-response observed.	Fahmy and Fahmy (1980)
Cell trans-formation	Hamster, LVG:LAK strain (virus free); transplacental host-mediated assay	Pregnant animals dosed i.p. with benzo[a]pyrene on GD 10; sacrificed on GD 13, fetal cell cultures prepared, 10×10^6 cells/plate; 5 d post-culture trypsinized; subcultured every 4–6 d thereafter and scored for plating efficiency and transformation.	+	3 mg/100 g body weight		Quarles et al. (1979)

[a]FM6 = First Multiple No. 6 is an X-chromosome with a complex of inversions (to suppress cross-over) and visible markers such as yellow body and white and narrow eyes.

NCE = normochromatic erythrocyte; PCE = polychromatic erythrocyte; UDS = unscheduled DNA synthesis; XPA = xeroderma pigmentosum group A.

ED_006137A_00009570-00138

D.5.2. Tumor Promotion and Progression

Cytotoxicity and Inflammatory Response

The cytotoxicity of benzo[a]pyrene metabolites may contribute to tumor promotion via inflammatory responses leading to cell proliferation (Burdick et al., 2003). Benzo[a]pyrene is metabolized to *o*-quinones, which are cytotoxic, and can generate ROS (Bolton et al., 2000; Penning et al., 1999). Benzo[a]pyrene *o*-quinones reduce the viability and survival of rat and human hepatoma cells (Flowers-Geary et al., 1996; Flowers-Geary et al., 1993). Cytotoxicity was also induced by benzo[a]pyrene and BPDE in a human prostate carcinoma cell line (Nwagbara et al., 2007). Inflammatory responses to cytotoxicity may contribute to the tumor promotion process. For example, benzo[a]pyrene quinones (1,6-, 3,6-, and 6,12-benzo[a]pyrene-quinone) generated ROS and increased cell proliferation by enhancing the epidermal growth factor receptor pathway in cultured breast epithelial cells (Burdick et al., 2003).

Several studies have demonstrated that exposure to benzo[a]pyrene increases the production of inflammatory cytokines, which may contribute to cancer progression. Garçon et al. (2001a) and Garçon et al. (2001b) exposed Sprague-Dawley rats by inhalation to benzo[a]pyrene with or without ferrous oxide (Fe_2O_3) particles. They found that benzo[a]pyrene alone or in combination with Fe_2O_3 particles elicited mRNA and protein synthesis of the inflammatory cytokine, IL-1. Tamaki et al. (2004) also demonstrated a benzo[a]pyrene-induced increase in IL-1 expression in a human fibroblast-like synoviocyte cell line (MH7A). Benzo[a]pyrene increases the expression of the mRNA for CCL1, an inflammatory chemokine, in human macrophages (N'Diaye et al., 2006). The benzo[a]pyrene-induced increase in CCL1 mRNA was inhibited by the potent AhR antagonist, 3′-methoxy-4′-nitroflavone.

AhR-Mediated Effects

The promotional effects of benzo[a]pyrene may also be related to AhR affinity and the upregulation of genes related to biotransformation (i.e., induction of CYP1A1), growth, and differentiation (Boström et al., 2002). Figure D-3 illustrates the function of the AhR and depicts the genes regulated by this receptor as belonging to two major functional groups (i.e., induction of metabolism or regulation cell differentiation and proliferation). PAHs bind to the cytosolic AhR in complex with heat shock protein 90 (Hsp90). The ligand-bound receptor is then transported to nucleus in complex with the Ah receptor nuclear translocator. The AhR complex interacts with the Ah responsive elements of the DNA to increase the transcription of proteins associated with induction of metabolism and regulation of cell differentiation and proliferation.

ED_006137A_00009570-00139



AHRE$_{DNA}$ = Ah-responsive elements of DNA; ARNT = Ah receptor nuclear translocator.

Source: Okey et al. (1994).

Figure D-3. Interaction of PAHs with the AhR.

Binding to the AhR induces enzymes that increase the formation of reactive metabolites, resulting in DNA binding and, eventually, tumor initiation. In addition, with persistent exposure, the ligand-activated AhR triggers epithelial hyperplasia, which provides the second step leading from tumor initiation to promotion and progression (Nebert et al., 1993). Ma and Lu (2007) reviewed several studies of benzo[a]pyrene toxicity and tumorigenicity in mouse strains with high and low affinity AhRs. Disparities were observed in the tumor pattern and toxicity of Ah-responsive (+/+ and +/−) and Ah-nonresponsive (−/−) mice. Ah-responsive mice were more susceptible to toxicity and tumorigenicity in proximal target tissues such as the liver, lung, and skin. For example, Shimizu et al. (2000) reported that AhR knock-out mice (−/−), treated with benzo[a]pyrene by s.c. injection or dermal painting, did not develop skin cancers at the treatment site, while AhR-responsive (+/+) or heterozygous (+/−) mice developed tumors within 18–25 weeks after treatment. Benzo[a]pyrene treatment increased CYP1A1 expression in the skin and liver of AhR-positive mice (+/− or +/+), but CYP1A1 expression was not altered by benzo[a]pyrene treatment in AhR knock-out mice (−/−). Talaska et al. (2006) also showed that benzo[a]pyrene adduct levels in skin were reduced by 50% in CYP1A2 knock-out mice and by 90%

ED_006137A_00009570-00140

in AhR knock-out mice compared with WT C57Bl6/J mice following a single dermal application of 33 mg/kg benzo[a]pyrene for 24 hours. Ma and Lu (2007) further noted that Ah-nonresponsive mice were at greater risk of toxicity and tumorigenicity in remote organs, distant from the site of exposure (i.e., bone marrow). As an example, Uno et al. (2006) showed that benzo[a]pyrene (125 mg/kg-day, orally for 18 days) caused marked wasting, immunosuppression, and bone marrow hypocellularity in CYP1A1 knock-out mice, but not in WT mice.

Some studies have demonstrated the formation of DNA adducts in the liver of AhR knock-out mice following i.p. or oral exposure to benzo[a]pyrene (Sagredo et al., 2006; Uno et al., 2006; Kondraganti et al., 2003). These findings suggest that there may be alternative (i.e., non-AhR mediated) mechanisms of benzo[a]pyrene activation in the mouse liver. Sagredo et al. (2006) studied the relationship between the AhR genotype and CYP metabolism in different organs of the mouse. AhR+/+, +/−, and −/− mice were treated once with 100 mg/kg benzo[a]pyrene by gavage. CYP1A1, CYP1B1, and AhR expression was evaluated in the lung, liver, spleen, kidney, heart, and blood, via real-time or reverse transcriptase polymerase chain reaction, 24 hours after treatment. CYP1A1 RNA was increased in the lung and liver and CYP1B1 RNA was increased in the lung following benzo[a]pyrene treatment in AhR+/+ and +/− mice (generally higher in heterozygotes). Benzo[a]pyrene treatment did not induce CYP1A1 or CYP1B1 enzymes in AhR−/− mice. The expression of CYP1A1 RNA, as standardized to β-actin expression, was generally about 40 times that of CYP1B1. The concentration of benzo[a]pyrene metabolites and the levels of DNA and protein adducts were increased in mice lacking the AhR, suggesting that there may be an AhR-independent pathway for benzo[a]pyrene metabolism and activation. The high levels of benzo[a]pyrene DNA adducts in organs other than the liver of AhR−/− mice may be the result of slow detoxification of benzo[a]pyrene in the liver, allowing high concentrations of the parent compound to reach distant tissues.

Uno et al. (2006) also demonstrated a paradoxical increase in liver DNA adducts in AhR knock-out mice following oral exposure to benzo[a]pyrene. WT C57BL/6 mice and several knock-out mouse strains (CYP1A2−/− and CYP1B1−/− single knock-out, CYP1A1/1B1−/− and CYP1A2/1B1−/− double knock-out) were studied. Benzo[a]pyrene was administered in the feed at 1.25, 12.5, or 125 mg/kg for 18 days (this dose is well-tolerated by WT C57BL/6 mice for 1 year, but lethal within 30 days to the CYP1A1−/− mice). Steady-state blood levels of benzo[a]pyrene, reached within 5 days of treatment, were ~25 times higher in CYP1A1−/− and ~75 times higher in CYP1A1/1B1−/− than in WT mice, while clearance was similar to WT mice in the other knock-out mouse strains. DNA adduct levels, measured by [32P]-postlabeling in liver, spleen, and bone marrow, were highest in the CYP1A1−/− mice at the two higher doses, and in the CYP1A1/1B1−/− mice at the mid dose only. Adduct patterns, as revealed by 2-dimensional chromatography, differed substantially between organs in the various knock-out types.

AhR signaling may play a role in cytogenetic damage caused by benzo[a]pyrene (Dertinger et al., 2001; Dertinger et al., 2000). The in vivo formation of MN in peripheral blood reticulocytes of

C57Bl/6J mice induced by a single i.p. injection of benzo[a]pyrene (150 mg/kg) was eliminated by prior treatment with the potent AhR antagonist 3'-methoxy-4'-nitroflavone. This antagonist also protected AhR-null allele mice from benzo[a]pyrene-induced increases in MN formation, suggesting that 3'-methoxy-4'-nitroflavone may also act through a mechanism independent of the AhR (Dertinger et al., 2000).

Several in vitro studies have suggested that the AhR plays a role in the disruption of cell cycle control, possibly leading to cell proliferation and tumor promotion following exposure to benzo[a]pyrene (Andrysík et al., 2007; Chung et al., 2007; Chen et al., 2003). Chung et al. (2007) showed that benzo[a]pyrene-induced cytotoxicity and apoptosis in mouse hepatoma (Hepa1c1c7) cells occurred through a *p53* and caspase-dependent process requiring the AhR. An accumulation of cells in the S-phase of the cell cycle (i.e., DNA synthesis and replication) was also observed, suggesting that this process may be related to cell proliferation. Chen et al. (2003) also demonstrated the importance of the AhR in benzo[a]pyrene-7,8-dihydrodiol- and BPDE-induced apoptosis in human HepG2 cells. Both the dihydrodiol and BPDE affected Bcl2 (a member of a family of apoptosis suppressors) and activated caspase and p38 mitogen-activated protein (MAP) kinases, both enzymes that promote apoptosis. When the experiments were conducted in a cell line that does not contain Ah receptor nuclear translocator (see Figure D-3), the dihydrodiol was not able to initiate apoptotic event sequences, indicating that activation to BPDE by CYP1A1 was required. BPDE did not induce apoptosis-related events in a p38-defective cell line, illustrating the importance of MAP kinases in this process. In rat liver epithelial cells (WB-F344 cells), in vitro exposure to benzo[a]pyrene resulted in apoptosis, a decrease in cell number, an increase in the percentage of cells in S-phase (comparable to a proliferating population of WB-F334 cells), and increased expression of cell cycle proteins (e.g., cyclin A) (Andrysík et al., 2007). Benzo[a]pyrene-induced apoptosis was attenuated in cells transfected with a dominant-negative mutation of the AhR.

Inhibition of gap junctional intercellular communication (GJIC)

Gap junctions are channels between cells that allow substances of a molecular weight up to roughly 1 kDa to pass from one cell to the other. This process of metabolic cooperation is crucial for differentiation, proliferation, apoptosis, and cell death and consequently for the two epigenetic steps of tumor formation, promotion, and progression. Chronic exposure to many toxicants results in down-regulation of gap junctions. For tumor promoters, such as TPA or TCDD, inhibition of intercellular communication is correlated with their promoting potency (Sharovskaya et al., 2006; Yamasaki, 1990).

Bláha et al. (2002) surveyed the potency of 35 PAHs, including benzo[a]pyrene, to inhibit GJIC. The scrape loading/dye transfer assay was employed using a rat liver epithelial cell line that was incubated in vitro for 15, 30, or 60 minutes with 50 μM benzo[a]pyrene. After incubation, cells were washed, and then a line was scraped through the cells with a surgical blade. Cells were exposed to the fluorescent dye lucifer yellow for 4 minutes and then fixed with formalin. Spread of

the dye from the scrape line into cells remote from the scrape was estimated under a fluorescence microscope. Benzo[a]pyrene reduced spread of the dye after 30 minutes of exposure (approximately 50% of control). Recovery of GJIC was observed 60 minutes after exposure.

Sharovskaya et al. (2006) studied the effects of carcinogenic and noncarcinogenic PAHs on GJIC in HepG2 cells. Individual carcinogenic PAHs inhibited GJIC in a temporary fashion (70–100% within 24 hours), but removal of the PAH from culture reversed the effect. Noncarcinogenic PAHs had very little effect on GJIC. Benzo[a]pyrene at 20 μM inhibited GJIC completely within 24 hours, while its noncarcinogenic homolog, benzo[e]pyrene, produced <20% inhibition. The effect was not AhR-dependent, because benzo[a]pyrene inhibited GJIC in HepG2 cells to the same extent as in hepatoma G27 cells, which express neither CYP1A1 nor AhR. The authors concluded that the effects of benzo[a]pyrene and benzo[e]pyrene on GJIC were direct (i.e., not caused by metabolites).

D.5.3. Benzo[a]pyrene Transcriptomic Microarray Analysis

The objective of this analysis was to use transcriptomic microarray analysis to help inform the cancer mode of action for benzo[a]pyrene. A systematic review and meta-analysis approach was used to: (1) identify studies; (2) analyze the raw data; (3) assess data quality; and (4) combine evidence from multiple studies to identify genes that were reproducibly active across all of the studies.

The Gene Expression Omnibus and Array Express microarray repositories were searched for studies that used benzo[a]pyrene as a test chemical and raw data were available. The search terms used and the number of studies retrieved are listed in Table D-34. Many of the search terms included terms for specific PAH mixtures, as benzo[a]pyrene is commonly used as a reference chemical in PAH mixture studies, to ensure the available and usable benzo[a]pyrene microarray data were identified.

Table D-34. Search terms and the number of studies retrieved from the gene expression omnibus and array express microarray repositories

Search term	Number of microarray studies retrieved
Coal tar	2
Polycyclic aromatic hydrocarbons	13
B[a]P	52
Diesel	11
Smoke NOT cigarette	16
Benzo[a]pyrene	53
Fuel oil	1
Cigarette smoke	63
Tobacco smoke	16

ED_006137A_00009570-00143

Forty responsive gene expression datasets were identified, representing 26 peer-reviewed publications. These datasets were further culled for analysis by focusing on publicly available results and species and organs represented by more than one available dataset on the same microarray platform. Crossing microarray platforms and species boundaries adds significant uncertainty to the interpretation with respect to comparisons of the probes being measured, how those different probes align to the genome and are mapped to specific genes, and creates an open question regarding the discovery and mapping of orthologous genes across species. Thus, the analysis included two studies that focused on mouse in vivo transcriptomic studies of the liver (Gene Expression Omnibus accessions: GSE24907 and GSE18789).

The first study (Malik et al., 2012), GSE24907, exposed five male Muta mice (a LacZ transgenic mouse line) per group to 25, 50, or 75 mg/kg benzo[a]pyrene or olive oil vehicle for 28 days by gavage. The second study (Yauk et al., 2011), GSE18789, exposed 27–30-day-old male $B6C3F_1$ mice to 150 mg/kg benzo[a]pyrene by gavage for 3 days and sacrificed 4 or 24 hours after the final dose. Both studies were subjected to study quality evaluation by the Systematic Omics Analysis Review (SOAR) tool.

SOAR was developed to assist in the quick and transparent identification of studies that are suitable for hazard assessment development. SOAR consists of a series of objective questions that examine the overall study quality of a transcriptomic microarray study. SOAR combines questions from the Toxicological Reliability Assessment (ToxR) Tool, the Minimum Information About a Microarray Experiment (MIAME) standard, and the Checklist for Exchange and Interpretation of Data from a Toxicology Study. Both studies were determined to be relevant and suitable for hazard assessment development using SOAR.

Data Analysis Overview

Raw data for both studies were obtained from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) using the GEOquery package (Davis and Meltzer, 2007) in Bioconductor (a bioinformatics software repository for packages that may be used in the R statistical environment). Each study was pre-processed, normalized, subjected to quality control analysis (see below) and analyzed independently to determine the number of active genes using a fold-change cut-off, and then a subsequent *p*-value cut-off.

Pre-processing involves the acquisition of data, background subtraction (not performed here), and synthesis of gene expression data across multiple probesets (only for Affymetrix data, and only if analysis is performed on a probeset basis). Normalization is the mathematical adjustment of data to correct. Data were normalized using fastlo within-groups to control for technical variance (Eckel et al., 2005).

The raw microarray data from both studies were analyzed for quality using Principal Components Analysis (PCA) and boxplot analysis. PCA is commonly used for cluster analysis based on the variance within the dataset. The PCA algorithm (in this case, singular value decomposition

was used) can be thought of projecting the data into a multidimensional space, and drawing an axis through the data cloud to explain the largest amount of variance. The next axis is drawn through the cloud to explain the next largest amount of variance while also being orthogonal to the first axis (e.g., the Y-axis is orthogonal to the X-axis in a Cartesian plane). The idea is that samples will naturally cluster in a way that is easily visualized in a simple 2-dimensional plot, where the axis representing the largest variance is the X-axis. For quality control purposes, observation of samples from the same biological grouping (e.g., all of the controls, or all of the samples treated the same way for the same duration) clustered in the X–Y plane is preferable. The samples in GSE24907 separated mostly by group when the normalized data were visualized by PCA. The boxplots exhibited a somewhat compressed interquartile range. Overall, the data were deemed to be of high enough quality to continue analysis, although the compressed interquartile range could manifest data compression issues which may decrease the overall statistical power.

The normalized samples in GSE18709 also separated mostly by group; however, one benzo[a]pyrene treated 24-hour sample and one 4-hour control sample clustered distantly from the rest of their groups. This raises concerns that there remains a significant amount of variance in the data that the normalization could not overcome. This variance may decrease the overall statistical power of the meta-analysis. The boxplots of normalized data for this study were more compressed than that for GSE24907.

Data were analyzed using limma and an empirical Bayes moderated t-test (Smyth, 2004). Following analysis, active genes were identified. A gene was considered active if it exhibited a 1.5-fold-change and a p-value <0.1 in at least one condition or group (e.g., time-point or dose).

A data mining/pathway analysis approach was undertaken using the GeneGo Metacore software and using the active gene lists. This approach compares the pathways identified from bioinformatics analyses of the active gene lists from both studies. The active gene lists from both studies were analyzed using the GeneGo Metacore software. The data were mined to identify GeneGo Metacore pathways that represent a large number of genes from both datasets. Gene expression data were overlaid only for those conditions where the gene was at least 1.5-fold up- or down-regulated. The GeneGo pathways were analyzed for relevance to the hypothesized mode of action for benzo[a]pyrene, and for pathways that may illustrate new modes of action. This analysis is strictly an exploratory pathway analysis to help inform the interpretation of the transcriptomics data.

The pathway analysis is a powerful method for comparing study results and identifying consistency than a direct comparison of the active gene list. For instance, differentially expressed gene lists reported in the peer-reviewed literature are not reproducible across similar studies (Shi et al., 2008; Chuang et al., 2007; Ein-Dor et al., 2005; Lossos et al., 2004; Fortunel et al., 2003). In one example, three different studies aimed at identifying genes that confer "stemness" (i.e., genes which are responsible for conferring stem-cell like capabilities) each yielded 230, 283, and 385 active genes, yet the overlap between them was only one gene (Fortunel et al., 2003). This

demonstrates that the use of simple Venn diagrams to show the overlap of genes across studies are not as informative as pathway analysis, and are less likely to provide support to potential mode-of-action hypotheses.

Three candidate pathways were identified. These are:

- AhR signaling
- DNA damage regulation of the G1/S phase transition
- Nrf2 regulation of oxidative stress

Gene differential expression is represented on the pathway map as a "thermometer" next to the protein symbol. Upregulation is symbolized by an upward pointing thermometer, where the length of the red bar represents a relative log2 fold-change. Downregulation is symbolized by a downward pointing thermometer, where the length of the blue bar represents a relative log2 fold-change. A red line connecting proteins represents inhibition. A green line connecting proteins represents activation. A symbol legend accompanies this report.

Table D-35. Mapping of group numbers to time/dose groups

Number under thermometer In Figures D-4–D-6	Dose	Time point	Reference
2	150 mg/kg	3-d exposure (sacrificed 4 hrs after final dose)	Yauk et al. (2011)
3	150 mg/kg	3-d exposure (sacrificed 24 hrs after final dose)	Yauk et al. (2011)
4	75 mg/kg	28-d exposure	Malik et al. (2012)
5	50 mg/kg	28-d exposure	Malik et al. (2012)
6	25 mg/kg	28-d exposure	Malik et al. (2012)



Figure D-4. AhR pathway. For Figures D-4–D-6, the "thermometers" display the fold change gene expression. The numbers under the thermometer represent the group within the two studies (see Table D-34). For instance, NRF2 is upregulated in the 25 mg/kg.

AhR Signaling

The AhR regulates the transcription of several genes, including xenobiotic metabolism genes (Figure D-4). It appears that benzo[a]pyrene is activating the AhR in these studies based on the expression of many of its transcriptional targets. Relevant to further analysis and investigating the mode of action, the c-Myc gene is upregulated at 4 and 24 hours in the time-course and at the 50 mg/kg dose in the dose-response, while Nrf2 is upregulated at the 4-hour time-point and at the 25 and 75 mg/kg doses. c-Myc has been shown to be upregulated following exposure to TCDD, and a putative dioxin response element has been detected in the c-Myc promoter (Dere et al., 2011; Kim

ED_006137A_00009570-00147

et al., 2000). The AhR has been demonstrated to bind and regulate the Nrf2 promoter (Dere et al., 2011; Lo et al., 2011; Nair et al., 2008).



Figure D-5. DNA damage pathway. Activation of transcriptional targets of *p53*, including *p21* and *GADD45*, and upregulation of the downstream transcriptional target, PCNA, suggests that *p53* is activated.

DNA Damage Signaling

The strong upregulation of p21 and MDM2 at 4 hours and 75 mg/kg suggests that *p53* is activated following exposure to benzo[a]pyrene, suggesting that benzo[a]pyrene induces DNA damage as early as the 4-hour time-point, and at 75 mg/kg in mice (Figure D-5). MDM2 is a target gene of *p53*, and also negatively feedback inhibits *p53* signaling through ubiquitination. Ubiquitin is also upregulated at 4 hours and 75 mg/kg, further suggesting that that *p53* may initially be upregulated at times prior to 4 hours and prior to sacrifice in the 75 mg/kg groups, and that at the time of sacrifice, the *p53* signal may be degraded due to MDM2-mediated ubiquitination. Coupled with the upregulation of Cyclin D and PCNA at 75 mg/kg (among other conditions), this suggests a

pro-mitotic shift may be occurring which could lead to cellular proliferation in the liver in the mice exposed to 75 mg/kg per day.

Nrf2 Signaling

Nrf2 transcription may be upregulated by benzo[a]pyrene through activation of the AhR (Figure D-4). The Nrf2 protein heterodimerizes with the MafF protein (Surh et al., 2008; Marini et al., 2002; Kim et al., 2000) to regulate the transcription of Phase II metabolism and anti-oxidative enzymes (Figure D-6). Activated *p53* competes with Nrf2 anti-oxidant signaling, perhaps to ensure a large oxidative stress response is present in the cell to promote the induction of apoptosis (Faraonio et al., 2006). Upregulation of Cul3 at 4 hours and the 75 mg/kg dose in concert with the upregulation of ubiquitin at the same time and dose suggests that repression of Nrf2 activity may occur. This would support the *p53*-mediated pro-oxidant hypothesis, which is further substantiated by the lack of upregulation of anti-oxidant genes at 75 mg/kg, with the exception of GCL cat.

ED_006137A_00009570-00149



Figure D-6. Nrf2 pathway. Nrf2 is upregulated by benzo[a]pyrene exposure, which results in the upregulation of Phase II detoxifying enzymes. This appears to be a compensatory response due to increased oxidative status within cells.

Pathway Analysis Summary

Activation of the AhR appears to be present based on the transcriptional data. This may lead to formation of oxidative metabolites and radicals which may lead to oxidative damage and DNA damage. Although the alterations to the Nrf2 pathway suggest cells are gearing up for a pro-apoptotic environment, there is no transcriptional evidence that the apoptotic pathways are being activated. Thus, there is significant uncertainty as to whether or not apoptosis may occur.

The transcriptomics data support a potential mutagenic and cellular proliferation mode of action. The transcriptomics data support the hypothesis that DNA damage is occurring at 4 hours following three daily doses of 150 mg/kg-day of benzo[a]pyrene and 75 mg/kg-day for 28 days. This is supported by the transcriptional activation of *p53* target genes, including p21 and MDM2. The transcriptional data further suggest that *p53* signaling may be waning under these conditions, as ubiquitin and MDM2 are both upregulated, and work together to degrade *p53*. Furthermore, the transcriptional upregulation of Cyclin D in the 75 mg/kg-day exposure may result in enough Cyclin D protein to overcome the p21 inhibitory competition for CDK4, allowing for G1/S phase transition to occur. In addition, the upregulation of PCNA in the 75 mg/kg-day exposure group together with upregulation of ubiquitin further supports the argument that cells are moving towards a more G1/S phase transition friendly environment. Translesion synthesis (i.e., a DNA repair/bypass mechanism, whereby DNA adducts are allowed to remain in newly synthesized DNA, so as to allow the cell to continue with DNA synthesis and complete the cell cycle) by ubiquitinated PCNA may favor mutagenesis if the G1/S phase transition occurs by allowing DNA adducts to persist in daughter cells.

There are a number of areas of uncertainty within the transcriptomics data that require additional research. For instance, transcriptomics data only measure changes in gene expression; these studies did not monitor changes in protein or metabolite expression, which would be more indicative of an actual cellular state change. Inferences of protein activation and changes in protein activity and cellular signaling are made based on the transcriptomics data. Further research is required at the molecular level to demonstrate that the cellular signaling events being inferred are actually taking place, and that these events result in phenotypic changes, consistent with the overall mode of action. The studies also have inherent uncertainty with respect to extrapolation from short term, high dose studies to low dose exposures across a lifetime. In addition, this work uses a hypothesized mode of action in the liver to support an overall mode of action.

ED_006137A_00009570-00151

APPENDIX E. DOSE-RESPONSE MODELING FOR THE DERIVATION OF REFERENCE VALUES FOR EFFECTS OTHER THAN CANCER AND THE DERIVATION OF CANCER RISK ESTIMATES

This appendix provides technical detail on dose-response evaluation and determination of points of departure (PODs) for relevant toxicological endpoints, organized by risk value (reference value or cancer risk value). Except where other software is noted, all endpoints were modeled using the U.S. Environmental Protection Agency's (EPA's) Benchmark Dose Software (BMDS) (U.S. EPA, 2012a); version 2.0 or later. The preambles for the cancer and noncancer parts below describe the practices used in evaluating the model fit and selecting the appropriate model for determining the POD, as outlined in the *Benchmark Dose Technical Guidance* (U.S. EPA, 2012b).

E.1. NONCANCER ENDPOINTS

E.1.1. Reference Dose (RfD)

Evaluation of Model Fit

For each dichotomous endpoint, BMDS dichotomous models were fitted to the data using the maximum likelihood method. For the log-logistic and dichotomous Hill models, slope parameters were restricted to be ≥1; for the gamma and Weibull models, power parameters were restricted to be ≥1; and for the multistage models, betas were restricted to be non-negative ($b_i \geq 0$). Each model was tested for goodness-of-fit using a chi-square goodness-of-fit test (χ^2 *p*-value <0.10 indicates lack of fit). Other factors were also used to assess model fit, such as scaled residuals, visual fit, and adequacy of fit in the low-dose region and in the vicinity of the benchmark response (BMR).

For each continuous endpoint, BMDS continuous models were fitted to the data using the maximum likelihood method. For the polynomial models, betas were restricted to be non-negative (in the case of increasing response) or non-positive (in the case of decreasing response data); and for the Hill, power, and exponential models, power parameters were restricted to be ≥1. Model fit was assessed by a series of tests as follows. For each model, first the homogeneity of the variances was tested using a likelihood ratio test (BMDS Test 2). If Test 2 was not rejected (χ^2 *p*-value ≥0.10), then the model was fitted to the data assuming constant variance. If Test 2 was rejected (χ^2 *p*-value <0.10), then the variance was modeled as a power function of the mean, and the variance model was tested for adequacy of fit using a likelihood ratio test (BMDS Test 3). For fitting models using

ED_006137A_00009570-00152

either constant variance or modeled variance, models for the mean response were tested for adequacy of fit using a likelihood ratio test (BMDS Test 4, with χ^2 *p*-value <0.10 indicating inadequate fit). Other factors were also used to assess the model fit, such as scaled residuals, visual fit, and adequacy of fit in the low-dose region and in the vicinity of the BMR.

Model selection

For each endpoint selected for modeling (see Table E-1), the BMDL estimate (95% lower confidence limit on the benchmark dose [BMD], as estimated by the profile likelihood method) and Akaike's Information Criterion (AIC) value were used to select a best-fit model from among the models exhibiting adequate fit. If the BMDL estimates were "sufficiently close," that is, differed by at most threefold, then the model selected was the one that yielded the lowest AIC value. If the BMDL estimates were not sufficiently close, then the lowest BMDL was selected as the POD.

Table E-1. Noncancer endpoints selected for dose-response modeling for benzo[a]pyrene: RfD

Study	Endpoint	Species/sex	Doses and effect data				
Kroese et al. (2001)	Thymus weight (mg)	Rat (Wistar)/ male	Dose (mg/kg-d)	0	3	10	30
			Mean ± SD[a]	380 ± 60	380 ± 110	330 ± 60	270 ± 40*
Kroese et al. (2001)	Thymus weight (mg)	Rat (Wistar)/ female	Dose (mg/kg-d)	0	3	10	30
			Mean ± SD[a]	320 ± 60	310 ± 50	300 ± 40	230 ± 30*
Xu et al. (2010)	Ovary weight (mg)	Sprague-Dawley/ female	Dose (mg/kg-d)[b]	0	2.5	5	
			Mean ± SD	0.160 ± 0.0146	0.143 ± 0.0098**	0.136 ± 0.0098**	
Chen et al. (2012)	Morris water maze	Sprague-Dawley/male and female	Dose (mg/kg-d)	0	0.02	0.2	2.0
			Escape latency (sec); mean ± SD	9.89 ± 5.76	12.5 ± 5.10	19.1 ± 5.85	33.5 ± 9.93
			Time spent in target quadrant (sec); mean ± SD	33.6 ± 8.92	31.9 ± 8.63	16.6 ± 5.74	11.1 ± 5.12
	Elevated plus maze	Sprague-Dawley/ female	Number of open arm entries	10.24 ± 1.905	10.36 ± 3.048	12.89 ± 2.667	16.39 ± 3.048
Gao et al. (2011)	Cervical epithelial hyperplasia	ICR/female	Dose (mg/kg-d)[c]	0	0.71	1.4	2.9
			Incidence	0/26	4/26	6/25	7/24

*Significantly ($p < 0.05$) different from control mean; student t-test (unpaired, two-tailed); n = 10/sex/group.
**Statistically different ($p < 0.05$) from controls using one-way analysis of variance (ANOVA).
[a]Reported as standard error (SE), but judged to be standard deviation (SD) (and confirmed by study authors).
[b]Time-weighted average (TWA) doses over the 60-day study period.
[c]Doses converted to mg/kg-day after adjustment for equivalent continuous dosing (2/7 days/week).

ED_006137A_00009570-00153

Modeling results

Below are tables and figures summarizing the modeling results for the noncancer endpoints modeled (see Tables E-2 through E-8 and Figures E-1 through E-7).

Table E-2. Summary of BMD modeling results for decreased thymus weight in male Wistar rats exposed to benzo[a]pyrene by gavage for 90 days (Kroese et al., 2001); BMR = 1 SD change from the control mean

Model	Variance *p*-value[a]	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
		p-value	AIC		
Constant variance					
Linear	0.01	0.74	384.84	12.97	8.97
Nonconstant variance					
Hill[b]	Insufficient degrees of freedom				
Linear, polynomial (2-degree), power[c]	**0.30**	**0.23**	**380.71**	**16.40**	**11.30**

[a]Values <0.10 fail to meet conventional goodness-of-fit criteria.
[b]Power restricted to ≥1.

ED_006137A_00009570-00154



15:33 10/15 2009

BMDs and BMDLs indicated are associated with a change of 1 SD from the control, and are in units of mg/kg-day.

Figure E-1. Fit of linear model (nonconstant variance) to data on decreased thymus weight in male Wistar rats—90 days (Kroese et al., 2001).

```
=====================================================================
        Polynomial Model. (Version: 2.13;  Date: 04/08/2008)
        Input                                    Data                             File:
C:\USEPA\IRIS\benzo[a]pyrene\RfD\Kroese2001\90day\thymusweight\male\durationadjusted\2Linkrolin.(
d)
        Gnuplot                                Plotting                           File:
C:\USEPA\IRIS\benzo[a]pyrene\RfD\Kroese2001\90day\thymusweight\male\durationadjusted\2Linkrolin.p
lt
=====================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the response function is:

   Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...


   Dependent variable = mean
   Independent variable = dose
   The polynomial coefficients are restricted to be negative
   The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho)

   Total number of dose groups = 4
```

```
Total number of records with missing values = 0
Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008



                Default Initial Parameter Values
                       lalpha =      8.56121
                          rho =            0
                       beta_0 =      380.763
                       beta_1 =      -5.3285


          Asymptotic Correlation Matrix of Parameter Estimates

                 lalpha          rho       beta_0       beta_1

   lalpha            1           -1        0.048       -0.061

      rho           -1            1       -0.048        0.061

   beta_0        0.048       -0.048            1        -0.84

   beta_1       -0.061        0.061        -0.84            1



                              Parameter Estimates

                                                    95.0% Wald Confidence Interval
      Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
        lalpha         -18.8293          9.75429            -37.9473            0.288754
           rho          4.66515          1.67581             1.38062             7.94967
        beta_0          378.954          16.5291             346.558             411.351
        beta_1         -5.14219          1.00497            -7.11189            -3.17249



     Table of Data and Estimated Values of Interest

 Dose       N    Obs Mean     Est Mean   Obs Std Dev  Est Std Dev   Scaled Res.
------     ---   --------     --------   -----------  -----------   ----------

    0    10        380          379          60          84.3         0.0392
  2.1    10        380          368         110          78.8          0.475
  7.1    10        330          342          60          66.6         -0.591
 21.4    10        270          269          40          37.9         0.0908



 Model Descriptions for likelihoods calculated


 Model A1:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = Sigma^2

 Model A2:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = Sigma(i)^2

 Model A3:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = exp(lalpha + rho*ln(Mu(i)))
     Model A3 uses any fixed variance parameters that
     were specified by the user

 Model  R:         Yi = Mu + e(i)
            Var$$e(i)} = Sigma^2


                       Likelihoods of Interest
```

```
             Model      Log(likelihood)   # Param's      AIC
              A1         -189.116991            5     388.233982
              A2         -183.673279            8     383.346558
              A3         -184.883626            6     381.767253
          fitted         -186.353541            4     380.707081
               R         -196.353362            2     396.706723


                    Explanation of Tests

 Test 1:  Do responses and/or variances differ among Dose levels?
          (A2 vs. R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 vs. A3)
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                      Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1              25.3602          6       0.0002928
   Test 2              10.8874          3         0.01235
   Test 3              2.42069          2          0.2981
   Test 4              2.93983          2          0.2299

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is less than .1.  A non-homogeneous variance
model appears to be appropriate

The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


             Benchmark Dose Computation

Specified effect =             1

Risk Type        =     Estimated standard deviations from the control mean

Confidence level =          0.95

             BMD =        16.4008


            BMDL =        11.2965
```

Table E-3. Summary of BMD modeling results for decreased thymus weight in female Wistar rats exposed to benzo[a]pyrene by gavage for 90 days (Kroese et al., 2001); BMR = 1 SD change from the control mean

Model (constant variance)	Goodness of fit			BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	Variance *p*-value[a]	Mean *p*-value[a]	AIC		
Hill[b]	NA				
Linear[c]	**0.17**	**0.81**	**349.12**	**10.52**	**7.64**
Polynomial (2-degree)[c,d]	0.17	0.77	350.80	13.29	7.77
Power[b]	NA				

[a]Values <0.10 fail to meet conventional goodness-of-fit criteria.
[b]Power restricted to ≥1.
[c]Coefficients restricted to be negative.
[d]Lowest degree polynomial with an adequate fit is reported.

BMD/BMC = maximum likelihood estimate (MLE) of the dose/concentration associated with the selected BMR; NA = not applicable; model failed to generate.

ED_006137A_00009570-00158



BMDs and BMDLs indicated are associated with a change of 1 SD from the control, and are in units of mg/kg-day.

Figure E-2. Fit of linear model (constant variance) to data on decreased thymus weight in female Wistar rats—90 days (Kroese et al., 2001).

```
=====================================================================
          Polynomial Model. (Version: 2.13;  Date: 04/08/2008)
          Input                                   Data                                        File:
C:\USEPA\IRIS\benzo[a]pyrene\RfD\Kroese2001\90day\thymusweight\female\durationadjusted\2Linkrolin
.(d)
          Gnuplot                                 Plotting                                    File:
C:\USEPA\IRIS\benzo[a]pyrene\RfD\Kroese2001\90day\thymusweight\female\durationadjusted\2Linkrolin
.plt
                                                    Thu Oct 15 16:27:44 2009
 ====================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the response function is:

   Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...


   Dependent variable = mean
   Independent variable = dose
   rho is set to 0
   The polynomial coefficients are restricted to be negative
   A constant variance model is fit

   Total number of dose groups = 4
   Total number of records with missing values = 0
   Maximum number of iterations = 250
   Relative Function Convergence has been set to: 1e-008
   Parameter Convergence has been set to: 1e-008
```


ED_006137A_00009570-00159

```
                    Default Initial Parameter Values
                            alpha =            1
                              rho =            0   Specified
                           beta_0 =      322.144
                           beta_1 =      -4.2018


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -rho
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                   alpha       beta_0       beta_1

     alpha             1     2.4e-008    -2.3e-008

    beta_0     2.4e-008            1        -0.68

    beta_1    -2.3e-008        -0.68            1



                                  Parameter Estimates

                                                        95.0% Wald Confidence Interval
        Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
           alpha           1954.92          437.134          1098.16             2811.69
         beta_0            322.144          9.48287          303.558              340.73
         beta_1            -4.2018         0.837537         -5.84334            -2.56026



     Table of Data and Estimated Values of Interest

  Dose       N    Obs Mean     Est Mean   Obs Std Dev  Est Std Dev   Scaled Res.
------      ---   --------     --------   -----------  -----------   ----------

     0     10        320          322          60         44.2         -0.153
   2.1     10        310          313          50         44.2         -0.237
   7.1     10        300          292          40         44.2           0.55
  21.4     10        230          232          30         44.2         -0.159



  Model Descriptions for likelihoods calculated


  Model A1:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma^2

  Model A2:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma(i)^2

  Model A3:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma^2
      Model A3 uses any fixed variance parameters that
      were specified by the user

  Model  R:         Yi = Mu + e(i)
             Var$$e(i)} = Sigma^2


                        Likelihoods of Interest

             Model      Log(likelihood)   # Param's      AIC
              A1         -171.357252          5     352.714504
              A2         -168.857234          8     353.714467
```


ED_006137A_00009570-00160

```
              A3         -171.357252            5     352.714504
          fitted         -171.562118            3     349.124237
               R         -181.324151            2     366.648303


                    Explanation of Tests

 Test 1:  Do responses and/or variances differ among Dose levels?
          (A2 vs. R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 vs. A3)
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                      Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1              24.9338          6       0.0003512
   Test 2              5.00004          3          0.1718
   Test 3              5.00004          3          0.1718
   Test 4             0.409733          2          0.8148

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is greater than .1.  A homogeneous variance
model appears to be appropriate here


The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


             Benchmark Dose Computation

Specified effect =             1

Risk Type        =     Estimated standard deviations from the control mean

Confidence level =          0.95

             BMD =        10.5228


            BMDL =        7.64037
```

Table E-4. Summary of BMD modeling results for decreased ovary weight in female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 60 days (Xu et al., 2010); BMR = 1 SD change from the control mean

Model	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	p-value	AIC		
Power	NA[a]			
Linear, polynomial (1°)	**0.39**	**-138.67**	**2.27**	**1.49**

[a]NA = not applicable; model failed to generate.



Figure E-3. Fit of linear/polynomial (1°) model to data on decreased ovary weight (Xu et al., 2010).

```
 ====================================================================
         Polynomial Model. (Version: 2.16;  Date: 05/26/2010)
         Input                                 Data                                 File:
C:/USEPA/BMDS212/Data/benzo[a]pyrene/Bap_AbsOvaryWeight/Xu2010_AbsOvaryWeight_Linear_1SD.(d)
         Gnuplot                              Plotting                              File:
C:/USEPA/BMDS212/Data/benzo[a]pyrene/Bap_AbsOvaryWeight/Xu2010_AbsOvaryWeight_Linear_1SD.plt
                                                   Tue Dec 14 13:51:32 2010
  ====================================================================
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
```


ED_006137A_00009570-00162

```
The form of the response function is:

Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...


Dependent variable = Mean
Independent variable = Dose
rho is set to 0
Signs of the polynomial coefficients are not restricted
A constant variance model is fit

Total number of dose groups = 3
Total number of records with missing values = 0
Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008



                    Default Initial Parameter Values
                            alpha =     0.000136
                              rho =            0   Specified
                           beta_0 =     0.158333
                           beta_1 =      -0.0048


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -rho
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                   alpha       beta_0       beta_1

      alpha            1       4e-010    -4.5e-010

     beta_0       4e-010            1        -0.77

     beta_1    -4.5e-010        -0.77            1



                                 Parameter Estimates

                                                        95.0% Wald Confidence Interval
        Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
           alpha       0.000118889     3.96296e-005        4.12162e-005         0.000196562
          beta_0          0.158333       0.00406354            0.150369            0.166298
          beta_1           -0.0048       0.00125904         -0.00726768         -0.00233232



      Table of Data and Estimated Values of Interest

 Dose       N    Obs Mean     Est Mean   Obs Std Dev  Est Std Dev   Scaled Res.
------     ---   --------     --------   -----------  -----------   ----------

    0       6      0.16        0.158       0.0147       0.0109          0.374
  2.5       6     0.143        0.146       0.0098       0.0109         -0.749
    5       6     0.136        0.134       0.0098       0.0109          0.374



 Model Descriptions for likelihoods calculated


 Model A1:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma^2

 Model A2:        Yij = Mu(i) + e(ij)
```

```
            Var$$e(ij)} = Sigma(i)^2

 Model A3:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma^2
     Model A3 uses any fixed variance parameters that
     were specified by the user

 Model  R:         Yi = Mu + e(i)
             Var$$e(i)} = Sigma^2


                       Likelihoods of Interest

             Model      Log(likelihood)   # Param's      AIC
              A1           72.766595            4    -137.533190
              A2           73.468565            6    -134.937129
              A3           72.766595            4    -137.533190
           fitted          72.335891            3    -138.671782
                R          67.008505            2    -130.017010


                     Explanation of Tests

 Test 1:  Do responses and/or variances differ among Dose levels?
          (A2 vs. R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 vs. A3)
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                      Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1              12.9201          4         0.01167
   Test 2              1.40394          2          0.4956
   Test 3              1.40394          2          0.4956
   Test 4             0.861408          1          0.3533

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is greater than .1.  A homogeneous variance
model appears to be appropriate here


The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


             Benchmark Dose Computation

Specified effect =             1

Risk Type        =     Estimated standard deviations from the control mean

Confidence level =          0.95

             BMD =        2.27159


            BMDL =        1.49968
```

Table E-5. Summary of BMD modeling results for Morris water maze: escape latency in male and female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 90 days (Chen et al., 2012); BMR = 1 SD change from the control mean

Model[a]	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	p-value	AIC		
Hill[b]	**0.515**	**386.3**	**0.106**	**0.061**
Exponential 4, 5	0.466	386.4	0.115	0.071
Polynomial (2°)	0.423	386.6	0.123	0.083
Linear, power	0.002	396.7	0.543	0.421
Exponential 2, 3	<0.001	400.3	0.815	0.687

[a]Includes modeling of heterogeneous variances (BMDS Test 3, $p = 0.313$).
[b]Power parameter *n* was estimated to be 1 (boundary of parameter space).

Data from Morris water maze was presented graphically in Chen et al. (2012), but dose group means and standard deviations (SDs) were provided upon request by the study authors, which enabled modeling of this endpoint. In addition, the data for male and female rats were combined for dose-response analysis because there was no substantive difference between males and females for each dose group (supported by statistical testing using two-way analysis of variance [ANOVA], and allowing for interactions), and because there was no rationale or information available suggesting there would be sex-mediated differences for these neurobehavioral tests.

ED_006137A_00009570-00165



Figure E-4. Fit of Hill model to data on Morris water maze test escape latency (Chen et al., 2012).

```
=====================================================================
          Hill Model. (Version: 2.16;  Date: 04/06/2011)
          Input  Data  File:  C:\Documents  and  Settings\jfox\My  Documents\_CURRENTWORK\_CAST
plus\BaP\BMDS\hil_Chen.FM.latency_Hil-ModelVariance-BMR1Std-Restrict.(d)
          Gnuplot Plotting File: C:\Documents and Settings\jfox\My Documents\_CURRENTWORK\_CAST
plus\BaP\BMDS\hil_Chen.FM.latency_Hil-ModelVariance-BMR1Std-Restrict.plt
                                                    Tue Apr 24 14:41:26 2012
 ====================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the response function is:

   Y[dose] = intercept + v*dose^n/(k^n + dose^n)


   Dependent variable = Mean
   Independent variable = Dose
   Power parameter restricted to be greater than 1
   The variance is to be modeled as Var(i) = exp(lalpha  + rho * ln(mean(i)))

   Total number of dose groups = 4
   Total number of records with missing values = 0
   Maximum number of iterations = 250
   Relative Function Convergence has been set to: 1e-008
   Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                         lalpha =      3.87128
                            rho =            0
                      intercept =        9.888
                              v =      23.6385
                              n =     0.187055
                              k =      3.47082


            Asymptotic Correlation Matrix of Parameter Estimates
```


ED_006137A_00009570-00166

```
( *** The model parameter(s)  -n
      have been estimated at a boundary point, or have been specified by the user,
      and do not appear in the correlation matrix )
```

	lalpha	rho	intercept	v	k
lalpha	1	-0.99	-0.27	0.062	-0.11
rho	-0.99	1	0.24	-0.063	0.12
intercept	-0.27	0.24	1	0.017	0.47
v	0.062	-0.063	0.017	1	0.73
k	-0.11	0.12	0.47	0.73	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval Lower Conf. Limit	Upper Conf. Limit
lalpha	0.88775	0.974841	-1.0229	2.7984
rho	0.998033	0.338845	0.33391	1.66216
intercept	10.6545	0.914127	8.86283	12.4461
v	28.7081	3.94381	20.9783	36.4378
n	1	NA		
k	0.494812	0.213359	0.0766351	0.912988

NA - Indicates that this parameter has hit a bound
implied by some inequality constraint and thus
has no standard error.

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	20	9.89	10.7	5.76	5.08	-0.675
0.02	20	12.5	11.8	5.1	5.33	0.641
0.2	20	19.1	18.9	5.85	6.76	0.0952
2	20	33.5	33.7	9.93	9.01	-0.0706

Model Descriptions for likelihoods calculated

```
Model A1:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = Sigma^2

Model A2:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = Sigma(i)^2

Model A3:        Yij = Mu(i) + e(ij)
           Var$$e(ij)} = exp(lalpha + rho*ln(Mu(i)))
      Model A3 uses any fixed variance parameters that
      were specified by the user

Model  R:         Yi = Mu + e(i)
            Var$$e(i)} = Sigma^2
```

Likelihoods of Interest

Model	Log(likelihood)	# Param's	AIC
A1	-192.799518	5	395.599036
A2	-186.795503	8	389.591006

```
              A3         -187.957975            6     387.915949
          fitted         -188.169983            5     386.339965
               R         -234.549118            2     473.098237


                    Explanation of Tests

 Test 1:  Do responses and/or variances differ among Dose levels?
          (A2 vs. R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 vs. A3)
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                      Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1              95.5072          6          <.0001
   Test 2               12.008          3        0.007356
   Test 3              2.32494          2          0.3127
   Test 4             0.424016          1          0.5149

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is less than .1.  A non-homogeneous variance
model appears to be appropriate

The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


        Benchmark Dose Computation

Specified effect =             1

Risk Type        =     Estimated standard deviations from the control mean

Confidence level =           0.95

             BMD =       0.106284

            BMDL =     0.0609511
```

Table E-6. Summary of BMD modeling results for Morris water maze: time spent in quadrant for in male and female Sprague-Dawley rats exposed to benzo[a]pyrene by gavage for 90 days (Chen et al., 2012); BMR = 1 SD change from the control mean

Model[a]	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	p-value	AIC		
Exponential 4	**0.576**	**395.4**	**0.065**	**0.043**
Exponential 5	NA[b]	397.1	0.084	0.044
Hill	NA[b]	397.1	0.071	0.038
Linear, power, polynomial (1°, 2°, 3°)	<0.001	433.1	1.23	0.98

[a]Includes modeling of heterogenous variances (BMDS Test 3, $p = 0.919$).
[b]NA: insufficient degrees of freedom to evaluate χ^2.



Figure E-5. Fit of exponential 4 model to data on Morris water maze time spent in target quadrant (Chen et al., 2012).

```
=====================================================================
          Exponential Model. (Version: 1.7;  Date: 12/10/2009)
          Input  Data  File:  C:\Documents  and  Settings\...\exp_Chen.FM.target_Exp-ModelVariance-
BMR1Std-Down.(d)
 ======================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the response function by Model:
      Model 2:     Y[dose] = a * exp$$sign * b * dose}
      Model 3:     Y[dose] = a * exp$$sign * (b * dose)^d}
```


ED_006137A_00009570-00169

```
  Model 4:     Y[dose] = a * [c-(c-1) * exp$$-b * dose}]
  Model 5:     Y[dose] = a * [c-(c-1) * exp$$-(b * dose)^d}]

 Note: Y[dose] is the median response for exposure = dose;
       sign = +1 for increasing trend in data;
       sign = -1 for decreasing trend.

  Model 2 is nested within Models 3 and 4.
  Model 3 is nested within Model 5.
  Model 4 is nested within Model 5.


Dependent variable = Mean
Independent variable = Dose
Data are assumed to be distributed: normally
Variance Model: exp(lnalpha +rho *ln(Y[dose]))
The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho)

Total number of dose groups = 4
Total number of records with missing values = 0
Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact


                Initial Parameter Values

                Variable          Model 4
                --------          --------
                  lnalpha             0.666712
                      rho              1.04799
                        a              35.3094
                        b              1.97191
                        c             0.300675
                        d                    1



                  Parameter Estimates

                 Variable          Model 4
                 --------          -------
                  lnalpha            0.601192
                      rho             1.05452
                        a             34.3199
                        b             7.26795
                        c            0.325841
                        d                   1

  NC = No Convergence


         Table of Stats From Input Data

  Dose      N         Obs Mean     Obs Std Dev
  -----    ---       ----------   -------------
      0     20        33.63        8.924
   0.02     20        31.94        8.633
    0.2     20        16.56        5.744
      2     20        11.15        5.117


                Estimated Values of Interest

   Dose      Est Mean      Est Std     Scaled Residual
 ------    ----------    ---------    ----------------
      0         34.32        8.713          -0.3551
   0.02         31.19        8.285           0.4069
    0.2         16.59        5.939         -0.02044
```

```
        2         11.18        4.824         -0.03277



Other models for which likelihoods are calculated:

  Model A1:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma^2

  Model A2:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = Sigma(i)^2

  Model A3:        Yij = Mu(i) + e(ij)
            Var$$e(ij)} = exp(lalpha + log(mean(i)) * rho)

  Model  R:        Yij = Mu + e(i)
            Var$$e(ij)} = Sigma^2


                             Likelihoods of Interest

                  Model      Log(likelihood)      DF         AIC
                -------    -----------------    ----   ------------
                    A1       -197.0118            5      404.0235
                    A2        -192.448            8       400.896
                    A3       -192.5331            6      397.0662
                     R       -238.8696            2      481.7393
                     4       -192.6894            5      395.3787


Additive constant for all log-likelihoods =     -73.52.  This constant added to the
above values gives the log-likelihood including the term that does not
depend on the model parameters.


                              Explanation of Tests

Test 1:  Does response and/or variances differ among Dose levels? (A2 vs. R)
Test 2:  Are Variances Homogeneous? (A2 vs. A1)
Test 3:  Are variances adequately modeled? (A2 vs. A3)

Test 6a: Does Model 4 fit the data? (A3 vs 4)


                          Tests of Interest

  Test          -2*log(Likelihood Ratio)       D. F.         p-value
--------        ------------------------      ------     --------------
  Test 1                         92.84          6            < 0.0001
  Test 2                         9.127          3             0.02764
  Test 3                        0.1701          2              0.9185
 Test 6a                        0.3126          1              0.5761


  The p-value for Test 1 is less than .05.  There appears to be a
  difference between response and/or variances among the dose
  levels, it seems appropriate to model the data.

  The p-value for Test 2 is less than .1.  A non-homogeneous
  variance model appears to be appropriate.

  The p-value for Test 3 is greater than .1.  The modeled
  variance appears to be appropriate here.

  The p-value for Test 6a is greater than .1.  Model 4 seems
  to adequately describe the data.


Benchmark Dose Computations:

  Specified Effect = 1.000000
```

```
        Risk Type = Estimated standard deviations from control

Confidence Level = 0.950000

             BMD =    0.0650194

            BMDL =    0.0432761
```

Table E-7. Summary of BMD modeling results for elevated plus maze: open arm entries for females at PND 70 (Chen et al., 2012); BMR = 1 SD change from the control mean

Model[a]	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	p-value[b]	AIC		
Exponential (M2) Exponential (M3)	0.107	125.93	1.086	0.845
Exponential (M4)	**0.840**	**123.51**	**0.184**	**0.086**
Exponential (M5)	NA	125.47	0.194	0.087
Hill	NA	125.47	0.193	0.066
Polynomial 1° Polynomial 2° Polynomial 3° Power	0.129	125.57	0.964	0.713

[a]Constant variance models are presented (BMDS Test 2 *p*-value = 0.46), with the selected model in bold. Scaled residuals for selected model for doses 0, 0.02, 0.2, and 2 mg/kg-d were 0.13, −0.15, 0.03, and −0.003, respectively.
For exponential model M3, parameter d = 1, reducing it to M2.
For the power model, the power parameter estimate was 1 (boundary of parameter space). For the polynomial 2° and 3° models, the b2 and b3 coefficient estimates were 0 (boundary of parameter space). Consequently, these three models all reduced to the polynomial 1° model.
[b]Exponential M5 and Hill model required four parameters and there are four dose groups, leaving no degrees of freedom for the goodness-of-fit test. Therefore, these were not considered for model selection

For the elevated plus maze data, although effects of exposure were observed across multiple ages and both sexes, the results from female rats at PND 70 were chosen for dose-response analyses as effects in females and older animals were of greater severity. While it is preferred that elevated plus maze results be presented as percent of open arm entries or percent of time in the open arms (as a function of total arm entries or time) in order to rule out potential differences in motor activity or general exploration (Hogg, 1996), the data provided in the study were sufficient to rule out that total arm entries were affected by treatment.



Figure E-6. Fit of exponential model (4) to data on elevated plus maze open arm maze entries (Chen et al., 2012).

```
 ====================================================================
          Exponential Model. (Version: 1.7;  Date: 12/10/2009)
          Input  Data  File:  C:\Documents  and  Settings\jfox\My  Documents\_CURRENTWORK\_CAST
plus\BaP\BMDS\exp_ChenFO70_Exp-ConstantVariance-BMR1Std-Up.(d)
          Gnuplot Plotting File: C:\Documents and Settings\jfox\My Documents\_CURRENTWORK\_CAST
plus\BaP\BMDS\exp_ChenFO70_Exp-ConstantVariance-BMR1Std-Up.plt
                                                  Thu Aug 02 12:35:33 2012
 ====================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the response function by Model:
      Model 2:     Y[dose] = a * exp{sign * b * dose}
      Model 3:     Y[dose] = a * exp{sign * (b * dose)^d}
      Model 4:     Y[dose] = a * [c-(c-1) * exp{-b * dose}]
      Model 5:     Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]

    Note: Y[dose] is the median response for exposure = dose;
          sign = +1 for increasing trend in data;
          sign = -1 for decreasing trend.

      Model 2 is nested within Models 3 and 4.
      Model 3 is nested within Model 5.
      Model 4 is nested within Model 5.


   Dependent variable = Mean
   Independent variable = Dose
   Data are assumed to be distributed: normally
   Variance Model: exp(lnalpha +rho *ln(Y[dose]))
   rho is set to 0.
   A constant variance model is fit.

   Total number of dose groups = 4
   Total number of records with missing values = 0
   Maximum number of iterations = 250
```

```
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact


                Initial Parameter Values

                Variable          Model 4
                --------          --------
                  lnalpha              1.88669
                      rho(S)                 0
                        a              9.72892
                        b              1.12212
                        c              1.76842
                        d                    1

  (S) = Specified



                  Parameter Estimates

                 Variable          Model 4
                 --------          -------
                  lnalpha              1.8877
                      rho                   0
                        a              10.136
                        b             2.86365
                        c             1.61881
                        d                   1


          Table of Stats From Input Data

  Dose      N         Obs Mean     Obs Std Dev
  -----    ---       ----------   -------------
      0     10        10.24        1.905
   0.02     10        10.36        3.048
    0.2     10        12.89        2.667
      2     10        16.39        3.048


                Estimated Values of Interest

   Dose      Est Mean      Est Std     Scaled Residual
 ------    ----------    ---------    ----------------
      0         10.14         2.57           0.1292
   0.02         10.49         2.57          -0.1521
    0.2         12.87         2.57          0.02563
      2         16.39         2.57        -0.002716



Other models for which likelihoods are calculated:

  Model A1:        Yij = Mu(i) + e(ij)
             Var{e(ij)} = Sigma^2

  Model A2:        Yij = Mu(i) + e(ij)
             Var{e(ij)} = Sigma(i)^2

  Model A3:        Yij = Mu(i) + e(ij)
             Var{e(ij)} = exp(lalpha + log(mean(i)) * rho)

  Model  R:        Yij = Mu + e(i)
             Var{e(ij)} = Sigma^2


                             Likelihoods of Interest
```

Model	Log(likelihood)	DF	AIC
A1	-57.73371	5	125.4674
A2	-56.43655	8	128.8731
A3	-57.73371	5	125.4674
R	-71.03323	2	146.0665
4	-57.75397	4	123.5079

Additive constant for all log-likelihoods = -36.76. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)
Test 2: Are Variances Homogeneous? (A2 vs. A1)
Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 6a: Does Model 4 fit the data? (A3 vs 4)

Tests of Interest

Test	-2*log(Likelihood Ratio)	D. F.	p-value
Test 1	29.19	6	< 0.0001
Test 2	2.594	3	0.4585
Test 3	2.594	3	0.4585
Test 6a	0.04053	1	0.8404

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

Benchmark Dose Computations:

Specified Effect = 1.000000

Risk Type = Estimated standard deviations from control

Confidence Level = 0.950000

BMD = 0.184087

BMDL = 0.0864691

Table E-8. Summary of BMD modeling results for incidence of cervical epithelial hyperplasia in female ICR mice exposed to benzo[a]pyrene by oral exposure for 98 days (Gao et al., 2011); BMR = 1 SD change from the control mean

Model	Goodness of fit		BMD_{1SD} (mg/kg-d)	$BMDL_{1SD}$ (mg/kg-d)
	p-value	AIC		
Gamma	0.6874	82.2821	0.659	0.452
Logistic	0.1422	88.4607	1.422	1.052
Log-logistic	**0.8360**	**81.7004**	**0.578**	**0.369**
Probit	0.1544	88.1151	1.326	0.979
Log-probit	0.0775	88.2004	1.012	0.686
Multistage	0.6874	82.2821	0.659	0.452



Figure E-7. Fit of log-logistic model to data on cervical epithelial hyperplasia (Gao et al., 2011)

ED_006137A_00009570-00176

```
        ==========================================================================
          Logistic Model. (Version: 2.13; Date: 10/28/2009)
          Input Data File: C:\Users\hclynch\Documents\_Active Projects\_FA498 IRIS\xBaP\IASC Aug
2011\bmd modeling\lnl_gao 2011 inflamm cells_Opt.(d)
          Gnuplot     Plotting     File:     C:\Users\hclynch\Documents\_Active     Projects\_FA498
IRIS\xBaP\IASC Aug 2011\bmd modeling\lnl_gao 2011 inflamm cells_Opt.plt
=====================================================================

 BMDS_Model_Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))]


   Dependent variable = Col3
   Independent variable = Col1
   Slope parameter is restricted as slope >= 1

   Total number of observations = 4
   Total number of records with missing values = 0
   Maximum number of iterations = 250
   Relative Function Convergence has been set to: 1e-008
   Parameter Convergence has been set to: 1e-008



   User has chosen the log transformed model


                  Default Initial Parameter Values
                     background =            0
                      intercept =     -1.60901
                          slope =            1


          Asymptotic Correlation Matrix of Parameter Estimates

          ( *** The model parameter(s)  -background    -slope
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

             intercept

 intercept            1



                                Parameter Estimates

                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     background               0            *               *                   *
      intercept          -1.6502           *               *                   *
          slope                1            *               *                   *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -39.4267         4
   Fitted model        -39.8502         1      0.847034      3          0.8382
  Reduced model        -45.7739         1       12.6945      3        0.005346

          AIC:          81.7004
```

Goodness of Fit

Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0000	0.000	0.000	26	0.000
0.7100	0.1200	3.119	4.000	26	0.532
1.4000	0.2119	5.297	6.000	25	0.344
2.9000	0.3577	8.584	7.000	24	-0.675

Chi^2 = 0.86 d.f. = 3 P-value = 0.8360

Benchmark Dose Computation

Specified effect = 0.1

Risk Type = Extra risk

Confidence level = 0.95

BMD = 0.578668

BMDL = 0.368701

E.1.2. Reference Concentration (RfC)

Candidate studies for the development of the RfC were not amenable to BMD modeling.

Dosimetry Modeling for Estimation of Human Equivalent Concentrations

As discussed in Section 2.2.2, the human equivalent concentration (HEC) was calculated from the POD_{ADJ} by multiplying by a dosimetric adjustment factor (DAF), which, in this case, was the regional deposited dose ratio ($RDDR_{ER}$) for extrarespiratory (i.e., systemic) effects. The observed developmental effects are considered systemic in nature (i.e., extrarespiratory) and the normalizing factor for extrarespiratory effects of particles is body weight. The $RDDR_{ER}$ was calculated as follows:

$$RDDR_{ER} = \frac{BW_H}{BW_A} \times \frac{(V_E)_A}{(V_E)_H} \times \frac{(F_{TOT})_A}{(F_{TOT})_H}$$

where:

BW = body weight (kg)

V_E = ventilation rate (L/minute)

F_{TOT} = total fractional deposition

The total fractional deposition includes particle deposition in the nasal-pharyngeal, tracheobronchial, and pulmonary regions. F_{TOT} for both animals and humans was calculated using the Multi-Path Particle Dosimetry (MPPD) model, a computational model used for estimating human and rat airway particle deposition and clearance (MPPD; Version 2.0 © 2006, publicly available through the Hamner Institute). See model output below.



Figure E-8. Human fractional deposition.

```
Species = humanlimited
FRC = 3300.0
Head volume = 50.0
Density = 1.0
Number of particles calculated = single
Diameter = 1.7000000000000002 µm  MMAD
Inhalability =   yes
GSD = 1.0
Breathing interval: One single breath
Concentration = 4.2
Breathing Frequency = 16.0
Tidal Volume = 860.0
Inspiratory Fraction = 0.5
Pause Fraction = 0.0
Breathing Route = nasal

Region: Entire Lung
Region: Entire Lung
Region  Deposition Fraction
--      --
Head    0.449
TB      0.045
 P      0.127
Total   0.621
```



Figure E-9. Rat fractional deposition.

```
Species = rat
FRC = 4.0
Head volume = 0.42
Density = 1.0
Number of particles calculated = single
Diameter = 1.7000000000000002 µm  MMAD
Inhalability =   yes
GSD = 1.0
Breathing interval: One single breath
Concentration = 4.2
Breathing Frequency = 102.0
Tidal Volume = 1.8
Inspiratory Fraction = 0.5
Pause Fraction = 0.0
Breathing Route = nasal

Region: Entire Lung
Region: Entire Lung
Region  Deposition Fraction
--      --
Head    0.072
TB      0.041
 P      0.068
Total   0.181
```

E.2. Cancer Endpoints

E.2.1. Dose-Response Modeling for the Oral Slope Factor

Dose-Response Models

Due to the occurrence of multiple tumor types, earlier occurrence with increasing exposure, and early termination of the high-dose group in the oral carcinogenicity studies (see Appendix D for study details), methods that can reflect the influence of competing risks and intercurrent mortality on site-specific tumor incidence rates are preferred. EPA has generally used a model that incorporates the time at which death-with-tumor occurred as well as the dose; the multistage-Weibull model is multistage in dose and Weibull in time, and has the form:

$$P(d, t) = 1 - exp[-(q_0 + q_1 d + q_2 d^2 + ... + q_k d^k) \times (t \pm t_0)^c],$$

where $P(d, t)$ represents the lifetime risk (probability) of cancer at dose d (i.e., human equivalent exposure in this case) and age t (in bioassay weeks); parameters $q_i \geq 0$, for $i = 0, 1, ..., k$; t is the time at which the tumor was observed; and c is a parameter which characterizes the change in response with age. The parameter t_0 represents the time between when a potentially fatal tumor becomes observable and when it causes death, and is generally set to 0 either when all tumors are considered incidental or because of a lack of data to estimate the time reliably. The dose-response analyses were conducted using the computer software program MultiStage-Weibull (U.S. EPA, 2010), which is based on Weibull models drawn from Krewski et al. (1983). Parameters were estimated using the method of maximum likelihood. From specific model fits using stages up to n −1, where n is the number of dose groups, the model fit with the lowest AIC was selected.

Data Adjustments Prior to Modeling

Two general characteristics of the observed tumor types were considered prior to modeling: allowance for different, although unidentified modes of action, and allowance for relative severity of tumor types. First, etiologically different tumor types were not combined across sites prior to modeling (i.e., overall counts of tumor-bearing animals were not tabulated) in order to allow for the possibility that different tumor types could have different dose-response relationships due to different underlying mechanisms or factors, such as latency. Consequently, all of the tumor types were also modeled separately.

Additionally, the multistage-Weibull model can address relative severity of tumor types to some extent by distinguishing between tumors as being either fatal or incidental to the death of an animal in order to adjust partially for competing risks. In contrast to fatal tumors, incidental tumors are those tumors thought not to have caused the death of an animal. Cause-of-death information for most early animal deaths was provided by the investigators of both bioassays. In

ED_006137A_00009570-00182

the rat study of Kroese et al. (2001), tumors of the forestomach or liver were the principal cause of death for most animals dying or sacrificed (due to moribundity) before the end of the study, while tumors of the forestomach were the most common cause of early deaths in the mouse study of Beland and Culp (1998). The incidence data modeled are listed in Tables E-9 (male rats), E-10 (female rats), and E-11 (female mice).

Human-equivalent dose (HED) estimates used for dose-response modeling were based on scaling by body weight$^{3/4}$, as there were no pharmacokinetic models or data to inform another approach. The dose estimates are provided in Tables E-12 (Kroese et al., 2001) and E-13 (Beland and Culp, 1998).

Evaluation of Model Fit and Model Selection

Each model was examined for adequacy of fit in the low-dose region and in the vicinity of the BMR of 10% extra risk. In general, the model fit with the lowest AIC was selected, except when model fit near the BMR and in the low-dose region was improved by including an additional stage (parameter) in the model.

PODs for estimating low-dose risk were identified at doses at the lower end of the observed data, generally corresponding to 10% extra risk, where extra risk is defined as [P(d) − P(0)]/ [1 − P(0)]. The lifetime oral cancer slope factor for humans is defined as the slope of the line from the lower 95% bound on the exposure at the POD to the control response (slope factor = $0.1/BMDL_{10}$). This slope, a 95% upper confidence limit (UCL), represents a plausible upper bound on the true risk.

Overall Risk

Although the time-to-tumor modeling helps account for competing risks associated with decreased survival times and other tumors, considering the tumor sites individually still does not convey the total amount of risk potentially arising from the sensitivity of multiple sites (i.e., the risk of developing any combination of the increased tumor types, not just the risk of developing all simultaneously). One approach suggested in the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005) would be to estimate cancer risk from tumor-bearing animals. EPA traditionally used this approach until the National Research Council (NRC) document *Science and Judgment in Risk Assessment* (NRC, 1994) made a case that this approach would tend to underestimate overall risk when tumor types occur in a statistically independent manner. In addition, application of one model to a composite data set does not accommodate biologically relevant information that may vary across sites or may only be available for a subset of sites. For instance, the time courses of the multiple tumor types evaluated varied, as is suggested by the variation in estimates of *c*, from 1.5 (e.g., male rat skin or mammary gland basal cell tumors), indicating relatively little effect of age on tumor incidence, to 3.7 (e.g., male mouse alimentary tract tumors), indicating a more rapidly increasing response with increasing age (in addition to exposure level). The result of fitting a model with parameters that can reflect underlying mechanisms, such as *z* in the multistage-Weibull

ED_006137A_00009570-00183

model, would be difficult to interpret with composite data (i.e., counts of tumor-bearing animals). A simpler model, such as the multistage model, could be used for the composite data, but relevant biological information would then be ignored.

Following the recommendations of the NRC (1994) regarding combining risk estimates, statistical methods that can accommodate the underlying distribution of slope factors are optimal, such as through maximum likelihood estimation or through bootstrapping or Bayesian analysis. However, these methods have not yet been extended to models such as the multistage-Weibull model. A method involving the assumption that the variability in the slope factors could be characterized by a normal distribution is detailed below (U.S. EPA, 2010). Using the results in female rats to illustrate, the overall risk estimate involved the following steps:

1) It was assumed that the tumor groupings modeled above were statistically independent (i.e., that the occurrence of a liver tumor was not dependent upon whether there was a forestomach tumor). This assumption cannot currently be verified, and if not correct, could lead to an overestimate of risk from summing across tumor sites. However, NRC (1994) argued that a general assumption of statistical independence of tumor-type occurrences within animals was not likely to introduce substantial error in assessing carcinogenic potency from rodent bioassay data.

2) The models previously fitted to estimate the BMDs and BMDLs were used to extrapolate to a lower level of risk (R), in order to reach the region of each estimated dose-response function where the slope was reasonably constant and upper bound estimation was still numerically stable. For these data, a 10^{-3} risk was generally the lowest risk necessary. The oral slope factor for each site was then estimated by $R/BMDL_R$, as for the estimates for each tumor site above.

3) The maximum likelihood estimates (MLE) of unit potency (i.e., risk per unit of exposure) estimated by R/BMD_R, were summed across the alimentary tract, liver, and jejunum/ duodenum in female rats.

4) An estimate of the 95% (one-sided) upper bound on the summed oral slope factor was calculated by assuming a normal distribution for the individual risk estimates, and deriving the variance of the risk estimate for each tumor site from its 95% UCL according to the formula:

$$95\%\ UCL = MLE + 1.645 \times SD,$$

rearranged to:

$$SD = (UCL - MLE) / 1.645,$$

where 1.645 is the t-statistic corresponding to a one-sided 95% confidence interval (CI) and >120 degrees of freedom, and the SD is the square root of the variance of the MLE. The variances (variance = SD^2) for each site-specific estimate were summed across tumor sites to obtain the variance of the sum of the MLEs. The 95% UCL on the sum of MLEs was calculated from the expression above for the UCL, using the variance of the sum of the MLE to obtain the relevant SD (SD = $variance^{1/2}$).

ED_006137A_00009570-00184

Table E-9. Tumor incidence data, with time to death with tumor for male Wistar rats exposed by gavage to benzo[a]pyrene for 104 weeks (Kroese et al., 2001)

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:							
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors	Skin or mammary gland		Kidney urothelial carcinoma
								Basal cell tumors	Squamous cell tumors	
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental	Incidental	Incidental	Incidental
0	44	1	0	0	0	0	0	1	0	0
	80	1	0	0	0	0	0	0	0	0
	82	1	0	0	0	0	0	0	0	0
	84	1	0	0	0	0	0	0	0	0
	89	1	0	0	0	0	0	0	0	0
	90	3	0	0	0	0	0	0	0	0
	91	1	0	0	0	0	0	0	0	0
	92	1	0	0	0	0	0	0	0	0
	93	1	0	0	0	0	0	0	0	0
	94	1	0	0	0	0	0	0	0	0
	95	2	0	0	0	0	0	0	0	0
	96	2	0	0	0	0	0	0	0	0
	97	1	0	0	0	0	0	0	0	0
	98	1	0	0	0	0	0	0	0	0
	100	3	0	0	0	0	0	1	0	0
	104	1	0	0	0	0	0	0	0	0
	105	1	0	0	0	0	0	0	0	0
	108	7	0	0	0	0	0	0	0	0
	109	22	0	0	0	0	0	0	0	0
3	29	1	0	0	0	0	0	0	0	0
	40	1	1	0	0	0	0	0	0	0
	74	1	0	0	0	0	0	0	0	0
	76	1	0	0	0	0	0	0	0	0
	79	1	0	0	0	0	0	0	0	0
	82	1	0	0	0	0	0	0	0	0
	92	2	0	0	0	0	0	0	0	0
	93	1	0	0	0	0	0	0	0	0
	94	1	0	0	0	0	0	0	0	0
	95	2	0	0	0	0	0	0	0	0
	98	1	0	0	0	0	0	0	0	0
	107	10	4	0	1	0	0	0	0	0
	108	15	2	0	3	0	0	1	1	0
	109	14	1	0	0	0	0	0	0	0

ED_006137A_00009570-00185

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:							
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors	Skin or mammary gland		Kidney urothelial carcinoma
								Basal cell tumors	Squamous cell tumors	
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental	Incidental	Incidental	Incidental
10	39	1	0	0	0	0	0	0	0	0
	47	2	0	0	0	0	0	0	0	0
	63	1	1	0	0	0	0	0	0	0
	68	2	2	0	0	0	0	0	0	0
	69	1	1	0	0	0	0	0	0	0
	77	1	0	0	1	0	0	0	0	0
	80	1	0	0	1	0	0	0	0	0
	81	1	1	0	0	0	1	0	0	0
	84	1	1	0	0	1	0	0	0	0
	86	1	0	0	1	0	0	0	0	0
	90	1	1	0	0	0	0	0	0	0
	95	3	3	0	2	0	0	0	0	0
	97	1	1	0	0	1	0	0	0	0
	100	1	1	0	1	0	0	0	0	0
	102	1	1	0	1	0	0	0	0	0
	103	1	1	0	1	0	0	0	0	0
	104	3	3	0	3	0	0	0	0	0
	107	12	12	0	11	0	0	0	1	0
	108	11	11	0	11	0	0	1	0	0
	109	6	5	0	3	0	0	0	0	0

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:							
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors	Skin or mammary gland		Kidney urothelial carcinoma
								Basal cell tumors	Squamous cell tumors	
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental	Incidental	Incidental	Incidental
30	32	1	1	0	0	0	0	0	0	0
	35	1	1	0	1	0	0	0	0	0
	37	1	1	0	0	0	0	0	0	0
	44	1	0	1	1	0	0	0	0	0
	45	2	2	0	2	0	0	0	0	0
	47	1	1	0	1	0	0	0	0	0
	48	1	1	0	1	0	0	0	0	0
	49	1	1	0	1	0	0	0	0	0
	50	1	1	0	1	0	0	0	0	0
	51	1	1	0	1	0	1	0	0	0
	52	4	3	1	3	1	0	1	1	0
	53	1	1	0	1	0	0	1	0	0
	56	2	1	1	1	1	0	0	0	0
	58	2	2	0	2	0	0	1	0	0
	59	2	2	0	2	0	0	0	0	0
	60	2	1	1	1	1	1	0	0	0
	61	3	2	1	1	2	1	0	0	0
	62	5	5	0	0	4	3	0	0	0
	63	5	5	0	4	1	1	2	1	2
	64	2	2	0	1	1	0	0	0	1
	65	3	2	1	1	2	0	3	2	0
	66	1	1	0	0	1	0	0	0	0
	67	3	1	2	2	1	1	1	1	0
	68	1	1	0	1	0	0	0	0	0
	70	2	2	0	1	1	1	1	0	0
	71	1	1	0	1	0	0	1	1	0
	73	1	0	1	1	0	0	1	0	0
	76	1	1	0	0	1	0	1	0	0

[a]"Incidental" denotes presence of tumors not known to have caused death of particular animals. "Fatal" denotes incidence of tumors reported by the study investigators to have caused death of particular animals.

Table E-10. Tumor incidence data, with time to death with tumor for female Wistar rats exposed by gavage to benzo[a]pyrene for 104 weeks (Kroese et al., 2001)

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:				
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental
0	64	1	0	0	0	0	0
	69	1	0	0	0	0	0
	75	1	0	0	0	0	0
	104	1	0	0	0	0	0
	106	4	0	0	0	0	0
	107	7	0	0	0	0	0
	108	7	0	0	0	0	0
	109	30	1	0	0	0	0
3	8	1	0	0	0	0	0
	47	1	0	0	0	0	0
	52	1	0	0	0	0	0
	60	1	0	0	0	0	0
	65	1	0	0	0	0	0
	76	1	0	0	0	0	0
	77	1	0	0	0	0	0
	83	2	0	0	0	0	0
	85	1	0	0	0	0	0
	86	1	0	0	0	0	0
	88	1	0	0	0	0	0
	93	2	0	0	0	0	0
	94	1	0	0	0	0	0
	97	1	1	0	0	0	0
	107	6	2	0	1	0	0
	108	9	2	0	0	0	0
	109	21	1	0	0	0	0

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:				
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental
10	42	1	0	0	0	0	0
	43	1	0	0	0	0	0
	44	1	0	0	0	0	0
	45	1	0	0	0	0	0
	48	1	0	0	0	0	0
	55	1	0	0	1	0	0
	59	1	0	0	0	0	0
	75	1	0	0	1	0	0
	76	2	0	0	1	0	0
	77	2	0	0	0	0	0
	80	1	1	0	1	0	0
	81	1	1	0	0	1	0
	82	1	1	0	1	0	0
	83	1	0	0	1	0	0
	85	2	1	0	1	1	0
	86	1	1	0	0	1	0
	87	1	0	0	1	0	0
	88	2	1	0	1	1	0
	89	1	1	0	0	1	0
	91	1	0	0	0	1	0
	95	1	0	0	0	0	0
	96	1	0	0	0	0	0
	98	2	2	0	1	1	0
	99	3	3	0	1	2	0
	102	1	1	0	0	1	0
	104	1	1	0	1	0	0
	105	2	1	0	1	1	0
	106	1	1	0	0	1	0
	107	5	5	0	5	0	0
	108	7	7	0	7	0	0
	109	4	2	0	2	0	0

Dose (mg/kg-d)	Wk of death	Total examined	Numbers of animals with:				
			Oral cavity or forestomach tumors		Liver tumors		Duodenum or jejunum tumors
			Incidental[a]	Fatal[a]	Incidental	Fatal	Incidental
30	26	1	0	0	0	0	0
	44	4	4	0	3	1	0
	47	3	3	0	2	1	0
	48	1	1	0	0	1	0
	54	1	0	0	1	0	0
	55	3	3	0	1	2	0
	56	2	2	0	0	2	0
	57	2	2	0	2	0	0
	58	4	3	1	0	4	0
	59	2	1	1	0	2	0
	60	1	0	1	1	0	0
	61	2	2	0	0	2	0
	62	2	2	0	1	1	0
	63	3	3	0	0	3	0
	64	5	5	0	0	5	3
	66	3	3	0	0	3	0
	67	2	1	1	0	2	0
	68	1	1	0	0	1	0
	69	4	3	1	1	3	1
	71	4	3	1	1	3	0
	72	2	1	1	0	2	0

[a]"Incidental" denotes presence of tumors not known to have caused death of particular animals. "Fatal" denotes incidence of tumors indicated by the study investigators to have caused death of particular animals.

ED_006137A_00009570-00190

Table E-11. Tumor incidence, with time to death with tumor; B6C3F$_1$ female mice exposed to benzo[a]pyrene via diet for 2 years (Beland and Culp, 1998)

Dose group (ppm in diet)	Wk of death	Total examined	Number of animals with alimentary tract squamous cell tumors	
			Fatal[a]	Incidental
0	31	1	0	0
	74	1	0	0
	89	2	0	0
	91	1	0	0
	93	2	0	0
	94	2	0	0
	97	2	0	0
	98	2	0	0
	99	1	0	0
	100	2	0	0
	101	2	0	0
	104	1	0	0
	105	29	0	1
5	25	1	0	0
	55	1	0	0
	83	1	0	0
	86	1	0	0
	87	2	0	0
	88	2	0	0
	90	1	0	0
	94	1	0	0
	95	2	0	0
	96	1	0	0
	97	2	0	0
	98	2	0	0
	101	2	0	0
	102	2	0	0
	105	27	0	3

ED_006137A_00009570-00191

Dose group (ppm in diet)	Wk of death	Total examined	Number of animals with alimentary tract squamous cell tumors	
25	44	1	1	0
	47	1	0	0
	64	1	0	0
	70	1	1	0
	77	1	1	0
	80	1	0	0
	81	1	1	0
	84	2	1	1
	85	1	1	0
	86	1	1	0
	88	1	1	0
	89	1	0	0
	90	4	4	0
	93	3	2	1
	94	2	2	0
	96	3	0	2
	97	1	1	0
	98	1	1	0
	99	2	1	1
	100	1	1	0
	101	1	0	0
	102	2	2	0
	104	1	1	0
	105	13	0	10

Dose group (ppm in diet)	Wk of death	Total examined	Number of animals with alimentary tract squamous cell tumors	
100	39	1	1	0
	40	1	1	0
	42	1	1	0
	47	2	2	0
	49	1	0	0
	50	1	1	0
	53	1	0	0
	55	3	3	0
	56	1	1	0
	57	1	1	0
	58	1	1	0
	59	3	3	0
	60	1	1	0
	61	3	3	0
	62	5	5	0
	63	4	4	0
	64	3	3	0
	65	2	2	0
	66	3	3	0
	68	1	1	0
	69	2	2	0
	70	2	2	0
	71	1	1	0
	72	1	1	0
	73	1	1	0
	74	1	1	0
	79	1	1	0

[a]"Incidental" denotes presence of tumors not known to have caused death of particular animals. "Fatal" denotes incidence of tumors indicated by the study investigators to have caused death of particular animals.

ED_006137A_00009570-00193

Table E-12. Derivation of HEDs to use for BMD modeling of Wistar rat tumor incidence data from Kroese et al. (2001)

Benzo[a]pyrene dose (mg/kg-d)	TWA body weight (kg)	Interspecies scaling factor[a]	HED[b] (mg/kg-d)
Male			
3	0.349	0.27	0.54
10	0.349	0.27	1.81
30	0.288	0.25	5.17
Female			
3	0.222	0.24	0.49
10	0.222	0.24	1.62
30	0.222	0.24	4.85

[a]Scaling factors were calculated using U.S. EPA (1988) reference body weights for humans (70 kg), and the TWA body weights for each dose group: rat-to-human = $(\text{TWA body weight}/70)^{0.25}$ = scaling factor.
[b]HED = administered dose × scaling factor.

Table E-13. Derivation of HEDs for dose-response modeling of B6C3F$_1$ female mouse tumor incidence data from Beland and Culp (1998)

Benzo[a]pyrene dose in diet (ppm)	Intake (µg/d)	TWA body weight average (kg)	Administered dose[a] (mg/kg-d)	Scaling factor[b]	HED[c] (mg/kg-d)
5	21	0.032	0.7	0.15	0.10
25	104	0.032	3.3	0.15	0.48
100	430	0.027	16.5	0.14	2.32

[a]Administered doses in mg/kg-day were calculated from dietary concentrations of benzo[a]pyrene using the TWA body weight and reported food intakes for mice.
[b]Scaling factors were calculated using U.S. EPA (1988) reference body weights for humans (70 kg), and the TWA body weights for each dose group: mouse-to-human = $(\text{TWA body weight}/70)^{0.25}$ = scaling factor.
[c]HED = administered dose × scaling factor.

Dose-Response Modeling Results

Tables E-14 (male and female rats) and E-16 (female mice) summarize the modeling results supporting the oral slope factor for benzo[a]pyrene. The model outputs and graphs following each of these tables (Figures E-10 through E-19) provide more details for the best-fitting models in each case.

Table E-14. Summary of BMD modeling results for best-fitting multistage-Weibull models, using time-to-tumor data for Wistar rats exposed to benzo[a]pyrene via gavage for 104 weeks (Kroese et al., 2001); BMR = 10% extra risk

	Endpoints	Model stages	AIC	BMD_{10}	$BMDL_{10}$ – $BMDU_{10}$	Basis for model selection
Male rats	Oral cavity and forestomach: squamous cell tumors	1 2 **3**	577.8 407.6 **229.0**	0.104 0.678 **0.453**	**0.281–0.612**	**Lowest AIC, best fit to low dose data**
	Hepatocellular tumors	1 2 **3**	367.3 301.5 **289.1**	0.181 0.472 **0.651**	**0.449–0.772**	**Lowest AIC, best fit to low dose data**
	Duodenum and jejunum tumors	1 2 **3**	69.6 65.9 **66.9**	2.64 3.04 **3.03**	**2.38–3.87**	**Best fit to data**
	Kidney: uroethelial carcinoma	1 2 **3**	31.9 31.7 **32.8**	9.16 5.71 **4.65**	**2.50–9.01**	**Best fit to data**
	Skin and mammary gland: basal cell tumors	1 2 **3**	110.6 105.1 **104.7**	1.88 2.58 **2.86**	**2.35–3.62**	**Lowest AIC, best fit to low dose data**
	Skin and mammary gland: squamous cell tumors	**1** 2 3	63.5 64.3 **65.3**	3.36 2.75 **2.64**	**1.77–4.42**	**Best fit to low dose data**
Female rats	Oral cavity and forestomach: squamous cell tumors	1 2 3	277.1 211.6 **201.0**	0.245 0.428 **0.539**	**0.328–0.717**	**Lowest AIC, best fit to low dose data**
	Hepatocellular tumors	1 2 3	595.5 774.9 **468.3**	0.146 0.370 **0.575**	**0.507–0.630**	**Lowest AIC, best fit to low dose data**
	Duodenum and jejunum tumors	1 2 **3**	37.9 37.0 **37.8**	6.00 4.33 **3.43**	**1.95–5.70**	**Best fit to low dose data**

ED_006137A_00009570-00195

Male Rat (Kroese et al., 2001): Squamous Cell Papilloma or Carcinoma in Oral Cavity or Forestomach

```
=========================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: OralForstKroeseM3.(d)
 ========================================================================
   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 3

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =          3.6
                         t_0    =      39.1111
                         beta_0 =            0
                         beta_1 =  8.8911e-009
                         beta_2 = 1.60475e-031
                         beta_3 = 1.95818e-008


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -beta_0    -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            t_0          beta_1       beta_3

    c                 1        -0.53        -0.93        -0.99

    t_0           -0.53            1         0.47         0.57

    beta_1        -0.93         0.47            1          0.9

    beta_3        -0.99         0.57          0.9            1


                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               3.74559         0.447309            2.86888              4.6223
         t_0             41.4581          2.14975            37.2447             45.6716
         beta_0                0               NA
         beta_1     4.37816e-009     1.07528e-008       -1.6697e-008        2.54533e-008
         beta_2                0               NA
         beta_3     1.01904e-008     1.94164e-008       -2.78651e-008       4.82458e-008

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model        -108.512         6         229.024


                     Data Summary
                         CONTEXT
```

```
                C      F      I      U  Total  Expected Response
     DOSE
         0     52      0      0      0     52      0.00
      0.54     44      0      8      0     52      6.77
       1.8      7      0     45      0     52     41.69
       5.2      0      9     43      0     52     49.97

     Minimum observation time for F tumor context =         44


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104


        Specified effect =  0     .     1   0.01            0.001
                     BMD =  0 . 4 5 3 4 7 1   0.0633681       0.00636659
                    BMDL =  0 . 2 8 1 0 4 4   0.0286649       0.00285563
                    BMDU =  0 . 6 1 2 4 6 2   0.248377        > 0.0509326
```



Figure E-10. Fit of multistage Weibull model to squamous cell papillomas or carcinomas in oral cavity or forestomach of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Male Rat (Kroese et al., 2001): Hepatocellular Adenoma or Carcinoma

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: LiverKroeseM3.(d)
=====================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 3


 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =          3.6
                         t_0    =      34.6667
                         beta_0 =            0
                         beta_1 = 2.73535e-009
                         beta_2 =   8.116e-028
                         beta_3 = 1.43532e-008


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -beta_0    -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            t_0          beta_1       beta_3

    c                 1        -0.84        -0.88           -1

    t_0           -0.84            1         0.71         0.86

    beta_1        -0.88         0.71            1         0.86

    beta_3           -1         0.86         0.86            1


                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               3.49582         0.629257            2.26249             4.72914
         t_0             40.2211          5.65421            29.1391             51.3032
         beta_0                0               NA
         beta_1     4.43906e-009     1.76051e-008       -3.00664e-008        3.89445e-008
         beta_2                0               NA
         beta_3     2.35065e-008     6.47999e-008       -1.03499e-007        1.50512e-007

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model        -138.544         6         289.088


                     Data Summary
                         CONTEXT
               C      F      I      U  Total  Expected Response
```

```
    DOSE
        0      52       0       0       0      52      0.00
     0.54      48       0       4       0      52      3.38
      1.8      14       2      36       0      52     36.81
      5.2       3      17      32       0      52     49.55

    Minimum observation time for F tumor context =         52


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104


       Specified effect =  0       .       1   0.01          0.001
                   BMD =  0  .  6  5  0  7   0.173556      0.0199908
                  BMDL =  0  .  4  4  8  6  8   0.0530469     0.00530386
                  BMDU =  0  .  7  7  2  4  6  7   0.352684      > 0.159927
```



Figure E-11. Fit of multistage Weibull model to hepatocellular adenomas or carcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Male Rat (Kroese et al., 2001): Duodenum or Jejunum Adenocarcinoma

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: DuoJejKroeseM3.(d)
=====================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 1
 Degree of polynomial = 3



   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =      1.63636
                         t_0    =            0   Specified
                         beta_0 = 4.31119e-027
                         beta_1 = 2.96347e-025
                         beta_2 =            0
                         beta_3 = 1.76198e-006


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -t_0       -beta_0    -beta_1    -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            beta_3

    c                 1           -1

    beta_3           -1            1


                                Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               1.77722          2.03042            -2.20233             5.75677
         beta_0                0               NA
         beta_1                0               NA
         beta_2                0               NA
         beta_3     9.82635e-007     8.29355e-006       -1.52724e-005        1.72377e-005

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


               Log(likelihood)   # Param             AIC
   Fitted Model        -28.4387         5         66.8773


                     Data Summary
                         CONTEXT
                C      F      I      U  Total  Expected Response
    DOSE
```

```
          0      52       0       0       0      52     0.00
       0.54      52       0       0       0      52     0.03
        1.8      51       0       1       0      52     1.04
        5.2      43       0       9       0      52     8.96


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Specified effect =            0.1
Confidence level =            0.9
Time              =            104


 Specified effect =  0     .     1   0.01          0.001
              BMD =  3 . 0 3 2 9 1   1.38578       0.642252
             BMDL =  2 . 3 7 7 8 2   0.418285      0.0420835
             BMDU =  3 . 8 7 1 8 3   1.76166       0.811476
```



Figure E-12. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Male Rat (Kroese et al., 2001): Skin or Mammary Gland Basal Cell Tumors

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: SKinMamBasalKroeseM3.(d)
=====================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 1
 Degree of polynomial = 3



   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c       =      1.38462
                         t_0     =            0   Specified
                         beta_0  = 3.84298e-005
                         beta_1  = 1.06194e-028
                         beta_2  =            0
                         beta_3  = 6.84718e-006


            Asymptotic Correlation Matrix of Parameter Estimates
            ( *** The model parameter(s)  -t_0       -beta_1    -beta_2
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                  c            beta_0       beta_3

    c                 1           -1           -1

    beta_0           -1            1         0.99

    beta_3           -1         0.99            1


                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               1.47227          1.76686             -1.9907             4.93525
         beta_0     2.54786e-005      0.000211261        -0.000388585         0.000439542
         beta_1                0               NA
         beta_2                0               NA
         beta_3     4.81611e-006        3.49e-005       -6.35866e-005        7.32188e-005

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model        -47.3623         5         104.725


                     Data Summary
                         CONTEXT
```

DOSE	C	F	I	U	Total	Expected Response
0	50	0	2	0	52	1.18
0.54	51	0	1	0	52	1.22
1.8	51	0	1	0	52	2.32
5.2	39	0	13	0	52	12.54

```
   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104

 Specified effect =  0     .     1   0.01          0.001
              BMD =  2 . 8 6 2 7 6   1.30804       0.606222
             BMDL =  2 . 3 5 1 1 8   0.415897      0.0424277
             BMDU =  3 . 6 2 2 5 8   1.69571       0.761447
```



Figure E-13. Fit of multistage Weibull model to skin or mammary gland basal cell tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Male Rat (Kroese et al., 2001): Skin or Mammary Gland Squamous Cell Tumors

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: SKinMamSCCKroeseM3.(d)
 ======================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 1
 Degree of polynomial = 3



   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =            3
                         t_0    =            0   Specified
                         beta_0 =            0
                         beta_1 = 1.25256e-008
                         beta_2 = 1.25627e-030
                         beta_3 = 3.34696e-009


            Asymptotic Correlation Matrix of Parameter Estimates
            ( *** The model parameter(s)  -t_0       -beta_0    -beta_2
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                  c            beta_1       beta_3

    c                 1        -0.99           -1

    beta_1        -0.99            1         0.99
    beta_3           -1         0.99            1


                                  Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               2.96213            2.591            -2.11613             8.04039
         beta_0                0               NA
         beta_1     1.50104e-008     1.86972e-007       -3.51447e-007        3.81468e-007
         beta_2                0               NA
         beta_3      3.9084e-009     4.15374e-008       -7.75033e-008        8.53201e-008

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model         -27.652         5          65.304


                     Data Summary
                         CONTEXT
               C      F      I      U  Total  Expected Response
```

```
DOSE
    0      52      0      0      0      52      0.00
 0.54      51      0      1      0      52      0.42
  1.8      51      0      1      0      52      2.12
  5.2      46      0      6      0      52      5.51


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104

        Specified effect =  0     .     1   0.01          0.001
                     BMD =  2 . 6 4 1 4    0.64109       0.070558
                    BMDL =  1 . 7 6 9 3 1  0.211043      0.0210552
                    BMDU =  4 . 4 2 1 4 5  2.03605       > 0.564463
```



Figure E-14. Fit of multistage Weibull model to skin or mammary gland squamous cell tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Male Rat (Kroese et al., 2001): Kidney Urothelial Carcinomas

```
=====================================================================
          Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
          Solutions are obtained using donlp2-intv, (c) by P. Spellucci
          Input Data File: KidneyUrothelialCarKroeseM3.(d)
=====================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 1
 Degree of polynomial = 3



   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =      1.63636
                         t_0    =            0   Specified
                         beta_0 = 3.78734e-027
                         beta_1 = 1.59278e-027
                         beta_2 =   2.718e-024
                         beta_3 = 4.96063e-007


            Asymptotic Correlation Matrix of Parameter Estimates
            ( *** The model parameter(s)  -t_0       -beta_0    -beta_1    -beta_2
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                  c            beta_3

    c                 1           -1

    beta_3           -1            1


                                 Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               1.74897          3.79403            -5.68719             9.18512
         beta_0                0               NA
         beta_1                0               NA
         beta_2                0               NA
         beta_3     3.11107e-007     4.90313e-006       -9.29885e-006        9.92107e-006

NA - Indicates that this parameter has hit a
     bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model        -11.3978         5         32.7956


                     Data Summary
                         CONTEXT
               C      F      I      U  Total  Expected Response
```

```
    DOSE
       0      52      0      0      0      52      0.00
    0.54      52      0      0      0      52      0.01
     1.8      52      0      0      0      52      0.29
     5.2      49      0      3      0      52      2.71


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104


        Specified effect =  0     .     1   0.01            0.001
                     BMD =  4 . 6 4 8 8 6   2.12413         0.984449
                    BMDL =  2 . 4 9 9 7 2   0.734665        0.0748097
                    BMDU =  9 . 0 1 0 2 3   3.49311         1.61892
```



Figure E-15. Fit of multistage Weibull model to kidney urothelial tumors of male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Female Rat (Kroese et al., 2001): Oral Cavity or Forestomach, Squamous Cell Papilloma or Carcinoma

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: OralForstKroeseF3.(d)
=====================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 3

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =          3.6
                         t_0    =      45.1111
                         beta_0 = 1.11645e-009
                         beta_1 = 4.85388e-009
                         beta_2 =            0
                         beta_3 = 1.95655e-008

           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            t_0          beta_0       beta_1       beta_3

    c                 1        -0.79        -0.92        -0.93           -1

    t_0           -0.79            1         0.73         0.72          0.8

    beta_0        -0.92         0.73            1         0.79         0.92

    beta_1        -0.93         0.72         0.79            1         0.91

    beta_3           -1          0.8         0.92         0.91            1


                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               3.52871         0.701117            2.15454             4.90287
         t_0              46.553          5.93306            34.9244             58.1816
         beta_0     1.53589e-009     5.40523e-009       -9.05817e-009        1.21299e-008
         beta_1     7.57004e-009      2.9647e-008       -5.05369e-008         6.5677e-008
         beta_2                0               NA
         beta_3     2.53126e-008     7.66404e-008         -1.249e-007        1.75525e-007

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param            AIC
   Fitted Model        -94.5119         6         201.024


                     Data Summary
```

```
                        CONTEXT
              C      F      I      U  Total  Expected Response
    DOSE
        0    51      0      1      0     52     1.14
     0.49    46      0      6      0     52     4.90
      1.6    22      0     30      0     52    31.81
      4.6     2      7     43      0     52    49.43

    Minimum observation time for F tumor context =         58

   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104


 Specified effect =  0       .       1   0.01                 0.001
              BMD =  0 . 5 3 8 8 0 1   0.0981283            0.0100797
             BMDL =  0 . 3 2 8 1 3 5   0.0345104            0.00344714
             BMDU =  0 . 7 1 7 1 2 7   0.325909             > 0.0806373
```



Figure E-16. Fit of multistage Weibull model to squamous cell papillomas or carcinomas in oral cavity or forestomach of female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Female Rat (Kroese et al., 2001): Hepatocellular Adenoma or Carcinoma

```
=========================================================================
          Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
          Solutions are obtained using donlp2-intv, (c) by P. Spellucci
          Input Data File: LiverKroeseF3.(d)
          Fri Apr 16 09:08:03 2010
 ========================================================================

 Timer to Tumor Model, Liver Hepatocellular Tumors, Kroese et al, Female

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 3


 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =          3.6
                         t_0    =      31.7778
                         beta_0 =            0
                         beta_1 =  4.9104e-031
                         beta_2 = 5.45766e-030
                         beta_3 = 3.44704e-008


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -beta_0    -beta_1    -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c             t_0          beta_3

    c                 1         -0.9           -1

    t_0             -0.9            1         0.92

    beta_3            -1         0.92            1


                                 Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               3.11076         0.549208             2.03434             4.18719
         t_0             38.6965          5.21028             28.4846             48.9085
         beta_0                0               NA
         beta_1                0               NA
         beta_2                0               NA
         beta_3      2.94354e-007     7.19418e-007       -1.11568e-006        1.70439e-006

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                 Log(likelihood)    # Param             AIC
   Fitted Model          -228.17          6          468.34
```

```
                    Data Summary
                        CONTEXT
                C       F       I       U  Total  Expected Response
    DOSE
        0      52       0       0       0     52      0.00
     0.49      51       0       1       0     52      3.02
      1.6      13      12      27       0     52     38.36
      4.6       1      38      13       0     52     51.36

    Minimum observation time for F tumor context =         44


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104


 Specified effect =  0     .     1   0.01           0.001
              BMD =  0.5751 27      0.262783       0.12179
             BMDL =  0.506633       0.134213       0.0152934
             BMDU =  0.629806       0.287232       0.133064
```



Figure E-17. Fit of multistage Weibull model to hepatocellular adenomas or carcinomas in female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Female Rat (Kroese et al., 2001): Duodenum or Jejunum Adenocarcinoma

```
=====================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: DuoJejKroeseF3.(d)
 ====================================================================
   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 208
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 1
 Degree of polynomial = 3


   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =         2.25
                         t_0    =            0   Specified
                         beta_0 =            0
                         beta_1 =            0
                         beta_2 =            0
                         beta_3 =   7.289e-008


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -t_0       -beta_0    -beta_1    -beta_2
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            beta_3

    c                 1           -1

    beta_3           -1            1


                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               2.32531          3.58729           -4.70565            9.35626
         beta_0                0               NA
         beta_1                0               NA
         beta_2                0               NA
         beta_3     5.32209e-008     7.98487e-007       -1.51178e-006        1.61823e-006

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param            AIC
   Fitted Model        -13.8784         5        37.7569


                     Data Summary
                         CONTEXT
               C      F      I      U  Total  Expected Response
    DOSE
        0     52      0      0      0     52      0.00
     0.49     52      0      0      0     52      0.01
```

```
        1.6      52       0       0       0      52      0.44
        4.6      48       0       4       0      52      3.57


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level  =            0.9
Time              =            104

 Specified effect =  0      .     1   0.01           0.001
              BMD =  3 . 4 3 1 2 9   1.56781        0.726615
             BMDL =  1 . 9 4 7 4 5   0.560867       0.0584891
             BMDU =  5 . 7 0 1 0 8   2.61447        1.21046
```



Figure E-18. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in female rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

Table E-15. Summary of human equivalent overall oral slope factors, based on tumor incidence in male and female Wistar rats exposed to benzo[a]pyrene by gavage for 104 weeks (Kroese et al., 2001)

Data set	Tumor site	BMD_{001}	$BMDL_{001}$	Risk value[a] at BMD_{001}	Risk value[a] at $BMDL_{001}$	SD	SD^2	Proportion of total variance
Males	Oral cavity/ forestomach	6.37×10^{-3}	2.86×10^{-3}	1.57×10^{-1}	3.50×10^{-1}	1.17×10^{-1}	1.38×10^{-2}	0.64
	Liver	2.00×10^{-2}	5.30×10^{-3}	5.00×10^{-2}	1.89×10^{-1}	8.42×10^{-2}	7.09×10^{-3}	0.33
	Duodenum/ jejunum	6.42×10^{-1}	4.21×10^{-2}	1.56×10^{-3}	2.38×10^{-2}	1.35×10^{-2}	1.82×10^{-4}	0.01
	Skin/mammary gland: basal cell	6.06×10^{-1}	4.24×10^{-2}	1.65×10^{-3}	2.36×10^{-2}	1.33×10^{-2}	1.78×10^{-4}	0.01
	Skin/mammary gland: squamous cell	7.06×10^{-2}	2.11×10^{-2}	1.42×10^{-2}	4.75×10^{-2}	2.03×10^{-2}	4.10×10^{-4}	0.02
	Kidney	9.84×10^{-1}	7.48×10^{-2}	1.02×10^{-3}	1.34×10^{-2}	7.51×10^{-3}	5.64×10^{-5}	0.00
	Sum, risk values at BMD_{001}:			2.25×10^{-1}	Sum, SD^2:		2.17×10^{-2}	
	Overall SD[b]:						1.47×10^{-1}	
	Upper bound on sum of risk estimates[c]:				4.68×10^{-1}			
Females	Oral cavity/ forestomach	3.45×10^{-3}	1.01×10^{-2}	2.90×10^{-1}	9.92×10^{-2}	1.16×10^{-1}	1.35×10^{-2}	0.91
	Liver	1.53×10^{-2}	1.22×10^{-1}	6.54×10^{-2}	8.21×10^{-3}	3.48×10^{-2}	1.21×10^{-3}	0.08
	Duodenum/ jejunum	5.85×10^{-2}	7.27×10^{-1}	1.71×10^{-2}	1.38×10^{-3}	9.56×10^{-3}	9.13×10^{-5}	0.01
	Sum, risk values at BMD_{001}:			1.09×10^{-1}	Sum, SD^2:		1.48×10^{-2}	
	Overall SD:						1.22×10^{-1}	
	Upper bound on sum of risk estimates[c]:				3.09×10^{-1}			

[a]Risk value = $0.001/BMDL_{001}$.
[b]Overall SD = $(\text{sum, } SD^2)^{0.5}$.
[c]Upper bound on the overall risk estimate = sum of BMD_{001} risk values + 1.645 × overall SD.

Table E-16. Summary of BMD model selection among multistage-Weibull models fit to alimentary tract tumor data for female $B6C3F_1$ mice exposed to benzo[a]pyrene for 2 years (Beland and Culp, 1998)

Model stages	AIC	BMD_{10}[a]	$BMDL_{10}$–$BMDU_{10}$[a]	Basis for model selection
1	688.5	0.104		
2	629.2	0.102		
3	**624.5**	**0.127**	**0.071–0.179**	**Lowest AIC, best fit to low dose data**

[a]Evaluated at 104 weeks

Female Mice (Beland and Culp, 1998): Alimentary Tract Squamous Cell Tumors

```
=========================================================================
         Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
         Solutions are obtained using donlp2-intv, (c) by P. Spellucci
         Input Data File: C:\msw10-09\benzo[a]pyrene_FemaleSquamF3i.(d)
=========================================================================

   The form of the probability function is:
   P[response] = 1-EXP$$-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2+beta_3*dose^3)}

   The parameter betas are restricted to be positive

   Dependent variable = Class
   Independent variables = Dose, time

 Total number of observations = 191
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 3


 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008



                User Inputs Initial Parameter Values
                        c      =            2
                        t_0    =           15
                        beta_0 =     1.6e-014
                        beta_1 =            0
                        beta_2 =     5.5e-012
                        beta_3 =     4.4e-012


           Asymptotic Correlation Matrix of Parameter Estimates
                 c            t_0          beta_0       beta_1       beta_2       beta_3

   c                1        -0.78        -0.97        -0.42        -0.99        -0.99

   t_0           -0.78            1         0.76         0.39         0.74         0.84

   beta_0        -0.97         0.76            1         0.33         0.97         0.96

   beta_1        -0.42         0.39         0.33            1         0.31         0.46

   beta_2        -0.99         0.74         0.97         0.31            1         0.97

   beta_3        -0.99         0.84         0.96         0.46         0.97            1


                                  Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               6.92317         1.33874            4.29929             9.54705
         t_0             13.9429         4.96646            4.20881              23.677
         beta_0     2.46916e-016     1.47619e-015      -2.64636e-015        3.14019e-015
         beta_1                0     1.30525e-014      -2.55825e-014        2.55825e-014
         beta_2     5.85452e-014     3.75144e-013      -6.76723e-013        7.93813e-013
         beta_3     9.76542e-014     5.62017e-013      -1.00388e-012        1.19919e-012


                Log(likelihood)   # Param            AIC
   Fitted Model        -306.265         6         624.53


                     Data Summary
                         Class
              C      F      I      U  Total  Expected Response
```

```
    Dose
       0      47       0       1       0      48      0.93
     0.1      45       0       3       0      48      3.21
    0.48       8      23      15       1      47     30.82
     2.3       1      46       0       1      48     41.91

    Minimum observation time for F tumor context =         39


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Specified effect  =            0.1
Confidence level  =            0.9

Time              =            104

              BMD =       0.126983
             BMDL =      0.0706103
             BMDU =       0.179419
```



Figure E-19. Fit of multistage Weibull model to duodenum or jejunum adenocarcinomas in male rats exposed orally to benzo[a]pyrene (Kroese et al., 2001).

E.2.2. Dose-Response Modeling for the Inhalation Unit Risk

Modeling Methods

As with the tumor data used for the oral slope factor (see Section E.2.1, *Dose Response-modeling for the Oral Slope Factor*), there was earlier occurrence of tumors with increasing exposure, and early termination of the high-dose group (Thyssen et al., 1981; see Appendix D for study details). The computer software program Multistage Weibull (U.S. EPA, 2010) was used as described in the analysis of the oral carcinogenicity data. See Section E.2.1 for details of the modeling methods. A previous time-to-tumor analysis (U.S. EPA, 1990) was not used because of several discrepancies between the summarized dose-response data and the individual pathology reports, because the use of age at necropsy rather than the time since first exposure, and because multistage Weibull provides a corrected estimate of the confidence bounds on the BMD.

Data Adjustments Prior to Modeling

As with the oral slope factor (see Section E.2.1, *Dose Response-modeling for the Oral Slope Factor*), etiologically similar tumor types (i.e., benign and malignant tumors of the same cell type) were combined for dose-response modeling. Here the benign tumors (papillomas, polyps, and papillary polyps) were judged to be of the same cell type as the squamous cell carcinomas (SCCs). As described in Section 2.4.2, the overall incidences of benign or malignant tumors in the respiratory tract (larynx, trachea, and nasal cavity) and pharynx were used for dose-response modeling.

Thyssen et al. (1981) did not determine cause of death for any of the animals. Since the investigators for the oral bioassays considered the same tumors to be fatal at least some of the time, bounding estimates for the Thyssen et al. (1981) data were developed by treating the tumors alternately as either all incidental or all fatal. In either case, therefore, an estimate of t_0 (the time between a tumor first becoming observable and causing death) could not be estimated and was set to 0. The data analyzed are summarized in Table E-17. Animals without confirmation of one or more of the pharynx or respiratory tract tissues being examined were not included in the incidences, unless a tumor was diagnosed in those that were examined. Group average TWA continuous exposures, based on chamber air monitoring data and individual hamsters' time on study, of 0, 0.25, 1.01, and 4.29 mg/m^3 corresponded to the 0, 2, 10, and 50 mg/m^3 nominal study concentrations, respectively (U.S. EPA, 1990).

Table E-17. Individual pathology and tumor incidence data for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime—Thyssen et al. (1981)[a]

Exposure concentration: target (lifetime average continuous exposure)[b], mg/m³	Time of tumor observed (d)	Incidence of papillomas, polyps, papillary polyps, or carcinomas (total malignant tumors)						Incidence of respiratory tract or pharynx tumors
		Larynx	Pharynx	Trachea	Nasal cavity	Esophagus	Fore-stomach	
0 (0)	112	0	—[c]	0	0	0	0	—
	270	0	0	0	0	0	0	0
	314	0	0	0	0	0	0	0
	553	0	0	0	0	0	0	0
	577	0	0	0	—	0	0	—
	594	0	—	0	0	0	0	—
	596	0	0	0	0	0	0	0
	611	0	0	0	0	0	0	0
	611	0	0	0	0	0	0	0
	616	0	0	0	0	0	0	0
	619	0	0	0	0	0	0	0
	623	0	0	0	0	0	0	0
	704	0	0	0	0	0	0	0
	710	0	0	0	0	0	0	0
	721	0	0	0	0	0	0	0
	739	0	0	0	0	0	0	0
	751	0	0	0	0	0	0	0
	762	0	0	0	0	0	0	0
	779	0	0	0	0	0	0	0
	800	0	0	0	0	0	0	0
	808	0	—	0	0	0	0	—
	847	0	0	0	0	0	0	0
	857	0	0	0	0	0	0	0
	867	—	0	0	0	0	0	—
	868	0	0	0	0	0	0	0
	885	0	—	0	0	0	0	—
	917	0	0	0	0	0	0	0
2 (0.25)	93	—	—	—	0	0	0	—
	247	0	0	0	0	0	0	0
	370	0	0	0	0	0	0	0
	407	0	0	0	0	0	0	0
	489	0	0	0	0	0	0	0
	539	0	0	0	0	0	0	0
	554	0	0	0	0	0	0	0
	591	0	0	0	0	0	0	0
	612	0	0	0	0	0	0	0
	650	0	0	0	0	0	0	0
	682	0	—	0	0	0	0	—
	690	0	0	0	0	0	0	0
	717	0	0	0	0	0	0	0

Exposure concentration: target (lifetime average continuous exposure)[b], mg/m^3	Time of tumor observed (d)	Incidence of papillomas, polyps, papillary polyps, or carcinomas (total malignant tumors)						Incidence of respiratory tract or pharynx tumors
		Larynx	Pharynx	Trachea	Nasal cavity	Esophagus	Fore-stomach	
	717	0	0	0	0	0	0	0
	755	0	0	0	0	0	0	0
	788	0	0	0	0	0	0	0
	795	0	0	0	0	0	0	0
	802	0	0	0	0	0	0	0
	808	0	0	0	0	0	0	0
	836	0	0	0	0	0	0	0
	848	—	—	0	0	0	0	—
	925	0	0	0	0	0	0	0
10 (1.01)	212	0	0	0	0	0	0	0
	227	0	0	0	0	0	0	0
	357	0	0	0	0	0	0	0
	465	0	0	0	0	0	0	0
	509	0	0	0	0	0	0	0
	530	0	1 (1)	0	0	0	0	1
	531	0	1 (1)	0	0	0	0	1
	557	1 (1)[d]	0	0	0	0	0	0
	597	0	0	0	0	0	0	0
	653	1 (1)	0	0	0	0	0	1
	695	0	0	0	0	0	0	0
	712	0	1 (0)	0	0	0	0	1
	732	1 (1)	1 (1)	0	0	0	0	1
	773	0	1 (1)	0	0	0	0	1
	788	0	1 (0)	0	0	0	0	1
	796	1 (1)	1 (1)	0	0	0	0	1
	803	1 (1)	—	1 (0)	1 (0)	0	0	1
	808	0	—	1 (0)	1 (1)[e]	0	0	1
	812	1 (0)	—	0	0	0	0	1
	822	1 (1)	1 (1)	0	0	0	0	1
	826	1 (0)	0	0	0	0	0	1
	826	0	—	0	0	0	0	—
	826	1 (1)	0	0	1 (0)	0	1 (1)	1
	848	1 (0)	0	0	0	0	0	1
	867	1 (1)	1 (1)	0	0	0	0	1
	868	0	0	0	1 (0)	0	0	1
50 (4.29)	144	—	—	—	0	0	0	—
	151	—	—	—	0	0	0	—
	178	—	—	—	0	0	0	—
	210	—	—	—	0	0	0	—
	211	0	—	0	0	0	0	—
	213	—	—	—	0	0	0	—
	242	—	—	—	0	0	0	—
	253	0	0	0	0	0	0	0
	255	—	—	—	0	0	0	—
	263	—	—	—	0	0	0	0

Exposure concentration: target (lifetime average continuous exposure)[b], mg/m^3	Time of tumor observed (d)	Incidence of papillomas, polyps, papillary polyps, or carcinomas (total malignant tumors)						Incidence of respiratory tract or pharynx tumors
		Larynx	Pharynx	Trachea	Nasal cavity	Esophagus	Fore-stomach	
	281	0[f]	1 (1)	1 (0)	0	0	0	1
	284	0	0	0	0	0	0	0
	284	—	—	—	0	0	0	—
	294	0	0	0	0	0	0	0
	296	0	0	0	0	0	0	0
	324	1 (1)	1 (1)	0	0	0	0	1
	329	0	1 (1)	0	0	0	0	1
	371	0	—	0	0	0	0	—
	388	1 (1)	1 (1)	0	0	0	0	1
	395	0	1 (1)	0	0	0	0	1
	421	0	1 (1)	0	0	0	0	1
	436	0	0	0	0	0	0	0
	442	0	1 (0)	0	0	0	1 (0)	1
	462	1 (1)	1 (1)	0	0	—	—	1
	471	0	1 (1)	0	0	0	0	1
	486	1 (0)	1 (1)	0	0	1 (0)	0	1
	494	1 (1)	1 (1)	1 (1)	0	0	0	1
	498	1 (0)	1 (1)	0	0	0	1 (0)	1
	504	1 (1)	1 (1)	0	0	0	0	1
	506	1 (1)	1 (1)	0	0	0	0	1
	572	0	1 (1)	0	0	0	0	1
	575	1 (1)	1 (1)	0	0	1 (0)	0	1
	578	1 (0)	1 (1)	0	0	0	0	1
	717[g]	1 (1)	1 (1)	1 (0)	1 (0)	0	0	1

[a]Histopathology incidence from (Clement Associates (1990); U.S. EPA (1990)).
[b]See Section D.4.2.
[c]Tissue was not examined.
[d]In situ carcinoma; not included in overall tumor incidence.
[e]Adenocarcinoma; not included in overall tumor incidence.
[f]Metastasis from pharynx not shown.
[g] Necropsy occurred 24 weeks after 79 weeks of exposure.

Dose-Response Modeling Results

Table E-18 summarizes the modeling results supporting the derivation of an inhalation unit risk value for benzo[a]pyrene. The model outputs and graphs (Figures E-20 and E-21) following Table E-18 provide more details for the best-fitting models under the conditions of taking all tumors to be incidental to the cause of death, or to be the cause of death, respectively.

Table E-18. Summary of BMD model selection among multistage-Weibull models fit to tumor data for male Syrian golden hamsters exposed to benzo[a]pyrene via inhalation for lifetime (Thyssen et al., 1981)

Tumor context	Model stages	AIC	BMD_{10}[a]	$BMDL_{10}$[a]	Basis for model selection
All tumors considered incidental to cause of death	1 **2**	50.5 **40.4**	0.076 **0.254**	0.052 **0.163**	**Lowest AIC, best fit to data ($BMDU_{10}$ = 0.324)**
All tumors considered to be cause of death	1 **2**	315.0 **302.9**	0.135 **0.468**	0.104 **0.256**	**Lowest AIC; best fit to data ($BMDU_{10}$ = 0.544)**

Output for Squamous Cell Neoplasia Following Inhalation Exposure to Benzo[a]pyrene: All Tumors Considered Incidental to Cause of Death

```
=========================================================================
          Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
          Solutions are obtained using donlp2-intv, (c) by P. Spellucci
          Input Data File: ThyssenInc2sL104noUB70.(d)
          Tue Mar 11 12:58:28 2014
 ==========================================================================

   The form of the probability function is:
   P[response] = 1-EXP{-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 88
 Total number of records with missing values = 0
 Total number of parameters in model = 5
 Total number of specified parameters = 1
 Degree of polynomial = 2



   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008


                  Default Initial Parameter Values
                         c      =          4.5
                         t_0    =            0   Specified
                         beta_0 = 1.32176e-037
                         beta_1 = 3.02455e-036
                         beta_2 = 2.03765e-013
```

```
            Asymptotic Correlation Matrix of Parameter Estimates
            ( *** The model parameter(s)  -t_0       -beta_0    -beta_1
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                  c            beta_2

     c                 1           -1

     beta_2           -1            1


                                 Parameter Estimates
                                                          95.0% Wald Confidence Interval
        Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
          c               4.71714         0.957627             2.84023             6.59406
          beta_0                0               NA
          beta_1                0               NA
          beta_2     5.16891e-014     3.13384e-013       -5.62533e-013        6.65911e-013

NA - Indicates that this parameter has hit a bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model        -16.2088         4         40.4176


                    Data Summary
                        CONTEXT
                C      F      I      U  Total  Expected Response
    DOSE
        0      21      0      0      0     21      0.00
     0.25      19      0      0      0     19      1.63
        1       8      0     17      0     25     16.27
      4.3       5      0     18      0     23     17.75

Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Specified effect =            0.1
Confidence level =            0.9

Time              =            728

             BMD =       0.253569
            BMDL =       0.163052
            BMDU =       0.323781
```



Figure E-20. Fit of multistage Weibull model to respiratory tract tumors in male hamsters exposed via inhalation to benzo[a]pyrene (Thyssen et al., 1981); tumors treated as incidental to death.

Output for Respiratory Tract Tumors: All Tumors Considered to be Cause Of Death

```
Time of tumor observation was converted to weeks in order to run this form of the multistage-
Weibull model.

=========================================================================
          Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
          Solutions are obtained using donlp2-intv, (c) by P. Spellucci
          Input Data File: ThyssenF2sL104noU.(d)
          Thu Mar 13 14:30:45 2014
 ==========================================================================

   The form of the probability function is:
   P[response] = 1-EXP{-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 88
 Total number of records with missing values = 0
```

```
Total number of parameters in model = 5
Total number of specified parameters = 1
Degree of polynomial = 2



  User specifies the following parameters:
         t_0    =          0

Maximum number of iterations = 64
Relative Function Convergence has been set to: 2.22045e-016
Parameter Convergence has been set to: 1.49012e-008


                 Default Initial Parameter Values
                        c      =            6
                        t_0    =            0   Specified
                        beta_0 =  2.0496e-036
                        beta_1 = 4.12988e-014
                        beta_2 = 3.37033e-013


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -t_0       -beta_0    -beta_1
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            beta_2

    c                 1           -1

    beta_2           -1            1


                                 Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               6.61992         0.915036             4.82649             8.41336
         beta_0                0               NA
         beta_1                0               NA
         beta_2     2.13816e-014     8.96466e-014       -1.54323e-013        1.97086e-013

NA - Indicates that this parameter has hit a
     bound implied by some inequality constraint
     and thus has no standard error.


                Log(likelihood)   # Param             AIC
   Fitted Model         -147.66         4         303.319


                     Data Summary
                         CONTEXT
               C      F      I      U  Total
    DOSE
        0     21      0      0      0     21
     0.25     19      0      0      0     19
        1      8     17      0      0     25
      4.3      5     18      0      0     23

    Minimum observation time for F tumor context =         40

   Benchmark Dose Computation
Risk Response    =          Fatal
Risk Type        =          Extra
Specified effect =            0.1
Confidence level =            0.9

Time             =            104

             BMD =       0.467752
            BMDL =       0.256206
            BMDU =       0.543965
```



Figure E-21. Fit of multistage Weibull model to respiratory tract tumors in male hamsters exposed via inhalation to benzo[a]pyrene (Thyssen et al., 1981); tumors treated as cause of death.

E.2.3. Dose-Response Modeling for the Dermal Slope Factor

Modeling Methods

As with the tumor data used for the oral slope factor (see Section E.2.1, *Dose Response-modeling for the Oral Slope Factor*) and the inhalation unit risk (see Section E.2.2, *Dose Response-modeling for the Inhalation Unit Risk*), there was earlier occurrence of tumors with increasing exposure, as shown in the individual animal data in the technical report for the National Institute for Occupational Safety and Health (NIOSH) study (Sivak et al., 1997; Arthur D Little, 1989). The computer software program Multistage Weibull (U.S. EPA, 2010) was used for the analysis of the dermal carcinogenicity data. See Section E.2.1 for details of the modeling approach, including evaluation of model fit and model selection. Tumors were classified as incidental because the appearance of tumors generally preceded death by weeks in all cases, and time of first appearance of tumors or time on study without tumors were used for the time input.

For the other supporting studies identified in Section 2.5.1, multistage models [BMDS; (U.S. EPA, 2012a); v 2.1] were used. See Section E.1.1 for details of fitting the multistage model. The BMDL estimate (95% lower confidence limit on the BMD, as estimated by the profile likelihood method) and AIC value were used to select a best-fit model from among the models exhibiting adequate fit. The data modeled are summarized in Tables E-19 through E-23.

Data Adjustments Prior to Modeling

For time-to-tumor modeling, no adjustment other than an estimate of daily exposure was used. The data modeled are provided in Table E-19.

For the remaining studies, two types of adjustments were considered: (1) for study groups that were reported to end before 104 weeks, but well after 1 year of exposure, it was judged reasonable to assume that the tumor incidence observed at the time of early termination could have been realized in a full lifetime study using a lower dose; and (2) reductions of the group sizes when there was mortality prior to the first appearance of tumors, in order to estimate the effective number at risk. Equivalent lifetime doses were estimated by multiplying the relevant average daily doses by $(L_e/104)^3$, where L_e is the length of exposure, based on observations that tumor incidence tends to increase with age (Doll, 1971). Note that exposure periods <52 weeks would lead to a relatively large adjustment [i.e., $(52/104)^3 = 0.125$, or an eightfold lower dose than administered], reflecting considerable uncertainty in lifetime equivalent dose estimates generated from relatively short studies. This adjustment was applied to all dose groups in Poel (1959) and Roe et al. (1970), and the highest dose group in Habs et al. (1980) and the grouped data reported by Sivak et al. (1997). The following discussion summarizes how each adjustment was carried out when relevant.

Roe et al. (1970) applied benzo[a]pyrene dermally for 93 weeks or until natural death; with the exception of the highest dose group, each group had approximately 20 animals (or ~40% survival) at 600 days (see Table D-17). The tumors were first observed in the lowest and highest dose groups during the interval of days 200–300. Mice dying before day 200 were likely not at risk long enough for tumor development. However, because tumor incidence and mortality were reported in 100-day intervals, mice that had not been on study long enough to develop tumors were

not easily identifiable. Incidence denominators reflect the number of animals alive at day 200, and may thus lead to underestimates of tumor risk if the number of animals at risk has been overestimated. Table E-20 summarizes the dose adjustments to estimate equivalent 104-week exposures, as well as incidence data adjusted for mortality prior to skin tumor appearance.

Schmidt et al. (1973) did not report survival information; instead, the authors provided incidences based on the numbers of mice initially included in each dose group at the start of the study. Overall latency was reported for the two high-dose groups in each series, but these data only describe the survival of mice with tumors (animals were removed from study when a tumor appeared). It is not clear how long exposures lasted overall in each dose group, or whether some mice may have died on study from other causes before tumors appeared. While it is possible that no mice died during the study, all of the other studies considered here demonstrate mortality. However, the data were modeled as reported, with no adjustments, recognizing the possibility of underestimating risk associated with incidences reported and lack of duration of exposure (see Table E-20).

Schmähl et al. (1977) reported that reduced numbers of animals at risk (77–88 mice per dose group compared with the initial group sizes of 100) resulted from varying rates of autolysis. No other survival or latency information was provided, so all exposures were assumed to have lasted for 104 weeks and were modeled as reported. Given the results of the other studies, it seems possible that the numbers at risk in each group may be overestimated, which could lead to an underestimate of lifetime risk (see Table E-20).

Habs et al. (1980) reported age-standardized skin tumor incidence rates, indicating earlier mortality in the two highest dose groups (2.8 and 4.6 μg/application). These rates were used to estimate the number at risk for dose-response modeling, by dividing the number of mice with tumors by the age-standardized rates. Exposure lasted longer than 104 weeks in the two lower exposure groups, at about 120 and 112 weeks, and until about 88 weeks in the highest exposure group. Incidence in the two lower exposure groups may be higher than if the exposure had lasted just 104 weeks. There was mortality in the first 52 weeks of exposure, about 10–15% in the three exposure groups, but because there was no information concerning when tumors first appeared, it is not possible to determine how much the early mortality may have impacted the number of mice at risk in each group (see Table E-20).

Habs et al. (1984) reported mean survival times (with 95% CIs) for each dose group. The CIs supported the judgment that the control and lower dose groups were treated for 104 weeks. The higher dose group (4 μg/application) was probably treated for <104 weeks, because the upper 95% confidence limit for the mean survival was approximately 79 weeks. However, since it was not possible to estimate a more realistic duration for this group, an estimate of 104 weeks was used (see Table E-20).

The Poel (1959) study was conducted in male mice and used toluene as the vehicle. In addition to a control group, there were nine dose groups. All C57L mice in dose groups with >3.8 μg/application died by week 44 of the study. Therefore, these five dose groups were omitted prior to dose-response modeling because of the relatively large uncertainty in extrapolating cancer risk as a result of lifetime exposure. Four dose groups in addition to control remained. Among

ED_006137A_00009570-00227

these groups, mice survived and were exposed until weeks 83–103. According to the lifespan ranges provided, at least one mouse in each dose group died before the first appearance of tumor, but insufficient information was available to determine how many; consequently, the incidence denominators were not adjusted. Although mice in the lowest exposure group were treated up to 103 weeks, the control group demonstrated a median survival time of 60 weeks and concluded at week 92, suggesting a lifetime <104 weeks is more relevant for this mouse strain. Doses were adjusted to approximate exposures resulting in the same responses at 104 weeks of exposure for comparability among these lifetime studies. This adjustment had little impact on the lowest exposure level, which had an observed response of 9%, close to the BMR of 10% extra risk; in this case, the adjustment is not expected to affect the BMD_{10} significantly. The dose-response data are summarized in Table E-21.

Grimmer et al. (1984) and Grimmer et al. (1983) studied female CFLP mice, using acetone:dimethyl sulfoxide (DMSO) (1:3) as the vehicle. Mean or median latency times were reported (as well as measures of variability), but no information concerning overall survival was included in the results. The total of tumor-bearing mice and the reported percentages of mice with any skin tumors was reported, and varied at most one animal from the number of animals initially placed on study. The decreasing latency and variability and increasing tumor incidence with increasing benzo[a]pyrene exposure suggests that exposure probably did not last for the full scheduled 104 weeks in at least the high-dose group. The data reported were modeled under the assumption that at least some animals in each group were treated and survived until week 104 (see Table E-22).

Table E-19. Tumor incidence, with time to observation of tumor or death; CeH/HeJ male mice exposed dermally to benzo[a]pyrene[a] (Sivak et al., 1997; Arthur D Little, 1989)

Average daily dose (µg/d)	Time of first appearance of tumor, or time on study (d)[b]	Total examined	Number of animals with papillomas or carcinomas	Average daily dose (µg/d)	Time of first appearance of tumor, or time on study (d)[b]	Total examined	Number of animals with papillomas or carcinomas
0	104	1	0	0.14	354	1	0
	237	1	0		453	1	1
	239	1	0		460	1	0
	444	1	0		509	1	0
	483	1	0		525	1	0
	504	1	0		537	1	0
	509	1	0		560	1	1
	537	1	0		573	1	1
	545	1	0		601	1	0
	590	1	0		663	1	1[b]
	609	1	0		669	1	0
	613	1	0		677	1	0
	615	2	0		685	1	0
	629	1	0		701	1	0
	630	1	0		727	1	1
	658	1	0		731	1	0
	699	1	0		732	1	0
	719	1	0		734	13	0
	748	11	0				
	Totals	30	0		Totals	30	5
0.014	235	1	0	1.4	233	1	0
	238	1	0		234	1	0
	430	1	0		235	1	0
	446	1	0		307	1	1
	456	1	0		348	2	2
	463	1	0		355	2	2
	470	1	0		362	2	2
	503	1	0		369	3	3
	511	1	0		376	1	1
	590	1	0		383	1	1
	604	1	0		390	1	1
	663	1	0		397	3	3
	680	1	0		404	1	1
	684	1	0		411	5	5
	727	1	0		418	1	1
	747	15	0		440	2	2
					446	1	1
					474	1	1
	Totals	30	0		Totals	30	27

[a]Doses were applied twice/weekly to shaved dorsal skin. Vehicle for all groups was 1:1 cyclohexanone/acetone.
[b]For animals with skin tumors, the time of the tumor; if no skin tumor was observed, the time is the time of death or sacrifice.
[c]The tumor diagnosis was keratoacanthoma.

Table E-20. Skin tumor incidence, benign or malignant in female Swiss or NMRI mice dermally exposed to benzo[a]pyrene; data from Roe et al. (1970), Schmidt et al. (1973), Schmähl et al. (1977), Habs et al. (1980), Habs et al. (1984)

Study	Mouse strain	Dose (µg)	Average daily dose (µg/d)	First appearance of tumor (wks)	Length of exposure (wks)	Lifetime average daily dose (µg/d)	Skin tumor incidence (all types)
Roe et al. (1970)[a,b]	Swiss	0 (acetone)	0	–	93	0.00	0/49 (0%)
		0.1	0.04	29–43	93	0.03	1/45 (2%)
		0.3	0.13	–	93	0.09	0/46 (0%)
		1	0.43	57–71	93	0.31	1/48 (2%)
		3	1.29	43–57	93	0.92	8/47 (20%)
		9	3.86	29–43	93	2.76	34/46 (74%)
Schmidt et al. (1973)[c]	NMRI	0 (acetone)	0	–	*104*[d]	0	0/100 (0%)
		0.05	0.01	–	*104*	0.01	0/100 (0%)
		0.2	0.06	–	*104*	0.06	0/100 (0%)
		0.8	0.23	53[e]	*104*	0.23	2/100 (2%)
		2	0.57	76[e]	*104*	0.57	30/100 (30%)
	Swiss	0 (acetone)	0	–	*104*	0	0/80 (0%)
		0.05	0.01	–	*104*	0.01	0/80 (0%)
		0.2	0.06	–	*104*	0.06	0/80 (0%)
		0.8	0.23	58[e]	*104*	0.23	5/80 (6%)
		2	0.57	61[e]	*104*	0.57	45/80 (56%)
Schmähl et al. (1977)[c]	NMRI	0 (acetone)	0	–	*104*	0	1/81 (1%)
		1	0.29	NR	*104*	0.29	11/77 (14%)
		1.7	0.49	NR	*104*	0.49	25/88 (28%)
		3	0.86	NR	*104*	0.86	45/81 (56%)
Habs et al. (1980)[c,f]	NMRI	0 (acetone)	0	–	128	0	0/35 (0%)
		1.7	0.49	NR	120	0.49	8/34 (24.8%)
		2.6	0.74	NR	112	0.74	24/27 (89.3%)
		4.6	1.31	NR	88	0.80	22/24 91.7%)
Habs et al. (1984)[c]	NMRI	0 (acetone)	0	–	104	0	0/20 (0%)
		2	0.57	NR	104	0.57	9/20 (45%)
		4	1.14	NR	104	1.14	17/20 (85%)

[a]Doses were applied 3 times/week for up to 93 weeks to shaved dorsal skin.
[b]Numerator: number of mice detected with a skin tumor. Tumors were thought to be malignant based on invasion or penetration of the panniculus carnosus muscle. Denominator: number of mice surviving to 29 weeks (200 days).
[c]Doses were applied 2 times/week to shaved skin of the back. Mice were exposed until natural death or until they developed a carcinoma at the site of application.
[d]Exposure periods not reported were assumed to be 104 weeks; indicated in italics.
[e]Central tendency estimates; range or other variability measure not reported.
[f]The percentages were reported by the authors as age-standardized incidences of animals with local tumors, derived using mortality data from the entire study population. The incidences reflect reported counts of tumor-bearing animals and denominators estimated from the reported age-standardized rates. The authors did not report the percentages of local tumors which were carcinomas or papillomas.

NR = not reported.

Table E-21. Skin tumor incidence, benign or malignant, in C57L male mice dermally exposed to benzo[a]pyrene; data from Poel (1959)

Study	Mouse strain	Dose (μg)[a]	Average daily dose (μg/d)	First appearance of tumor (wks)	Length of exposure (wks)	Lifetime average daily dose[b]	Skin tumor incidence (all types)[c]
Poel (1959)	C57L	0 (toluene)	0	–	92	0.00	0/33 (0%)
		0.15	0.06	42	98	0.05	5/55 (9%)
		0.38	0.16	24	103	0.16	11/55 (20%)
		0.75	0.32	36	94	0.24	7/56 (13%)
		3.8	1.63	21–25	82	0.80	41/49 (84%)

[a]Doses were applied to interscapular skin 3 times/week for up to 103 weeks or until time of appearance of a grossly detected skin tumor. See Table E-15 for data of five highest dose groups (19–752 μg) in which all mice died by week 44. These groups were not considered for dose-response modeling.
[b]See text in this section for discussion of extrapolation to lifetime average daily doses.
[c]Tumors were histologically confirmed as epidermoid carcinomas.

Table E-22. Skin tumor incidence, benign or malignant, in female CFLP mice dermally exposed to benzo[a]pyrene; data from Grimmer et al. (1983), Grimmer et al. (1984)

Study	Dose (μg)[a]	Average daily dose (μg/d)	Mean or median time of tumor appearance (wks)	Length of exposure (wks)[b]	Lifetime average daily dose (μg/d)	Skin tumor incidence (all types)[c]
Grimmer et al. (1983)	0 (1:3 acetone:DMSO)	0	–	*104*	0	0/80 (0%)
	3.9	1.1	74.6 ± 16.8[d]	*104*	1.1	22/65 (34%)
	7.7	2.2	60.9 ± 13.9	*104*	2.2	39/64 (61%)
	15.4	4.4	44.1 ± 7.7	*104*	4.4	56/64 (88%)
Grimmer et al. (1984)	0 (1:3 acetone:DMSO)	0	–	*104*	0	0/80 (0%)
	3.4	0.97	61 (53–65)[e]	*104*	0.97	43/64 (67%)
	6.7	1.9	47 (43–50)	*104*	1.9	53/65 (82%)
	13.5	3.9	35 (32–36)	*104*	3.9	57/65 (88%)

[a]Indicated doses were applied twice/week to shaved skin of the back for up to 104 weeks.
[b]Assumed exposure period is indicated in italics.
[c]Incidence denominators were calculated from reported tumor-bearing animals and reported percentages.
[d]Mean ± SD.
[e]Median and 95% confidence limit.

Dose-Response Modeling Results

The modeling results are summarized in Tables E-23 (time-to-tumor modeling of individual data) and E-24 (multistage modeling of group incidence data). The modeling details are provided with Figures E-22 through E-33.

Adequate model fits for the supporting studies were found using the multistage model for all but one of the mouse skin tumor incidence data sets (Table E-24). The data from Grimmer et al.

ED_006137A_00009570-00231

(1984) could not be adequately fit by the multistage model initially, and the other dichotomous models available in BMDS were used. Due to the supralinear shape of the dose-response data, only the log-logistic and dichotomous Hill models provided adequate fits. Also due to the supralinear dose-response shape, the POD for slope factor derivation was identified near the lowest response of ~70%, because of the lack of data to inform the dose-response relationship at lower doses. Overall, model fits demonstrated typical statistical variability at the PODs, with BMDLs generally less than twofold lower than corresponding BMDs.

A comparison of model types was feasible for the NIOSH study data (Arthur D Little, 1989), which included the keratoacanthoma in the mid-dose group. The multistage model fit of the grouped data reported by (Sivak et al., 1997) yielded BMD_{10} and $BMDL_{10}$ values of 0.109 and 0.058 μg/day, respectively, while the multistage-Weibull fit of the corresponding individual data yielded BMD_{10} and $BMDL_{10}$ values of 0.0890 and 0.0514 μg/day, respectively. Use of the multistage-Weibull model was associated with a 10–20% lower POD for these data.

Table E-23. Summary of BMD modeling results for best-fitting multistage-Weibull models, using time-to-tumor data for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997; Arthur D Little, 1989)

Endpoints	Model stages	AIC	BMD_{10} (μg/d)	$BMDL_{10}$–$BMDU_{10}$ (μg/d)	Basis for model selection
Skin papilloma or carcinoma	1 **2** 3	51.9 **42.9** 44.3	0.0410 **0.0985** 0.1047	**0.0600–0.1466**	Lowest AIC, best fit to low dose data
Skin papilloma, keratoacanthoma or carcinoma	1 **2** 3	53.7 **46.2** 47.9	0.0391 **0.0890** 0.0919	**0.0514–0.1303**	Lowest AIC, best fit to low dose data

Male Mice (Sivak et al., 1997; Arthur D Little, 1989): Skin Papilloma or Carcinoma

```
=====================================================================
        Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
        Solutions are obtained using donlp2-intv, (c) by P. Spellucci
        Input Data File: SivakCarPapM2.(d)
=====================================================================
  The form of the probability function is:
  P[response] = 1-EXP{-(t - t_0)^c *
                (beta_0+beta_1*dose^1+beta_2*dose^2)}

  The parameter betas are restricted to be positive

  Dependent variable = CONTEXT
  Independent variables = DOSE, TIME

Total number of observations = 120
Total number of records with missing values = 0
Total number of parameters in model = 5
Total number of specified parameters = 1
Degree of polynomial = 2

  User specifies the following parameters:
         t_0    =          0

Maximum number of iterations = 64
Relative Function Convergence has been set to: 2.22045e-016
Parameter Convergence has been set to: 1.49012e-008

                 Default Initial Parameter Values
                        c      =      2.57143
                        t_0    =            0   Specified
                        beta_0 =            0
                        beta_1 = 5.45626e-028
                        beta_2 = 3.97261e-007

          Asymptotic Correlation Matrix of Parameter Estimates
          ( *** The model parameter(s)  -t_0       -beta_0    -beta_1
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

                c            beta_2
    c                1           -1
    beta_2          -1            1

                                 Parameter Estimates
                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c                2.75512          0.94014          0.912478             4.59776
         beta_0                 0               NA
         beta_1                 0               NA
         beta_2      1.31225e-007     7.47141e-007       -1.33315e-006         1.5956e-006

NA - Indicates that this parameter has hit a
     bound implied by some inequality constraint
     and thus has no standard error.

                Log(likelihood)   # Param             AIC
   Fitted Model         -17.4278         4         42.8557

                     Data Summary
                         CONTEXT
                C      F      I      U  Total  Expected Response
    DOSE
        0      30      0      0      0     30      0.00
    0.014      30      0      0      0     30      0.05
     0.14      26      0      4      0     30      4.38
      1.4       3      0     27      0     30     27.72


   Benchmark Dose Computation
Risk Response     =     Incidental
Risk Type         =          Extra
Confidence level =            0.9
Time              =            748
```

```
Specified effect = 0.1              0.01                0.001
             BMD = 0.0984828        0.0304167           0.00959688
            BMDL = 0.0599711        0.00728535          0.000745583
            BMDU = 0.14663          0.0434989           0.0137323
```



Figure E-22. Fit of multistage Weibull model to skin carcinomas or papilloma for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997); BMR = 10% extra risk.

Male Mice (Sivak et al., 1997): Skin papilloma, Keratoacanthoma, or Carcinoma

```
 ======================================================================
          Multistage Weibull Model. (Version: 1.6.1;  Date: 11/24/2009)
          Solutions are obtained using donlp2-intv, (c) by P. Spellucci
          Input Data File: SivakCarPapKerM2.(d)
=====================================================================
   The form of the probability function is:
   P[response] = 1-EXP{-(t - t_0)^c *
                 (beta_0+beta_1*dose^1+beta_2*dose^2)}

   The parameter betas are restricted to be positive

   Dependent variable = CONTEXT
   Independent variables = DOSE, TIME

 Total number of observations = 120
 Total number of records with missing values = 0
 Total number of parameters in model = 5
 Total number of specified parameters = 1
 Degree of polynomial = 2

   User specifies the following parameters:
          t_0    =          0

 Maximum number of iterations = 64
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008

                  Default Initial Parameter Values
                         c      =            3
                         t_0    =            0   Specified
                         beta_0 = 4.46003e-033
                         beta_1 =            0
                         beta_2 = 3.21731e-008


           Asymptotic Correlation Matrix of Parameter Estimates
           ( *** The model parameter(s)  -t_0       -beta_0    -beta_1
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                 c            beta_2
    c                 1           -1
    beta_2           -1            1

                                Parameter Estimates
                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
         c               2.97877         0.91338             1.18857             4.76896
         beta_0                0              NA
         beta_1                0              NA
         beta_2      3.6606e-008      2.0366e-007       -3.62561e-007        4.35773e-007

NA - Indicates that this parameter has hit a
     bound implied by some inequality constraint
     and thus has no standard error.

                 Log(likelihood)   # Param             AIC
   Fitted Model         -19.076         4         46.1521

                     Data Summary
                         CONTEXT
               C      F      I      U  Total  Expected Response
    DOSE
        0     30      0      0      0     30      0.00
    0.014     30      0      0      0     30      0.05
     0.14     25      0      5      0     30      5.12
      1.4      3      0     27      0     30     27.79

   Benchmark Dose Computation
Risk Response    =     Incidental
Risk Type        =          Extra
Confidence level =            0.9
Time             =            748
```

```
Specified effect = 0.1              0.01                0.001
             BMD = 0.0889653        0.0274772           0.00866942
            BMDL = 0.0514113        0.00585974          0.000598209
            BMDU = 0.130325         0.0401556           0.012538
```



Figure E-23. Fit of multistage Weibull model to skin carcinomas, keratoacanthoma or papilloma for male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997); BMR = 10% extra risk.

Table E-24. Summary of BMD model selection and modeling results using multistage models, for multiple data sets of skin tumors in mice following lifetime dermal benzo[a]pyrene exposure

Data set	Model	Goodness-of-fit		BMD_{10} (μg/d)	$BMDL_{10}$ (μg/d)	Basis for model selection[a]	Figure number
		p-value	AIC				
Poel (1959) Male C57L	Multistage 1°	0.011	191.5	0.070	0.057		
	Multistage 2°	0.027	188.6	0.134	0.078		
	Multistage 3°	**0.053**	**186.9**	**0.127**	**0.078**	**No significant improvement in model fit with higher stage**	E-24
	Multistage 4°	0.068	186.2	0.123	0.077		
Roe et al. (1970) Female Swiss	Multistage 1°	0.110	131.1	0.318	0.249		
	Multistage 2°	**0.485**	**123.6**	**0.748**	**0.480**	**No significant improvement in model fit with higher stages**	E-25
	Multistage 3°	0.485	123.6	0.748	0.480		
Schmidt et al. (1973) Female NMRI	Multistage 1°	0.008	162.7	0.256	0.194		
	Multistage 2°	**0.609**	**147.4**	**0.329**	**0.287**	**No significant improvement in model fit with higher stages**	E-26
	Multistage 3°	0.999	143.9	0.381	0.326		
Schmidt et al. (1973) Female Swiss	Multistage 1°	<0.01	178.0	0.116	0.093		
	Multistage 2°	0.514	153.3	0.216	0.192		
	Multistage 3°	**0.983**	**151.3**	**0.282**	**0.223**	**No significant improvement in model fit with higher stage**	E-27
	Multistage 4°	0.983	151.3	0.282	0.223		
Schmähl et al. (1977) Female NMRI	Multistage 1°	0.136	298.4	0.140	0.117		
	Multistage 2°	**0.939**	296.3	**0.233**	**0.149**	**No significant improvement in model fit with higher stage**	E-28
	Multistage 3°	**0.939**	296.3	0.233	0.143		
Habs et al. (1980) Female NMRI	Multistage 1°	0.0	96.5	0.063	0.050		
	Multistage 2°	0.009	84.4	0.198	0.143		
	Multistage 3°	**0.207**	**76.7**	**0.294**	**0.215**	**Only model with adequate fit**	E-29
Habs et al. (1984) Female NMRI	**Multistage 1°**	**0.577**	**48.4**	**0.078**	**0.056**	**No significant improvement in model fit with higher stage**	E-30
	Multistage 2°	1.000	47.6	0.171	0.060		
Grimmer et al. (1983) Female CFLP	**Multistage 1°**	**0.850**	**219.9**	**0.245**	**0.208**	**No significant improvement in model fit with higher stages**	E-31
	Multistage 2°	0.972	221.1	0.292	0.213		
	Multistage 3°	0.972	221.1	0.292	0.213		
Grimmer et al. (1984)[b] Female CFLP	Multistage 1°	0.003	205.3	0.132	0.113	(Higher stages did not provide better fit)	E-32
	LogLogistic	**0.919**	**195.8**	**1.07**	**0.479**	**Lowest AIC among adequately fitting models.**	**E-33**
	Dichotomous-Hill	1.000	197.7	0.902	0.533		
	LogProbit	0.047	200.2	1.33	1.11		
	Gamma, Weibull	0.003	205.3	0.132	0.113	(Same as Multistage 1°)	
	Logistic	0.0	250.5	2.03	1.76		
	Probit	0.0	255.4	2.29	2.03		
	Multistage 1°, high dose dropped	**0.499**	—	**1.21**	**1.01**		E-34

Data set	Model	Goodness-of-fit		BMD_{10} (µg/d)	$BMDL_{10}$ (µg/d)	Basis for model selection[a]	Figure number
		p-value	AIC				
Sivak et al. (1997) Male CeH/HeJ	Multistage 1°	0.059	57.8	0.036	0.026		E-35
	Multistage 2°	**0.998**	**48.6**	**0.109**	**0.058**	**No significant improvement in model fit with higher stage**	
	Multistage 3°	0.998	48.6	0.109	0.052		

[a]Adequate fit: goodness-of-fit $p > 0.05$, scaled residuals <2.0, good fit near BMR, lack of extreme curvature not reflected in the observed data.

[b]The POD forGrimmer et al. (1984), using a BMR of 70% (near response at the lowest dose), was based on the LogLogistic model. For comparison purposes, the multistage model was it fit to the Grimmer et al. (1984) data with the highest dose dropped (AIC not provided because it is not comparable to fits of the full dataset).



Figure E-24. Fit of multistage model to skin tumors in C57L mice exposed dermally to benzo[a]pyrene (Poel, 1959).

```
=================================================================
         Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
         Input Data File: C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Poel_1959_MultiCanc3_0.1.(d)
         Gnuplot                                Plotting                                File:
C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Poel_1959_MultiCanc3_0.1.plt

 ================================================================


   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2-beta3*dose^3)]

   The parameter betas are restricted to be positive


   Dependent variable = NumAff
   Independent variable = LADD
```

```
Total number of observations = 5
Total number of records with missing values = 0
Total number of parameters in model = 4
Total number of specified parameters = 0
Degree of polynomial = 3


Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008



                 Default Initial Parameter Values
                    Background =    0.0449589
                       Beta(1) =     0.490451
                       Beta(2) =            0
                       Beta(3) =      2.68146


          Asymptotic Correlation Matrix of Parameter Estimates

          ( *** The model parameter(s)  -Beta(2)
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

            Background      Beta(1)      Beta(3)

Background           1        -0.87         0.74

   Beta(1)       -0.87            1        -0.92

   Beta(3)        0.74        -0.92            1



                              Parameter Estimates

                                                        95.0% Wald Confidence Interval
      Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
    Background        0.0176699            *                *                  *
       Beta(1)          0.79766            *                *                  *
       Beta(2)                0            *                *                  *
       Beta(3)          2.17146            *                *                  *

* - Indicates that this value is not calculated.



                       Analysis of Deviance Table

      Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
    Full model        -87.1835         5
  Fitted model        -90.4265         3       6.48606      2         0.03905
 Reduced model        -141.614         1        108.86      4         <.0001

          AIC:         186.853


                              Goodness  of  Fit
                                                                  Scaled
    Dose     Est._Prob.    Expected    Observed     Size       Residual
 ----------------------------------------------------------------------
   0.0000     0.0177         0.583     0.000          33       -0.770
   0.0500     0.0563         3.098     5.000          55        1.112
   0.1600     0.1430         7.866    11.000          55        1.207
   0.2400     0.2128        11.917     7.000          56       -1.605
   0.8000     0.8293        40.635    41.000          49        0.139

Chi^2 = 5.88      d.f. = 2        P-value = 0.0528


  Benchmark Dose Computation
```

```
Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.126567

            BMDL =      0.0777875

            BMDU =       0.272961

Taken together, (0.0777875, 0.272961) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =       1.28555
```



Figure E-25. Fit of multistage model to skin tumors in female Swiss mice exposed dermally to benzo[a]pyrene (Roe et al., 1970).

```
 ====================================================================
          Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
          Input Data File: C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Roe_1970_Setting.(d)
          Gnuplot Plotting File:  C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Roe_1970_Setting.plt

 ====================================================================
 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2-beta3*dose^3-beta4*dose^4-beta5*dose^5)]

   The parameter betas are restricted to be positive

   Dependent variable = tumors
   Independent variable = LADD

 Total number of observations = 6
 Total number of records with missing values = 0
 Total number of parameters in model = 6
 Total number of specified parameters = 0
 Degree of polynomial = 5

 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                     Background =            0
                        Beta(1) =    0.0962491
```

```
                        Beta(2) =     0.141689
                        Beta(3) =            0
                        Beta(4) =            0
                        Beta(5) =            0


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -Beta(3)    -Beta(4)    -Beta(5)
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

              Background      Beta(1)      Beta(2)

Background            1        -0.57         0.45

   Beta(1)        -0.57            1        -0.94

   Beta(2)         0.45        -0.94            1


                                 Parameter Estimates

                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background        0.00584893            *                *                  *
        Beta(1)        0.0379152            *                *                  *
        Beta(2)         0.166839            *                *                  *
        Beta(3)                0            *                *                  *
        Beta(4)                0            *                *                  *
        Beta(5)                0            *                *                  *

* - Indicates that this value is not calculated.

                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -56.1835         6
   Fitted model        -57.5694         3       2.77176      3          0.4282
  Reduced model        -118.948         1       125.529      5         <.0001

            AIC:         121.139

                                 Goodness  of  Fit
                                                                    Scaled
      Dose     Est._Prob.    Expected    Observed     Size       Residual
  ---------------------------------------------------------------------
     0.0000     0.0058         0.275     0.000          47       -0.526
     0.0300     0.0071         0.321     1.000          45        1.204
     0.0900     0.0106         0.444     0.000          42       -0.670
     0.3100     0.0331         1.423     1.000          43       -0.361
     0.9200     0.1664         6.821     8.000          41        0.494
     2.7600     0.7488        34.444    34.000          46       -0.151

 Chi^2 = 2.57      d.f. = 3        P-value = 0.4626


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.689131
            BMDL =       0.393806
            BMDU =       0.952365

Taken together, (0.393806, 0.952365) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.253932
```



Figure E-26. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Schmidt et al., 1973).

```
==================================================================
        Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
        Input                                 Data                                  File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmidt1973femaleNMRI\2MulSchMS_.(d)
        Gnuplot                               Plotting                              File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmidt1973femaleNMRI\2MulSchMS_.plt
 ==================================================================
 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2)]

   The parameter betas are restricted to be positive

   Dependent variable = incidence
   Independent variable = dose

 Total number of observations = 5
 Total number of records with missing values = 0
 Total number of parameters in model = 3
 Total number of specified parameters = 0
 Degree of polynomial = 2

 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008

****  We are sorry but Relative Function and Parameter Convergence    ****
****  are currently unavailable in this model.  Please keep checking  ****
****  the web sight for model updates which will eventually           ****
****  incorporate these convergence criterion.  Default values used.  ****
```

```
                 Default Initial Parameter Values
                    Background =            0
                       Beta(1) =            0
                       Beta(2) =      1.11271


          Asymptotic Correlation Matrix of Parameter Estimates

          ( *** The model parameter(s)  -Background    -Beta(1)
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

               Beta(2)

   Beta(2)            1


                                Parameter Estimates

                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                   *
        Beta(1)                0            *                *                   *
        Beta(2)         0.970648            *                *                   *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -70.8903         5
   Fitted model        -72.6831         1       3.58562      4           0.465
  Reduced model        -118.917         1        96.054      4         <.0001

          AIC:         147.366

                                 Goodness  of  Fit
                                                                  Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ------------------------------------------------------------------------
    0.0000     0.0000         0.000     0.000         100        0.000
    0.0100     0.0001         0.010     0.000         100       -0.099
    0.0600     0.0035         0.349     0.000         100       -0.592
    0.2300     0.0501         5.005     2.000         100       -1.378
    0.5700     0.2705        27.048    30.000         100        0.665

 Chi^2 = 2.70      d.f. = 4        P-value = 0.6091


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.329464

            BMDL =       0.286624

            BMDU =       0.384046

Taken together, (0.286624, 0.384046) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.348889
```



Figure E-27. Fit of multistage model to skin tumors in female Swiss mice exposed dermally to benzo[a]pyrene (Schmidt et al., 1973).

```
====================================================================
         Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
         Input                                    Data                                    File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmidt1973swissmice\3MulSchMS_.(d)
         Gnuplot                                  Plotting                                File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmidt1973swissmice\3MulSchMS_.plt
====================================================================
 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2-beta3*dose^3)]

   The parameter betas are restricted to be positive

   Dependent variable = incidence
   Independent variable = dose

 Total number of observations = 5
 Total number of records with missing values = 0
 Total number of parameters in model = 4
 Total number of specified parameters = 0
 Degree of polynomial = 3

 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008

****  We are sorry but Relative Function and Parameter Convergence    ****
****  are currently unavailable in this model.  Please keep checking  ****
****  the web sight for model updates which will eventually           ****
****  incorporate these convergence criterion.  Default values used.  ****
```

```
                    Default Initial Parameter Values
                       Background =            0
                          Beta(1) =            0
                          Beta(2) =     0.338951
                          Beta(3) =       3.8728


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -Background    -Beta(1)
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                 Beta(2)      Beta(3)

   Beta(2)            1        -0.99

   Beta(3)        -0.99            1


                                 Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                   *
        Beta(1)                0            *                *                   *
        Beta(2)         0.108125            *                *                   *
        Beta(3)          4.31441            *                *                   *

* - Indicates that this value is not calculated.

                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -73.5285         5
   Fitted model        -73.6628         2      0.268637      3          0.9658
  Reduced model        -150.708         1       154.359      4         <.0001

           AIC:         151.326

                                 Goodness  of  Fit
                                                                    Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000      0.000          80        0.000
    0.0100     0.0000         0.001      0.000          80       -0.035
    0.0600     0.0013         0.106      0.000          80       -0.325
    0.2300     0.0566         4.524      5.000          80        0.230
    0.5700     0.5657        45.260     45.000          80       -0.059

 Chi^2 = 0.16      d.f. = 3        P-value = 0.9833

   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.282007
            BMDL =       0.223401
            BMDU =       0.309888

Taken together, (0.223401, 0.309888) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.447626
```



Figure E-28. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Schmähl et al., 1977).

```
====================================================================
         Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
         Input                                    Data                                    File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmahl1977femaleNMRI\2MulschMS_.(d)
         Gnuplot                                Plotting                                  File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Schmahl1977femaleNMRI\2MulschMS_.plt
====================================================================
 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2)]

   The parameter betas are restricted to be positive


   Dependent variable = incidence
   Independent variable = dose

 Total number of observations = 4
 Total number of records with missing values = 0
 Total number of parameters in model = 3
 Total number of specified parameters = 0
 Degree of polynomial = 2


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008

****  We are sorry but Relative Function and Parameter Convergence    ****
****  are currently unavailable in this model.  Please keep checking  ****
```

```
****  the web sight for model updates which will eventually          ****
****  incorporate these convergence criterion.  Default values used.  ****


                  Default Initial Parameter Values
                     Background =    0.0115034
                        Beta(1) =     0.284955
                        Beta(2) =     0.750235


           Asymptotic Correlation Matrix of Parameter Estimates

             Background      Beta(1)      Beta(2)

Background            1        -0.67         0.47

   Beta(1)        -0.67            1        -0.94

   Beta(2)         0.47        -0.94            1


                                Parameter Estimates

                                                        95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background        0.0123066            *                *                   *
        Beta(1)         0.274413            *                *                   *
        Beta(2)         0.764244            *                *                   *

* - Indicates that this value is not calculated.


                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -145.127         4
   Fitted model         -145.13         3    0.00579898      1          0.9393
  Reduced model        -184.158         1       78.0608      3         <.0001

           AIC:         296.261


                                Goodness  of  Fit
                                                                    Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0123         0.997      1.000        81         0.003
    0.2900     0.1446        11.137     11.000        77        -0.045
    0.4900     0.2813        24.756     25.000        88         0.058
    0.8600     0.5567        45.096     45.000        81        -0.022

 Chi^2 = 0.01      d.f. = 1        P-value = 0.9393


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.232893
            BMDL =       0.148895
            BMDU =       0.320396

Taken together, (0.148895, 0.320396) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.671616
```



Figure E-29. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Habs et al., 1980).

```
=================================================================
          Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
          Input Data File: M:\_BMDS\msc_BAP_HABS1980_MultiCanc3_0.1.(d)
          Gnuplot Plotting File:  M:\_BMDS\msc_BAP_HABS1980_MultiCanc3_0.1.plt

        ================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2-beta3*dose^3)]

   The parameter betas are restricted to be positive


   Dependent variable = NumAff
   Independent variable = LADD

 Total number of observations = 4
 Total number of records with missing values = 0
 Total number of parameters in model = 4
 Total number of specified parameters = 0
 Degree of polynomial = 3


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                     Background =            0
                        Beta(1) =            0
                        Beta(2) =      4.23649
                        Beta(3) =            0
```

```
          Asymptotic Correlation Matrix of Parameter Estimates
          ( *** The model parameter(s)  -Background    -Beta(1)    -Beta(2)
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

               Beta(3)

   Beta(3)           1



                                Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                  *
        Beta(1)                0            *                *                  *
        Beta(2)                0            *                *                  *
        Beta(3)           4.1289            *                *                  *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -34.8527         4
   Fitted model        -37.3373         1       4.96903      3          0.1741
  Reduced model        -82.5767         1       95.4478      3         <.0001

           AIC:         76.6745


                                 Goodness  of  Fit
                                                                  Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000     0.000          35        0.000
    0.4900     0.3848        13.082     8.000          34       -1.791
    0.7400     0.8123        21.933    24.000          27        1.019
    0.8000     0.8792        21.102    22.000          24        0.563

 Chi^2 = 4.56      d.f. = 3        P-value = 0.2067


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.294407

            BMDL =       0.215151

            BMDU =       0.320955

Taken together, (0.215151, 0.320955) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =       0.46479
```



Figure E-30. Fit of multistage model to skin tumors in female NMRI mice exposed dermally to benzo[a]pyrene (Habs et al., 1984).

```
=================================================================
          Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
          Input Data File: C:\Usepa\BMDS21\mscDax_Setting.(d)
          Gnuplot Plotting File:  C:\Usepa\BMDS21\mscDax_Setting.plt

        ==================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1)]

   The parameter betas are restricted to be positive


   Dependent variable = tumors
   Independent variable = LADD

 Total number of observations = 3
 Total number of records with missing values = 0
 Total number of parameters in model = 2
 Total number of specified parameters = 0
 Degree of polynomial = 1


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008
```

```
                    Default Initial Parameter Values
                       Background =            0
                          Beta(1) =      1.66414


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -Background
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                 Beta(1)

   Beta(1)            1



                                 Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                   *
        Beta(1)          1.35264            *                *                   *

* - Indicates that this value is not calculated.



                         Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model         -22.217         3
    Fitted model       -22.7878         1       1.14175      2          0.565
  Reduced model        -41.0539         1       37.6739      2        <.0001

           AIC:         47.5757


                                 Goodness  of  Fit
                                                                    Scaled
     Dose     Est._Prob.    Expected    Observed     Size        Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000      0.000          20         0.000
    0.5700     0.5375        10.749      9.000          20        -0.784
    1.1400     0.7860        15.721     17.000          20         0.697

 Chi^2 = 1.10      d.f. = 2        P-value = 0.5765


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =      0.0778926

            BMDL =      0.0558466

            BMDU =       0.111853

Taken together, (0.0558466, 0.111853) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =       1.79062
```



Figure E-31. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1983).

```
=================================================================
         Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
         Input                                    Data                                    File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Grimmer1983CFLPmice\1MulGriMS_.(d)
         Gnuplot                                  Plotting                                File:
C:\USEPA\IRIS\benzo[a]pyrene\dermalslopefactor\Grimmer1983CFLPmice\1MulGriMS_.plt
 ===================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1)]

   The parameter betas are restricted to be positive

   Dependent variable = incidence
   Independent variable = dose

 Total number of observations = 4
 Total number of records with missing values = 0
 Total number of parameters in model = 2
 Total number of specified parameters = 0
 Degree of polynomial = 1


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 2.22045e-016
 Parameter Convergence has been set to: 1.49012e-008

****  We are sorry but Relative Function and Parameter Convergence    ****
****  are currently unavailable in this model.  Please keep checking  ****
```

```
****  the web sight for model updates which will eventually          ****
****  incorporate these convergence criterion.  Default values used.  ****



                  Default Initial Parameter Values
                     Background =           0
                        Beta(1) =     0.478645


           Asymptotic Correlation Matrix of Parameter Estimates

           ( *** The model parameter(s)  -Background
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

                Beta(1)

   Beta(1)            1



                                Parameter Estimates

                                                        95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background              0            *                *                   *
        Beta(1)         0.430366          *                *                   *

* - Indicates that this value is not calculated.


                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -108.532         4
   Fitted model        -108.943         1      0.823537      3          0.8438
  Reduced model        -186.434         1       155.805      3         <.0001

           AIC:         219.887


                                 Goodness  of  Fit
                                                                    Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000      0.000        80        -0.000
    1.1100     0.3798        24.687     22.000        65        -0.687
    2.2000     0.6120        39.169     39.000        64        -0.043
    4.4000     0.8495        54.366     56.000        64         0.571

 Chi^2 = 0.80      d.f. = 3        P-value = 0.8496


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.244816

            BMDL =       0.208269

            BMDU =       0.289606

Taken together, (0.208269, 0.289606) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.480148
```



Figure E-32. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984).

```
=================================================================
          Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
          Input Data File: C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Grimmer1984_MultiCanc1_0.1.(d)
          Gnuplot                                  Plotting                                  File:
C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Grimmer1984_MultiCanc1_0.1.plt
                                                     Wed Apr 27 17:11:28 2011

 [add notes here]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1)]

   The parameter betas are restricted to be positive


   Dependent variable = NumAff
   Independent variable = LADD

 Total number of observations = 4
 Total number of records with missing values = 0
 Total number of parameters in model = 2
 Total number of specified parameters = 0
 Degree of polynomial = 1


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                     Background =     0.311241
                        Beta(1) =     0.502556


            Asymptotic Correlation Matrix of Parameter Estimates
```

```
          ( *** The model parameter(s)  -Background
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

               Beta(1)

   Beta(1)           1



                              Parameter Estimates

                                                        95.0% Wald Confidence Interval
      Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
    Background                0            *                *                  *
       Beta(1)         0.796546            *                *                  *

* - Indicates that this value is not calculated.



                       Analysis of Deviance Table

      Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
    Full model        -95.8385         4
  Fitted model        -101.643         1        11.61      3        0.008846
 Reduced model        -175.237         1      158.797      3         <.0001

          AIC:         205.287


                              Goodness  of  Fit
                                                                  Scaled
    Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
   0.0000     0.0000         0.000     0.000          65        0.000
   0.9700     0.5382        34.446    43.000          64        2.145
   1.9100     0.7816        50.804    53.000          65        0.659
   3.9000     0.9552        62.091    57.000          65       -3.054

 Chi^2 = 14.36     d.f. = 3        P-value = 0.0025


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.132272

            BMDL =       0.113427

            BMDU =       0.154848

Taken together, (0.113427, 0.154848) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =      0.881621
```



Figure E-33. Fit of log-logistic model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984).

```
=====================================================================
          Logistic Model. (Version: 2.12; Date: 05/16/2008)
          Input                                   Data                                        File:
C:\Usepa\BMDS21\Data\lnl_benzo[a]pyrene_Grimmer1984_Grimmer1984_0.70u.(d)
          Gnuplot                                 Plotting                                    File:
C:\Usepa\BMDS21\Data\lnl_benzo[a]pyrene_Grimmer1984_Grimmer1984_0.70u.plt

 ====================================================================

 BMDS Model Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))]


   Dependent variable = NumAff
   Independent variable = LADD
   Slope parameter is not restricted

   Total number of observations = 4
   Total number of records with missing values = 0
   Maximum number of iterations = 250
   Relative Function Convergence has been set to: 1e-008
   Parameter Convergence has been set to: 1e-008



   User has chosen the log transformed model


                  Default Initial Parameter Values
                     background =            0
                      intercept =     0.799142
                          slope =     0.894129


            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -background
```

```
                 have been estimated at a boundary point, or have been specified by the user,
                 and do not appear in the correlation matrix )

              intercept        slope

 intercept            1        -0.68

     slope        -0.68            1



                                 Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     background               0            *                *                  *
      intercept         0.783559            *                *                  *
          slope         0.922655            *                *                  *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -95.8385         4
   Fitted model        -95.9236         2       0.17031      2          0.9184
  Reduced model        -175.237         1       158.797      3         <.0001

           AIC:         195.847


                                  Goodness  of  Fit
                                                                  Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ------------------------------------------------------------------------
    0.0000     0.0000         0.000     0.000          65        0.000
    0.9700     0.6804        43.543    43.000          64       -0.146
    1.9100     0.7991        51.941    53.000          65        0.328
    3.9000     0.8849        57.516    57.000          65       -0.200

 Chi^2 = 0.17      d.f. = 2        P-value = 0.9190


   Benchmark Dose Computation

Specified effect =            0.7

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =        1.07152

            BMDL =       0.478669
```



Figure E-34. Fit of multistage model to skin tumors in female CFLP mice exposed dermally to benzo[a]pyrene (Grimmer et al., 1984), highest dose dropped.

```
=====================================================================
         Multistage Cancer Model. (Version: 1.9;  Date: 05/26/2010)
         Input Data File: C:/Usepa/_BaP/msc_BaP_Grimmer1984_drophidose_MultiCancl_0.7.(d)
         Gnuplot Plotting File:  C:/Usepa/_BaP/msc_BaP_Grimmer1984_drophidose_MultiCancl_0.7.plt
 ====================================================================

 [add_notes_here]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1)]

   The parameter betas are restricted to be positive


   Dependent variable = NumAff
   Independent variable = LADD

 Total number of observations = 3
 Total number of records with missing values = 0
 Total number of parameters in model = 2
 Total number of specified parameters = 0
 Degree of polynomial = 1


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                     Background =    0.0806622
                        Beta(1) =      0.88595


           Asymptotic Correlation Matrix of Parameter Estimates
```

```
          ( *** The model parameter(s)  -Background
                have been estimated at a boundary point, or have been specified by the user,
                and do not appear in the correlation matrix )

               Beta(1)

   Beta(1)            1



                                Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                  *
        Beta(1)         0.997117            *                *                  *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -71.5928         3
   Fitted model        -72.2756         1       1.36568      2          0.5052
  Reduced model         -134.46         1       125.735      2         <.0001

           AIC:         146.551


                                 Goodness  of  Fit
                                                                  Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000     0.000          65        0.000
    0.9700     0.6199        39.671    43.000          64        0.857
    1.9100     0.8511        55.322    53.000          65       -0.809

 Chi^2 = 1.39      d.f. = 2        P-value = 0.4992


   Benchmark Dose Computation

Specified effect =            0.7

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =        1.20745

            BMDL =        1.00734

            BMDU =        1.45789

Taken together, (1.00734, 1.45789) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =        0.6949
```



Figure E-35. Fit of multistage model to skin tumors in male CeH/HeJ mice exposed dermally to benzo[a]pyrene (Sivak et al., 1997).

```
=================================================================
         Multistage Cancer Model. (Version: 1.7;  Date: 05/16/2008)
         Input Data File: C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Sivak1993_MultiCanc2_0.1.(d)
         Gnuplot                                  Plotting                                  File:
C:\Usepa\BMDS21\Data\msc_benzo[a]pyrene_Sivak1993_MultiCanc2_0.1.plt

 ================================================================

 [add notes here]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

   The form of the probability function is:

   P[response] = background + (1-background)*[1-EXP(
                 -beta1*dose^1-beta2*dose^2)]

   The parameter betas are restricted to be positive


   Dependent variable = NumAff
   Independent variable = LADD

 Total number of observations = 4
 Total number of records with missing values = 0
 Total number of parameters in model = 3
 Total number of specified parameters = 0
 Degree of polynomial = 2


 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008



                  Default Initial Parameter Values
                     Background =            0
                        Beta(1) =    0.0936505
                        Beta(2) =      8.67239
```

```
            Asymptotic Correlation Matrix of Parameter Estimates

            ( *** The model parameter(s)  -Background    -Beta(1)
                  have been estimated at a boundary point, or have been specified by the user,
                  and do not appear in the correlation matrix )

                 Beta(2)

   Beta(2)            1



                                 Parameter Estimates

                                                          95.0% Wald Confidence Interval
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper Conf. Limit
     Background                0            *                *                   *
        Beta(1)                0            *                *                   *
        Beta(2)           8.9375            *                *                   *

* - Indicates that this value is not calculated.



                        Analysis of Deviance Table

       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value
     Full model        -23.2693         4
   Fitted model        -23.3009         1     0.0631003      3          0.9959
  Reduced model        -69.5898         1        92.641      3         <.0001

            AIC:         48.6018


                                 Goodness  of  Fit
                                                                    Scaled
     Dose     Est._Prob.    Expected    Observed     Size       Residual
  ----------------------------------------------------------------------
    0.0000     0.0000         0.000     0.000          30        0.000
    0.0100     0.0009         0.027     0.000          30       -0.164
    0.1400     0.1607         4.821     5.000          30        0.089
    0.5100     0.9022        27.065    27.000          30       -0.040

 Chi^2 = 0.04      d.f. = 3        P-value = 0.9982


   Benchmark Dose Computation

Specified effect =            0.1

Risk Type        =      Extra risk

Confidence level =           0.95

             BMD =       0.108575

            BMDL =       0.058484

            BMDU =       0.129641

Taken together, (0.058484, 0.129641) is a 90     % two-sided confidence
interval for the BMD

Multistage Cancer Slope Factor =       1.70987
```

Alternative Approaches for Cross-Species Scaling of the Dermal Slope Factor

Several publications that develop a dermal slope factor for benzo[a]pyrene are available in the peer-reviewed literature (Knafla et al., 2011; Knafla et al., 2006; Hussain et al., 1998; Lagoy and Quirk, 1994; Sullivan et al., 1991). With the exception of Knafla et al. (2011), none of these approaches applied quantitative adjustments to account for interspecies differences, although the proposed slope factors were developed to account for human risk. Knafla et al. (2011) qualitatively discuss processes that could affect the extrapolation between mice and humans, including skin metabolic activity adduct formation, stratum corneum thickness, epidermal thickness, etc. Ultimately, the authors apply an adjustment based on the increased epidermal thickness of human skin on the arms and hands compared to mouse interscapular epidermal thickness. They hypothesize that the carcinogenic potential of benzo[a]pyrene may be related to the thickness of the epidermal layer.

Because there is no established methodology for cross-species extrapolation of dermal toxicity, several alternative approaches were evaluated. Each approach begins with the POD of 0.066 μg/day that was based on a 10% extra risk for skin tumors in male mice. Based on the assumptions of each approach, a dermal slope factor for humans is calculated. The discussion of these approaches uses the following abbreviations:

DSF = dermal slope factor
POD_M = point of departure (for 10% extra risk) from mouse bioassay, in μg/day
BW_M = mouse body weight = 0.035 kg (assumed)
BW_H = human body weight = 70 kg (assumed)
SA_H = total human surface area = 19,000 cm^2 (assumed)
SA_M = total mouse surface area = 100 cm^2 (assumed)

Approach 1. No Interspecies Adjustment to Daily Applied Dose (POD) in Mouse Model

Under this approach, a given mass of benzo[a]pyrene, applied daily, would pose the same risk in an animal or in humans, regardless of whether it is applied to a small surface area or to a larger surface area at a proportionately lower concentration.

$DSF = 0.1/ POD_M$
DSF = 0.1/0.060 μg/day = **1.7 (μg/day)$^{-1}$**

Assumptions: The same mass of benzo[a]pyrene, applied daily, would have same potency in mice as in human skin regardless of treatment area.

Approach 2. Cross-Species Adjustment Based on Whole-Body Surface-Area Scaling

Under this approach, animals and humans are assumed to have equal lifetime cancer risk with equal average whole-body exposures in loading units (μg/cm^2-day). As long as doses are low

enough that risk is proportional to the mass of applied compound, the daily dermal dose of benzo[a]pyrene can be normalized over the total surface area.

POD (μg/cm^2-day) = $POD_{M/SA}$ (μg/cm^2-day) = POD_M (μg/day) / SA_M (cm^2)
POD = (0.060 μg/day) / 100 cm^2 = 0.00060 μg/cm^2-day
DSF = 0.1/(0.00060 μg/cm^2-day) ≈ **170 (μg/cm^2-day)$^{-1}$**

Assumptions: Mouse and human slope factors are equipotent if total dermal dose is averaged over equal fractions of the entire surface area. Tumor potency of benzo[a]pyrene is assumed to be related to overall dose and not dose per unit area. For example, a human exposed to 0.01 μg/day on 10 cm^2 would be assumed to have the same potential to form a skin tumor as someone treated with 0.01 μg/day over 19,000 cm^2 (assumed human surface area).

Approach 3. Cross-Species Adjustment Based on Body Weight

Under this approach, a given mass of benzo[a]pyrene is normalized relative to the body weight of the animal or human.

POD_M/ BW_M= 0.060 μg/0.035 kg-day = 1.7 μg/kg-day
DSF = 0.1/1.7 μg/kg-day = **0.058 (μg/kg-day)$^{-1}$**

Assumptions: The potency of point of contact skin tumors is related to body weight, and humans and mice would have an equal likelihood of developing skin tumors based on a dermal dose per kg basis.

Issues: Skin cancer following benzo[a]pyrene exposure is a local effect and not likely dependent on body weight.

Approach 4. Cross-Species Adjustment Based on Allometric Scaling Using Body Weight to the 3/4 Power

Under this approach, rodents and humans exposed to the same daily dose of a carcinogen, adjusted for $BW^{3/4}$, would be expected to have equal lifetime risks of cancer. That is, a lifetime dose expressed as μg/kg$^{3/4}$-day would lead to an equal risk in rodents and humans. This scaling reflects the empirically observed phenomena of more rapid distribution, metabolism, and clearance in smaller animals. The metabolism of benzo[a]pyrene to reactive intermediates is a critical step in the carcinogenicity of benzo[a]pyrene, and this metabolism occurs in the skin.

POD (μg/day) = POD_M (μg/day) × $(BW_H / BW_M)^{3/4}$
POD (μg/day) = 0.060 μg/day × $(70 \text{ kg} / 0.035 \text{ kg})^{3/4}$ = 17.9 μg/day
DSF = 0.1/(17.9 μg/day) ≈ **0.0056 (μg/day)$^{-1}$**

Assumptions: Risk at low doses of benzo[a]pyrene is dependent on absolute dermal dose and not dose per unit of skin, meaning that a higher exposure concentration of benzo[a]pyrene

contacting a smaller area of exposed skin could carry the same risk of skin tumors as a lower exposure concentration of benzo[a]pyrene that contacts a larger area of skin.

Issues: It is unclear if scaling of doses based on body weight ratios will correspond to differences in metabolic processes in the skin of mice and humans.

Synthesis of the Alternative Approaches to Cross-Species Scaling

A comparison of the above approaches is provided in Table E-25. The lifetime risk from a nominal human dermal exposure to benzo[a]pyrene over a 5% area of exposed skin (approximately 950 cm^2), estimated at 1×10^{-4} μg/day, is calculated for each of the approaches in order to judge whether the method yields risk estimates that are unrealistically high.

Other Potential Interspecies Adjustments

The above discussion presents several mathematical approaches that result from varying assumptions about what is the relevant dose metric for determining equivalence across species. Biological information (that is not presently comprehensive or detailed enough to develop robust models) that could be used in future biologically based models for cross-species extrapolation include:

a. Quantitative information on interspecies differences in partitioning from exposure medium to the skin and absorption through the skin

b. Thickness of the stratum corneum between anatomical sites and between species

c. Thickness of epidermal layer

d. Skin permeability

e. Metabolic activity of skin

f. Formation of DNA adducts in skin

1 **Table E-25. Alternative approaches to cross-species scaling**

Approach	Assumptions	Dose metric	Dermal slope factor	Risk at nominal exposure (0.0004 µg/day)[a]
1. Mass-per-day scaling (no adjustment)	Equal mass per day (µg/d), if applied to equal areas of skin (cm^2), will affect similar numbers of cells across species. Cancer risk is proportional to the area (cm^2) exposed if the loading rate (µg/cm^2-d) is the same. This approach assumes that risk is proportional to dose expressed as mass per day. This approach implies that any combination of loading rate (µg/cm^2-day) and skin area exposed (cm^2) that have the same product when multiplied will result in the same risk.	µg/day	1.7 per µg/d	7×10^{-4}
2. Surface-area scaling	Equal mass per day (µg/d), if applied to equal fractions of total skin surface (cm^2) will have similar cancer risks. That is, lifetime exposure normalized over the whole body (e.g., 5%-of-the-body lifetime exposure) at the same loading rate (µg/cm^2-d) gives similar cancer risks across species. This approach assumes that risk is proportional to dose expressed as mass per area per day. This approach implies that risk does not increase with area exposed as long as dose per area remains constant.	µg/cm^2-day	170 per µg/cm^2-d	4×10^{-6}
3. Body-weight scaling	The skin is an organ with thickness and volume; benzo[a]pyrene is distributed within this volume of skin. Cancer risk is proportional to the concentration of benzo[a]pyrene in the exposed volume of skin. Equal mass per day (µg/d), if distributed within equal fractions of total body skin will have similar cancer risks. That is, whole-body lifetime exposure (e.g., 5%-of-the-body lifetime exposure) at the same loading rate (µg/cm^2-d) gives similar cancer risks across species. This approach assumes that risk is proportional to dose expressed as mass per kg body weight per day. This approach implies that any combination of dose (µg/d) and body weight (kg) that have the same result when divided will result in the same risk.	µg/kg-day	0.058 per µg/kg-d	3×10^{-7}
4. Allometric scaling ($BW^{3/4}$)	Same as for body-weight scaling, except that benzo[a]pyrene distribution and metabolism takes place within this volume of skin. Allometric scaling is generally regarded as describing the relative rate of toxicokinetic processes across species. This approach also is used by EPA to scale oral exposures.	µg/day	0.0056 per µg/d	2×10^{-6}

[a]Calculated as a central tendency exposure using an average benzo[a]pyrene soil concentration of 100 ppb, rounded to one significant figure (see Appendix A, Table A-4) and standard exposure assumptions from U.S. EPA (2004).

ED_006137A_00009570-00266

APPENDIX F. DOCUMENTATION OF IMPLEMENTATION OF THE 2011 NATIONAL RESEARCH COUNCIL RECOMMENDATIONS

Background: On December 23, 2011, The Consolidated Appropriations Act, 2012, was signed into law[3]. The report language included direction to the U.S. Environmental Protection Agency (EPA) for the Integrated Risk Information System (IRIS) Program related to recommendations provided by the National Research Council (NRC) in their review of EPA's draft IRIS assessment of formaldehyde[4]. The report language included the following:

> The Agency shall incorporate, as appropriate, based on chemical-specific datasets and biological effects, the recommendations of Chapter 7 of the National Research Council's Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde into the IRIS process… For draft assessments released in fiscal year 2012, the Agency shall include documentation describing how the Chapter 7 recommendations of the National Academy of Sciences (NAS) have been implemented or addressed, including an explanation for why certain recommendations were not incorporated.

The NRC's recommendations, provided in Chapter 7 of their review report, offered suggestions to EPA for improving the development of IRIS assessments. Consistent with the direction provided by Congress, documentation of how the recommendations from Chapter 7 of the NRC report have been implemented in this assessment is provided in the table below. Where necessary, the documentation includes an explanation for why certain recommendations were not incorporated.

The IRIS Program's implementation of the NRC recommendations is following a phased approach that is consistent with the NRC's "Roadmap for Revision" as described in Chapter 7 of the formaldehyde review report. The NRC stated that "the committee recognizes that the changes suggested would involve a multi-year process and extensive effort by the staff at the National Center for Environmental Assessment and input and review by the EPA Science Advisory Board and others."

Phase 1 of implementation has focused on a subset of the short-term recommendations, such as editing and streamlining documents, increasing transparency and clarity, and using more tables, figures, and appendices to present information and data in assessments. Phase 1 also

[3]Pub. L. No. 112-74, Consolidated Appropriations Act, 2012.

[4](_ENREF_351). Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde.

ED_006137A_00009570-00267

focused on assessments near the end of the development process and close to final posting. The IRIS benzo[a]pyrene assessment is in Phase 2 and represents a significant advancement in implementing the NRC recommendations shown in Table F-1 below. The Program is implementing all of these recommendations, but recognizes that achieving full and robust implementation of certain recommendations will be an evolving process with input and feedback from the public, stakeholders, and external peer review committees. Phase 3 of implementation will incorporate the longer-term recommendations made by the NRC as outlined below in Table F-2, including the development of a standardized approach to describe the strength of evidence for noncancer effects. In May 2014, the NRC released their report reviewing the IRIS assessment development process. As part of this review, the NRC reviewed current methods for evidence-based reviews and made several recommendations with respect to integrating scientific evidence for chemical hazard and dose-response assessments. In their report, the NRC states that EPA should continue to improve its evidence-integration process incrementally and enhance the transparency of its process. The committee did not offer a preference but suggests that EPA consider which approach best fits its plans for the IRIS process. The NRC recommendations will inform the IRIS Program's efforts in this area going forward.

Table F-1. The EPA's implementation of the National Research Council's recommendations in the benzo[a]pyrene assessment

National Research Council recommendations that EPA is implementing in the short term	Implementation status
General recommendations for completing the IRIS formaldehyde assessment that EPA will adopt for all IRIS assessments (p. 152 of the NRC report)	
1. To enhance the clarity of the document, the draft IRIS assessment needs rigorous editing to reduce the volume of text substantially and address redundancies and inconsistencies. Long descriptions of particular studies should be replaced with informative evidence tables. When study details are appropriate, they could be provided in appendices.	**Implemented.** The overall document structure has been revised in consideration of this NRC recommendation. The new structure includes a concise Executive Summary and an explanation of the literature review search strategy, study selection criteria, and methods used to develop the assessment. The main body of the assessment has been reorganized into two sections, Hazard Identification and Dose-Response Analysis, to help reduce the volume of text and redundancies that were a part of the previous document structure. Section 1 provides evidence tables and a concise synthesis of hazard information organized by health effect. The Supplemental Information provides more detailed summaries of the most pertinent epidemiology and experimental animal studies (Appendix D), as well as information on chemical and physical properties and toxicokinetics (Appendix D). The main text of the Toxicological Review is approximately 130 pages, which is a major reduction from previous IRIS assessments. Technical and scientific edits were performed to

ED_006137A_00009570-00268

National Research Council recommendations that EPA is implementing in the short term	Implementation status
	eliminate any redundancies or inconsistencies.
2. Chapter 1 needs to be expanded to describe more fully the methods of the assessment, including a description of search strategies used to identify studies with the exclusion and inclusion criteria articulated and a better description of the outcomes of the searches and clear descriptions of the weight-of-evidence approaches used for the various noncancer outcomes. The committee emphasizes that it is not recommending the addition of long descriptions of EPA guidelines to the introduction, but rather clear concise statements of criteria used to exclude, include, and advance studies for derivation of the reference concentrations (RfCs) and unit risk estimates.	**Implemented.** Chapter 1 has been replaced with a Preamble that describes the application of existing EPA guidance and the methods and criteria used in developing the assessment. The term "Preamble" was chosen to emphasize that these methods and criteria are being applied consistently across IRIS assessments. The new Preamble includes information on identifying and selecting pertinent studies, evaluating the quality of individual studies, weighing the overall evidence of each effect, selecting studies for derivation of toxicity values, and deriving toxicity values. These topics correspond directly to the five steps that the NRC identified in Figure 7-2 of their 2011 report. A new section, Literature Search Strategy and Study Selection, provides detailed information on the search strategy used to identify health effect studies, search outcomes, and selection of studies for hazard identification. This information is chemical-specific and has been designed to provide enough information that an independent literature search would be able to replicate the results. This section also includes information on how studies were selected to be included in the document and provides a link to EPA's Health and Environmental Research Online (HERO) database (www.epa.gov/hero) that contains the references that were cited in the document, along with those that were considered but not cited.
3. Standardized evidence tables for all health outcomes need to be developed. If there were appropriates tables, long text descriptions of studies could be moved to an appendix.	**Implemented.** In the new document template, standardized evidence tables that present key study findings that support how toxicological hazards are identified for all major health effects are provided in Section 1.1. More detailed summaries of the most pertinent epidemiology and experimental animal studies are provided in the Supplemental Information (Appendix D).
4. All critical studies need to be thoroughly evaluated with standardized approaches that are clearly formulated and based on the type of research, for example, observational epidemiologic or animal bioassays. The findings of the reviews might be presented in tables to ensure transparency.	**Partially Implemented.** Information in Section 4 of the Preamble provides an overview of the approach used to evaluate the quality of individual studies. Critical evaluation of the epidemiologic and experimental animal studies is included in the evidence tables in Section 1.1. As more rigorous systematic review processes are developed, they will be utilized in future assessments.
5. The rationales for the selection of the studies that are advanced for consideration in calculating the RfCs and unit risks need to be expanded. All candidate	**Implemented.** The Dose-Response Analysis section of the new document structure provides a clear explanation of the rationale used to select and advance studies that

National Research Council recommendations that EPA is implementing in the short term	Implementation status
RfCs should be evaluated together with the aid of graphic displays that incorporate selected information on attributes relevant to the database.	were considered for calculating toxicity values. Rationales for the selection of studies advanced for reference value derivation are informed by the weight-of-evidence for hazard identification as discussed in Section 1.2. In support of the derivation of reference values for benzo[a]pyrene, exposure-response arrays are included that compare effect levels for several toxicological effects (Section 2.1, Figure 2-1; Section 2.2, Figure 2.2). The exposure-response array provides a visual representation of points of departure (PODs) for various effects resulting from exposure to benzo[a]pyrene. The array informs the identification of doses associated with specific effects, and the choice of principal study and critical effects. In the case of the benzo[a]pyrene RfD, the database supported the development of multiple organ/system-specific RfDs. Such values have been developed previously on a case-by-case basis and will be developed in future assessments, where the data allow.
6. Strengthened, more integrative, and more transparent discussions of weight-of-evidence are needed. The discussions would benefit from more rigorous and systematic coverage of the various determinants of weight-of-evidence, such as consistency.	**Partially implemented.** The new Hazard Identification (Section 1) provides a more strengthened, integrated, and transparent discussion of the weight of the available evidence. This section includes standardized evidence tables to present the key study findings that support how potential toxicological hazards are identified and exposure-response arrays for each potential toxicological effect. Summary discussions are provided as a statement of hazard for each major effect (Section 1.1.1—developmental toxicity, Section 1.1.2—reproductive toxicity, Section 1.1.3—immunotoxicity, Section 1.1.4—other toxicological effects, and Section 1.1.5 —carcinogenicity) as well as a general weight-of-evidence discussion for effects other than cancer (Section 1.2.1) and cancer (Section 1.2.2). A more rigorous and formalized approach for characterizing the weight-of-evidence will be developed as a part of Phase 3 of the implementation process.

ED_006137A_00009570-00270

National Research Council recommendations that EPA is implementing in the short term	Implementation status
Other specific recommendations (p. # in NRC report)	
General Guidance for the Overall Process (p. 164) 7. Elaborate an overall, documented, and quality-controlled process for IRIS assessments.	**Implemented.** EPA has created Chemical Assessment Support Teams to formalize an internal process to provide additional overall quality control for the development of IRIS assessments. This initiative uses a team approach to making timely, consistent decisions about the development of IRIS assessments across the Program. This team approach has been utilized for the development of the benzo[a]pyrene assessment. Additional objectives of the teams are to help ensure that the necessary disciplinary expertise is available for assessment development and review, to provide a forum for identifying and addressing key issues prior to external peer review, and to monitor progress in implementing the NRC recommendations.
8. Ensure standardization of review and evaluation approaches among contributors and teams of contributors; for example, include standard approaches for reviews of various types of studies to ensure uniformity.	
9. Assess disciplinary structure of teams needed to conduct the assessments.	
Evidence Identification: Literature Collection and Collation Phase (p. 164) 10. Select outcomes on the basis of available evidence and understanding of mode of action.	**Partially Implemented.** A new section, Literature Search Strategy and Study Selection, contains detailed information on the search strategy used for the benzo[a]pyrene assessment, including key words used to identify relevant health effect studies. Figure LS-1 depicts the study selection strategy and the number of references obtained at each stage of literature screening. This section also includes information on how studies were selected to be included in the document and provides a link to an external database (www.epa.gov/hero) that contains the references that were cited in the document, along with those that were considered but not cited. Each citation in the Toxicological Review is linked to HERO such that the public can access the references and abstracts to the scientific studies used in the assessment. The implementation of these NRC recommendations in the benzo[a]pyrene assessment represents a major advance in the standardization and transparency of evidence identification. Section 3 of the Preamble summarizes the standard protocols for evidence identification that are provided in EPA guidance. For each potential toxicological effect identified for benzo[a]pyrene, the available evidence is informed by the mode-of-action information as discussed in Section 1.1. As more rigorous systematic review processes are developed, they will be utilized in future assessments.
11. Establish standard protocols for evidence identification.	
12. Develop a template for description of the search approach.	
13. Use a database, such as the HERO database, to capture study information and relevant quantitative data.	
Evidence Evaluation: Hazard Identification and Dose-Response Modeling (p. 165) **14.** Standardize the presentation of reviewed studies in tabular or graphic form to capture the key dimensions of study characteristics, weight-of-	**Implemented.** Standardized tables have been developed that provide summaries of key study design information and results by health effect. The inclusion of all positive and negative findings in each health effect-specific evidence table supports a weight-of-evidence analysis. In

ED_006137A_00009570-00271

National Research Council recommendations that EPA is implementing in the short term	Implementation status
evidence, and utility as a basis for deriving reference values and unit risks.	addition, exposure-response arrays are utilized in the assessment to provide a graphical representation of PODs for various effects resulting from exposure to benzo[a]pyrene. The exposure-response arrays inform the identification of doses associated with specific effects and the weight-of-evidence for those effects.
15. Develop templates for evidence tables, forest plots, or other displays.	**Implemented.** Templates for evidence tables and exposure-response arrays have been developed and are utilized in Section 1.1.
16. Establish protocols for review of major types of studies, such as epidemiologic and bioassay.	**Partially Implemented.** General principles for reviewing epidemiologic and experimental animal studies are described in Section 4 of the Preamble. The development of standardized protocols for systematic review of evidence is an ongoing process.
Selection of Studies for Derivation of Reference Values and Unit Risks (p. 165) 17. Establish clear guidelines for study selection.	**Implemented.** EPA guidelines for study selection, including balancing strengths and weaknesses and weighing human vs. experimental evidence, are described in the Preamble (Sections 3–6). These guidelines have been applied in Section 2 of the benzo[a]pyrene assessment to evaluate the strengths and weaknesses of individual studies considered for reference value derivation. In the case of benzo[a]pyrene, the database did not support the combination of estimates across studies. In future assessments, combining estimates across studies will be routinely considered.
a) Balance strengths and weaknesses.	
b) Weigh human vs. experimental evidence.	
c) Determine whether combining estimates among studies is warranted.	
Calculation of Reference Values and Unit Risks (pp. 165–166) 18. Describe and justify assumptions and models used. This step includes review of dosimetry models and the implications of the models for uncertainty factors; determination of appropriate PODs (such as benchmark dose [BMD], NOAEL, and LOAEL), and assessment of the analyses that underlie the PODs.	**Implemented.** The rationale for the selection of the PODs for the organ/system-specific oral reference values is provided in Section 2.1. The rationale for the selection of the POD and the inhalation dosimetry modeling (for the approximation of a HEC) for the derivation of the inhalation reference value is transparently described in Section 2.2. The BMD modeling for candidate reference values is transparently described in the Supplemental Information (Appendix E).
19. Provide explanation of the risk-estimation modeling processes (for example, a statistical or biologic model fit to the data) that are used to develop a unit risk estimate.	**Implemented.** The risk-estimation modeling processes used to develop cancer risk estimates for benzo[a]pyrene are described in Section 2 of the Toxicological Review and in the Supplemental Information (Appendix E).
20. Provide adequate documentation for conclusions and estimation of reference values and unit risks. As noted by the committee throughout the present report, sufficient support for conclusions in the formaldehyde draft IRIS assessment is often lacking. Given that the development of specific IRIS	**Implemented.** The new template structure that has been developed in response to the NRC recommendations provides a clear explanation of the literature search strategy, study selection criteria, and methods used to develop the benzo[a]pyrene assessment. It provides for a clear description of the decisions made in developing the

ED_006137A_00009570-00272

National Research Council recommendations that EPA is implementing in the short term	Implementation status
assessments and their conclusions are of interest to many stakeholders, it is important that they provide sufficient references and supporting documentation for their conclusions. Detailed appendixes, which might be made available only electronically, should be provided when appropriate.	hazard identification and dose-response analysis. Information contained in the Preamble and throughout the document reflects the guidance that has been utilized in developing the assessment. As recommended, supplementary information is provided in the accompanying appendices. Detailed modeling analyses are presented in the appendices.

Table F-2. National Research Council recommendations that the EPA is generally implementing in the long term

National Research Council recommendations that EPA is generally implementing in the long-term (p. # in NRC report)	Implementation status
Weight-of-Evidence Evaluation: Synthesis of Evidence for Hazard Identification (p. 165) 1. Review use of existing weight-of-evidence guidelines. 2. Standardize approach to using weight-of-evidence guidelines. 3. Conduct agency workshops on approaches to implementing weight-of-evidence guidelines. 4. Develop uniform language to describe strength of evidence on noncancer effects. 5. Expand and harmonize the approach for characterizing uncertainty and variability. 6. To the extent possible, unify consideration of outcomes around common modes of action rather than considering multiple outcomes separately.	As indicated above, Phase 3 of EPA's implementation plan will incorporate the longer-term recommendations made by the NRC, including the development of a standardized approach to describe the strength of evidence for noncancer effects. On May 16, 2012, EPA announced[6] that as a part of a review of the IRIS Program's assessment development process, the NRC will also review current methods for weight-of-evidence analyses and recommend approaches for weighing scientific evidence for chemical hazard identification. In addition, EPA will hold a workshop on August 26, 2013 on issues related to weight-of-evidence.
Calculation of Reference Values and Unit Risks (pp. 165–166) 7. Assess the sensitivity of derived estimates to model assumptions and endpoints selected. This step should include appropriate tabular and graphic displays to illustrate the range of the estimates and the effect of uncertainty factors on the estimates.	Multiple, endpoint-specific reference values were derived for benzo[a]pyrene (RfD: Table 2-3 and Figure 2-1; RfC: Table 2-5 and Figure 2-2) and demonstrate the sensitivity of the overall reference values depending on the selection of the overall endpoints.

[6]EPA Announces NAS' Review of IRIS Assessment Development Process (www.epa.gov/iris).

ED_006137A_00009570-00273

APPENDIX G. SUMMARY OF EXTERNAL PEER REVIEW AND PUBLIC COMMENTS AND EPA'S DISPOSITION

EPA's Response to Selected Major Public Comments on the Public Comment Draft (August 2013) of the IRIS Toxicological Review of Benzo[a]pyrene

Purpose: The Integrated Risk Information System (IRIS) assessment development process of May 2009, includes release of the draft IRIS assessment for public review and comment and independent expert peer review (Step 4). During this step, EPA holds a public meeting to discuss the draft assessment and draft peer review charge. As part of enhancements to the IRIS assessment development process announced in July 2013, in some cases, the IRIS Program may decide to revise the draft assessment and peer review charge after hearing the public's comments about these materials. For a complete description of the IRIS process, visit the IRIS website at www.epa.gov/iris.

The following are EPA's responses to the scientific issues raised in the public comments received on the draft IRIS Toxicological Review of Benzo[a]pyrene (dated August 2013). The comments have been synthesized and paraphrased, and are organized to follow the order of the Toxicological Review. Editorial changes were incorporated in the document as appropriate and are not discussed further. All public comments provided were taken into consideration in revising the draft assessment prior to posting for external peer review. The complete set of public comments are available on the docket at http://www.regulations.gov (Docket ID No. EPA-HQ-ORD-2011-0391).

Background: The Toxicological Review of Benzo[a]pyrene was released for a 60-day public comment period on August 21, 2013. The comment period was subsequently extended to 90 days, ending on November 21, 2013. During this period, public comments on the assessment were submitted to EPA by the Utility Solid Waste Activities Group (USWAG), CDM Smith Inc, Pavement Coating Technology Council, Electric Power Research Institute (EPRI), Duke Energy, CH2M Hill, Gradient, American Chemistry Council (ACC), Agnes Francisco, Melanie Nembhard, and by Arcadis on behalf of American Coke and Coal Chemicals Institute, American Fuels and Petrochemical Manufacturers, American Petroleum Institute, Asphalt Institute, Association of American Railroads, Beazer East, Inc. and Pavement Coatings Technology Council. In addition, a public meeting was held in December 2013 to provide the public an opportunity to engage in early discussions on the draft IRIS Toxicological Review of Benzo[a]pyrene and the draft charge to the peer review panel prior to release for external peer review.

RESOLUTION OF PUBLIC COMMENTS ON THE DRAFT TOXICOLOGICAL REVIEW (dated August 2013)

ED_006137A_00009570-00274

CONSIDERATION OF ADDITIONAL LITERATURE

Comment: *Inclusion of supporting data for critical study used to derive the dermal slope factor.* The August 2013 public comment draft derived the dermal slope factor from points of departure from two lifetime dermal cancer bioassays that were deemed to be of similar quality (Sivak et al., 1997; Poel, 1959). Gradient identified a report (Arthur D Little, 1989) that presents the original results, including the individual animal data, for the NIOSH dermal study publication (Sivak et al., 1997). In addition, Gradient also provided an additional reference, Clark et al. (2011), for consideration in the development of the dermal slope factor.

EPA Response: EPA has revised the dose response analysis for the derivation of the dermal slope factor to incorporate the individual animal survival data identified by the public commenter (Section 2.5.2 of the Toxicological Review and Appendix E.2.3 of the Supplemental Information). This allowed EPA to utilize the MultiStage-Weibull model, a model that incorporates dose and the time at which death with tumor occurred. Use of this model accounts for competing risks associated with decreased survival times and other causes of death, including other tumors.

Previously, the PODs from the Sivak et al. (1997) and Poel (1959) studies were considered to be of similar quality and thus were averaged to derive the dermal slope factor. In consideration of these additional supporting data, EPA selected the NIOSH dermal study (Sivak et al., 1997; Arthur D Little, 1989) as the best available study for dose-response analysis and extrapolation to lifetime cancer risk following dermal exposure to benzo[a]pyrene.

The publication by Clark et al. (2011), reported results of a lifetime dermal cancer bioassay which primarily tested polycyclic aromatic hydrocarbon (PAH) mixtures, and included one high dose group of benzo[a]pyrene as a positive control. EPA considered this study, but did not present Clark et al. (2011) in the revised assessment due to the availability of several dermal lifetime cancer bioassays for benzo[a]pyrene with multiple doses which enable greater characterization of the dose-response relationship, especially in the low dose range.

Comment: *Further consideration of human skin graft mouse bioassay studies.* Arcadis, EPRI and CDM Smith recommended increased consideration of studies of PAH exposure in murine models with human skin xenografts (Atillasoy et al., 1997; Soballe et al., 1996; Urano et al., 1995; Graem, 1986). These studies transplanted human skin onto the backs of immunodeficient mice and after grafts had been established, treated the skin with carcinogens, including PAHs, and mice did not develop tumors. The commenters stated that these papers demonstrate that human skin is resistant to the skin tumorigenesis that is seen in mouse skin with benzo[a]pyrene and other PAHs.

EPA Response: Several studies identified by the commenters used the potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) (Soballe et al., 1996; Urano et al., 1995; Graem, 1986) and a single study tested benzo[a]pyrene (Urano et al., 1995). In the studies using benzo[a]pyrene or DMBA alone, tumors were identified at the graft border, and judged to be of mouse skin origin, but no tumors were identified as originating from the human skin graft. The ability of this model system to predict hazard for human skin cancer risk from dermally active procarcinogens is unclear. Though some studies indicate that the skin grafts maintain some metabolic function (Das et al., 1986), it is unclear whether the human skin grafts (some obtained from cadavers) maintain the same viability, vascularization, and full metabolic capacity as human skin in vivo (Kappes et al., 2004). Potent mutagenic carcinogens such as DMBA, methylcholanthrene, methylnitronitrosoguanidine also fail to produce skin tumors in this model system (Soballe et al.,

ED_006137A_00009570-00275

1996; Urano et al., 1995; Graem, 1986). In addition, the treatment time and the period of observation was quite short in all identified studies. The mice with the benzo[a]pyrene-treated human skin grafts in Urano et al. (1995) died within six months after the initial benzo[a]pyrene treatment. In addition, the PAH-treated skin graft mice in Graem (1986) and Soballe et al. (1996) were only followed for an average of 4-7 months from the start of treatment. While six months is generally sufficient for the development of skin tumors in mouse skin (depending on dose level), human latency for squamous cell carcinoma in PAH-exposed occupational cohorts is thought to be greater than 20 years (Young et al., 2012; Voelter-Mahlknecht et al., 2007; Everall and Dowd, 1978). Therefore, the single available study (Urano et al., 1995) evaluating the carcinogenicity of benzo[a]pyrene in this model system was considered in the Toxicological Review, but was regarded with low confidence.

Additional text to clarify these points has been added to Section 1.1.5 of the Toxicological Review.

Comment: *Inclusion of studies of patients therapeutically treated with coal tar.* Arcadis, EPRI, and CDM Smith suggested the inclusion of epidemiologic studies of skin cancer risk in eczema and psoriasis patients treated therapeutically with a dermatological formulations containing coal tar (a PAH mixture). These commenters suggested that the available epidemiological studies of coal tar treated patients clearly demonstrate that benzo[a]pyrene does not cause skin cancer in humans.

EPA Response: In addition to the comments described above, EPA received comments from the American Petroleum Institute in March 2013 listing references related to therapeutic coal tar use. EPA reviewed the references noted in these comments, as well as those identified through additional review of citations contained in the identified studies and related reviews. Studies that included a measure of coal tar exposure in relation to a measure of skin cancer risk were considered and discussed in the Toxicological Review and Supplemental Information drafts dated August 2013. Specifically, Table D-6 of the Supplemental Information presents a summary of the methodological features as well as the results of these studies. A discussion of this database was also included in Section 1.1.5 of the Toxicological Review and Appendix D.3.3 of the Supplemental Information. Case reports and studies that did not include a measure of coal tar exposure were not included in the August 2013 draft assessment.

EPA noted considerable limitations to this body of literature, particularly relating to the level of detail pertaining to exposure measures, length of follow-up, and ability to address effects attributable to other types of therapies. A single population-based case-control study was identified (Mitropoulos and Norman, 2005); this study examined self-reported use of coal tar/dandruff shampoo and the association with increased incidence of dermal squamous cell carcinomas. EPA considered this exposure measure to be highly susceptible to misclassification. Other epidemiological studies of patients with specific types of skin conditions (e.g., psoriasis, eczema) were limited by the quality of the exposure data and inability to examine variation in exposure level (i.e., duration of use), sample size and duration of follow-up, and choice of referent rates and differences in disease ascertainment between cases and the reference population. In addition, clinic-based studies focused on the commonly used regimen of coal tar in conjunction with ultraviolet (UV) B therapy (e.g., the Goeckerman treatment), and could not distinguish effects of coal tar alone.

EPA does not consider the identified studies to adequately address the question of the potential association between coal tar treatments and skin cancer due to limitations in design and conduct.

Thus, EPA disagrees with the commenters' view that these studies demonstrate that benzo[a]pyrene does not cause skin cancer in humans.

Although EPA does not consider the available studies sufficient to evaluate the potential association between use of coal tar therapies and risk of skin cancer, acute studies of coal tar treated patients provide in vivo evidence of benzo[a]pyrene-specific genotoxicity (increased BPDE-DNA adducts) in human skin (Godschalk et al., 2001; Rojas et al., 2001; Zhang et al., 1990), an early key event in the carcinogenic mode of action of benzo[a]pyrene (Figure 1-6 of Section 1.1.5 of the Toxicological Review).

COMMENTS ON THE WEIGHT OF EVIDENCE AND MODE OF ACTION FOR CANCER

Comment: *Use of epidemiological studies to support the weight of evidence for cancer.* Arcadis and EPRI commented that the draft benzo[a]pyrene assessment has mischaracterized the evidence supporting an association between benzo[a]pyrene exposure and lung and skin cancers in humans. They further state that the human studies that have been presented are studies of worker groups who were exposed to complex mixtures and it is not possible to attribute the effects of the mixture to one component.

EPA Response: EPA agrees that benzo[a]pyrene exposure in the environment occurs as a complex mixture with many components including other PAHs, and notes in Section 1.1 of the Toxicological Review that accordingly, there are few epidemiologic studies designed to investigate the effects of benzo[a]pyrene, though there are many that have investigated the effects of exposure to PAH mixtures as a whole. EPA's *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005) emphasize the importance of weighing all of the evidence in reaching conclusions about human carcinogenic potential. Specifically, the guidelines describe that the descriptor of "carcinogenic to humans" can be used when the following conditions are met: (a) there is strong evidence of an association between human exposure and either cancer or the key precursor events of the agent's mode of action but not enough for a causal association, (b) there is extensive evidence of carcinogenicity in animals, (c) the mode or modes of carcinogenic action and associated key precursor events have been identified in animals, and (d) there is strong evidence that the key precursor events that precede the cancer response in animals are anticipated to occur in humans and progress to tumors, based on available biological information. In Section 1.2.2 and Table 1-18 of the Toxicological Review the data for benzo[a]pyrene supporting these four conditions are presented.

Extensive evidence of carcinogenicity in animal bioassays along with strong and consistent mechanistic data for a mutagenic mode of action support conditions (b) and (c) above. Numerous studies demonstrate the carcinogenicity of benzo[a]pyrene in multiple species by all tested routes of administration. In addition, mechanistic studies provide strong evidence that links the metabolism of benzo[a]pyrene to DNA reactive agents with key mutational events in genes that can lead to tumor development. These events include the formation of specific DNA adducts and characteristic mutations in oncogenes and tumor suppressor genes.

Several human exposure studies are available supporting both conditions (a) and (d) above. Specifically, epidemiological studies evaluating exposure to PAH mixtures (both occupational exposures and tobacco smoke) containing benzo[a]pyrene demonstrate an association with cancer. Furthermore, multiple studies have reported benzo[a]pyrene-specific DNA adducts as well as

characteristic mutations in oncogenes and tumor suppressor genes in humans exposed to PAH mixtures.

EPA recognizes that benzo[a]pyrene is one of many PAHs that could contribute to the observed increases in cancer in humans exposed to PAH mixtures. However, the combination of strong and consistent human, animal, and mechanistic evidence for the carcinogenicity of benzo[a]pyrene provides the basis for characterizing benzo[a]pyrene as "carcinogenic to humans".

COMMENTS ON THE DERIVATION OF THE REFERENCE DOSE AND REFERENCE CONCENTRATION

Comment: *Metric used to characterize results in the elevated plus maze.* Dose-related differences in number of open arm entries, increased time spent in the open arms, and decreased closed arm entries were observed in the study by Chen et al. (2012). The number of entries into the open arms was used for benchmark dose modeling to extrapolate a POD for the RfD. Arcadis commented that according to Hogg (1996), the preferred way to express results from the elevated plus maze is as percentage of open arm entries (among total arm entries) or percentage of time spent in open arms, to correct for overall changes in exploration and reduce activity-induced artifacts.

EPA Response: EPA agrees that the optimal way to express elevated plus maze data is in relation to the total number of arm entries or to the total amount of time spent in the arms of the maze. The reason for presenting the information in such a way is to account for potential differences due to changes in general locomotor or exploratory behaviors, rather than changes in anxiety (which is the critical effect). While Chen et al. (2012) did not present the data in this manner (EPA's attempts to obtain the raw data have been unsuccessful), the authors did present enough information for EPA to arrive at the conclusion that general locomotor or exploratory behaviors were not affected by exposure. Specifically, as a measure of total locomotor activity and exploration in the elevated plus maze test, the *total* number of arm entries between control and benzo[a]pyrene-treated animals were calculated from the graphically reported results provided for open and closed arm entries; total arm entries were unchanged with treatment (e.g., the number of closed arm entries was decreased with exposure). Therefore, it is unlikely that the results observed were confounded by a general increase in locomotor activity in the benzo[a]pyrene treated animals.

Two additional studies which tested the effects of benzo[a]pyrene exposure in the elevated plus maze (Bouayed et al., 2009a; Grova et al., 2008) reported findings consistent with Chen et al. (2012), and similarly did not observe an increase in general locomotor activity with treatment. Although they tested higher doses of benzo[a]pyrene than Chen et al. (2012), both Bouayed et al. (2009a) and Grova et al. (2008) observed statistically significant effects of exposure on percentage of open arm entries and no effects on the total number of arm entries, the former following oral exposure during lactation and the latter following i.p. injection in adulthood. See Section 1.1.1 and Section 2.1.1 for discussion of the consistency of the decreased anxiety-like effects in the evidence database.

Although EPA concluded that the elevated plus maze data presented by Chen et al. (2012) is appropriate for use in dose-response modeling, EPA also conducted a sensitivity analysis using the metric proposed by Hogg (1996), expressing the data as a fraction of the open arm entries over the total arm entries. The data for this endpoint were only available as group means and standard deviations for the open and closed arm entries (separately), presented graphically; the group means and standard deviations for total arm entries were not reported, and would ideally be

ED_006137A_00009570-00278

calculated from individual animal data. However, it was feasible to derive inputs for dose-response analysis by summing the group means for open and closed arm entries to yield total arm entries, and by using Monte Carlo simulations (assuming a normal distribution) to estimate the variance of the ratio of open arm entries to total arm entries. The resulting BMD and BMDL for a one standard deviation decrease in mean percentage of open arm entries among total entries were 0.09 and 0.05 mg/kg-day, respectively. Compared to the BMD and BMDL (POD) of 0.16 and 0.09 mg/kg-day based on the Chen et al. (2012) data, the analysis incorporating total arm entries suggests a lower POD for this effect; however, EPA notes that the two sets of results overlap substantially. EPA considers the results corroborative of the POD for this effect based on the published data.

Comment: *Use of decreased anxiety-like effects as a critical effect.* Arcadis and ACC questioned why the behavioral effect of "decreased anxiety" observed in rodents tested in the elevated plus maze was regarded as an adverse effect given that this test is used in pharmacology to evaluate the efficacy of anxiety reducing drugs.

EPA Response: A normal level of anxiety is a protective function of the nervous system. A decrease in anxiety, a clear change in nervous system function, can impair an organism's ability to react to a potentially harmful situation. The decreased ability of an organism to adapt to the environment is considered to be an adverse effect (U.S. EPA, 1998). In addition, any functional alteration resulting from developmental exposure is considered biologically significant (U.S. EPA, 1991c). Additional discussion of the significance of this endpoint has been added in Section 2.1.1 of the Toxicological Review.

In contrast to environmental exposure, exposure to drugs is intended to occur at a controlled dosage and with a defined periodicity and duration, and drugs are only administered to a subset of the population with an underlying, clinically-identified neurological dysfunction that requires treatment.

Comment: *Consideration of additional studies for the derivation of the RfC.* Arcadis commented that the RfC should quantitatively consider the NOAELs and LOAELs from Archibong et al. (2002) and Wu et al. (2003a) to develop the RfC based on decreased pup survival. They state that the publication by {Archibong, 1007602} reported a LOAEL for this effect as 25 μg/m^3, but that another publication, from the same laboratory, Wu et al. (2003a), reported that this exposure concentration was a NOAEL. They suggest that both studies can be used quantitatively to establish the point of departure for the RfC.

EPA Response: The publications by Archibong et al. (2002) and Wu et al. (2003a) were generated by the same laboratory and used identical exposure methods. As both publications reported similar results for fetal survival, it appears possible that both reported effects on the same group of exposed dams. EPA notes that reporting for the endpoint of decreased fetal survival met a higher standard in Archibong et al. (2002) compared with Wu et al. (2003a), with Archibong et al. (2002) reporting means and variances for implantation sites, pups per litter, and % litter survival and Wu et al. (2003a) reporting decreased survival graphically. Although the focus of this study was on metabolic activation in the liver and brain of exposed offspring, Wu et al. (2003a) did report that "the number of resorptions was more at 75 and 100 μg/m^3 compared to 25 μg/m^3 and was statistically significant," but did not report whether the apparent decrease in birth index at 25 μg/m^3 was statistically significant compared to the vehicle control group. This decrease in fetal survival at 25 μg/m^3 is consistent with the lowest exposure level being a LOAEL rather than a NOAEL as suggested by the commenters. Due to incomplete reporting on this endpoint, the dataset reported by Wu et al. (2003a) was inadequate for the derivation of a candidate RfC. These points

ED_006137A_00009570-00279

have been clarified in the discussion of Wu et al. (2003a) in Section 1.1.1 and 2.2.1 of the Toxicological Review.

GENERAL COMMENTS ON THE QUANTITATIVE CANCER ASSESSMENT

Comment: *Apparent threshold in animal cancer bioassays.* Arcadis, CDM Smith, and USWAG commented that the animal carcinogenicity studies of benzo[a]pyrene used as the bases of the oral slope factor (Beland and Culp, 1998), inhalation unit risk (Thyssen et al., 1981), and dermal slope factor (Sivak et al., 1997; Poel, 1959), demonstrate threshold exposures for benzo[a]pyrene. They state that plots resulting from EPA's Benchmark Dose Modeling Software show that the bioassay data exhibit threshold responses near the origin and that the tumor incidence of 0% at the low doses demonstrate evidence of a threshold below which no cancer effects are seen.

EPA Response: EPA disagrees that the cited studies establish thresholds. Although animal bioassays may seem to suggest thresholds, even the largest studies that are feasible to conduct have insufficient power to detect risk levels of concern for public health. For example, a response of 1/50, or 2%, is the lowest response that can be observed in typical carcinogenicity bioassays. Such a study cannot demonstrate a response of 0.1% (1/1000), say, often considered a high level of cancer risk in a human population. If the true cancer rate at a particular exposure level is 0.1%, the experimental outcome in a group of 50 will be 0% about 95% of the time.

Evidence for thresholds is more solidly determined through consideration of modes of action and toxicokinetic pathways. Without consideration of such information, lack of response at low exposures in animal bioassays cannot be distinguished from lack of statistical power.

COMMENTS ON THE INHALATION UNIT RISK

Comment: *Availability of an additional benzo[a]pyrene inhalation study.* Arcadis and EPRI commented that an abstract for an unpublished study by Pauluhn et al. (1985) contradicts the findings of carcinogenicity in Thyssen et al. (1981), and recommended that EPA acquire the raw data.

EPA Response: The study referred to by the commenters, "Long-term inhalation study with benzo[a]pyrene and SO_2 in Syrian golden hamsters," assesses the effects of combined SO_2 and benzo[a]pyrene (abbreviated as BP in the abstract) exposure in hamsters. It is unclear how this study provides negative or contradictory evidence because the abstract indicates a carcinogenic response: "[i]n hamsters which were exposed to 2 or 10 mg BP/m^3 air without SO_2, a few neoplastic alterations were found". While it would be useful to have another study of inhalation exposure, no further information is available in the published literature, and EPA's attempts to obtain the raw data have been unsuccessful.

Comment: *Exceedance of maximum tolerated dose in Inhalation Unit Risk study.* In comments submitted by Arcadis and EPRI, it was stated that the exposure concentrations in the inhalation study by Thyssen et al. (1981) likely caused particle overload, exceeding the maximum tolerated dose (MTD), and according to U.S. EPA (2005), data that exceed the MTD should not be used for quantitative risk assessment purposes.

ED_006137A_00009570-00280

EPA Response: In Thyssen et al. (1981), hamsters received time-weighted, average daily concentrations of 0.25, 1.01, and 4.29 mg/m^3 benzo[a]pyrene condensed onto sodium chloride particles (calculated based on weekly exposure chamber measurements). Animals in the low and mid benzo[a]pyrene concentration groups had comparable survival to the vehicle control group. The study authors reported that decreased survival in the high concentration group was associated with increased incidence of tumors in the larynx and pharynx (affecting approximately half of the high dose group). The study authors also concluded that particle clearance mechanisms of the respiratory epithelium remained intact since the tumors of the upper respiratory and digestive tract occurred relatively late in life.

EPA's Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) distinguish between cancer and other effects when assessing toxicity, e.g.: "If adequate data demonstrate that the effects are solely the result of excessive toxicity *rather than carcinogenicity* [emphasis added] of the tested agent *per se*, then the effects may be regarded as not appropriate to include in assessment of the potential for human carcinogenicity of the agent." No evidence supports that the tumors noted by Thyssen et al. (1981) in the upper respiratory and digestive tract were solely the result of excessive toxicity rather than carcinogenicity. The decreased survival observed in the high dose group appears to be a direct effect of the early occurrence of tumors in this group. Therefore, the Thyssen et al. (1981) study was judged to support the derivation of a unit risk.

Comment: *Apparent discrepancies in cancer incidence data used in the derivation of the inhalation unit risk.* In comments submitted by Arcadis and EPRI, it was noted that the total number of animals at risk and the total number of tumors observed in each treatment group from the Thyssen et al. (1981) study varied between that publication, a secondary analysis (U.S. EPA, 1990), and study design descriptions and tables (D-13, D-14, E-17, and dose-response model output summaries) presented in the Toxicological Review.

EPA Response: Concerning the number of tumor-bearing animals, Thyssen et al. (1981) summarized only the animals with malignant tumors without identifying them as such; EPA's review (U.S. EPA, 1990) of the individual animal pathology reports provided by the investigators (Clement Associates, 1990) showed that totals reported in the publication matched the incidence of malignant tumors, and that there were benign tumors as well. Table D-13 of the Supplemental Information has been revised to reflect the incidence of benign and malignant tumors.

Concerning the numbers of animals at risk, the totals in Thyssen et al. (1981), U.S. EPA (1990), and the draft Toxicological Review differed because the number of animals examined for histopathology varied for different tissues:

- Thyssen et al. (1981) reported the overall number of animals evaluated for histopathology, but did not clarify when individual tissues were not available for examination.
- The draft Toxicological Review (August 2013) relied on the summaries in U.S. EPA (1990) augmented by details from the histopathology reports (Clement Associates, 1990), such as clarifications that some tumors were metastases or types not likely related to squamous neoplasia. Upon re-review of the histopathology reports, EPA determined that results were not available for five low-exposure animals included in the U.S. EPA (1990) analysis. EPA has revised the incidence summaries and the dose-response modeling and has omitted data for these animals.

Comment: *Exposure variability in the study used to derive inhalation unit risk.* Arcadis and EPRI stated that Thyssen et al. (1981) is inappropriate for dose response modeling given concerns regarding variability in exposure concentrations.

EPA Response: As discussed in Sections 2.4.1 and 2.4.4 of the Toxicological Review, the lifetime inhalation bioassay by Thyssen et al. (1981), reported weekly averages of chamber concentrations of benzo[a]pyrene which varied two- to fivefold from the overall average for each group, which exceeds the limit for exposure variability of <20% for aerosols recommended by OECD (2009). Continuous time weighted group average concentrations were calculated for use in dose response modeling under the assumption that equal cumulative exposures are expected to lead to similar outcomes. For risk assessment purposes, EPA generally assumes that cancer risk is proportional to cumulative exposure, and therefore to lifetime average exposure as estimated here, when there is no information to the contrary. Under this assumption, the variability of the chamber concentrations has little impact on the estimated exposure-response relationship.

COMMENTS ON THE DERMAL SLOPE FACTOR

Comment: *Consideration of nonlinear MOAs for dermal carcinogenicity.* USWAG commented that EPA failed to consider nonlinear dose-response models to extrapolate from dermal exposure studies to predict cancer risk. USWAG cited the availability of a dermal exposure study in mice (and follow up study) that measured DNA adducts, necrosis, and inflammation after 5 weeks of exposure and observed the tumor response at approximately 8 months of treatment (Albert et al., 1996; Albert et al., 1991). This commenter stated that the observed tumor response in this study was "remarkably nonlinear, with pronounced tumor formation at 35 weeks observed only in the high dose group" and that this study "demonstrated definitively, and quantitatively, that pervasive dermal tissue injury was induced by all benzo[a]pyrene dose levels investigated in this study." They also go on to state that "[t]he studies by (Albert et al. (1996); Albert et al. (1991)) demonstrate that benzo[a]pyrene-induced inflammation, cell killing, and cell replication was highly likely to have occurred at tumorigenic benzo[a]pyrene dose levels used in every bioassay that EPA relied on to calculate a DSF."

EPA Response: EPA agrees that the studies by (Albert et al. (1996); Albert et al. (1991)) appear to indicate that at high doses of benzo[a]pyrene, inflammation promotes the formation of tumors. Albert et al. (1991) treated animals with 16, 32, or 64 μg of benzo[a]pyrene once per week and reported the number of tumors per mouse after 8 months (current standardized rodent cancer bioassays treat animals for 18 to 24 months (U.S. EPA, 2005)). The mice in the 16 and 32 μg dose groups had an average of 1 tumor/animal, whereas the animals in the highest dose group had approximately 8 tumors/animal. A follow up to this study, by the same authors, measured DNA adducts, necrosis, and inflammation in treated mice (at the site of exposure) after 5 weeks of dermal exposure. In the 64 μg/week dose group, statistically elevated levels of DNA adducts, inflammation, and necrosis were reported; however, in the lower dose group (16 μg/week), DNA adducts were statistically significantly elevated without increases in inflammation and necrosis.

In comparison, the lifetime dermal cancer bioassay in mice used for the derivation of the dermal slope factor, Sivak et al. (1997), used much lower exposure concentrations of benzo[a]pyrene (0.1, 1 or 10 μg/week). Even so, after two years of exposure, animals in highest dose group had a tumor incidence of 27/30 with dermal scabs and sores reported in 80% of animals. However, the next dose level down reported tumors in 5/30 animals with no elevation of cytotoxic lesions.

Cytotoxicity and mutation are not mutually exclusive modes of action; some observed effects can be consistent with more than one mode of action. A mutagen at high doses can cause cytotoxicity and regenerative proliferation that is a secondary response to massive DNA damage. As discussed in Section 1.1.5 of the Toxicological Review, benzo[a]pyrene is a complete carcinogen; the contributing roles of other processes involved in the promotion and progression of benzo[a]pyrene-induced tumors, including cytotoxicity, inflammation, and regenerative cell proliferation, are acknowledged within the MOA discussion. However, there is insufficient evidence that these mechanisms act independently of DNA damage and mutation to produce benzo[a]pyrene-induced tumors.

EPA has revised the assessment to provide additional discussion of the (Albert et al. (1996); Albert et al. (1991)) studies in the cancer MOA section with particular attention to the observed quantitative and temporal relationship between DNA adducts and indicators of cytotoxicity (including inflammation and necrosis).

Comment: *Potential for different mode of action for benzo[a]pyrene-induced tumors in mouse skin versus human skin.* Arcadis and EPRI commented that PAH-induced mouse skin tumors have a different genetic signature than tumors in human skin. They cited Balmain and Harris (2000) as support for their hypothesis that PAH-induced tumors in mouse skin have an H-ras mutation signature whereas human skin cancers have a p53 mutation signature, therefore showing that PAHs are not causally related to human skin cancers.

EPA Response: The review article cited above (Balmain and Harris, 2000) does not discuss PAH-induced skin tumors in mouse skin or human skin. This article reviews the association between benzo[a]pyrene exposure from tobacco smoke and p53 mutations in human lung cancer, the association between sun exposure and p53 mutations in human skin cancer, and the association between dietary aflatoxin B1 exposure and p53 mutations in human liver cancer.

Benzo[a]pyrene has been shown to be a complete carcinogen in multiple animal species. Skin tumors in mice, rats, rabbits, and guinea pigs have been associated with repeated application of benzo[a]pyrene to skin in the absence of exogenous promoters (Sivak et al., 1997; Grimmer et al., 1984; Habs et al., 1984; Grimmer et al., 1983; Habs et al., 1980; Schmähl et al., 1977; Schmidt et al., 1973; Roe et al., 1970; Poel, 1959). The proposed mutagenic MOA for benzo[a]pyrene involves the bioactivation of benzo[a]pyrene to DNA-reactive metabolites, direct DNA damage by reactive metabolites, formation and fixation of DNA mutations, and clonal expansion of mutated cells. These key events have been observed in animals and humans and by multiple routes of exposure (see Table 1-17 of the Toxicological Review). Benzo[a]pyrene specific skin adducts have been observed in vivo in both benzo[a]pyrene-treated mouse skin and human skin exposed to PAH-mixtures (Godschalk et al., 2001; Rojas et al., 2001; Zhang et al., 1990). In addition, studies of dermal benzo[a]pyrene exposure in mice have shown increased mutations in several gene targets including the tumor suppressor p53 (Ruggeri et al., 1993), the proto-oncogene H-Ras (Wei et al., 1999; Chakravarti et al., 1995) and the lacz transgene (Miller et al., 2000). Studies which examine mutational spectra in human skin tumors thought to be related to PAH exposure are not available in the literature.

The lack of specific H-ras mutational evidence in humans (due to lack of human studies) or suggestive evidence of p53 mutations in UV-induced human skin tumors does not preclude the fact that benzo[a]pyrene can initiate DNA damage via DNA adducts. If not adequately repaired, this damage can form mutations and mutagenesis is a well-established cause of carcinogenesis.

Text in the mode of action analysis for carcinogenicity (in Section 1.1.5) has been modified to include studies observing additional target gene mutations (in addition to H-ras) in dermally exposed mice (Miller et al., 2000; Ruggeri et al., 1993).

Comment: *Exceedance of maximum tolerated dose in studies used to derive the dermal slope factor.* Arcadis and EPRI disagreed with the study that EPA selected for characterizing the dermal slope factor, Sivak et al. (1997), stating that this study included exposure levels that exceeded the maximum tolerated dose (MTD) by causing significant skin toxicity and excessive mortality, and therefore is not suitable for the derivation of the dermal slope factor.

EPA Response: While lower lifetime exposures are preferred for cancer risk estimation, EPA disagrees that studies demonstrating carcinogenicity, with or without causing mortality, should automatically be excluded from cancer risk assessment. EPA's Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) distinguish between cancer and other effects when assessing toxicity at exposures at or above the maximum tolerated dose, e.g.: "If adequate data demonstrate that the effects are solely the result of excessive toxicity *rather than carcinogenicity* [emphasis added] of the tested agent *per se*, then the effects may be regarded as not appropriate to include in assessment of the potential for human carcinogenicity of the agent." Therefore, EPA concluded it is justified in excluding individual *dose groups* with exposure above the MTD, but not necessarily the entire study.

Some skin toxicity was noted in the highest dose group with an 80% incidence of scabs and sores. However, the next lower dose group did not produce notable non-cancer skin lesions. An analysis excluding the high dose group from Sivak et al. (1997) (not shown in the assessment) showed no impact on the resulting dermal slope factor (within one significant figure), because the slope factor reflects the dose-response relationship at the lower exposure levels. When reported by study authors, text to clarify incidence of any non-cancerous skin lesions has been added to Section 1.1.5.

Comment: *Cross-species extrapolation of dermal slope factor.* CDM Smith, Arcadis and EPRI commented that differences between mouse and human skin should be recognized and accounted for in the calculation of the dermal slope factor for skin cancer. Specifically, the commenters stated mouse skin is thinner and more permeable to benzo[a]pyrene and produces more benzo[a]pyrene-diol epoxide metabolites than humans. They also stated that aryl hydrocarbon hydroxylase inducibility is higher in mice than humans and that DNA-adducts are formed at higher rates in mouse skin and repaired at lower rates relative to human skin. Another commenter, CH2M Hill recommended increased discussion of the uncertainty regarding the method for interspecies scaling of the dermal slope factor.

EPA Response: The key events in the mutagenic mode of action of benzo[a]pyrene are well conserved between species and tissues (see Section 1.1.5 and Table 1-17 of the Toxicological Review). However, the quantitative differences in processes that may presumably affect the carcinogenicity of benzo[a]pyrene are not well known. These processes likely include species (and inter-individual) differences in rates of absorption, metabolism into reactive metabolites, de-activation of reactive metabolites, DNA repair, and DNA replication. As mentioned in Section E of the Supplemental Information, biological information is not currently comprehensive or detailed enough to develop robust models for cross-species extrapolation. This assessment evaluated several alternative approaches in Appendix E of the Supplemental Information. Of these potential approaches, allometric scaling using body weight to the ¾ power was selected based on observed species differences in the rate of dermal absorption and metabolism of benzo[a]pyrene. Using this

approach, rodents and humans exposed to the same daily dose of a carcinogen, adjusted for $BW^{3/4}$, would be expected to have equal lifetime risks of cancer. Several assumptions are made in the use of this scaling method. First, it is assumed that the toxicokinetic processes in the skin will scale similarly to interspecies differences in whole-body toxicokinetics. Secondly, it is assumed that the risk at low doses of benzo[a]pyrene is linear. A charge question on the method used for interspecies scaling of the dermal slope factor has been included in the charge to the external peer reviewers.

Comment: *Uncertainties regarding the implementation of the dermal slope factor.* CH2M Hill suggested that the IRIS assessment for benzo[a]pyrene could be strengthened with increased discussion of uncertainties in assessing risk from exposure to benzo[a]pyrene in soil. In addition, they noted that EPA's Risk Assessment Guidelines for Superfund part E (U.S. EPA, 2004) recommend an absorption factor of 13% for benzo[a]pyrene exposure through soil, but that this is for systemic absorption and may not be consistent with the mode of action of benzo[a]pyrene in the skin. Another commenter, USWAG, stated that expressing skin cancer risk for benzo[a]pyrene in terms of $(ug/d)^{-1}$ is not appropriate because of the implicit assumption that the surface area over which exposure occurs is irrelevant.

EPA Response: The lifetime dermal cancer bioassays available for benzo[a]pyrene reported the total dose applied to skin and reported the general area treated (i.e. dorsal or interscapular area), but did not quantify the actual cm^2 of skin treated. For this reason, the draft dermal slope factor expresses risk of skin tumors from benzo[a]pyrene dermal exposure as risk per ug/d. The assumption of this dose metric is that risk at low doses of benzo[a]pyrene is dependent on absolute dermal dose and not dose per unit of skin, meaning that a higher exposure concentration of benzo[a]pyrene contacting a smaller area of exposed skin could carry the same risk of skin tumors as a lower exposure concentration of benzo[a]pyrene that contacts a larger area of skin. The skin surface area exposed to benzo[a]pyrene contaminated media is an important variable in the exposure assessment calculation of the absolute dermal dose of benzo[a]pyrene. An increase in skin area exposed to benzo[a]pyrene contaminated media would result in an increased absolute dermal dose, and therefore an associated increase in risk. Example equations for calculating the absolute dermal dose of benzo[a]pyrene are included below.

The dermal slope factor is based on applied dose of benzo[a]pyrene in solvent. As environmental dermal exposure is assumed to be predominantly through contaminated soil, it is recommended that exposure assessment include an adjustment for exposure through soil. In the attached example exposure calculations for exposure to benzo[a]pyrene through soil, a soil to skin transfer coefficient (Ksoil) of 0.25 was estimated based on a study in monkeys (Wester et al., 1990) which measured dermal absorption of benzo[a]pyrene from soil as 13% and from acetone as 51%. In the acetone vehicle, all of the benzo[a]pyrene contacts the skin after the acetone evaporates, implying that 51% of the benzo[a]pyrene contacting the skin is absorbed. The soil experiment found that 13% was absorbed, so dividing this by 0.51 indicates that 25% of the benzo[a]pyrene in soil must have contacted the skin. This may be a high estimate because Wester et al. (1990) used a low carbon soil (0.9%).

Comment: *"Real world" validation of dermal slope factor.* Arcadis and EPRI recommended that EPA perform calculations to determine if the proposed dermal slope factor is scientifically supportable. These commenters stated that based on their calculations (details not provided to EPA) the current dermal slope factor would indicate that benzo[a]pyrene and benzo[a]pyrene-toxic equivalents in soil throughout the United States are the cause of 30% of all human skin cancers and that 100% of

ED_006137A_00009570-00285

users of pharmaceutical coal tar products should develop skin cancer due to exposure to benzo[a]pyrene. The commenters recommended that EPA not derive a dermal slope factor in the benzo[a]pyrene assessment, but stated that if a dermal slope factor was included a real world validation should be included to determine if the value is scientifically supportable.

EPA Response: The commenters did not provide the exposure equation, benzo[a]pyrene soil concentration, or assumptions used in their calculation of a 30% risk estimate. Without these details, EPA could not reproduce the exposure and associated risk estimates presented in the written comments.

EPA has used the proposed dermal slope factor to calculate average daily dermal doses and associated risks at those dermal doses. A modified exposure equation, similar to equation 3.11 (for dermal absorbed dose upon soil contact) in EPA's Risk Assessment Guidelines for Superfund part E (U.S. EPA, 2004), was used to calculate the average-daily dose of benzo[a]pyrene absorbed into the skin (not absorbed systemically, which is the original intent of the equation). Central tendency exposures using benzo[a]pyrene soil concentrations of 100 ppb (a central estimate of several published measurements of uncontaminated sites) and default exposure assumptions result in risk estimates of approximately 6×10^{-6} for average lifetime exposure that occurs during childhood, and 1×10^{-6} for average lifetime exposure that occurs during adulthood.

Example exposure calculations for risk associated with a central tendency exposure to benzo[a]pyrene throughout a lifetime (including childhood) are included below.

1

Example Calculations: Estimated Dermal Dose and Risk from Exposure to Benzo[a]pyrene in Soil

$$\mathbf{LADD_{dermal}} = \frac{\mathbf{C_{soil} \times CF \times SA \times AF \times ED \times EF \times K_{soil}}}{\mathbf{AT}}$$

$$\mathbf{Risk_{dermal}} = \mathbf{LADD_{dermal} \times SF_{dermal} \times ADAF}$$

$LADD_{dermal}$ = Lifetime Average Daily Dose (ug/day)

C_{soil} = Soil Concentration (ug/kg)

CF = Conversion Factor (kg/ug)

SA = Surface Area of Skin Exposed (cm^2)

AF = Soil Adherence Factor (ug/cm^2-day)
AT = averaging time, the period over which the exposure is averaged (days)

ED = Exposure Duration (years)

EF = Exposure Frequency (days/year)
K_{soil} = Soil to skin Transfer Coefficient for benzo[a]pyrene (unitless)

SF_{dermal} = Dermal Slope Factor for benzo[a]pyrene $(ug/day)^{-1}$

ADAF = Age Dependent Adjustment Factor (unitless)

2
3

Central Tendency Exposure (CTE) Dose: Dermal Contact with benzo[a]pyrene in Soil - Child age 1-<2 years

$LADD_{dermal}$	C_{soil}	CF	$SA_{child\ 1-<6}$	$AF_{child\ 1-<6}$	$ED_{child\ 1-<6}$	EF	K_{soil}	AT
ug/day	ug/kg	kg/ug	cm^2	ug/cm^2-day	years	days/year	unitless	days
3.84E-05	100	1.00E-09	2800	40	1	350	0.25	25550

$Risk_{dermal}$	LADD	SF_{dermal}	ADAF
unitless	ug/day	$(ug/day)^{-1}$	
2.30E-06	3.84E-05	0.006	10

4

Central Tendency Exposure (CTE) Dose: Dermal Contact with benzo[a]pyrene in Soil - Child age 2-<6 years

$LADD_{dermal}$	C_{soil}	CF	$SA_{child\ 1-<6}$	$AF_{child\ 1-<6}$	$ED_{child\ 1-<6}$	EF	K_{soil}	AT
ug/day	ug/kg	kg/ug	cm^2	ug/cm^2-day	years	days/year	unitless	days
1.53E-04	100	1.00E-09	2800	40	4	350	0.25	25550

$Risk_{dermal}$	LADD	SF_{dermal}	ADAF
unitless	ug/day	$(ug/day)^{-1}$	
2.76E-06	1.53E-04	0.006	3

Central Tendency Exposure (CTE) Dose: Dermal Contact with benzo[a]pyrene in Soil - Child age 6-<10 years

$LADD_{dermal}$	C_{soil}	CF	$SA_{child\ 6-<10}$	$AF_{child\ 6-<10}$	$ED_{child\ 6-<10}$	EF	K_{soil}	AT
ug/day	ug/kg	kg/ug	cm^2	ug/cm^2-day	years	days/year	unitless	days
7.81E-05	100	1.00E-09	5700	10	4	350	0.25	25550

$Risk_{dermal}$	LADD	SF_{dermal}	ADAF
unitless	ug/day	$(ug/day)^{-1}$	
1.41E-06	7.81E-05	0.006	3

Total CTE $Risk_{child}$	**6.47E-06**

1

Central Tendency Exposure (CTE) Dose: Dermal Contact with benzo[a]pyrene in Soil – Adult

$LADD_{dermal}$	C_{soil}	CF	SA_{adult}	AF_{adult}	ED_{adult}	EF	K_{soil}	AT
ug/day	ug/kg	kg/ug	cm^2	ug/cm^2-day	years	days/year	unitless	days
1.76E-04	100	1.00E-09	5700	10	9	350	0.25	25550

$Risk_{dermal}$	LADD	SF_{dermal}	ADAF
unitless	ug/day	$(ug/day)^{-1}$	
1.05E-06	1.76E-04	0.006	1

CTE Assumptions:

C_{soil} = an assumed concentration of 0.1 ppm or 100 ug/kg; central tendency value based on average of data for all sites (to 1 significant figure) in Table A-4 of Supplemental Information of the Public Comment Draft (dated August 2013) except the 3 high-end urban sites.
$SA_{child\ 1\text{-}<6\ years}$ = 2800 cm^2 for child residents; average of the 50th percentile values for males and females 1 to <6 years of age (U.S. EPA, 2004, Exhibit 3-5); the child resident was assumed to wear a short-sleeved shirt, and shorts (no shoes); therefore, the exposed skin surface is limited to the head, hands, forearms, lower legs, and feet.
$SA_{child\ 6\text{-}<10\ years}$ = 5700 cm^2; adult value assumed based on (U.S. EPA, 2004, Page 3-19).
SA_{adult} = 5700 cm^2 for adults; average of the 50th percentile values for males and females greater than 18 years of age (U.S. EPA, 2004, Exhibit 3-5); assumed to wear a short-sleeved shirt, short pants and shoes; therefore, the exposed skin surface is limited to the head, hands, lower legs, and forearms.
$AF_{child\ 1\text{-}<6\ years}$ = 40 ug/cm^2-day for children; based on the 50th percentile weighted AF for children playing at a daycare center (U.S. EPA, 2004, Exhibit 3-3 and 3-5); weighted based on body parts exposed.
$AF_{child\ 6\text{-}<10\ years}$ = 10 ug/cm^2-day; adult value assumed based on (U.S. EPA, 2004, Page 3-19).
AF_{adult} = 10 ug/cm^2-day for adult residents; based on the geometric mean weighted AFs for groundskeepers (U.S. EPA, 2004, Exhibit 3-3 and 3-5); weighted based on body parts exposed.
AT = averaging time (the period over which the exposure is averaged).
$ED_{child\ 1\text{-}<2\ years}$ = 1 year for a child resident.
$ED_{child\ 2\text{-}<6\ years}$ = 4 years for a child resident.
$ED_{child\ 6\text{-}<10\ years}$ = 4 years for a child resident based on a central tendency residency time of 9 years minus 5 years as a child age 1-<6 years at that residence.
ED_{adult} = 9 years for adults based on a central tendency residency time of 9 years.
EF = 350 days per year; assumes 2 weeks away from the contaminated area each year for vacation.
K_{soil} = 0.25; This estimate was based on a study in monkeys (Wester et al., 1990) which measured dermal absorption of benzo[a]pyrene from soil as 13% and from acetone as 51%. In the acetone vehicle, all of the benzo[a]pyrene contacts the skin after the acetone evaporates, implying that 51% of the benzo[a]pyrene contacting the skin is absorbed. The soil experiment found that 13% was absorbed, so dividing this by 0.51 indicates that 25% must have contacted the skin.
AT = assumed to be 70 years converted to days: 25550 days.
SF_{dermal} = 0.006 $(ug/day)^{-1}$
ADAF = 10 for children 1-<2 years; 3 for children 2-<10 years.

ED_006137A_00009570-00289

REFERENCES FOR APPENDICES

Abe, S; Nemoto, N; Sasaki, M. (1983a). Comparison of aryl hydrocarbon hydroxylase activity and inducibility of sister-chromatid exchanges by polycyclic aromatic hydrocarbons in mammalian cell lines. Mutat Res 122: 47-51. http://dx.doi.org/10.1016/0165-7992(83)90141-0

Abe, S; Nemoto, N; Sasaki, M. (1983b). Sister-chromatid exchange induction by indirect mutagens/carcinogens, aryl hydrocarbon hydroxylase activity and benzo[alpha]pyrene metabolism in cultured human hepatoma cells. Mutat Res 109: 83-90. http://dx.doi.org/10.1016/0027-5107(83)90097-0

Achard, S; Perderiset, M; Jaurand, MC. (1987). Sister chromatid exchanges in rat pleural mesothelial cells treated with crocidolite, attapulgite, or benzo 3-4 pyrene. Br J Ind Med 44: 281-283.

Adler, ID; Ingwersen, I. (1989). Evaluation of chromosomal aberrations in bone marrow of 1C3F1 mice. Mutat Res 224: 343-345. http://dx.doi.org/10.1016/0165-1218(89)90176-6

Adler, ID; Kliesch, U; Kiefer, F. (1989). Clastogenic effects of benzo[a]pyrene in postimplantation embryos with different genetic background. Teratog Carcinog Mutagen 9: 383-392. http://dx.doi.org/10.1002/tcm.1770090606

Agarwal, R; Medrano, EE; Khan, IU; Nordlund, JJ; Mukhtar, H. (1991). Metabolism of benzo[a]pyrene by human melanocytes in culture. Carcinogenesis 12: 1963-1966. http://dx.doi.org/10.1093/carcin/12.10.1963

Agrelo, C; Amos, H. (1981). DNA repair in human fibroblasts. In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 528-532). New York, NY: Elsevier/North-Holland.

Albert, RE; Miller, ML; Cody, T; Andringa, A; Shukla, R; Baxter, CS. (1991). Benzo[a]pyrene-induced skin damage and tumor promotion in the mouse. Carcinogenesis 12: 1273-1280. http://dx.doi.org/10.1093/carcin/12.7.1273

Albert, RE; Miller, ML; Cody, TE; Talaska, G; Underwood, P; Andringa, A. (1996). Epidermal cytokinetics, DNA adducts, and dermal inflammation in the mouse skin in response to repeated benzo[a]pyrene exposures. Toxicol Appl Pharmacol 136: 67-74.

Alderson, MR; Clarke, JA. (1983). Cancer incidence in patients with psoriasis. Br J Cancer 47: 857-859.

Alexandrie, AK; Nyberg, F; Warholm, M; Rannug, A. (2004). Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13: 908-914.

Alexandrov, K; Rojas, M; Goldberg, M; Camus, AM; Bartsch, H. (1990). A new sensitive fluorometric assay for the metabolism of (--)-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by human hair follicles. Carcinogenesis 11: 2157-2161.

Alfheim, I; Ramdahl, T. (1984). Contribution of wood combustion to indoor air pollution as measured by mutagenicity in Salmonella and polycyclic aromatic hydrocarbon concentration. Environ Mol Mutagen 6: 121-130.

Allen-Hoffmann, BL; Rheinwald, JG. (1984). Polycyclic aromatic hydrocarbon mutagenesis of human epidermal keratinocytes in culture. PNAS 81: 7802-7806.

Alzieu, P; Cassand, P; Colin, C; Grolier, P; Narbonne, JF. (1987). Effect of vitamins A, C and glutathione on the mutagenicity of benzo[a]pyrene mediated by S9 from vitamin A-deficient rats. Mutat Res 192: 227-231.

Amacher, DE; Paillet, SC. (1983). The activation of procarcinogens to mutagens by cultured rat hepatocytes in the L5178Y/TK mutation assay. Mutat Res 113: 77-88. http://dx.doi.org/10.1016/0165-1161(83)90242-X

Amacher, DE; Paillet, SC; Turner, GN; Ray, VA; Salsburg, DS. (1980). Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells. II. Test validation and interpretation. Mutat Res 72: 447-474. http://dx.doi.org/10.1016/0027-5107(80)90118-9

Amacher, DE; Turner, GN. (1980). Promutagen activation by rodent-liver postmitochondrial fractions in the L5178Y/TK cell mutation assay. Mutat Res 74: 485-501. http://dx.doi.org/10.1016/0165-1161(80)90179-X

Ames, BN; Durston, WE; Yamasaki, E; Lee, FD. (1973). Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. PNAS 70: 2281-2285.

Ames, BN; Mccann, J; Yamasaki, E. (1975). Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. DNA Repair 31: 347-363.

Ampy, FR; Saxena, S; Verma, K. (1988). Mutagenicity of benzo(a)pyrene in uninduced tissues from BALB/c mice and Sprague-Dawley rats as an index of possible health risks using the Salmonella mutagenicity assay. Cytobios 56: 81-87.

Anderson, KE; Kadlubar, FF; Kulldorff, M; Harnack, L; Gross, M; Lang, NP; Barber, C; Rothman, N; Sinha, R. (2005). Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14: 2261-2265. http://dx.doi.org/10.1158/1055-9965.epi-04-0514

Andrysík, Z; Vondrácek, J; Machala, M; Krcmár, P; Svihálková-Sindlerová, L; Kranz, A; Weiss, C; Faust, D; Kozubík, A; Dietrich, C. (2007). The aryl hydrocarbon receptor-dependent deregulation of cell cycle control induced by polycyclic aromatic hydrocarbons in rat liver epithelial cells. Mutat Res 615: 87-97. http://dx.doi.org/10.1016/j.mrfmmm.2006.10.004

Antignac, E; Koch, B; Grolier, P; Cassand, P; Narbonne, JF. (1990). Prochloraz as potent inhibitor of benzo[a]pyrene metabolism and mutagenic activity in rat liver fractions. Toxicol Lett 54: 309-315.

Arafa, HM; Aly, HA; Abd-Ellah, MF; El-Refaey, HM. (2009). Hesperidin attenuates benzo[alpha] pyrene-induced testicular toxicity in rats via regulation of oxidant/antioxidant balance. Toxicol Ind Health 25: 417-427. http://dx.doi.org/10.1177/0748233709106624

Arce, GT; Allen, JW; Doerr, CL; Elmore, E; Hatch, GG; Moore, MM; Sharief, Y; Grunberger, D; Nesnow, S. (1987). Relationships between benzo(a)pyrene-DNA adduct levels and genotoxic effects in mammalian cells. Cancer Res 47: 3388-3395.

Archibong, AE; Inyang, F; Ramesh, A; Greenwood, M; Nayyar, T; Kopsombut, P; Hood, DB; Nyanda, AM. (2002). Alteration of pregnancy related hormones and fetal survival in F-344 rats exposed by inhalation to benzo(a)pyrene. Reprod Toxicol 16: 801-808.

Archibong, AE; Inyang, FE; Ramesh, A; Hood, DB; Greenwood, M; Nunes, MG; Nayyar, T; Kopsumbut, P; Nyanda, AM. (2001). Reduction in luteotropic activity and embryonic survival in pregnant rats by inhaled benzo(a)pyrene. Toxicologist 60: 274.

Archibong, AE; Ramesh, A; Niaz, MS; Brooks, CM; Roberson, SI; Lunstra, DD. (2008). Effects of benzo(a)pyrene on intra-testicular function in F-344 rats. Int J Environ Res Public Health 5: 32-40. http://dx.doi.org/10.3390/ijerph5010032

Armstrong, B; Hutchinson, E; Unwin, J; Fletcher, T. (2004). Lung cancer risk after exposure to polycyclic aromatic hydrocarbons: A review and meta-analysis [Review]. Environ Health Perspect 112: 970-978. http://dx.doi.org/10.1289/ehp.6895

Armstrong, B; Tremblay, C; Baris, D; Thériault, G. (1994). Lung cancer mortality and polynuclear aromatic hydrocarbons: A case-cohort study of aluminum production workers in Arvida, Quebec, Canada. Am J Epidemiol 139: 250-262.

Arthur D Little (Arthur D Little Inc.). (1989). Assessment of the cocarcinogenic/promoting activity of asphalt fumes. National Institute for Occupational Safety and Health. http://www.ntis.gov/search/product.aspx?ABBR=PB91110213

Atillasoy, ES; Elenitsas, R; Sauter, ER; Soballe, PW; Herlyn, M. (1997). UVB induction of epithelial tumors in human skin using a RAG-1 mouse xenograft model. J Invest Dermatol 109: 704-709. http://dx.doi.org/10.1111/1523-1747.ep12340661

ATSDR (Agency for Toxic Substances and Disease Registry). (1995). Toxicological profile for polycyclic aromatic hydrocarbons [ATSDR Tox Profile]. Washington, DC: U.S. Department of Health and Human Services. http://www.atsdr.cdc.gov/toxprofiles/tp69.pdf

Autrup, H; Harris, CC; Stoner, GD; Selkirk, JK; Schafer, PW; Trump, BF. (1978). Metabolism of [3H]benzo[a]pyrene by cultured human bronchus and cultured human pulmonary alveolar macrophages. Lab Invest 38: 217-224.

Autrup, H; Seremet, T. (1986). Excretion of benzo[a]pyrene-Gua adduct in the urine of benzo[a]pyrene-treated rats. Chem Biol Interact 60: 217-226. http://dx.doi.org/10.1016/0009-2797(86)90030-X

Autrup, H; Wefald, FC; Jeffrey, AM; Tate, H; Schwartz, RD; Trump, BF; Harris, CC. (1980). Metabolism of benzo[a]pyrene by cultured tracheobronchial tissues from mice, rats, hamsters, bovines and humans. Int J Cancer 25: 293-300. http://dx.doi.org/10.1002/ijc.2910250219

Awogi, T; Sato, T. (1989). Micronucleus test with benzo[a]pyrene using a single peroral administration and intraperitoneal injection in males of the MS/Ae and CD-1 mouse strains. Mutat Res 223: 353-356. http://dx.doi.org/10.1016/0165-1218(89)90084-0

Babson, JR; Russo-Rodriguez, SE; Rastetter, WH; Wogan, GN. (1986). In vitro DNA-binding of microsomally-activated fluoranthene: evidence that the major product is a fluoranthene

N2-deoxyguanosine adduct. Carcinogenesis 7: 859-865. http://dx.doi.org/10.1093/carcin/7.6.859

Balansky, R; Mircheva, Z; Blagoeva, P. (1994). Modulation of the mutagenic activity of cigarette smoke, cigarette smoke condensate and benzo[a]pyrene in vitro and in vivo. Mutagenesis 9: 107-112. http://dx.doi.org/10.1093/mutage/9.2.107

Balmain, A; Harris, CC. (2000). Carcinogenesis in mouse and human cells: parallels and paradoxes [Review]. Carcinogenesis 21: 371-377.

Bao, H; Vepakomma, M; Sarkar, MA. (2002). Benzo(a)pyrene exposure induces CYP1A1 activity and expression in human endometrial cells. J Steroid Biochem Mol Biol 81: 37-45. http://dx.doi.org/10.1016/S0960-0760(02)00045-6

Barfknecht, TR; Hites, RA; Cavaliers, EL; Thilly, WG. (1982). Human cell mutagenicity of polycyclic aromatic hydrocarbon components of diesel emissions. Dev Toxicol Environ Sci 10: 277-294.

Bayer, U. (1978). In vivo induction of sister chromatid exchanges by three polyaromatic hydrocarbons. In PW Jones; RI Freudenthal (Eds.), Polynuclear aromatic hydrocarbons: Second international symposium on analysis, chemistry, and biology (pp. 423-428). New York, NY: Raven Press.

Bayer, U; Younes, M; Siegers, CP. (1981). Enhancement of benzo(a)pyrene-induced sister chromatid exchanges as a consequence of glutathione depletion in vivo. Toxicol Lett 9: 339-343.

Beland, F; Culp, S. (1998). Chronic bioassay of two composite samples from selected manufactured gas plant waste sites [unpublished report]. (Technical Report 6722.02). Jefferson, AK: National Center for Toxicological Research.

Benjamin, H; Storkson, J; Tallas, PG; Pariza, MW. (1988). Reduction of benzo[a]pyrene-induced forestomach neoplasms in mice given nitrite and dietary soy sauce. Food Chem Toxicol 26: 671-678. http://dx.doi.org/10.1016/0278-6915(88)90066-X

Berenblum, I; Haran, N. (1955). The influence of croton oil and of polyethylene glycol-400 on carcinogenesis in the forestomach of the mouse. Cancer Res 15: 510-516.

Bevan, DR; Sadler, VM. (1992). Quinol diglucuronides are predominant conjugated metabolites found in bile of rats following intratracheal instillation of benzo[a]pyrene. Carcinogenesis 13: 403-407. http://dx.doi.org/10.1093/carcin/13.3.403

Bevan, DR; Ulman, MR. (1991). Examination of factors that may influence disposition of benzo[a]pyrene in vivo: Vehicles and asbestos. Cancer Lett 57: 173-179. http://dx.doi.org/10.1016/0304-3835(91)90212-Z

Bevan, DR; Weyand, EH. (1988). Compartmental analysis of the disposition of benzo[a]pyrene in rats. Carcinogenesis 9: 2027-2032.

Biancifiori, C; Caschera, F; Giornelli-Santulli, F; Bucciarelli, E. (1967). The action of oestrone and four chemical carcinogens in intact and ovariectomized BALB/c/Cb/Se mice. Br J Cancer 21: 452-459.

Bingham, E; Falk, HL. (1969). Environmental carcinogens. The modifying effect of cocarcinogens on the threshold response. Arch Environ Health 19: 779-783.

Bláha, L; Kapplová, P; Vondrácek, J; Upham, B; Machala, M. (2002). Inhibition of gap-junctional intercellular communication by environmentally occurring polycyclic aromatic hydrocarbons. Toxicol Sci 65: 43-51. http://dx.doi.org/10.1093/toxsci/65.1.43

Bock, KW; Clausbruch, UC, v; Winne, D. (1979). Absorption and metabolism of naphthalene and benzo(a)pyrene in the rat jejunum in situ. Med Biol 57: 262-264.

Boerrigter, ME. (1999). Treatment of lacZ plasmid-based transgenic mice with benzo[a]pyrene: Measurement of DNA adduct levels, mutant frequencies, and mutant spectra. Environ Mol Mutagen 34: 140-147. http://dx.doi.org/10.1002/(SICI)1098-2280(1999)34:2/3<140::AID-EM13>3.0.CO;2-J

Boffetta, P; Jourenkova, N; Gustavsson, P. (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons [Review]. Cancer Causes Control 8: 444-472. http://dx.doi.org/10.1023/A:1018465507029

Bol, SA; van Steeg, H; Jansen, JG; Van Oostrom, C; de Vries, A; de Groot, AJ; Tates, AD; Vrieling, H; van Zeeland, AA; Mullenders, LH. (1998). Elevated frequencies of benzo(a)pyrene-induced Hprt mutations in internal tissue of XPA-deficient mice. Cancer Res 58: 2850-2856.

Bolton, JL; Trush, MA; Penning, TM; Dryhurst, G; Monks, TJ. (2000). Role of quinones in toxicology [Review]. Chem Res Toxicol 13: 135-160. http://dx.doi.org/10.1021/tx9902082

Bos, RP; Theuws, JLG; Jongeneelen, FJ; Henderson, PT. (1988). Mutagenicity of bi-, tri- and tetra-cyclic aromatic hydrocarbons in the taped-plate assay and in the conventional Salmonella mutagenicity assay. Mutat Res Genet Toxicol 204: 203-206. http://dx.doi.org/10.1016/0165-1218(88)90090-0

Bosetti, C; Boffetta, P; La Vecchia, C. (2007). Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005 [Review]. Ann Oncol 18: 431-446. http://dx.doi.org/10.1093/annonc/mdl172

Boström, CE; Gerde, P; Hanberg, A; Jernström, B; Johansson, C; Kyrklund, T; Rannug, A; Törnqvist, M; Victorin, K; Westerholm, R. (2002). Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air [Review]. Environ Health Perspect 110 Suppl 3: 451-488.

Bouayed, J; Desor, F; Rammal, H; Kiemer, AK; Tybl, E; Schroeder, H; Rychen, G; Soulimani, R. (2009a). Effects of lactational exposure to benzo[alpha]pyrene (B[alpha]P) on postnatal neurodevelopment, neuronal receptor gene expression and behaviour in mice. Toxicology 259: 97-106. http://dx.doi.org/10.1016/j.tox.2009.02.010

Bouayed, J; Desor, F; Soulimani, R. (2009b). Subacute oral exposure to benzo[alpha]pyrene (B[alpha]P) increases aggressiveness and affects consummatory aspects of sexual behaviour in male mice. J Hazard Mater 169: 581-585. http://dx.doi.org/10.1016/j.jhazmat.2009.03.131

Bowman, ED; Rothman, N; Hackl, C; Santella, RM; Weston, A. (1997). Interindividual variation in the levels of certain urinary polycyclic aromatic hydrocarbon metabolites following medicinal exposure to coal tar ointment. Biomarkers 2: 321-327. http://dx.doi.org/10.1080/135475097231553

Briedé, JJ; Godschalk, RW; Emans, MT; De Kok, TM; Van Agen, E; Van Maanen, J; Van Schooten, FJ; Kleinjans, JC. (2004). In vitro and in vivo studies on oxygen free radical and DNA adduct formation in rat lung and liver during benzo[a]pyrene metabolism. Free Radic Res 38: 995-1002. http://dx.doi.org/10.1080/10715760400000976

Brooks, RA; Gooderham, NJ; Edwards, RJ; Boobis, AR; Winton, DJ. (1999). The mutagenicity of benzo[a]pyrene in mouse small intestine. Carcinogenesis 20: 109-114. http://dx.doi.org/10.1093/carcin/20.1.109

Bruce, WR; Heddle, JA. (1979). The mutagenic activity of 61 agents as determined by the micronucleus, Salmonella, and sperm abnormality assays. Can J Genet Cytol 21: 319-333.

Brune, H; Deutsch-Wenzel, RP; Habs, M; Ivankovic, S; Schmähl, D. (1981). Investigation of the tumorigenic response to benzo(a)pyrene in aqueous caffeine solution applied orally to Sprague-Dawley rats. J Cancer Res Clin Oncol 102: 153-157. http://dx.doi.org/10.1007/BF00410666

Buckley, TJ; Waldman, JM; Dhara, R; Greenberg, A; Ouyang, Z; Lioy, PJ. (1995). An assessment of a urinary biomarker for total human environmental exposure to benzo[a]pyrene. Int Arch Occup Environ Health 67: 257-266. http://dx.doi.org/10.1007/BF00409408

Burdick, AD; Davis, JW; Liu, KJ; Hudson, LG; Shi, H; Monske, ML; Burchiel, SW. (2003). Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Res 63: 7825-7833.

Burstyn, I; Kromhout, H; Johansen, C; Langard, S; Kauppinen, T; Shaham, J; Ferro, G; Boffetta, P. (2007). Bladder cancer incidence and exposure to polycyclic aromatic hydrocarbons among asphalt pavers. Occup Environ Med 64: 520-526. http://dx.doi.org/10.1136/oem.2006.029801

Burstyn, I; Kromhout, H; Partanen, T; Svane, O; Langård, S; Ahrens, W; Kauppinen, T; Stücker, I; Shaham, J; Heederik, D; Ferro, G; Heikkilä, P; Hooiveld, M; Johansen, C; Randem, BG; Boffetta, P. (2005). Polycyclic aromatic hydrocarbons and fatal ischemic heart disease. Epidemiology 16: 744-750. http://dx.doi.org/10.1097/01.ede.0000181310.65043.2f

Butler, JD; Butterworth, V; Kellow, SC; Robinson, HG. (1984). Some observations on the polycyclic aromatic hydrocarbon (PAH) content of surface soils in urban areas. Sci Total Environ 33: 75-85. http://dx.doi.org/10.1016/0048-9697(84)90382-6

Byczkowski, JZ; Kulkarni, AP. (1990). Lipid peroxidation-coupled co-oxygenation of benzo(a)pyrene and benzo(a)pyrene-7,8-dihydrodiol in human term placental microsomes. Placenta 11: 17-26.

Cal/EPA (California Environmental Protection Agency). (1994). Benzo[a]pyrene as a toxic air contaminant. Sacramento, CA. http://oehha.ca.gov/air/toxic_contaminants/html/benzo%5Ba%5Dpyrene.htm

Cal/EPA (California Environmental Protection Agency). (2010). Public health goals for chemicals in drinking water. Benzo(a)pyrene. http://oehha.ca.gov/water/phg/pdf/091610Benzopyrene.pdf

Calaf, G; Russo, J. (1993). Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483-492. http://dx.doi.org/10.1093/carcin/14.3.483

Carver, JH; Machado, ML; Macgregor, JA. (1986). Application of modified Salmonella/microsome prescreen to petroleum-derived complex mixtures and polynuclear aromatic hydrocarbons (PAH). Mutat Res Lett 174: 247-253. http://dx.doi.org/10.1016/0165-7992(86)90042-4

Casto, BC; Janosko, N; Dipaolo, JA. (1977). Development of a focus assay model for transformation of hamster cells in vitro by chemical carcinogens. Cancer Res 37: 3508-3515.

Casto, BC; Pieczynski, WJ; Janosko, N; Dipaolo, JA. (1976). Significance of treatment interval and DNA repair in the enhancement of viral transformation by chemical carcinogens and mutagens. Chem Biol Interact 13: 105-125.

Cavalieri, E; Rogan, E; Toth, B; Munhall, A. (1981). Carcinogenicity of the environmental pollutants cyclopenteno-[cd]pyrene and cyclopentano[cd]pyrene in mouse skin. Carcinogenesis 2: 277-281.

Cavalieri, EL; Higginbotham, S; Ramakrishna, NV; Devanesan, PD; Todorovic, R; Rogan, EG; Salmasi, S. (1991). Comparative dose-response tumorigenicity studies of dibenzo[alpha,l]pyrene versus 7,12-dimethylbenz[alpha]anthracene, benzo[alpha]pyrene and two dibenzo[alpha,l]pyrene dihydrodiols in mouse skin and rat mammary gland. Carcinogenesis 12: 1939-1944. http://dx.doi.org/10.1093/carcin/12.10.1939

Cavret, S; Laurent, C; Feidt, C; Laurent, F; Rychen, G. (2003). Intestinal absorption of 14C from 14C-phenanthrene, 14C-benzo[a]pyrene and 14C-tetrachlorodibenzo-para-dioxin: approaches with the Caco-2 cell line and with portal absorption measurements in growing pigs. Reprod Nutr Dev 43: 145-154. http://dx.doi.org/10.1051/md:2003014

Chakradeo, PP; Kayal, JJ; Bhide, SV. (1993). Effect of benzo(a)pyrene and methyl(acetoxymethyl) nitrosamine on thymidine uptake and induction of aryl hydrocarbon hydroxylase activity in human fetal oesophageal cells in culture. Cell Biol Int 17: 671-676. http://dx.doi.org/10.1006/cbir.1993.1117

Chakravarti, D; Pelling, JC; Cavalieri, EL; Rogan, EG. (1995). Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic sites. PNAS 92: 10422-10426.

ChemIDplus. (2012). Benzo(a)pyrene [Database]. Bethesda, MD: National Library of Medicine. Retrieved from http://chem.sis.nlm.nih.gov/chemidplus

Chen, C; Tang, Y; Jiang, X; Qi, Y; Cheng, S; Qiu, C; Peng, B; Tu, B. (2012). Early postnatal benzo(a)pyrene exposure in Sprague-Dawley rats causes persistent neurobehavioral impairments that emerge postnatally and continue into adolescence and adulthood. Toxicol Sci 125: 248-261. http://dx.doi.org/10.1093/toxsci/kfr265

Chen, G; Gingerich, J; Soper, L; Douglas, GR; White, PA. (2010). Induction of lacZ mutations in MutaMouse primary hepatocytes. Environ Mol Mutagen 51: 330-337. http://dx.doi.org/10.1002/em.20540

Chen, L; Devanesan, PD; Higginbotham, S; Ariese, F; Jankowiak, R; Small, GJ; Rogan, EG; Cavalieri, EL. (1996). Expanded analysis of benzo[a]pyrene-DNA adducts formed in vitro and in mouse skin: their significance in tumor initiation. Chem Res Toxicol 9: 897-903. http://dx.doi.org/10.1021/tx960004a

Chen, S; Nguyen, N; Tamura, K; Karin, M; Tukey, RH. (2003). The role of the Ah receptor and p38 in benzo[a]pyrene-7,8-dihydrodiol and benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced apoptosis. J Biol Chem 278: 19526-19533. http://dx.doi.org/10.1074/jbc.M300780200

Chen, X; An, H; Ao, L; Sun, L; Liu, W; Zhou, Z; Wang, Y; Cao, J. (2011). The combined toxicity of dibutyl phthalate and benzo(a)pyrene on the reproductive system of male Sprague Dawley rats in vivo. J Hazard Mater 186: 835-841. http://dx.doi.org/10.1016/j.jhazmat.2010.11.078

Chiazze, L; Watkins, DK; Amsel, J. (1991). Asphalt and risk of cancer in man [Review]. Br J Ind Med 48: 538-542.

Choi, JY; Lee, KM; Cho, SH; Kim, SW; Choi, HY; Lee, SY; Im, HJ; Yoon, KJ; Choi, H; Choi, I; Hirvonen, A; Hayes, RB; Kang, D. (2003). CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13: 349-355. http://dx.doi.org/10.1097/01.fpc.0000054096.48725.25

Choi, S; Nishikawa, M; Sakoda, A; Sakai, Y. (2004). Feasibility of a simple double-layered coculture system incorporating metabolic processes of the intestine and liver tissue: application to the analysis of benzo[a]pyrene toxicity. Toxicol In Vitro 18: 393-402. http://dx.doi.org/10.1016/j.tiv.2003.09.010

Chouroulinkov, I; Gentil, A; Guerin, M. (1967). [Study of the carcinogenic activity of 9,10-dimethyl-benzanthracene and of 3,4-benzopyrene given orally]. Bull Cancer 54: 67-78.

Chuang, HY; Lee, E; Liu, YT; Lee, D; Ideker, T. (2007). Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140. http://dx.doi.org/10.1038/msb4100180

Chung, JY; Kim, JY; Kim, WR; Lee, SG; Kim, YJ; Park, JE; Hong, YP; Chun, YJ; Park, YC; Oh, S; Yoo, KS; Yoo, YH; Kim, JM. (2007). Abundance of aryl hydrocarbon receptor potentiates benzo[a]pyrene-induced apoptosis in Hepa1c1c7 cells via CYP1A1 activation. Toxicology 235: 62-72. http://dx.doi.org/10.1016/j.tox.2007.03.013

Chung, JY; Kim, YJ; Kim, JY; Lee, SG; Park, JE; Kim, WR; Yoon, YD; Yoo, KS; Yoo, YH; Kim, JM. (2011). Benzo[a]pyrene reduces testosterone production in rat Leydig cells via a direct disturbance of testicular steroidogenic machinery. Environ Health Perspect 119: 1569-1574. http://dx.doi.org/10.1289/ehp.1003391

Clark, CR; Burnett, DM; Parker, CM; Arp, EW; Swanson, MS; Minsavage, GD; Kriech, AJ; Osborn, LV; Freeman, JJ; Barter, RA; Newton, PE; Beazley, SL; Stewart, CW. (2011). Asphalt fume dermal carcinogenicity potential: I. Dermal carcinogenicity evaluation of asphalt (bitumen) fume condensates. Regul Toxicol Pharmacol 61: 9-16. http://dx.doi.org/10.1016/j.yrtph.2011.04.003

Clement Associates, Inc, . (1990). Comparative potency approach for estimation of the total cancer risk associated with exposures to mixtures of polycyclic aromatic hydrocarbons in the environment: Appendices.

Clive, D; Johnson, KO; Spector, JF; Batson, AG; Brown, MM. (1979). Validation and characterization of the L5178Y/TK+/- mouse lymphoma mutagen assay system. Mutat Res 59: 61-108.

Cohen, GM; Haws, SM; Moore, BP; Bridges, JW. (1976). Benzo(a)pyren-3-yl hydrogen sulphate, a major ethyl acetate-extractable metabolite of benzo(a)pyrene in human, hamster and

rat lung cultures. Biochem Pharmacol 25: 2561-2570. http://dx.doi.org/10.1016/0006-2952(76)90510-4

Colapietro, AM; Goodell, AL; Smart, RC. (1993). Characterization of benzo[a]pyrene-initiated mouse skin papillomas for Ha-ras mutations and protein kinase C levels. Carcinogenesis 14: 2289-2295. http://dx.doi.org/10.1093/carcin/14.11.2289

Conney, AH; Chang, RL; Jerina, DM; Wei, SJ. (1994). Studies on the metabolism of benzo[a]pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite [Review]. Drug Metab Rev 26: 125-163. http://dx.doi.org/10.3109/03602539409029788

Cook, JW; Hewett, CL; Hieger, I. (1933). 106. The isolation of a cancer-producing hydrocarbon from coal tar. Parts I, II, and III. J Chem Soc395. http://dx.doi.org/10.1039/JR9330000395

Cooper, AR; Moley, KH. (2008). Maternal tobacco use and its preimplantation effects on fertility: More reasons to stop smoking [Review]. Seminars in Reproductive Medicine 26: 204-212. http://dx.doi.org/10.1055/s-2008-1042959

Cosma, GN; Jamasbi, R; Marchok, AC. (1988). Growth inhibition and DNA damage induced by benzo[a]pyrene and formaldehyde in primary cultures of rat tracheal epithelial cells. Mutat Res 201: 161-168. http://dx.doi.org/10.1016/0027-5107(88)90122-4

Cosma, GN; Marchok, AC. (1988). Benzo[a]pyrene- and formaldehyde-induced DNA damage and repair in rat tracheal epithelial cells. Toxicology 51: 309-320. http://dx.doi.org/10.1016/0300-483X(88)90159-X

Craig-Holmes, A; Shaw, M. (1977). Effects of six carcinogens on SCE frequency and cell kinetics in cultured human lymphocytes. Mutat Res Environ Mutagen Relat Subj 46: 375-384. http://dx.doi.org/10.1016/0165-1161(77)90014-0

Crespi, CL; Altman, JD; Marletta, MA. (1985). Xenobiotic metabolism and mutation in a human lymphoblastoid cell line. Chem Biol Interact 53: 257-271.

Crofton-Sleigh, C; Doherty, A; Ellard, S; Parry, EM; Venitt, S. (1993). Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. Mutagenesis 8: 363-372. http://dx.doi.org/10.1093/mutage/8.4.363

Crowell, SR; Amin, SG; Anderson, KA; Krishnegowda, G; Sharma, AK; Soelberg, JJ; Williams, DE; Corley, RA. (2011). Preliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodents. Toxicol Appl Pharmacol 257: 365-376. http://dx.doi.org/10.1016/j.taap.2011.09.020

Culp, SJ; Gaylor, DW; Sheldon, WG; Goldstein, LS; Beland, FA. (1998). A comparison of the tumors induced by coal tar and benzo[a]pyrene in a 2-year bioassay. Carcinogenesis 19: 117-124.

Culp, SJ; Warbritton, AR; Smith, BA; Li, EE; Beland, FA. (2000). DNA adduct measurements, cell proliferation and tumor mutation induction in relation to tumor formation in B6C3F1 mice fed coal tar or benzo[a]pyrene. Carcinogenesis 21: 1433-1440. http://dx.doi.org/10.1093/carcin/21.7.1433

Dahl, AR; Coslett, DS; Bond, JA; Hesseltine, GR. (1985). Metabolism of benzo[a]pyrene on the nasal mucosa of Syrian hamsters: comparison to metabolism by other extrahepatic

tissues and possible role of nasally produced metabolites in carcinogenesis. J Natl Cancer Inst 75: 135-139.

Danheiser, SL; Liber, HL; Thilly, WG. (1989). Long-term, low-dose benzo[a]pyrene-induced mutation in human lymphoblasts competent in xenobiotic metabolism. Mutat Res 210: 143-147. http://dx.doi.org/10.1016/0027-5107(89)90053-5

Das, M; Asokan, P; Don, PS; Krueger, GG; Bickers, DR; Mukhtar, H. (1986). Carcinogen metabolism in human skin grafted onto athymic nude mice: a model system for the study of human skin carcinogenesis. Biochem Biophys Res Commun 138: 33-39.

Davidson, GE; Dawson, GW. (1976). Chemically induced presumed somatic mutations in the mouse. Mutat Res 38: 151-154.

Davis, S; Meltzer, PS. (2007). GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. 23: 1846-1847. http://dx.doi.org/10.1093/bioinformatics/btm254

De Flora, S; D'Agostini, F; Izzotti, A; Balansky, R. (1991). Prevention by N-acetylcysteine of benzo[a]pyrene clastogenicity and DNA adducts in rats. Mutat Res 250: 87-93. http://dx.doi.org/10.1016/0027-5107(91)90165-K

De Jong, WH; Kroese, ED; Vos, JG; Van Loveren, H. (1999). Detection of immunotoxicity of benzo[a]pyrene in a subacute toxicity study after oral exposure in rats. Toxicol Sci 50: 214-220. http://dx.doi.org/10.1093/toxsci/50.2.21

de Raat, WK. (1979). Comparison of the induction by cigarette smoke condensates of sister-chromatid exchanges in Chinese hamster cells and of mutations in Salmonella typhimurium. Mutat Res 66: 253-259.

Dean, BJ. (1981). Activity of 27 coded compounds in the RL1 chromosome assay. In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 570-579). New York, NY: Elsevier/North-Holland.

Dean, JH; Luster, MI; Boorman, GA; Lauer, LD; Leubke, RW; Lawson, L. (1983). Selective immunosuppression resulting from exposure to the carcinogenic congener of benzopyrene in B6C3F1 mice. Clin Exp Immunol 52: 199-206.

Dean, SW; Coates, A; Brooks, TM; Burlinson, B. (1998). Benzo[a]pyrene site of contact mutagenicity in skin of MutaTM Mouse [Letter]. Mutagenesis 13: 515-518. http://dx.doi.org/10.1093/mutage/13.5.515

Dere, E; Lo, R; Celius, T; Matthews, J; Zacharewski, TR. (2011). Integration of genome-wide computation DRE search, AhR ChIP-chip and gene expression analyses of TCDD-elicited responses in the mouse liver. BMC Genomics 12: 365. http://dx.doi.org/10.1186/1471-2164-12-365

Dertinger, SD; Lantum, HB; Silverstone, AE; Gasiewicz, TA. (2000). Effect of 3'-methoxy-4'-nitroflavone on benzo[a]pyrene toxicity: Aryl hydrocarbon receptor-dependent and -independent mechanisms. Biochem Pharmacol 60: 189-196. http://dx.doi.org/10.1016/S0006-2952(00)00314-2

Dertinger, SD; Nazarenko, DA; Silverstone, AE; Gasiewicz, TA. (2001). Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo. Carcinogenesis 22: 171-177. http://dx.doi.org/10.1093/carcin/22.1.171

Deutsch, J; Vatsis, KP; Coon, MJ; Leutz, JC; Gelboin, HV. (1979). Catalytic activity and stereoselectivity of purified forms of rabbit liver microsomal cytochrome P-450 in the oxygenation of the (-) and (+) enantiomers of trans-7,8-dihydroxy-7,8-dihydrobenzo[alpha]pyrene. Mol Pharmacol 16: 1011-1018.

Diamond, L; Kruszewski, F; Aden, DP; Knowles, BB; Baird, WM. (1980). Metabolic activation of benzo[a]pyrene by a human hepatoma cell line. Carcinogenesis 1: 871-875. http://dx.doi.org/10.1093/carcin/1.10.871

Dipaolo, JA; Donovan, P; Nelson, R. (1969). Quantitative studies of in vitro transformation by chemical carcinogens. J Natl Cancer Inst 42: 867-874.

Dipaolo, JA; Donovan, PJ; Nelson, RL. (1971). X-irradiation enhancement of transformation by benzo(a)pyrene in hamster embryo cells. PNAS 68: 1734-1737.

Doll, R. (1971). The age distribution of cancer: Implication for models of carcinogenesis. Journal of the Royal Statistical Society Series A 134: 133-166.

Dreij, K; Sundberg, K; Johansson, AS; Nordling, E; Seidel, A; Persson, B; Mannervik, B; Jernström, B. (2002). Catalytic activities of human alpha class glutathione transferases toward carcinogenic dibenzo[a,l]pyrene diol epoxides. Chem Res Toxicol 15: 825-831. http://dx.doi.org/10.1021/tx025519i

Dunkel, VC; Pienta, RJ; Sivak, A; Traul, KA. (1981). Comparative neoplastic transformation responses of Balb/3T3 cells, Syrian hamster embryo cells, and Rauscher murine leukemia virus-infected Fischer 344 rat embryo cells to chemical compounds. J Natl Cancer Inst 67: 1303-1312.

EC (European Commission). (2002). Opinion of the scientific committee on food on the risks to human health of polycyclic aromatic hydrocarbons in food. European Commission, Scientific Committee on Food.

Eckel, JE; Gennings, C; Therneau, TM; Burgoon, LD; Boverhof, DR; Zacharewski, TR. (2005). Normalization of two-channel microarray experiments: a semiparametric approach. Bioinformatics 21: 1078-1083. http://dx.doi.org/10.1093/bioinformatics/bti105

Egert, G; Greim, H. (1976). Formation of mutagenic N-nitroso compounds from the pesticides prometryne, dodine and carbaryl in the presence of nitrite at pH 1. Mutat Res 37: 179-186. http://dx.doi.org/10.1016/0027-5107(76)90031-2

Ein-Dor, L; Kela, I; Getz, G; Givol, D; Domany, E. (2005). Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171-178. http://dx.doi.org/10.1093/bioinformatics/bth469

El-Bayoumy, K. (1985). Effects of organoselenium compounds on induction of mouse forestomach tumors by benzo(a)pyrene. Cancer Res 45: 3631-3635.

El-Bayoumy, K; Hecht, SS; Hoffmann, D. (1982). Comparative tumor initiating activity on mouse skin of 6-nitrobenzo[a]pyrene, 6-nitrochrysene, 3-nitroperylene, 1-nitropyrene and their parent hydrocarbons. Cancer Lett 16: 333-337. http://dx.doi.org/10.1016/0304-3835(82)90015-5

Eling, T; Curtis, J; Battista, J; Marnett, LJ. (1986). Oxidation of (+)-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by mouse keratinocytes: evidence for peroxyl radical- and monoxygenase-dependent metabolism. Carcinogenesis 7: 1957-1963.

Emmett, EA; Bingham, EM; Barkley, W. (1981). A carcinogenic bioassay of certain roofing materials. Am J Ind Med 2: 59-64. http://dx.doi.org/10.1002/ajim.4700020110

Emura, M; Mohr, U; Riebe, M; Aufderheide, M; Dungworth, DL. (1987). Predisposition of cloned fetal hamster lung epithelial cells to transformation by a precarcinogen, benzo(a)pyrene, using growth hormone supplementation and collagen gel substratum. Cancer Res 47: 1155-1160.

Emura, M; Richter-Reichhelm, HB; Schneider, P; Mohr, U. (1980). Sensitivity of Syrian golden hamster fetal lung cells to benzo[a]pyrene and other polycyclic hydrocarbons in vitro. Toxicology 17: 149-155. http://dx.doi.org/10.1016/0300-483X(80)90087-6

Epler, JL; Winton, W; Ho, T; Larimer, FW; Rao, TK; Hardigree, AA. (1977). Comparative mutagenesis of quinolines [Review]. Mutat Res 39: 285-296. http://dx.doi.org/10.1016/0165-1110(77)90009-4

EU (European Union). (2005). Directive 2004/107/EC of the European Parliament and of the council of 15 December 2004 relating to arsenic, cadmium, mercury, nickel and polycyclic aromatic hydrocarbons in ambient air. Official Journal of the European Union 23: 3-16.

Everall, JD; Dowd, PM. (1978). Influence of environmental factors excluding ultra violet radiation on the incidence of skin cancer. Bull Cancer 65: 241-247.

Fahmy, MJ; Fahmy, OG. (1980). Altered control of gene activity in the soma by carcinogens. Mutat Res 72: 165-172. http://dx.doi.org/10.1016/0027-5107(80)90234-1

Falco, G; Domingo, JL; Llobet, JM; Teixido, A; Casas, C; Muller, L. (2003). Polycyclic aromatic hydrocarbons in foods: Human exposure through the diet in Catalonia, Spain. J Food Prot 66: 2325-2331.

Fang, JL; Lazarus, P. (2004). Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 13: 102-109.

Faraonio, R; Vergara, P; Di Marzo, D; Pierantoni, MG; Napolitano, M; Russo, T; Cimino, F. (2006). p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281: 39776-39784. http://dx.doi.org/10.1074/jbc.M605707200

Fedorenko, Z; Yansheva, N. (1967). [Experimental reproduction of tumors of the antral part of the stomach in mice by administration of various dose of 3,4-benzpyrene]. Gig Sanit 32: 168-173.

Feldman, G; Remsen, J; Shinohara, K; Cerutti, P. (1978). Excisability and persistence of benzo(a)pyrene DNA adducts in epithelioid human lung cells. Nature 274: 796-798.

Feron, VJ; de Jong, D; Emmelot, P. (1973). Letter: Dose-response correlation for the induction of respiratory-tract tumours in Syrian golden hamsters by intratracheal instillations of benzo(a)pyrene. Eur J Cancer 9: 387-390.

Feron, VJ; Kruysse, A. (1978). Effects of exposure to furfural vapour in hamsters simultaneously treated with benzo[alpha] pyrene or diethylnitrosamine. Toxicology 11: 127-144.

Field, WE; Roe, FJ. (1965). Tumor promotion in the forestomach epithelium of mice by oral administration of citrus oils. J Natl Cancer Inst 35: 771-787.

ED_006137A_00009570-00301

Flowers-Geary, L; Bleczinki, W; Harvey, RG; Penning, TM. (1996). Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon ortho-quinones produced by dihydrodiol dehydrogenase. Chem Biol Interact 99: 55-72. http://dx.doi.org/10.1016/0009-2797(95)03660-1

Flowers-Geary, L; Harvey, RG; Penning, TM. (1993). Cytotoxicity of polycyclic aromatic hydrocarbon o-quinones in rat and human hepatoma cells. Chem Res Toxicol 6: 252-260. http://dx.doi.org/10.1021/tx00033a002

Flowers, L; Bleczinski, WF; Burczynski, ME; Harvey, RG; Penning, TM. (1996). Disposition and biological activity of benzo[a]pyrene-7,8-dione. A genotoxic metabolite generated by dihydrodiol dehydrogenase. Biochemistry 35: 13664-13672. http://dx.doi.org/10.1021/bi961077w

Flowers, L; Ohnishi, ST; Penning, TM. (1997). DNA strand scission by polycyclic aromatic hydrocarbon o-quinones: role of reactive oxygen species, Cu(II)/Cu(I) redox cycling, and o-semiquinone anion radicals. Biochemistry 36: 8640-8648. http://dx.doi.org/10.1021/bi970367p

Fortunel, NO; Otu, HH; Ng, HH; Chen, J; Mu, X; Chevassut, T; Li, X; Joseph, M; Bailey, C; Hatzfeld, JA; Hatzfeld, A; Usta, F; Vega, VB; Long, PM; Libermann, TA; Lim, B. (2003). Comment on " 'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature&quot [Letter]. Science 302: 393; author reply 393. http://dx.doi.org/10.1126/science.1086384

Foth, H; Kahl, R; Kahl, GF. (1988). Pharmacokinetics of low doses of benzo[a]pyrene in the rat. Food Chem Toxicol 26: 45-51. http://dx.doi.org/10.1016/0278-6915(88)90040-3

Fowler, P; Whitwell, J; Jeffrey, L; Young, J; Smith, K; Kirkland, D. (2010). Cadmium chloride, benzo[a]pyrene and cyclophosphamide tested in the in vitro mammalian cell micronucleus test (MNvit) in the human lymphoblastoid cell line TK6 at Covance laboratories, Harrogate UK in support of OECD draft Test Guideline 487. Mutat Res 702: 171-174. http://dx.doi.org/10.1016/j.mrgentox.2010.02.016

Friesen, MC; Demers, PA; Spinelli, JJ; Eisen, EA; Lorenzi, MF; Le, ND. (2010). Chronic and acute effects of coal tar pitch exposure and cardiopulmonary mortality among aluminum smelter workers. Am J Epidemiol 172: 790-799. http://dx.doi.org/10.1093/aje/kwq208

Gangar, SC; Sandhir, R; Rai, DV; Koul, A. (2006). Preventive effects of Azadirachta indica on benzo(a)pyrene-DNA adduct formation in murine forestomach and hepatic tissues. Phytother Res 20: 889-895. http://dx.doi.org/10.1002/ptr.1967

Gao, M; Li, Y; Sun, Y; Shah, W; Yang, S; Wang, Y; Long, J. (2011). Benzo[a]pyrene exposure increases toxic biomarkers and morphological disorders in mouse cervix. Basic & Clinical Pharmacology & Toxicology Online Pharmacology Online 109: 398-406. http://dx.doi.org/10.1111/j.1742-7843.2011.00755.x

Gao, N; Aidoo, A; Heflich, RH. (1991). Analysis of rat lymphocyte activation of benzo[a]pyrene, 2-acetylaminofluorene, and several of their metabolites to mutagenic and DNA-damaging species in vitro. Teratog Carcinog Mutagen 11: 65-76.

Garçon, G; Gosset, P; Garry, S; Marez, T; Hannothiaux, MH; Shirali, P. (2001a). Pulmonary induction of proinflammatory mediators following the rat exposure to benzo(a)pyrene-coated onto Fe2O3 particles. Toxicol Lett 121: 107-117.

Garçon, G; Zerimech, F; Hannothiaux, M; Gosset, P; Martin, A; Marez, T; Shirali, P. (2001b). Antioxidant defense disruption by polycyclic aromatic hydrocarbons-coated onto Fe(2)O(3) particles in human lung cells (A549). Toxicology 166: 129-137.

Garry, S; Nesslany, F; Aliouat, E; Haguenoer, JM; Marzin, D. (2003a). Assessment of genotoxic effect of benzo[a]pyrene in endotracheally treated rat using the comet assay. Mutat Res 534: 33-43.

Garry, S; Nesslany, F; Aliouat, E; Haguenoer, JM; Marzin, D. (2003b). Hematite (Fe(2)O(3)) enhances benzo[a]pyrene genotoxicity in endotracheally treated rat, as determined by Comet Assay. Mutat Res 538: 19-29. http://dx.doi.org/10.1016/S1383-5718(03)00082-2

Gelboin, HV. (1980). Benzo[alpha]pyrene metabolism, activation and carcinogenesis: Role and regulation of mixed-function oxidases and related enzymes [Review]. Physiol Rev 60: 1107-1166.

Generoso, WM; Cain, KT; Hellwig, CS; Cacheiro, NL. (1982). Lack of association between induction of dominant-lethal mutations and induction of heritable translocations with benzo[a]pyrene in postmeiotic germ cells of male mice. Mutat Res 94: 155-163.

Generoso, WM; Cain, KT; Krishna, M; Huff, SW. (1979). Genetic lesions induced by chemicals in spermatozoa and spermatids of mice are repaired in the egg. PNAS 76: 435-437.

Gerde, P; Muggenburg, BA; Lundborg, M; Dahl, AR. (2001). The rapid alveolar absorption of diesel soot-adsorbed benzo[a]pyrene: bioavailability, metabolism and dosimetry of an inhaled particle-borne carcinogen. Carcinogenesis 22: 741-749.

Gerde, P; Muggenburg, BA; Sabourin, PA; Harkema, JR; Hotchkiss, JA; Hoover, MD; Henderson, RF. (1993). Disposition of polycyclic aromatic hydrocarbons in the respiratory tract of the beagle dog: II the conducting airways. Toxicol Appl Pharmacol 121: 319-327.

Gibbs, GW. (1985). Mortality of aluminum reduction plant workers, 1950 through 1977. J Occup Environ Med 27: 761-770.

Ginsberg, G; Hattis, D; Sonawane, B. (2004). Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants [Review]. Toxicol Appl Pharmacol 198: 164-183. http://dx.doi.org/10.1016/j.taap.2003.10.010

Ginsberg, GL; Atherholt, TB. (1989). Transport of DNA-adducting metabolites in mouse serum following benzo[a]pyrene administration. Carcinogenesis 10: 673-679.

Glatt, H; Bücker, M; Platt, KL; Oesch, F. (1985). Host-mediated mutagenicity experiments with benzo[a]pyrene and two of its metabolites. Mutat Res 156: 163-169. http://dx.doi.org/10.1016/0165-1218(85)90059-X

Glatt, H; Seidel, A; Ribeiro, O; Kirkby, C; Hirom, P; Oesch, F. (1987). Metabolic activation to a mutagen of 3-hydroxy-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene, a secondary metabolite of benzo[a]pyrene. Carcinogenesis 8: 1621-1627. http://dx.doi.org/10.1093/carcin/8.11.1621

Glatt, HR; Oesch, F; Frigerio, A; Garattini, S. (1975). Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity. Int J Cancer 16: 787-797. http://dx.doi.org/10.1002/ijc.2910160511

GLC (Great Lakes Commission). (2007). Assessment of benzo(a)pyrene air emissions in the Great Lakes region: A report of the Great Lakes Regional Toxic Air Emissions Inventory Steering Committee. Ann Arbor, MI.

Godschalk, RW; Ostertag, JU; Zandsteeg, AM; Van Agen, B; Neuman, HA; Van Straaten, H; Van Schooten, FJ. (2001). Impact of GSTM1 on aromatic-DNA adducts and p53 accumulation in human skin and lymphocytes. Pharmacogenetics 11: 537-543.

Graem, N. (1986). Epidermal changes following application of 7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate to human skin transplanted to nude mice studied with histological species markers. Cancer Res 46: 278-284.

Greb, W; Strobel, R; Röhrborn, G. (1980). Transformation of BHK 21/CL 13 cells by various polycyclic aromatic hydrocarbons using the method of Styles. Toxicol Lett 7: 143-148.

Grimmer, G; Brune, H; Deutsch-Wenzel, R; Dettbarn, G; Misfeld, J. (1984). Contribution of polycyclic aromatic hydrocarbons to the carcinogenic impact of gasoline engine exhaust condensate evaluated by implantation into the lungs of rats. J Natl Cancer Inst 72: 733-739.

Grimmer, G; Brune, H; Deutsch-Wenzel, R; Naujack, KW; Misfeld, J; Timm, J. (1983). On the contribution of polycyclic aromatic hydrocarbons to the carcinogenic impact of automobile exhaust condensate evaluated by local application onto mouse skin. Cancer Lett 21: 105-113.

Grimmer, G; Dettbarn, G; Naujack, K, -W; Jacob, J. (1994). Relationship between inhaled PAH and urinary excretion of phenanthrene, pyrene and benzo(a)pyrene metabolites in coke plant workers. Polycycl Aromat Compd 5: 269-277. http://dx.doi.org/10.1080/10406639408015180

Gross, P; Tolker, E; Babyak, MA; Kaschak, M. (1965). Experimental lung cancer in hamsters: repetitive intratracheal applications of two carcinogenic hydrocarbons. Arch Environ Occup Health 11: 59-65.

Grova, N; Schroeder, H; Farinelle, S; Prodhomme, E; Valley, A; Muller, CP. (2008). Sub-acute administration of benzo[a]pyrene (B[a]P) reduces anxiety-related behaviour in adult mice and modulates regional expression of N-methyl-D-aspartate (NMDA) receptors genes in relevant brain regions. Chemosphere 73: S295-S302. http://dx.doi.org/10.1016/j.chemosphere.2007.12.037

Grover, PL. (1986). Pathways involved in the metabolism and activation of polycyclic hydrocarbons [Review]. Xenobiotica 16: 915-931. http://dx.doi.org/10.3109/00498258609038974

Gu, J; Horikawa, Y; Chen, M; Dinney, CP; Wu, X. (2008). Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 17: 2445-2450. http://dx.doi.org/10.1158/1055-9965.EPI-07-2890

Gunter, MJ; Divi, RL; Kulldorff, M; Vermeulen, R; Haverkos, KJ; Kuo, MM; Strickland, P; Poirier, MC; Rothman, N; Sinha, R. (2007). Leukocyte polycyclic aromatic hydrocarbon-DNA adduct formation and colorectal adenoma. Carcinogenesis 28: 1426-1429. http://dx.doi.org/10.1093/carcin/bgm022

Gupta, RS; Goldstein, S. (1981). Mutagen testing in the human fibroblast diphtheria toxin resistance (HF Dipr) system. In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 614-625). New York, NY: Elsevier/North-Holland.

Gupta, RS; Singh, B. (1982). Mutagenic responses of five independent genetic loci in CHO cells to a variety of mutagens. Development and characteristics of a mutagen screening system based on selection for multiple drug-resistant markers. Mutat Res 94: 449-466.

Gyorffy, E; Anna, L; Kovács, K; Rudnai, P; Schoket, B. (2008). Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts [Review]. Mutagenesis 23: 1-18. http://dx.doi.org/10.1093/mutage/gem043

Habs, M; Jahn, SA; Schmähl, D. (1984). Carcinogenic activity of condensate from coloquint seeds (Citrullus colocynthis) after chronic epicutaneous administration to mice. J Cancer Res Clin Oncol 108: 154-156. http://dx.doi.org/10.1007/BF00390988

Habs, M; Schmähl, D; Misfeld, J. (1980). Local carcinogenicity of some environmentally relevant polycyclic aromatic hydrocarbons after lifelong topical application to mouse skin. Arch Geschwulstforsch 50: 266-274.

Hackman, P; Hou, SM; Nyberg, F; Pershagen, G; Lambert, B. (2000). Mutational spectra at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in T-lymphocytes of nonsmoking and smoking lung cancer patients. Mutat Res 468: 45-61.

Hakura, A; Tsutsui, Y; Sonoda, J; Kai, J; Imade, T; Shimada, M; Sugihara, Y; Mikami, T. (1998). Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse). Mutat Res 398: 123-130. http://dx.doi.org/10.1016/S0027-5107(97)00248-0

Hall, M; Grover, PL. (1988). Stereoselective aspects of the metabolic activation of benzo[a]pyrene by human skin in vitro. Chem Biol Interact 64: 281-296.

Hammond, EC; Selikoff, IJ; Lawther, PL; Seidman, H. (1976). Inhalation of benzpyrene and cancer in man. Ann N Y Acad Sci 271: 116-124. http://dx.doi.org/10.1111/j.1749-6632.1976.tb23100.x

Hanelt, S; Helbig, R; Hartmann, A; Lang, M; Seidel, A; Speit, G. (1997). A comparative investigation of DNA adducts, DNA strand breaks and gene mutations induced by benzo[a]pyrene and (+/-)-anti-benzo[a]pyrene-7,8-diol 9,10-oxide in cultured human cells. Mutat Res 390: 179-188. http://dx.doi.org/10.1016/S0165-1218(97)00019-0

Hansen, ES. (1989). Cancer incidence in an occupational cohort exposed to bitumen fumes. Scand J Work Environ Health 15: 101-105.

Hansen, ES. (1991). Mortality of mastic asphalt workers. Scand J Work Environ Health 17: 20-24. http://dx.doi.org/10.5271/sjweh.1739

Hara, T; Nishikawa, T; Sui, H; Kawakami, K; Matsumoto, H; Tanaka, N. (2007). In vivo photochemical skin micronucleus test using a sunlight simulator: detection of 8-methoxypsoralen and benzo[a]pyrene in hairless mice. Mutat Res 631: 1-8. http://dx.doi.org/10.1016/j.mrgentox.2007.03.007

Harper, BL; Ramanujam, VM; Legator, MS. (1989). Micronucleus formation by benzene, cyclophosphamide, benzo(a)pyrene, and benzidine in male, female, pregnant female,

and fetal mice. Teratog Carcinog Mutagen 9: 239-252. http://dx.doi.org/10.1002/tcm.1770090406

Harrigan, JA; Mcgarrigle, BP; Sutter, TR; Olson, J. R. (2006). Tissue specific induction of cytochrome P450 (CYP) 1A1 and 1B1 in rat liver and lung following in vitro (tissue slice) and in vivo exposure to benzo(a)pyrene. Toxicol In Vitro 20: 426-438. http://dx.doi.org/10.1016/j.tiv.2005.08.015

Harrigan, JA; Vezina, CM; Mcgarrigle, BP; Ersing, N; Box, HC; Maccubbin, AE; Olson, J. R. (2004). DNA adduct formation in precision-cut rat liver and lung exposed to benzo[a]pyrene. Toxicol Sci 77: 307-314. http://dx.doi.org/10.1093/toxsci/kfh030

He, SL; Baker, R. (1991). Micronuclei in mouse skin cells following in vivo exposure to benzo[a]pyrene, 7,12-dimethylbenz[a]anthracene, chrysene, pyrene and urethane. Environ Mol Mutagen 17: 163-168. http://dx.doi.org/10.1002/em.2850170305

Health Canada. (1998). Environmental and workplace health. Benzo[a]pyrene. http://www.hc-sc.gc.ca/ewh-semt/pubs/water-eau/benzo_a_pyrene/index-eng.php

Health Canada. (2010). Guidelines for Canadian drinking water quality-summary table. Benzo[a]pyrene. http://www.hc-sc.gc.ca/ewh-semt/pubs/water-eau/2010-sum_guide-res_recom/index-eng.php#a14

Hecht, SS; Grabowski, W; Groth, K. (1979). Analysis of faeces for benzo[a]pyrene after consumption of charcoal-broiled beef by rats and humans. Food Cosmet Toxicol 17: 223-227.

Heidelberger, C; Freeman, AE; Pienta, RJ; Sivak, A; Bertram, JS; Casto, BC; Dunkel, VC; Francis, MW; Kakunaga, T; Little, JB; Schechtman, LM. (1983). Cell transformation by chemical agents--a review and analysis of the literature A report of the US Environmental Protection Agency Gene-Tox Program [Review]. DNA Repair 114: 283-385.

Hemminki, K; Dickey, C; Karlsson, S; Bell, D; Hsu, Y; Tsai, WY; Mooney, LA; Savela, K; Perera, FP. (1997). Aromatic DNA adducts in foundry workers in relation to exposure, life style and CYP1A1 and glutathione transferase M1 genotype. Carcinogenesis 18: 345-350. http://dx.doi.org/10.1093/carcin/18.2.345

Henry, MC; Port, CD; Bates, RR; Kaufman, DG. (1973). Respiratory tract tumors in hamsters induced by benzo(a)pyrene. Cancer Res 33: 1585-1592.

Hermann, M. (1981). Synergistic effects of individual polycyclic aromatic hydrocarbons on the mutagenicity of their mixtures. Mutat Res 90: 399-409. http://dx.doi.org/10.1016/0165-1218(81)90062-8

Herrold, KM; Dunham, LJ. (1962). Induction of carcinoma and papilloma of the Syrian hamster by intratracheal instillation of benzo[a]-pyrene. J Natl Cancer Inst 28: 467-491.

Higginbotham, S; Ramakrishna, NVS; Johansson, SL; Rogan, EG; Cavalieri, EL. (1993). Tumor-initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene at low doses in mouse skin. Carcinogenesis 14: 875-878. http://dx.doi.org/10.1093/carcin/14.5.875

Hirom, PC; Chipman, JK; Millburn, P; Pue, MA; Rydstrom, J; Montelius, J; Bengtsson, M. (1983). Enterohepatic circulation of the aromatic hydrocarbons benzo[a]pyrene and naphthalene. In J Rydstrom; J Montelius; M Bengtsson (Eds.), Extrahepatic drug

metabolism and chemical carcinogenesis (pp. 275-281). Amsterdam, The Netherlands: Elsvier Science Publishers.

Hoffmann, D; Rathkamp, G; Nesnow, S; Wynder, EL. (1972). Fluoranthenes: Quantitative determination in cigarette smoke, formation by pyrolysis, and tumor-initiating activity. J Natl Cancer Inst 49: 1165-1175.

Hogg, S. (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety [Review]. Pharmacol Biochem Behav 54: 21-30.

Hood, DB; Nayyar, T; Ramesh, A; Greenwood, M; Inyang, F. (2000). Modulation in the developmental expression profile of Sp1 subsequent to transplacental exposure of fetal rats to desorbed benzo[a]pyrene following maternal inhalation. Inhal Toxicol 12: 511-535. http://dx.doi.org/10.1080/089583700402897

Howard, P; Meylan, W. (1997). Handbook of physical properties of organic chemicals. Boca Raton, FL: Lewis Publishers.

HSDB (Hazardous Substances Data Bank). (2012). Benzo(a)pyrene [Database]. Bethesda, MD: National Library of Medicine. Retrieved from http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB

Hu, Z; Wells, PG. (2004). Human interindividual variation in lymphocyte UDP-glucuronosyltransferases as a determinant of in vitro benzo[a]pyrene covalent binding and cytotoxicity. Toxicol Sci 78: 32-40. http://dx.doi.org/10.1093/toxsci/kfh010

Huberman, E; Sachs, L; Yang, SK; Gelboin, HV. (1976). Identification of mutagenic metabolites of benzo[a]pyrene in mammalian cells. PNAS 73: 607-611.

Huh, N; Nemoto, N; Utakoji, T. (1982). Metabolic activation of benzo[a]pyrene, aflatoxin B1, and dimethylnitrosamine by a human hepatoma cell line. Mutat Res 94: 339-348.

Husgafvel-Pursiainen, K; Sorsa, M; Moller, M; Benestad, C. (1986). Genotoxicity and polynuclear aromatic hydrocarbon analysis of environmental tobacco smoke samples from restaurants. Mutagenesis 1: 287-292.

Hussain, M; Rae, J; Gilman, A; Kauss, P. (1998). Lifetime health risk assessment from exposure of recreational users to polycyclic aromatic hydrocarbons. Arch Environ Contam Toxicol 35: 527-531.

IARC (International Agency for Research on Cancer). (1973). Certain polycyclic aromatic hydrocarbons and heterocyclic compounds. (HEEP/74/11596). Lyon, France.

IARC (International Agency for Research on Cancer). (1983). Polynuclear aromatic compounds, part 1: Chemical, environmental and experimental data. Lyon, France: World Health Organization. http://monographs.iarc.fr/ENG/Monographs/vol32/volume32.pdf

IARC (International Agency for Research on Cancer). (2010). Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures [IARC Monograph] (pp. 1-853). Lyon, France. http://monographs.iarc.fr/ENG/Monographs/vol92/mono92.pdf

Inyang, F; Ramesh, A; Kopsombut, P; Niaz, MS; Hood, DB; Nyanda, AM; Archibong, AE. (2003). Disruption of testicular steroidogenesis and epididymal function by inhaled benzo(a)pyrene. Reprod Toxicol 17: 527-537.

IPCS (International Programme on Chemical Safety). (1998). Selected non-heterocyclic polycyclic aromatic hydrocarbons [WHO EHC]. In Environmental Health Criteria (pp. CHF

174). (CIS/00/00657). Geneva, Switzerland: World Health Organization. http://www.inchem.org/documents/ehc/ehc/ehc202.htm

Juhl, HJ; Schürer, CC; Bartram, CR; Kohl, FV; Melderis, H; von Wichert, P; Rüdiger, HW. (1978). Retinoids induce sister-chromatid exchanges in human diploid fibroblasts. Mutat Res 58: 317-320.

Jules, GE; Pratap, S; Ramesh, A; Hood, DB. (2012). In utero exposure to benzo(a)pyrene predisposes offspring to cardiovascular dysfunction in later-life. Toxicology 295: 56-67. http://dx.doi.org/10.1016/j.tox.2012.01.017

Kalina, I; Brezáni, P; Gajdosová, D; Binková, B; Salagovic, J; Habalová, V; Mracková, G; Dobiás, L; Srám, RJ. (1998). Cytogenetic monitoring in coke oven workers. Mutat Res 417: 9-17.

Kao, J; Patterson, FK; Hall, J. (1985). Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: an in vitro study with benzo[a]pyrene and testosterone. Toxicol Appl Pharmacol 81: 502-516.

Kappes, U; Schliemann-Willers, S; Bankova, L; Heinemann, C; Fischer, TW; Ziemer, M; Schubert, H; Norgauer, J; Fluhr, JW; Elsner, P. (2004). The quality of human skin xenografts on SCID mice: A noninvasive bioengineering approach. Br J Dermatol 151: 971-976. http://dx.doi.org/10.1111/j.1365-2133.2004.06191.x

Kawamura, Y; Kamata, E; Ogawa, Y; Kaneko, T; Uchiyama, S; Saito, Y. (1988). The effect of various foods on the intestinal absorption of benzo(a)pyrene in rats. Shokohin Eiseigaku Zasshi 29: 21-25.

Kazerouni, N; Sinha, R; Hsu, CH; Greenberg, A; Rothman, N. (2001). Analysis of 200 food items for benzo[a]pyrene and estimation of its intake in an epidemiologic study. Food Chem Toxicol 39: 423-436. http://dx.doi.org/10.1016/S0278-6915(00)00158-7

Ketkar, M; Reznik, G; Schneider, P; Mohr, U. (1978). Investigations on the carcinogenic burden by air pollution in man. Intratracheal instillation studies with benzo(a)pyrene in bovine serum albumin in Syrian hamsters. Cancer Lett 4: 235-239. http://dx.doi.org/10.1016/S0304-3835(78)94787-0

Kiefer, F; Cumpelik, O; Wiebel, FJ. (1988). Metabolism and cytotoxicity of benzo(a)pyrene in the human lung tumour cell line NCI-H322. Xenobiotica 18: 747-755. http://dx.doi.org/10.3109/00498258809041713

Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE. (2000). The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 19: 5498-5506. http://dx.doi.org/10.1038/sj.onc.1203945

Kim, IY; Hyun, CK. (2006). Comparative evaluation of the alkaline comet assay with the micronucleus test for genotoxicity monitoring using aquatic organisms. Ecotoxicol Environ Saf 64: 288-297. http://dx.doi.org/10.1016/j.ecoenv.2005.05.019

Kishikawa, N; Wada, M; Kuroda, N; Akiyama, S; Nakashima, K. (2003). Determination of polycyclic aromatic hydrocarbons in milk samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 789: 257-264. http://dx.doi.org/10.1016/S1570-0232(03)00066-7

Kleiner, HE; Vulimiri, SV; Hatten, WB; Reed, MJ; Nebert, DW; Jefcoate, CR; Digiovanni, J. (2004). Role of cytochrome p4501 family members in the metabolic activation of polycyclic

aromatic hydrocarbons in mouse epidermis. Chem Res Toxicol 17: 1667-1674. http://dx.doi.org/10.1021/tx049919c

Knafla, A; Petrovic, S; Richardson, M; Campbell, J; Rowat, C. (2011). Development and application of a skin cancer slope factor for exposures to benzo[a]pyrene in soil. Regul Toxicol Pharmacol 59: 101-110. http://dx.doi.org/10.1016/j.yrtph.2010.09.011

Knafla, A; Phillipps, KA; Brecher, RW; Petrovic, S; Richardson, M. (2006). Development of a dermal cancer slope factor for benzo[a]pyrene [Review]. Regul Toxicol Pharmacol 45: 159-168. http://dx.doi.org/10.1016/j.yrtph.2006.02.008

Knuckles, ME; Inyang, F; Ramesh, A. (2001). Acute and subchronic oral toxicities of benzo[a]pyrene in F-344 rats. Toxicol Sci 61: 382-388.

Kobayashi, N. (1975). Production of respiratory tract tumors in hamsters by benzo[a]pyrene. Cancer Sci 66: 311-315.

Kondraganti, SR; Fernandez-Salguero, P; Gonzalez, FJ; Ramos, KS; Jiang, W; Moorthy, B. (2003). Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo. Int J Cancer 103: 5-11. http://dx.doi.org/10.1002/ijc.10784

Koratkar, R; Das, UN; Sagar, PS; Ramesh, G; Padma, M; Kumar, GS; Vijay, K; Madhavi, N. (1993). Prostacyclin is a potent anti-mutagen. Prostaglandins Leukot Essent Fatty Acids 48: 175-184. http://dx.doi.org/10.1016/0952-3278(93)90107-8

Krewski, D; Crump, KS; Farmer, J; Gaylor, DW; Howe, R; Portier, C; Salsburg, D; Sielken, RL; Van Ryzin, J. (1983). A comparison of statistical methods for low dose extrapolation utilizing time-to-tumor data. Fundam Appl Toxicol 3: 140-160. http://dx.doi.org/10.1016/s0272-0590(83)80075-x

Kristensen, P; Eilertsen, E; Einarsdottir, E; Haugen, A; Skaug, V; Ovrebo, S. (1995). Fertility in mice after prenatal exposure to benzo[a]pyrene and inorganic lead. Environ Health Perspect 103: 588-590. http://dx.doi.org/10.1289/ehp.95103588

Kroese, ED; Muller, JJA; Mohn, GR; Dortant, PM; Wester, PW. (2001). Tumorigenic effects in Wistar rats orally administered benzo[a]pyrene for two years (gavage studies): Implications for human cancer risks associated with oral exposure to polycyclic aromatic hydrocarbons. (658603 010). Bilthoven, The Netherlands: National Institute for Public Health and the Environment (RIVM). http://www.rivm.nl/bibliotheek/rapporten/658603010.pdf

Kulka, U; Doehmer, J; Glatt, HR; Bauchinger, M. (1993a). Cytogenetic effects of promutagens in genetically engineered V79 Chinese hamster cells expressing cytochromes P450. Eur J Pharmacol 228: 299-304. http://dx.doi.org/10.1016/0926-6917(93)90064-W

Kulka, U; Paul, D; Bauchinger, M. (1993b). Development of short-term mutagenicity test systems in vitro: metabolic activation of indirectly acting mutagens by three immortal rat hepatocyte lines. Mutagenesis 8: 193-197. http://dx.doi.org/10.1093/mutage/8.3.193

Kunstler, K. (1983). Failure to induce tumors by intratracheal instillation of automobile exhaust condensate and fractions thereof in Syrian golden hamsters. Cancer Lett 18: 105-108. http://dx.doi.org/10.1016/0304-3835(83)90123-4

Lagoy, PK; Quirk, TC. (1994). Establishing generic remediation goals for the polycyclic aromatic hydrocarbons: Critical issues [Review]. Environ Health Perspect 102: 348-352.

Lavoie, EJ; Amin, S; Hecht, SS; Furuya, K; Hoffmann, D. (1982). Tumour initiating activity of dihydrodiols of benzo[b]fluoranthene, benzo[j]fluoranthene, and benzo[k]fluoranthene. Carcinogenesis 3: 49-52. http://dx.doi.org/10.1093/carcin/3.1.49

Lavoie, EJ; Bedenko, EV; Hirota, N; Hecht, SS; Hoffmann, D. (1979). A comparison of the mutagenicity, tumor-initiating activity and complete carcinogenicity of polynuclear aromatic hydrocarbons. In PW Jones; P Leber (Eds.), Polynuclear aromatic hydrocarbons (pp. 705-721). Ann Arbor, MI: Ann Arbor Science Publishers, Inc.

Leadon, SA; Stampfer, MR; Bartley, J. (1988). Production of oxidative DNA damage during the metabolic activation of benzo[a]pyrene in human mammary epithelial cells correlates with cell killing. PNAS 85: 4365-4368.

Leboeuf, RA; Kerckaert, GA; Aardema, MJ; Gibson, DP. (1990). Multistage neoplastic transformation of Syrian hamster embryo cells cultured at pH 6.70. Cancer Res 50: 3722-3729.

Lee, H; Lin, JY. (1988). Antimutagenic activity of extracts from anticancer drugs in Chinese medicine. Mutat Res 204: 229-234.

Lemieux, CL; Douglas, GR; Gingerich, J; Phonethepswath, S; Torous, DK; Dertinger, SD; Phillips, DH; Arlt, VM; White, PA. (2011). Simultaneous measurement of benzo[a]pyrene-induced Pig-a and lacZ mutations, micronuclei and DNA adducts in Muta Mouse. Environ Mol Mutagen 52: 756-765. http://dx.doi.org/10.1002/em.20688

Leng, SG; Zheng, YX; Pan, ZF; Niu, Y; Dai, YF; Wang, YW; Zhang, WZ; Xiao, J; Wang, ZX; Li, T; He, FS. (2004). [A study on the inherited susceptibility of chromosomal damage in peripheral blood lymphocytes among coke oven workers]. Zhonghua Yufang Yixue Zazhi 38: 94-98.

Levin, W; Wood, A; Chang, RL; Etal. (1982). Oxidative metabolism of polycyclic aromatic hydrocarbons to ultimate carcinogens [Review]. Drug Metab Rev 13: 555-580. http://dx.doi.org/10.3109/03602538209011087

Levin, W; Wood, AW; Wislocki, PG; Kapitulnik, J; Yagi, H; Jerina, DM; Conney, AH. (1977). Carcinogenicity of benzo-ring derivatives of benzo(a)pyrene on mouse skin. Cancer Res 37: 3356-3361.

Li, D; Day, RS; Bondy, ML; Sinha, R; Nguyen, NT; Evans, DB; Abbruzzese, JL; Hassan, MM. (2007). Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 655-661. http://dx.doi.org/10.1158/1055-9965.EPI-06-0993

Li, D; Firozi, PF; Wang, LE; Bosken, CH; Spitz, MR; Hong, WK; Wei, Q. (2001). Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. Cancer Res 61: 1445-1450.

Li, P; Li, X; Stagnitti, F; Zhang, H; Lin, X; Zang, S; Zhuo, J; Xiong, X. (2009). Studies on the sources of benzo[a]pyrene in grain and aboveground tissues of rice plants. J Hazard Mater 162: 463-468. http://dx.doi.org/10.1016/j.jhazmat.2008.05.064

Likhachev, AJ; Beniashvili, DS, h; Bykov, VJ; Dikun, PP; Tyndyk, ML; Savochkina, IV; Yermilov, VB; Zabezhinski, MA. (1992). Relevance of quantitation of benzo(a)pyrene metabolites in animal excretes to evaluate individual human cancer risk [Review]. Prog Clin Biol Res 374: 435-452.

Lin, P; Hsueh, YM; Ko, JL; Liang, YF; Tsai, KJ; Chen, CY. (2003). Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 40: 123-129.

Lindelöf, B; Sigurgeirsson, B. (1993). PUVA and cancer: a case-control study. Br J Dermatol 129: 39-41. http://dx.doi.org/10.1111/j.1365-2133.1993.tb03308.x

Little, JB; Vetrovs, H. (1988). Studies of ionizing radiation as a promoter of neoplastic transformation in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 53: 661-666.

Lo Jacono, F; Stecca, C; Duverger, M. (1992). Mutagenic activation of benzo[a]pyrene by human red blood cells. Mutat Res 268: 21-26. http://dx.doi.org/10.1016/0027-5107(92)90078-G

Lo, R; Celius, T; Forgacs, AL; Dere, E; Macpherson, L; Harper, P; Zacharewski, T; Matthews, J. (2011). Identification of aryl hydrocarbon receptor binding targets in mouse hepatic tissue treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 257: 38-47. http://dx.doi.org/10.1016/j.taap.2011.08.016

Lossos, IS; Czerwinski, DK; Alizadeh, AA; Wechser, MA; Tibshirani, R; Botstein, D; Levy, R. (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837. http://dx.doi.org/10.1056/NEJMoa032520

Lubet, RA; Kiss, E; Gallagher, MM; Dively, C; Kouri, RE; Schechtman, LM. (1983). Induction of neoplastic transformation and DNA single-strand breaks in C3H/10T1/2 clone 8 cells by polycyclic hydrocarbons and alkylating agents. J Natl Cancer Inst 71: 991-997.

Ma, Q; Lu, AY. (2007). CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies [Review]. Drug Metab Dispos 35: 1009-1016. http://dx.doi.org/10.1124/dmd.107.015826

Mackenzie, KM; Angevine, DM. (1981). Infertility in mice exposed in utero to benzo(a)pyrene. Biol Reprod 24: 183-192.

Mager, R; Huberman, E; Yang, SK; Gelboin, HV; Sachs, L. (1977). Transformation of normal hamster cells by benzo(a)pyrene diol-epoxide. Int J Cancer 19: 814-817.

Mahler, BJ; Van Metre, PC; Bashara, TJ; Wilson, JT; Johns, DA. (2005). Parking lot sealcoat: an unrecognized source of urban polycyclic aromatic hydrocarbons. Environ Sci Technol 39: 5560-5566. http://dx.doi.org/10.1021/es0501565

Malik, AI; Williams, A; Lemieux, CL; White, PA; Yauk, CL. (2012). Hepatic mRNA, microRNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. Environ Mol Mutagen 53: 10-21. http://dx.doi.org/10.1002/em.20668

Maliszewska-Kordybach, B; Smreczak, B; Klimkowicz-Pawlas, A. (2009). Concentrations, sources, and spatial distribution of individual polycyclic aromatic hydrocarbons (PAHs) in agricultural soils in the Eastern part of the EU: Poland as a case study. Sci Total Environ 407: 3746-3753. http://dx.doi.org/10.1016/j.scitotenv.2009.01.010

Mallet, WG; Mosebrook, DR; Trush, MA. (1991). Activation of (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase. Carcinogenesis 12: 521-524.

Mamber, SW; Bryson, V; Katz, SE. (1983). The Escherichia coli WP2/WP100 rec assay for detection of potential chemical carcinogens. Mutat Res 119: 135-144. http://dx.doi.org/10.1016/0165-7992(83)90121-5

Mane, SS; Purnell, DM; Hsu, IC. (1990). Genotoxic effects of five polycyclic aromatic hydrocarbons in human and rat mammary epithelial cells. Environ Mol Mutagen 15: 78-82.

Marini, MG; Asunis, I; Chan, K; Chan, JY; Kan, YW; Porcu, L; Cao, A; Moi, P. (2002). Cloning MafF by recognition site screening with the NFE2 tandem repeat of HS2: analysis of its role in globin and GCSI genes regulation. Blood Cells Mol Dis 29: 145-158.

Marino, DJ. (1987). Evaluation of Pluronic Polyol F127 as a vehicle for petroleum hydrocarbons in the Salmonella/microsomal assay. Environ Mutagen 9: 307-316.

Marnett, LJ. (1990). Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates [Review]. Environ Health Perspect 88: 5-12.

Martin, CN; Mcdermid, AC; Garner, RC. (1978). Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells. Cancer Res 38: 2621-2627.

Matsuoka, A; Hayashi, M; Ishidate, M. (1979). Chromosomal aberration tests on 29 chemicals combined with S9 mix in vitro. Mutat Res 66: 277-290.

Matsuoka, A; Matsuura, K; Sakamoto, H; Hayashi, M; Sofuni, T. (1998). Spindle disturbances induced by benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene in a Chinese hamster cell line (V79-MZ) and the stability of the numerical chromosome aberrations that follow. Mutat Res 419: 1-12. http://dx.doi.org/10.1016/S1383-5718(98)00069-2

Matsuoka, A; Matsuura, K; Sakamoto, H; Hayashi, M; Sofuni, T. (1999). A proposal for a simple way to distinguish aneugens from clastogens in the in vitro micronucleus test. Mutagenesis 14: 385-389.

Matthews, EJ. (1993). Transformation of BALB/c-3T3 cells: III. Development of a co-culture clonal survival assay for quantification of chemical cytotoxicity in high-density cell cultures. Environ Health Perspect 101 Suppl 2: 311-318.

Maughan, WZ; Muller, SA; Perry, HO; Pittelkow, MR; O'Brien, PC. (1980). Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar: A 25-year follow-up study. J Am Acad Dermatol 3: 612-615.

McCabe, DP; Flynn, EJ. (1990). Deposition of low dose benzo(a)pyrene into fetal tissue: influence of protein binding. Teratology 41: 85-95. http://dx.doi.org/10.1002/tera.1420410109

McCallister, MM; Maguire, M; Ramesh, A; Qiao, AM; Sheng, L; Khoshbouei, H; Aschner, M; Ebner, FF; Hood, DB. (2008). Prenatal exposure to benzo(a)pyrene impairs later-life cortical neuronal function. Neurotoxicology 29: 846-854. http://dx.doi.org/10.1016/j.neuro.2008.07.008

Mccann, J; Spingarn, NE; Kobori, J; Ames, BN. (1975). Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids. PNAS 72: 979-983.

Melikian, AA; Sun, P; Prokopczyk, B; El-Bayoumy, K; Hoffmann, D; Wang, X; Waggoner, S. (1999). Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett 146: 127-134. http://dx.doi.org/10.1016/S0304-3835(99)00203-7

Meng, F; Knapp, GW; Green, T; Ross, JA; Parsons, BL. (2010). K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose. Environ Mol Mutagen 51: 146-155. http://dx.doi.org/10.1002/em.20513

Mensing, T; Marczynski, B; Engelhardt, B; Wilhelm, M; Preuss, R; Kappler, M; Angerer, J; Kafferlein, HU; Scherenberg, M; Seidel, A; Brüning, T. (2005). DNA adduct formation of benzo[a]pyrene in white blood cells of workers exposed to polycyclic aromatic hydrocarbons. Int J Hyg Environ Health 208: 173-178. http://dx.doi.org/10.1016/j.ijheh.2005.01.023

Merk, HF; Mukhtar, H; Kaufmann, I; Das, M; Bickers, DR. (1987). Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolism: effect of exposure to a coal tar-containing shampoo. J Invest Dermatol 88: 71-76.

Merlo, F; Bolognesi, C; Peluso, M; Valerio, F; Abbondandolo, A; Puntoni, R. (1997). Airborne levels of polycyclic aromatic hydrocarbons: 32P-postlabeling DNA adducts and micronuclei in white blood cells from traffic police workers and urban residents. J Environ Pathol Toxicol Oncol 16: 157-162.

Mersch-Sundermann, V; Mochayedi, S; Kevekordes, S. (1992). Genotoxicity of polycyclic aromatic hydrocarbons in Escherichia coli PQ37. Mutat Res 278: 1-9. http://dx.doi.org/10.1016/0165-1218(92)90279-9

Michalopoulos, G; Sattler, GL; O'Connor, L; Pitot, HC. (1978). Unscheduled DNA synthesis induced by procarcinogens in suspensions and primary cultures of hepatocytes on collagen membranes. Cancer Res 38: 1866-1871.

Midgette, AS; Baron, JA. (1990). Cigarette smoking and the risk of natural menopause [Review]. Epidemiology 1: 474-480.

Mielke, HW; Wang, G; Gonzales, CR; Le, B; Quach, VN; Mielke, PW. (2001). PAH and metal mixtures in New Orleans soils and sediments. Sci Total Environ 281: 217-227.

Mielzyńska, D; Siwińska, E; Kapka, L; Szyfter, K; Knudsen, LE; Merlo, DF. (2006). The influence of environmental exposure to complex mixtures including PAHs and lead on genotoxic effects in children living in Upper Silesia, Poland. Mutagenesis 21: 295-304. http://dx.doi.org/10.1093/mutage/gel037

Miller, KP; Ramos, KS. (2001). Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons [Review]. Drug Metab Rev 33: 1-35. http://dx.doi.org/10.1081/DMR-100000138

Miller, ML; Vasunia, K; Talaska, G; Andringa, A; de Boer, J; Dixon, K. (2000). The tumor promoter TPA enhances benzo[a]pyrene and benzo[a]pyrene diolepoxide mutagenesis in Big Blue mouse skin. Environ Mol Mutagen 35: 319-327. http://dx.doi.org/10.1002/1098-2280(2000)35:4<319::AID-EM6>3.0.CO;2-H

Milo, GE; Blakeslee, J; Yohn, DS; Dipaolo, JA. (1978). Biochemical activation of aryl hydrocarbon hydroxylase activity, cellular distribution of polynuclear hydrocarbon metabolites, and DNA damage by polynuclear hydrocarbon products in human cells in vitro. Cancer Res 38: 1638-1644.

Mirsalis, JC; Tyson, CK; Butterworth, BE. (1982). Detection of genotoxic carcinogens in the in vivo-in vitro hepatocyte DNA repair assay. Environ Mol Mutagen 4: 553-562.

Mirvish, SS; Ghadirian, P; Wallcave, L; Raha, C; Bronczyk, S; Sams, JP. (1981). Effect of diet on fecal excretion and gastrointestinal tract distribution of unmetabolized benzo(a)pyrene and 3- methylcholanthrene when these compounds are administered orally to hamsters. Cancer Res 41: 2289-2293.

Mishra, NK; Wilson, CM; Pant, KJ; Thomas, FO. (1978). Simultaneous determination of cellular mutagenesis and transformation by chemical carcinogens in Fischer rat embryo cells. J Toxicol Environ Health 4: 79-91. http://dx.doi.org/10.1080/15287397809529646

Mitra, S; Ray, B. (1995). Patterns and sources of polycyclic aromatic hydrocarbons and their derivatives in indoor air. Atmos Environ 29: 3345-3356. http://dx.doi.org/10.1016/1352-2310(95)00214-j

Mitra, S; Wilson, NK. (1992). Pattern of polynuclear aromatic hydrocarbons in indoor air: exploratory principal component analysis. Environ Int 18: 477-487. http://dx.doi.org/10.1016/0160-4120(92)90266-7

Mitropoulos, P; Norman, R. (2005). Occupational nonsolar risk factors of squamous cell carcinoma of the skin: a population-based case-controlled study. Dermatol Online J 11: 5.

Mohamed, E; Song, WH; Oh, SA; Park, YJ; You, YA; Lee, S; Choi, JY; Kim, YJ; Jo, I; Pang, MG. (2010). The transgenerational impact of benzo(a)pyrene on murine male fertility. Hum Reprod 25: 2427-2433. http://dx.doi.org/10.1093/humrep/deq205

Mohr, U. (1971). Diethylnitrosamine-induced carcinogenesis. Diaplacental effect. Fortschr Med 89: 251-253.

Moir, D. (1999). Physiological modeling of benzo(a)pyrene pharmacokinetics in the rat. In H Salem; SA Katz (Eds.), Toxicity assessment alternatives: Methods, issues, opportunities (pp. 79-95). Totowa, NJ: Humana Press.

Moir, D; Viau, A; Chu, I; Withey, J; Mcmullen, E. (1998). Pharmacokinetics of benzo[a]pyrene in the rat. J Toxicol Environ Health A 53: 507-530.

Moore, LE; Wiencke, JK; Bates, MN; Zheng, S; Rey, OA; Smith, AH. (2004). Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 211: 199-207. http://dx.doi.org/10.1016/j.canlet.2004.04.011

Mori, M; Kobayashi, H; Sugiyama, C; Katsumura, Y; Furihata, C. (1999). Induction of unscheduled DNA synthesis in hairless mouse epidermis by skin carcinogens. J Toxicol Sci 24: 217-226.

Morse, MA; Carlson, GP. (1985). Distribution and macromolecular binding of benzo[a]pyrene in SENCAR and BALB/c mice following topical and oral administration. J Toxicol Environ Health 16: 263-276. http://dx.doi.org/10.1080/15287398509530739

Motykiewicz, G; Michalska, J; Pendzich, J; Małusecka, E; Strózyk, M; Kalinowska, E; Butkiewicz, D; Mielzyńska, D; Midro, A; Santella, RM; Chorazy, M. (1998). A molecular epidemiology study in women from Upper Silesia, Poland. Toxicol Lett 96-97: 195-202.

Mullaart, E; Buytenhek, M; Brouwer, A; Lohman, PH; Vijg, J. (1989). Genotoxic effects of intragastrically administered benzo[a]pyrene in rat liver and intestinal cells. Carcinogenesis 10: 393-395.

N'Diaye, M; Le Ferrec, E; Lagadic-Gossmann, D; Corre, S; Gilot, D; Lecureur, V; Monteiro, P; Rauch, C; Galibert, MD; Fardel, O. (2006). Aryl hydrocarbon receptor- and calcium-

dependent induction of the chemokine CCL1 by the environmental contaminant benzo[a]pyrene. J Biol Chem 281: 19906-19915. http://dx.doi.org/10.1074/jbc.M601192200

Nadal, M; Schuhmacher, M; Domingo, JL. (2004). Levels of PAHs in soil and vegetation samples from Tarragona County, Spain. Environ Pollut 132: 1-11. http://dx.doi.org/10.1016/j.envpol.2004.04.003

Nair, S; Doh, ST; Chan, JY; Kong, AN; Cai, L. (2008). Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 99: 2070-2082. http://dx.doi.org/10.1038/sj.bjc.6604703

Nam, JJ; Thomas, GO; Jaward, FM; Steinnes, E; Gustafsson, O; Jones, KC. (2008). PAHs in background soils from Western Europe: influence of atmospheric deposition and soil organic matter. Chemosphere 70: 1596-1602. http://dx.doi.org/10.1016/j.chemosphere.2007.08.010

Naufal, Z; Zhiwen, L; Zhu, L; Zhou, GD; Mcdonald, T; He, LY; Mitchell, L; Ren, A; Zhu, H; Finnell, R; Donnelly, KC. (2010). Biomarkers of exposure to combustion by-products in a human population in Shanxi, China. J Expo Sci Environ Epidemiol 20: 310-319. http://dx.doi.org/10.1038/jes.2009.19

Naumova, YY; Eisenreich, SJ; Turpin, BJ; Weisel, CP; Morandi, MT; Colome, SD; Totten, LA; Stock, TH; Winer, AM; Alimokhtari, S; Kwon, J; Shendell, D; Jones, J; Maberti, S; Wall, SJ. (2002). Polycyclic aromatic hydrocarbons in the indoor and outdoor air of three cities in the US. Environ Sci Technol 36: 2552-2559. http://dx.doi.org/10.1021/es015727h

Neal, J; Rigdon, RH. (1967). Gastric tumors in mice fed benzo(a)pyrene: A quantitative study. Tex Rep Biol Med 25: 553-557.

Neal, MS; Zhu, J; Foster, WG. (2008). Quantification of benzo[a]pyrene and other PAHs in the serum and follicular fluid of smokers versus non-smokers. Reprod Toxicol 25: 100-106. http://dx.doi.org/10.1016/j.reprotox.2007.10.012

Nebert, DW; Puga, A; Vasiliou, V. (1993). Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction [Review]. Ann N Y Acad Sci 685: 624-640. http://dx.doi.org/10.1111/j.1749-6632.1993.tb35928.x

Nesnow, S; Davis, C; Nelson, G; Ross, JA; Allison, J; Adams, L; King, LC. (1997). Comparison of the morphological transforming activities of dibenzo[a,l]pyrene and benzo[a]pyrene in C3H10T1/2CL8 cells and characterization of the dibenzo[a,l]pyrene-DNA adducts. Carcinogenesis 18: 1973-1978.

Nesnow, S; Davis, C; Nelson, GB; Lambert, G; Padgett, W; Pimentel, M; Tennant, AH; Kligerman, AD; Ross, JA. (2002). Comparison of the genotoxic activities of the K-region dihydrodiol of benzo[a]pyrene with benzo[a]pyrene in mammalian cells: Morphological cell transformation; DNA damage; and stable covalent DNA adducts. Mutat Res 521: 91-102. http://dx.doi.org/10.1016/S1383-5718(02)00218-8

Nesnow, S; Triplett, LL; Slaga, TJ. (1983). Mouse skin tumor initiation-promotion and complete carcinogenesis bioassays: mechanisms and biological activities of emission samples. Environ Health Perspect 47: 255-268.

Neubert, D; Tapken, S. (1988). Transfer of benzo(a)pyrene into mouse embryos and fetuses. Arch Toxicol 62: 236-239. http://dx.doi.org/10.1007/BF00570149

Nishikawa, T; Nakamura, T; Fukushima, A; Takagi, Y. (2005). Further evaluation of the skin micronucleus test: results obtained using 10 polycyclic aromatic hydrocarbons. Mutat Res 588: 58-63. http://dx.doi.org/10.1016/j.mrgentox.2005.09.004

Niu, Q; Zhang, H; Li, X; Li, M. (2010). Benzo[a]pyrene-induced neurobehavioral function and neurotransmitter alterations in coke oven workers. Occup Environ Med 67: 444-448. http://dx.doi.org/10.1136/oem.2009.047969

Norpoth, K; Kemena, A; Jacob, J; Schümann, C. (1984). The influence of 18 environmentally relevant polycyclic aromatic hydrocarbons and clophen A50, as liver monooxygenase inducers, on the mutagenic activity of benz[a]anthracene in the Ames test. Carcinogenesis 5: 747-752. http://dx.doi.org/10.1093/carcin/5.6.747

NRC (National Research Council). (1994). Science and judgment in risk assessment. Washington, DC: National Academy Press. http://www.nap.edu/openbook.php?isbn=030904894X

NRC (National Research Council). (2011). Review of the Environmental Protection Agency's draft IRIS assessment of formaldehyde. Washington, DC: National Academies Press. http://www.nap.edu/catalog/13142.html

NTP (National Toxicology Program). (2011). Report on carcinogens: Twelfth edition (12th ed.). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf

Nwagbara, O; Darling-Reed, SF; Tucker, A; Harris, C; Abazinge, M; Thomas, RD; Gragg, RD. (2007). Induction of cell death, DNA strand breaks, and cell cycle arrest in DU145 human prostate carcinoma cell line by benzo[a]pyrene and benzo[a]pyrene-7,8-diol-9,10-epoxide. Int J Environ Res Public Health 4: 10-14. http://dx.doi.org/10.3390/ijerph2007010002

O'Donovan, MR. (1990). Mutation assays of ethyl methanesulphonate, benzidine and benzo[a]pyrene using Chinese hamster V79 cells. Mutagenesis 5 Suppl: 9-13.

O'Neil, MJ; Smith, A; Heckelman, PE; Obenchain, JR; Gallipeau, JR; D'Arecca, MA. (2001). The Merck index: An encyclopedia of chemicals, drugs, and biologicals. In MJ O'Neil; A Smith; PE Heckelman; JR Obenchain; JR Gallipeau; MA D'Arecca (Eds.), (13th ed.). Whitehouse Station, NJ: Merck & Co., Inc.

O'Neill, IK; Goldberg, MT; El Ghissassi, F; Rojas-Moreno, M. (1991). Dietary fibre, fat and beef modulation of colonic nuclear aberrations and microcapsule-trapped gastrointestinal metabolites of benzo[a]pyrene-treated C57/B6 mice consuming human diets. Carcinogenesis 12: 175-180.

Obana, H; Hori, S; Kashimoto, T; Kunita, N. (1981). Polycyclic aromatic hydrocarbons in human fat and liver. Bull Environ Contam Toxicol 27: 23-27. http://dx.doi.org/10.1007/BF01610981

Obermeier, J; Frohberg, H. (1977). Mutagenicity studies with praziquantel, a new anthelmintic drug: tissue-, host-, and urine-mediated mutagenicity assays. Arch Toxicol 38: 149-161.

OECD (Organisation for Economic Co-operation and Development). (2009). Series on testing and assesment: Number 39. Guidance document on acute inhalation toxicity testing [OECD SIDS]. (ENV/JM/MONO(2009)28; JT03268144). Paris, Fr.

http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282009%2928&doclanguage=en

Oesch, F; Bentley, P; Glatt, HR. (1976). Prevention of benzo(a)pyrene-induced mutagenicity by homogeneous epoxide hydratase. Int J Cancer 18: 448-452. http://dx.doi.org/10.1002/ijc.2910180408

Okey, AB; Riddick, DS; Harper, PA. (1994). Molecular biology of the aromatic hydrocarbon (dioxin) receptor [Review]. Trends Pharmacol Sci 15: 226-232. http://dx.doi.org/10.1016/0165-6147(94)90316-6

Olsen, AK; Andreassen, A; Singh, R; Wiger, R; Duale, N; Farmer, PB; Brunborg, G. (2010). Environmental exposure of the mouse germ line: DNA adducts in spermatozoa and formation of de novo mutations during spermatogenesis. PLoS ONE 5: e11349. http://dx.doi.org/10.1371/journal.pone.0011349

Oueslati, R; Alexandrov, K; Chouikha, M; Chouroulinkov, I. (1992). Formation and persistence of DNA adducts in epidermal and dermal mouse skin exposed to benzo(a)pyrene in vivo. In Vivo 6: 231-235.

Pahlman, R; Pelkonen, O. (1987). Mutagenicity studies of different polycyclic aromatic hydrocarbons the significance of enzymatic factors and molecular structure. Carcinogenesis 8: 773-778.

Pal, K; Tierney, B; Grover, PL; Sims, P. (1978). Induction of sister-chromatid exchanges in Chinese hamster ovary cells treated in vitro with non-K-region dihydrodiols of 7-methylbenz[a]anthracene and benzo[a]pyrene. Mutat Res 50: 367-375.

Park, JS; Wade, TL; Sweet, S. (2001). Atmospheric distribution of polycyclic aromatic hydrocarbons and deposition to Galveston Bay, Texas, USA. Atmos Environ 35: 3241-3249. http://dx.doi.org/10.1016/s1352-2310(01)00080-2

Park, SJ; Zhao, H; Spitz, MR; Grossman, HB; Wu, X. (2003). An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536: 131-137.

Partanen, T; Boffetta, P. (1994). Cancer risk in asphalt workers and roofers: review and meta-analysis of epidemiologic studies [Review]. Am J Ind Med 26: 721-740.

Pastorelli, R; Guanci, M; Cerri, A; Negri, E; La Vecchia, C; Fumagalli, F; Mezzetti, M; Cappelli, R; Panigalli, T; Fanelli, R; Airoldi, L. (1998). Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 7: 703-709.

Pauluhn, J; Thyssen, J; Althoff, J; Kimmerle, G; Mohr, U. (1985). Long-term inhalation study with benzo(a)pyrene and SO2 in Syrian golden hamsters [Abstract]. Exp Pathol 28: 31. http://dx.doi.org/10.1016/S0232-1513(85)80029-3

Pavanello, S; Favretto, D; Brugnone, F; Mastrangelo, G; Dal Pra, G; Clonfero, E. (1999). HPLC/fluorescence determination of anti-BPDE-DNA adducts in mononuclear white blood cells from PAH-exposed humans. Carcinogenesis 20: 431-435.

Pavanello, S; Pulliero, A; Saia, BO; Clonfero, E. (2006). Determinants of anti-benzo[a]pyrene diol epoxide-DNA adduct formation in lymphomonocytes of the general population. Mutat Res 611: 54-63. http://dx.doi.org/10.1016/j.mrgentox.2006.06.034

Pavanello, S; Pulliero, A; Siwinska, E; Mielzynska, D; Clonfero, E. (2005). Reduced nucleotide excision repair and GSTM1-null genotypes influence anti-B[a]PDE-DNA adduct levels in mononuclear white blood cells of highly PAH-exposed coke oven workers. Carcinogenesis 26: 169-175. http://dx.doi.org/10.1093/carcin/bgh303

Pelkonen, O; Nebert, DW. (1982). Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis [Review]. Pharmacol Rev 34: 189-222.

Penning, TM; Burczynski, ME; Hung, CF; Mccoull, KD; Palackal, NT; Tsuruda, LS. (1999). Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones [Review]. Chem Res Toxicol 12: 1-18. http://dx.doi.org/10.1021/tx980143n

Pereira, MA; Mcmillan, L; Kaur, P; Gulati, DK; Sabharwal, PS. (1982). Effect of benzo[a]pyrene on sister-chromatid exchange in fetal hamster liver exposed in utero. Mutat Res 105: 343-347. http://dx.doi.org/10.1016/0165-7992(82)90105-1

Perera, FP; Dickey, C; Santella, R; O'Neill, JP; Albertini, RJ; Ottman, R; Tsai, WY; Mooney, LA; Savela, K; Hemminki, K. (1994). Carcinogen-DNA adducts and gene mutation in foundry workers with low-level exposure to polycyclic aromatic hydrocarbons. Carcinogenesis 15: 2905-2910. http://dx.doi.org/10.1093/carcin/15.12.2905

Perera, FP; Rauh, V; Whyatt, RM; Tang, D; Tsai, WY; Bernert, JT; Tu, YH; Andrews, H; Barr, DB; Camann, DE; Diaz, D; Dietrich, J; Reyes, A; Kinney, PL. (2005a). A summary of recent findings on birth outcomes and developmental effects of prenatal ETS, PAH, and pesticide exposures [Review]. Neurotoxicology 26: 573-587. http://dx.doi.org/10.1016/j.neuro.2004.07.007

Perera, FP; Rauh, V; Whyatt, RM; Tsai, WY; Bernert, JT; Tu, YH; Andrews, H; Ramirez, J; Qu, L; Tang, D. (2004). Molecular evidence of an interaction between prenatal environmental exposure and birth outcomes in a multiethnic population. Environ Health Perspect 112: 626-630.

Perera, FP; Tang, D; Rauh, V; Lester, K; Tsai, WY; Tu, YH; Weiss, L; Hoepner, L; King, J; Del Priore, G; Lederman, SA. (2005b). Relationships among polycyclic aromatic hydrocarbon-DNA adducts, proximity to the World Trade Center, and effects on fetal growth. Environ Health Perspect 113: 1062-1067.

Perera, FP; Tang, DL; O'Neill, JP; Bigbee, WL; Albertini, RJ; Santella, R; Ottman, R; Tsai, WY; Dickey, C; Mooney, LA. (1993). HPRT and glycophorin A mutations in foundry workers: Relationship to PAH exposure and to PAH-DNA adducts. Carcinogenesis 14: 969-973. http://dx.doi.org/10.1093/carcin/14.5.969

Peterson, AR; Landolph, JR; Peterson, H; Spears, CP; Heidelberger, C. (1981). Oncogenic transformation and mutation of C3H/10T 1/2 clone 8 mouse embryo fibroblasts by alkylating agents. Cancer Res 41: 3095-3099.

Petridou-Fischer, J; Whaley, SL; Dahl, AR. (1988). In vivo metabolism of nasally instilled benzo[a]pyrene in dogs and monkeys. Toxicology 48: 31-40. http://dx.doi.org/10.1016/0300-483X(88)90056-X

Petry, T; Schmid, P; Schlatter, C. (1996). The use of toxic equivalency factors in assessing occupational and environmental health risk associated with exposure to airborne

mixtures of polycyclic aromatic hydrocarbons (PAHs). Chemosphere 32: 639-648. http://dx.doi.org/10.1016/0045-6535(95)00348-7

Phillips, DH. (1983). Fifty years of benzo(a)pyrene [Review]. Nature 303: 468-472. http://dx.doi.org/10.1038/303468a0

Phillipson, CE; Ioannides, C. (1989). Metabolic activation of polycyclic aromatic hydrocarbons to mutagens in the Ames test by various animal species including man. Mutat Res 211: 147-151.

Pittelkow, MR; Perry, HO; Muller, SA; Maughan, WZ; O'Brien, PC. (1981). Skin cancer in patients with psoriasis treated with coal tar: A 25-year follow-up study. Arch Dermatol 117: 465-468.

Pitts, JN, Jr; Van Cauwenberghe, KA; Grosjean, D; Schmid, JP; Fitz, DR; Belser, WL, Jr; Knudson, GB; Hynds, PM. (1978). Atmospheric reactions of polycyclic aromatic hydrocarbons: facile formation of mutagenic nitro derivatives. Science 202: 515-519.

Poel, WE. (1959). Effect of carcinogenic dosage and duration of exposure on skin-tumor induction in mice. J Natl Cancer Inst 22: 19-43.

Poel, WE. (1963). Skin as a test site for the bioassay of carcinogens and carcinogen precursors [IARC Monograph]. In Biology of cutaneous cancers (pp. 611-631). Poel, WE.

Popescu, NC; Turnbull, D; Dipaolo, JA. (1977). Sister chromatid exchange and chromosome aberration analysis with the use of several carcinogens and noncarcinogens. J Natl Cancer Inst 59: 289-293.

Potter, D; Booth, ED; Brandt, HC; Loose, RW; Priston, RA; Wright, AS; Watson, WP. (1999). Studies on the dermal and systemic bioavailability of polycyclic aromatic compounds in high viscosity oil products. Arch Toxicol 73: 129-140.

Prasanna, P; Jacobs, MM; Yang, SK. (1987). Selenium inhibition of benzo[a]pyrene, 3-methylcholanthrene, and 3-methylcholanthrylene mutagenicity in Salmonella typhimurium strains TA98 and TA100. Mutat Res 190: 101-105.

Quarles, JM; Sega, MW; Schenley, CK; Ljinsky, W. (1979). Transformation of hamster fetal cells by nitrosated pesticides in a transplacental assay. Cancer Res 39: 4525-4533.

Quinn, AM; Penning, TM. (2008). Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels. Chem Res Toxicol 21: 1086-1094. http://dx.doi.org/10.1021/tx700345v

Ramesh, A; Greenwood, M; Inyang, F; Hood, DB. (2001a). Toxicokinetics of inhaled benzo[a]pyrene: plasma and lung bioavailability. Inhal Toxicol 13: 533-555. http://dx.doi.org/10.1080/08958370118859

Ramesh, A; Greenwood, M; Inyang, F; Niaz, M; Kopsombut, P; Hood, DB; Archibong, AE; Nyanda, AM. (2003). Aryl hydrocarbon hydroxylase (AHH) and benzo(a)pyrene metabolite in F-344 rats subchronically exposed to inhaled BaP. Toxicologist 72: 325.

Ramesh, A; Inyang, F; Hood, DB; Archibong, AE; Knuckles, ME; Nyanda, AM. (2001b). Metabolism, bioavailability, and toxicokinetics of benzo(alpha)pyrene in F-344 rats following oral administration. Exp Toxicol Pathol 53: 275-290.

Ramesh, A; Inyang, F; Lunstra, DD; Niaz, MS; Kopsombut, P; Jones, KM; Hood, DB; Hills, ER; Archibong, AE. (2008). Alteration of fertility endpoints in adult male F-344 rats by

subchronic exposure to inhaled benzo(a)pyrene. Exp Toxicol Pathol 60: 269-280. http://dx.doi.org/10.1016/j.etp.2008.02.010

Ramesh, A; Knuckles, ME. (2006). Dose-dependent benzo(a)pyrene [B(a)P]-DNA adduct levels and persistence in F-344 rats following subchronic dietary exposure to B(a)P. Cancer Lett 240: 268-278. http://dx.doi.org/10.1016/j.canlet.2005.09.016

Ramesh, A; Walker, SA; Hood, DB; Guillén, MD; Schneider, K; Weyand, EH. (2004). Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons [Review]. Int J Toxicol 23: 301-333. http://dx.doi.org/10.1080/10915810490517063

Rao, KP; Nandan, BD. (1990). Modification of benzo(a)pyrene induced chromosomal damage in mouse bone marrow by vitamin A. Bull Environ Contam Toxicol 45: 829-832. http://dx.doi.org/10.1007/BF01701079

Rastetter, WH; Nachbar, RB; Russo-Rodriguez, S; Wattley, RV; Thilly, WG; Andon, BM; Jorgensen, WL; Ibrahim, M. (1982). Fluoranthene: Synthesis and mutagenicity of four diol epoxides. J Org Chem 47: 4873-4878. http://dx.doi.org/10.1021/jo00146a011

Raveh, D; Slaga, TJ; Huberman, E. (1982). Cell-mediated mutagenesis and tumor-initiating activity of the ubiquitous polycyclic hydrocarbon, cyclopenta[c,d]pyrene. Carcinogenesis 3: 763-766. http://dx.doi.org/10.1093/carcin/3.7.763

Reddy, M; Gupta, R; Randerath, E; Randerath, K. (1984). 32P-postlabeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogens and methylating agents. Carcinogenesis 5: 231-243.

Renzik-Schüller, H; Mohr, U. (1974). Investigations on the carcinogenic burden by air pollution in man. IX. Early pathological alterations of the bronchial epithelium in Syrian gloden hamsters after intratracheal instillation of benzo (a) pyrene. 1. Morphological studies from semithin sections. Zentralbl Bakteriol, Parasitenkd, Infektionskrankh Hyg, Abt 1: Orig, Reihe B 159: 493-502.

Rice, JE; Makowski, GS; Hosted, TJ; Lavoie, EJ. (1985). Methylene-bridged bay region chrysene and phenanthrene derivatives and their keto-analogs: mutagenicity in Salmonella typhimurium and tumor-initiating activity on mouse skin. Cancer Lett 27: 199-206. http://dx.doi.org/10.1016/0304-3835(84)90119-8

Rigdon, RH; Neal, J. (1965). Effects of feeding benzo[a]pyrene on fertility, embryos, and young mice. J Natl Cancer Inst 34: 297-305.

Rigdon, RH; Rennels, EG. (1964). Effect of feeding benzpyrene on reproduction in the rat. Cell Mol Life Sci 20: 224-226. http://dx.doi.org/10.1007/BF02135417

Robertson, IG; Guthenberg, C; Mannervik, B; Jernström, B. (1986). Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene. Cancer Res 46: 2220-2224.

Robinson, DE; Mitchell, AD. (1981). Unscheduled DNA synthesis response of human fibroblasts, WI-38 cells, to 20 coded chemicals. In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 517-527). New York, NY: Elsevier/North-Holland.

Robinson, M; Laurie, RD; Bull, RJ; Stober, JA. (1987). Carcinogenic effects in A/J mice of particulate of a coal tar paint used in potable water systems. Cancer Lett 34: 49-54. http://dx.doi.org/10.1016/0304-3835(87)90072-3

Rocchi, P; Ferreri, AM; Borgia, R; Prodi, G. (1980). Polycyclic hydrocarbons induction of diphtheria toxin-resistant mutants in human cells. Carcinogenesis 1: 765-767.

Rodriguez-Romero, IM; Gomez-Arroyo, S; Villalobos-Pietrini, R; Martinez-Valenzuela, C; Cortes-Eslava, J; Calderon-Ezquerro, MC; Garcia-Martinez, R; Arenas-Huertero, F; Calderon-Segura, ME. (2012). Evaluation of 8-hydroxy-2'-deoxyguanosine (8-OHdG) adduct levels and DNA strand breaks in human peripheral blood lymphocytes exposed in vitro to polycyclic aromatic hydrocarbons with or without animal metabolic activation. Toxicol Mech Meth 22: 170-183. http://dx.doi.org/10.3109/15376516.2011.623330

Roe, FJ; Peto, R; Kearns, F; Bishop, D. (1970). The mechanism of carcinogenesis by the neutral fraction of cigarette smoke condensate. Br J Cancer 24: 788-806.

Roelofzen, JH; Aben, KK; Oldenhof, UT; Coenraads, PJ; Alkemade, HA; van de Kerkhof, PC; van der Valk, PG; Kiemeney, LA. (2010). No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol 130: 953-961. http://dx.doi.org/10.1038/jid.2009.389

Roggeband, R; Wolterbeek, AP; van den Berg, PT; Baan, RA. (1994). DNA adducts in hamster and rat tracheas exposed to benzo(a)pyrene in vitro. Toxicol Lett 72: 105-111.

Rojas, M; Alexandrov, K; Cascorbi, I; Brockmöller, J; Likhachev, A; Pozharisski, K; Bouvier, G; Auburtin, G; Mayer, L; Kopp-Schneider, A; Roots, I; Bartsch, H. (1998). High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics 8: 109-118.

Rojas, M; Cascorbi, I; Alexandrov, K; Kriek, E; Auburtin, G; Mayer, L; Kopp-Schneider, A; Roots, I; Bartsch, H. (2000). Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis 21: 35-41. http://dx.doi.org/10.1093/carcin/21.1.35

Rojas, M; Godschalk, R; Alexandrov, K; Cascorbi, I; Kriek, E; Ostertag, J; Van Schooten, FJ; Bartsch, H. (2001). Myeloperoxidase--463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis 22: 1015-1018. http://dx.doi.org/10.1093/carcin/22.7.1015

Romundstad, P; Andersen, A; Haldorsen, T. (2000a). Cancer incidence among workers in six Norwegian aluminum plants. Scand J Work Environ Health 26: 461-469.

Romundstad, P; Haldorsen, T; Andersen, A. (2000b). Lung and bladder cancer among workers in a Norwegian aluminium reduction plant. Occup Environ Med 57: 495-499. http://dx.doi.org/10.1136/oem.57.7.495

Rosenkranz, HS; Poirier, LA. (1979). Evaluation of the mutagenicity and DNA-modifying activity of carcinogens and noncarcinogens in microbial systems. J Natl Cancer Inst 62: 873-892.

Ross, J; Nelson, G; Erexson, G; Kligerman, A; Earley, K; Gupta, RC; Nesnow, S. (1991). DNA adducts in rat lung, liver and peripheral blood lymphocytes produced by i.p. administration of benzo[a]pyrene metabolites and derivatives. Carcinogenesis 12: 1953-1955. http://dx.doi.org/10.1093/carcin/12.10.1953

Roszinsky-Köcher, G; Basler, A; Röhrborn, G. (1979). Mutagenicity of polycyclic hydrocarbons. V. Induction of sister-chromatid exchanges in vivo. Mutat Res 66: 65-67. http://dx.doi.org/10.1016/0165-1218(79)90008-9

Roth, RA; Vinegar, A. (1990). Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition [Review]. Pharmacol Ther 48: 143-155.

Rowe, AA; O'Connor, TP. (2011). Assessment of water quality of runoff from sealed asphalt surfaces. (EPA/600/R-10/178). Cincinnati, OH: U.S. Environmental Protection Agency.

Roy, TA; Singh, R. (2001). Effect of soil loading and soil sequestration on dermal bioavailability of polynuclear aromatic hydrocarbons. Bull Environ Contam Toxicol 67: 324-331.

Ruchirawat, M; Navasumrit, P; Settachan, D. (2010). Exposure to benzene in various susceptible populations: co-exposures to 1,3-butadiene and PAHs and implications for carcinogenic risk. Chem Biol Interact 184: 67-76. http://dx.doi.org/10.1016/j.cbi.2009.12.026

Rudiger, HW; Kohl, F; Mangels, W; Von Wichert, P; Bartram, CR; Wohler, W; Passarge, E. (1976). Benzpyrene induces sister chromatid exchanges in cultured human lymphocytes. Nature 262: 290-292.

Ruggeri, B; Dirado, M; Zhang, SY; Bauer, B; Goodrow, T; Kleinszanto, AJP. (1993). Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. PNAS 90: 1013-1017. http://dx.doi.org/10.1073/pnas.90.3.1013

Russell, LB. (1977). Validation of the in vivo somatic mutation method in the mouse as a prescreen for germinal point mutations. Arch Toxicol 38: 75-85.

Saffiotti, U; Cefis, F; Kolb, LH. (1968). A method for the experimental induction of bronchogenic carcinoma. Cancer Res 28: 104-124.

Saffiotti, U; Montesano, R; Sellakumar, AR; Kaufman, DG. (1972). Respiratory tract carcinogenesis induced in hamsters by different dose levels of benzo[a]pyrene and ferric oxide. J Natl Cancer Inst 49: 1199-1204.

Sagredo, C; Øvrebø, S; Haugen, A; Fujii-Kuriyama, Y; Baera, R; Botnen, IV; Mollerup, S. (2006). Quantitative analysis of benzo[a]pyrene biotransformation and adduct formation in Ahr knockout mice. Toxicol Lett 167: 173-182. http://dx.doi.org/10.1016/j.toxlet.2006.09.005

Sakai, M; Yoshida, D; Mizusaki, S. (1985). Mutagenicity of polycyclic aromatic hydrocarbons and quinones on Salmonella typhimurium TA97. Mutat Res 156: 61-67. http://dx.doi.org/10.1016/0165-1218(85)90007-2

Salama, SA; Sierra-Torres, CH; Oh, HY; Hamada, FA; Au, WW. (2001). Variant metabolizing gene alleles determine the genotoxicity of benzo[a]pyrene. Environ Mol Mutagen 37: 17-26. http://dx.doi.org/10.1002/1098-2280(2001)37:1<17::AID-EM1002>3.0.CO;2-F

Santodonato, J; Howard, P; Basu, D. (1981). Health and ecological assessment of polynuclear aromatic hydrocarbons. Park Forest South, IL: Pathotox Publishers.

Saunders, CR; Ramesh, A; Shockley, DC. (2002). Modulation of neurotoxic behavior in F-344 rats by temporal disposition of benzo(a)pyrene. Toxicol Lett 129: 33-45.

Schlede, E; Kuntzman, R; Haber, S; Conney, AH. (1970). Effect of enzyme induction on the metabolism and tissue distribution of benzo(alpha)pyrene. Cancer Res 30: 2893-2897.

Schmähl, D; Schmidt, KG; Habs, M. (1977). Syncarcinogenic action of polycyclic hydrocarbons in automobile exhaust gas condensates. In U Mohr; D Schmahl; L Tomatis; W Davis (Eds.), Air pollution and cancer in man (pp. 53-59). Lyon, France: IARC.

Schmidt, KG; Schmähl, D; Misfeld, J. (1973). Investigations on the carcinogenic burden by air pollution in man. VI. Experimental investigations to determine a dose-response relationship and to estimate a threshold dose of benzo(a)pyrene in the skin of two different mouse strains. Zentralbl Bakteriol, Parasitenkd, Infektionskrankh Hyg, Abt 1: Orig, Reihe B 158: 62-68.

Schnizlein, CT; Munson, AE; Rhoades, RA. (1987). Immunomodulation of local and systemic immunity after subchronic pulmonary exposure of mice to benzo(a)pyrene. International Journal of Immunopharmacology 9: 99-106.

Schonwald, AD; Bartram, CR; Rudiger, HW. (1977). Benzpyrene-induced sister chromatid exchanges in lymphocytes of patients with lung cancer. Hum Genet 36: 261-264.

Schwarz, D; Kisselev, P; Cascorbi, I; Schunck, WH; Roots, I. (2001). Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 22: 453-459. http://dx.doi.org/10.1093/carcin/22.3.453

Sega, GA. (1979). Unscheduled DNA synthesis (DNA repair) in the germ cells of male mice--its role in the study of mammalian mutagenesis. Genetics 92: s49-s58.

Sega, GA. (1982). DNA repair in spermatocytes and spermatids of the mouse. (CONF-820448-4). Oak Ridge, TN: Oak Ridge National Laboratory. http://www.osti.gov/bridge/product.biblio.jsp?osti_id=5207659

Sharovskaya, J; Kobliakova, I; Solomatina, N; Kobliakov, V. (2006). Effect of some carcinogenic and non-carcinogenic polycyclic aromatic hydrocarbons on gap junction intercellular communication in hepatoma cell cultures. Eur J Cell Biol 85: 387-397. http://dx.doi.org/10.1016/j.ejcb.2005.11.006

Shendrikova, IA; Aleksandrov, VA. (1974). Comparative penetration of polycyclic hydrocarbons through the rat placenta into the fetus. Bull Exp Biol Med 77: 169-171.

Shi, L; Jones, WD; Jensen, RV; Harris, SC; Perkins, RG; Goodsaid, FM; Guo, L; Croner, LJ; Boysen, C; Fang, H; Qian, F; Amur, S; Bao, W; Barbacioru, CC; Bertholet, V; Cao, XM; Chu, TM; Collins, PJ; Fan, XH; Frueh, FW; Fuscoe, JC; Guo, X; Han, J; Herman, D; Hong, H; Kawasaki, ES; Li, QZ; Luo, Y; Ma, Y; Mei, N; Peterson, RL; Puri, RK; Shippy, R; Su, Z; Sun, YA; Sun, H; Thorn, B; Turpaz, Y; Wang, C; Wang, SJ; Warrington, JA; Willey, JC; Wu, J; Xie, Q; Zhang, L; Zhang, L; Zhong, S; Wolfinger, RD; Tong, W. (2008). The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics 9 Suppl 9: S10. http://dx.doi.org/10.1186/1471-2105-9-S9-S10

Shimada, H; Satake, S; Itoh, S; Hattori, C; Hayashi, M; Ishidate, M. (1990). Multiple-dosing effects of benzo[a]pyrene in the mouse bone marrow micronucleus test. Mutat Res 234: 179-181.

Shimada, H; Suzuki, H; Itoh, S; Hattori, C; Matsuura, Y; Tada, S; Watanabe, C. (1992). The micronucleus test of benzo[a]pyrene with mouse and rat peripheral blood reticulocytes. Mutat Res 278: 165-168.

Shimizu, RW; Sun, JD; Li, AP; Newton, GJ; Brooks, AL. (1984). The use of sister-chromatid exchange in Chinese hamster primary lung cell cultures to measure genotoxicity. Mutat Res 130: 333-342.

Shimizu, Y; Nakatsuru, Y; Ichinose, M; Takahashi, Y; Kume, H; Mimura, J; Fujii-Kuriyama, Y; Ishikawa, T. (2000). Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. PNAS 97: 779-782. http://dx.doi.org/10.1073/pnas.97.2.779

Shinohara, K; Cerutti, PA. (1977). Excision repair of benzo[a]pyrene-deoxyguanosine adducts in baby hamster kidney 21/C13 cells and in secondary mouse embryo fibroblasts C57BL/6J. PNAS 74: 979-983.

Siebert, D; Marquardt, H; Friesel, H; Hecker, E. (1981). Polycyclic aromatic hydrocarbons and possible metabolites: convertogenic activity in yeast and tumor initiating activity in mouse skin. J Cancer Res Clin Oncol 102: 127-139.

Simmon, VF. (1979a). In vitro assays for recombinogenic activity of chemical carcinogens and related compounds with Saccharomyces cerevisiae D3. J Natl Cancer Inst 62: 901-909.

Simmon, VF. (1979b). In vitro mutagenicity assays of chemical carcinogens and related compounds with Salmonella typhimurium. J Natl Cancer Inst 62: 893-899.

Singh, VK; Singh, J; Anand, M; Kumar, P; Patel, DK; Krishna Reddy, MM; Javed Siddiqui, MK. (2008). Comparison of polycyclic aromatic hydrocarbon levels in placental tissues of Indian women with full- and preterm deliveries. Int J Hyg Environ Health 211: 639-647. http://dx.doi.org/10.1016/j.ijheh.2007.11.004

Sinha, R; Kulldorff, M; Gunter, MJ; Strickland, P; Rothman, N. (2005). Dietary benzo[a]pyrene intake and risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 14: 2030-2034. http://dx.doi.org/10.1158/1055-9965.epi-04-0854

Sipinen, V; Laubenthal, J; Baumgartner, A; Cemeli, E; Linschooten, JO; Godschalk, RW; Van Schooten, FJ; Anderson, D; Brunborg, G. (2010). In vitro evaluation of baseline and induced DNA damage in human sperm exposed to benzo[a]pyrene or its metabolite benzo[a]pyrene-7,8-diol-9,10-epoxide, using the comet assay. Mutagenesis 25: 417-425. http://dx.doi.org/10.1093/mutage/geq024

Sivak, A; Niemeier, R; Lynch, D; Beltis, K; Simon, S; Salomon, R; Latta, R; Belinky, B; Menzies, K; Lunsford, A; Cooper, C; Ross, A; Bruner, R. (1997). Skin carcinogenicity of condensed asphalt roofing fumes and their fractions following dermal application to mice. Cancer Lett 117: 113-123. http://dx.doi.org/10.1016/S0304-3835(97)00214-0

Slaga, TJ; Gleason, GL; Mills, G; Ewald, L; Fu, PP; Lee, HM; Harvey, RG. (1980). Comparison of the skin tumor-initiating activities of dihydrodiols and diol-epoxides of various polycyclic aromatic hydrocarbons. Cancer Res 40: 1981-1984.

Slaga, TJ; Huberman, E; Selkirk, JK; Harvey, RG; Bracken, WM. (1978). Carcinogenicity and mutagenicity of benz(a)anthracene diols and diol-epoxides. Cancer Res 38: 1699-1704.

Smyth, GK. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3. http://dx.doi.org/10.2202/1544-6115.1027

Soares, SR; Melo, MA. (2008). Cigarette smoking and reproductive function [Review]. Curr Opin Obstet Gynecol 20: 281-291. http://dx.doi.org/10.1097/GCO.0b013e3282fc9c1e

Soballe, PW; Montone, KT; Satyamoorthy, K; Nesbit, M; Herlyn, M. (1996). Carcinogenesis in human skin grafted to SCID mice. Cancer Res 56: 757-764.

Sotomayor, RE; Sega, GA. (2000). Unscheduled DNA synthesis assay in mammalian spermatogenic cells: an update. Environ Mol Mutagen 36: 255-265. http://dx.doi.org/10.1002/1098-2280(2000)36:4<255::AID-EM1>3.0.CO;2-O

Spinelli, JJ; Band, PR; Svirchev, LM; Gallagher, RP. (1991). Mortality and cancer incidence in aluminum reduction plant workers. J Occup Med 33: 1150-1155.

Spinelli, JJ; Demers, PA; Le, ND; Friesen, MD; Lorenzi, MF; Fang, R; Gallagher, RP. (2006). Cancer risk in aluminum reduction plant workers (Canada). Cancer Causes Control 17: 939-948. http://dx.doi.org/10.1007/s10552-006-0031-9

Stavric, B; Klassen, R. (1994). Dietary effects on the uptake of benzo[a]pyrene. Food Chem Toxicol 32: 727-734. http://dx.doi.org/10.1016/S0278-6915(09)80005-7

Stern, RS; Laird, N. (1994). The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 73: 2759-2764.

Stern, RS; Liebman, EJ; Väkevä, L. (1998). Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 90: 1278-1284.

Stern, RS; Zierler, S; Parrish, JA. (1980). Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1: 732-735.

Sullivan, MJ; Miller, CJ; Custance, SR. (1991). A risk assessment for crude oil in residential surface soils. In EJ Calabrese; PT Kostecki (Eds.), Hydrocarbon contaminated soils, v I: remediation techniques, environmental fate, risk assessment, analytical methodologies, regulatory considerations. Chelsea, MI: Lewis Publishers, Inc.

Sun, JD; Wolff, RK; Kanapilly, GM. (1982). Deposition, retention, and biological fate of inhaled benzo(a)pyrene adsorbed onto ultrafine particles and as a pure aerosol. Toxicol Appl Pharmacol 65: 231-244.

Surh, YJ; Kundu, JK; Na, HK. (2008). Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals [Review]. Planta Med 74: 1526-1539. http://dx.doi.org/10.1055/s-0028-1088302

Surh, YJ; Tannenbaum, SR. (1995). Sulfotransferase-mediated activation of 7,8,9,10-tetrahydro-7-ol, 7,8-dihydrodiol, and 7,8,9,10-tetraol derivatives of benzo[a]pyrene. Chem Res Toxicol 8: 693-698. http://dx.doi.org/10.1021/tx00047a008

Suter, M; Abramovici, A; Showalter, L; Hu, M; Shope, CD; Varner, M; Aagaard-Tillery, K. (2010). In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism 59: 1481-1490. http://dx.doi.org/10.1016/j.metabol.2010.01.013

Takehisa, S; Wolff, S. (1978). Sister-chromatid exchanges induced in rabbit lymphocytes by 2-aminofluorene and 2-acetylaminofluorene after in vitro and in vivo metabolic activation. Mutat Res 58: 321-329.

Talaska, G; Ginsburg, D; Ladow, K; Puga, A; Dalton, T; Warshawsky, D. (2006). Impact of Cyp1a2 or Ahr gene knockout in mice: implications for biomonitoring studies. Toxicol Lett 162: 246-249. http://dx.doi.org/10.1016/j.toxlet.2005.09.020

Tamaki, A; Hayashi, H; Nakajima, H; Takii, T; Katagiri, D; Miyazawa, K; Hirose, K; Onozaki, K. (2004). Polycyclic aromatic hydrocarbon increases mRNA level for interleukin 1 beta in human fibroblast-like synoviocyte line via aryl hydrocarbon receptor. Biol Pharm Bull 27: 407-410.

Tang, D; Li, TY; Liu, JJ; Chen, YH; Qu, L; Perera, F. (2006). PAH-DNA adducts in cord blood and fetal and child development in a Chinese cohort. Environ Health Perspect 114: 1297-1300. http://dx.doi.org/10.1289/ehp.8939

Tang, D; Warburton, D; Tannenbaum, SR; Skipper, P; Santella, RM; Cereijido, GS; Crawford, FG; Perera, FP. (1999). Molecular and genetic damage from environmental tobacco smoke in young children. Cancer Epidemiol Biomarkers Prev 8: 427-431.

Tang, T; Friedman, MA. (1977). Carcinogen activation by human liver enzymes in the Ames mutagenicity test. DNA Repair 46: 387-394.

Tarantini, A; Maitre, A; Lefebvre, E; Marques, M; Marie, C; Ravanat, JL; Douki, T. (2009). Relative contribution of DNA strand breaks and DNA adducts to the genotoxicity of benzo[a]pyrene as a pure compound and in complex mixtures. Mutat Res 671: 67-75. http://dx.doi.org/10.1016/j.mrfmmm.2009.08.014

Theriault, G; Tremblay, C; Cordier, S; Gingras, S. (1984). Bladder cancer in the aluminium industry. Lancet 1: 947-950.

Thyssen, J; Althoff, J; Kimmerle, G; Mohr, U. (1981). Inhalation studies with benzo[a]pyrene in Syrian golden hamsters. J Natl Cancer Inst 66: 575-577.

Tohda, H; Khoraguchi; Alkte. (1980). Epstein-Barr virus-transformed human lymphoblastoid cells for study of sister chromatid exchange and their evaluation as a test system. Cancer Res 40: 4775-4780.

Tong, C; Brat, SV; Williams, GM. (1981). Sister-chromatid exchange induction by polycyclic aromatic hydrocarbons in an intact cell system of adult rat-liver epithelial cells. Mutat Res 91: 467-473.

Torinuki, W; Tagami, H. (1988). Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies: A 10-year follow-up study. J Am Acad Dermatol 18: 1278-1281.

Trapido, M. (1999). Polycyclic aromatic hydrocarbons in Estonian soil: contamination and profiles. Environ Pollut 105: 67-74. http://dx.doi.org/10.1016/s0269-7491(98)00207-3

Tremblay, C; Armstrong, B; Thériault, G; Brodeur, J. (1995). Estimation of risk of developing bladder cancer among workers exposed to coal tar pitch volatiles in the primary aluminum industry. Am J Ind Med 27: 335-348. http://dx.doi.org/10.1002/ajim.4700270303

Triolo, AJ; Aponte, GE; Herr, DL. (1977). Induction of aryl hydrocarbon hydroxylase and forestomach tumors ben benzo(a)pyrene. Cancer Res 37: 3018-3021.

Tuntawiroon, J; Mahidol, C; Navasumrit, P; Autrup, H; Ruchirawat, M. (2007). Increased health risk in Bangkok children exposed to polycyclic aromatic hydrocarbons from traffic-related sources. Carcinogenesis 28: 816-822. http://dx.doi.org/10.1093/carcin/bgl175

Turkall, RM; Abdel-Rahman, MS; Skowronski, GA. (2008). Effects of soil matrix and aging on the dermal bioavailability of hydrocarbons and metals in the soil: Dermal bioavailability of

soil contaminants. Paper presented at 23rd Annual International Conference on Soils, Sediments and Water, October 15-18, 2007, Amherst, MA.

Tweats, DJ. (1981). Activity of 42 coded compounds in a differential killing test using Escherichia coli strains WP2, WP67 (uvrA polA), and CM871 (uvrA lexA recA). In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 199-209). New York, NY: Elsevier/North-Holland.

U.S. EPA (U.S. Environmental Protection Agency). (1988). Recommendations for and documentation of biological values for use in risk assessment. (EPA/600/6-87/008). Cincinnati, OH: U.S. Environmental Protection Agency, National Center for Environmental Assessment. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855

U.S. EPA (U.S. Environmental Protection Agency). (1990). Development of a dose-response model for inhaled B(a)P [EPA Report]. (EPA-600/R-92-135). http://www.ntis.gov/search/product.aspx?ABBR=PB93161016

U.S. EPA (U.S. Environmental Protection Agency). (1991a). Dose-response analysis of ingested Benzo(a)pyrene (CAS No. 50-32-8) [EPA Report]. (EPA600R92045). http://www.ntis.gov/search/product.aspx?ABBR=PB93167484

U.S. EPA (U.S. Environmental Protection Agency). (1991b). Drinking water criteria document for polycyclic aromatic hydrocarbons (PAHs). (ECAOCIND010). http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=9100CSXZ.txt

U.S. EPA (U.S. Environmental Protection Agency). (1991c). Guidelines for developmental toxicity risk assessment. (EPA/600/FR-91/001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. http://www.epa.gov/raf/publications/guidelines-dev-toxicity-risk-assessment.htm

U.S. EPA (U.S. Environmental Protection Agency). (1996). Guidelines for reproductive toxicity risk assessment. (EPA/630/R-96/009). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. http://www.epa.gov/raf/publications/pdfs/REPRO51.PDF

U.S. EPA (U.S. Environmental Protection Agency). (1998). Guidelines for neurotoxicity risk assessment. (EPA/630/R-95/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. http://www.epa.gov/raf/publications/pdfs/NEUROTOX.PDF

U.S. EPA (U.S. Environmental Protection Agency). (2004). Risk Assessment Guidance for Superfund (RAGS), Volume I: Human health evaluation manual, (part E: Supplemental guidance for dermal risk assessment): Final. (EPA/540/R/99/005). Washington, DC. http://www.epa.gov/oswer/riskassessment/ragse/index.htm

U.S. EPA (U.S. Environmental Protection Agency). (2005). Guidelines for carcinogen risk assessment. (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. http://www.epa.gov/cancerguidelines/

U.S. EPA (U.S. Environmental Protection Agency). (2010). Revised draft: Multistage Weibull time-to-tumor model in EPA's benchmark dose software (BMDS): Methodology description. Washington, DC.

U.S. EPA (U.S. Environmental Protection Agency). (2012a). Benchmark Dose Software (BMDS). Version 2.2. Retrieved from http://www.epa.gov/NCEA/bmds/index.html

U.S. EPA (U.S. Environmental Protection Agency). (2012b). Benchmark dose technical guidance. (EPA/100/R-12/001). Washington, DC: Risk Assessment Forum. http://www.epa.gov/raf/publications/pdfs/benchmark_dose_guidance.pdf

Uno, S; Dalton, TP; Derkenne, S; Curran, CP; Miller, ML; Shertzer, HG; Nebert, DW. (2004). Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65: 1225-1237. http://dx.doi.org/10.1124/mol.65.5.1225

Uno, S; Dalton, TP; Dragin, N; Curran, CP; Derkenne, S; Miller, ML; Shertzer, HG; Gonzalez, FJ; Nebert, DW. (2006). Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 69: 1103-1114. http://dx.doi.org/10.1124/mol.105.021501

Uno, S; Dalton, TP; Shertzer, HG; Genter, MB; Warshawsky, D; Talaska, G; Nebert, DW. (2001). Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem Biophys Res Commun 289: 1049-1056. http://dx.doi.org/10.1006/bbrc.2001.6110

Urano, K; Katakai, Y; Tokuda, Y; Ueyama, Y; Nomura, T; Yamamoto, S. (1995). Failure of genotoxic carcinogens to produce tumors in human skin xenografts transplanted to SCID mice. Carcinogenesis 16: 2223-2226. http://dx.doi.org/10.1093/carcin/16.9.2223

Valencia, R; Houtchens, K. (1981). Mutagenic activity of 10 coded compounds in the Drosophila sex-linked recessive lethal test. In FJ de Serres; J Ashby (Eds.), Evaluation of short-term tests for carcinogens: Report of the International Collaborative Program (pp. 651-659). New York, NY: Elsevier/North-Holland.

Valentin-Severin, I; Thybaud, V; Le Bon, AM; Lhuguenot, JC; Chagnon, MC. (2004). The autoradiographic test for unscheduled DNA synthesis: a sensitive assay for the detection of DNA repair in the HepG2 cell line. Mutat Res 559: 211-217. http://dx.doi.org/10.1016/j.mrgentox.2003.12.007

van Agen, B; Maas, LM; Zwingmann, IH; Van Schooten, FJ; Kleinjans, JC. (1997). B[a]P-DNA adduct formation and induction of human epithelial lung cell transformation. Environ Mol Mutagen 30: 287-292. http://dx.doi.org/10.1002/(SICI)1098-2280(1997)30:3<287::AID-EM6>3.0.CO;2-I

Van Metre, PC; Mahler, BJ. (2010). Contribution of PAHs from coal-tar pavement sealcoat and other sources to 40 U.S. lakes. Sci Total Environ 409: 334-344. http://dx.doi.org/10.1016/j.scitotenv.2010.08.014

VanRooij, JGM; Bodelier-Bade, MM; Jongeneelen, FJ. (1993). Estimation of individual dermal and respiratory uptake of polycyclic aromatic hydrocarbons in 12 coke oven workers. Br J Ind Med 50: 623-632. http://dx.doi.org/10.1136/oem.50.7.623

Verhofstad, N; van Oostrom, CT; Zwart, E; Maas, LM; van Benthem, J; van Schooten, FJ; van Steeg, H; Godschalk, RW. (2011). Evaluation of benzo(a)pyrene-induced gene mutations in male germ cells. Toxicol Sci 119: 218-223. http://dx.doi.org/10.1093/toxsci/kfq325

Verschueren, K. (2001). Handbook of environmental data on organic chemicals. New York, NY: John Wiley & Sons, Incorporated. internal-pdf://Verschueren 2001-2436785413/Verschueren 2001.pdf

Voelter-Mahlknecht, S; Scheriau, R; Zwahr, G; Koch, B; Escobar Pinzon, LC; Drexler, H; Letzel, S. (2007). Skin tumors among employees of a tar refinery: the current data and their implications. Int Arch Occup Environ Health 80: 485-495. http://dx.doi.org/10.1007/s00420-006-0155-y

Vogel, EW; Zijlstra, JA; Blijleven, WG. (1983). Mutagenic activity of selected aromatic amines and polycyclic hydrocarbons in Drosophila melanogaster. Mutat Res 107: 53-77. http://dx.doi.org/10.1016/0027-5107(83)90078-7

Vogt, NB; Brakstad, F; Thrane, K; Nordenson, S; Krane, J; Aamot, E; Kolset, K; Esbensen, K; Steinnes, E. (1987). Polycyclic aromatic hydrocarbons in soil and air: statistical analysis and classification by the SIMCA method. Environ Sci Technol 21: 35-44. http://dx.doi.org/10.1021/es00155a003

Wang, JJ; Frazer, DG; Law, B; Lewis, DM. (2003). Identification and quantification of urinary benzo[a]pyrene and its metabolites from asphalt fume exposed mice by microflow LC coupled to hybrid quadrupole time-of-flight mass spectrometry. Analyst 128: 864-870.

Warshawsky, D; Barkley, W. (1987). Comparative carcinogenic potencies of 7H-dibenzo[c,g]carbazole, dibenz[a,j]acridine and benzo[a]pyrene in mouse skin. Cancer Lett 37: 337-344. http://dx.doi.org/10.1016/0304-3835(87)90119-4

Wattenberg, LW. (1972). Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin. J Natl Cancer Inst 48: 1425-1430.

Wattenberg, LW. (1974). Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by several sulfur-containing compounds. J Natl Cancer Inst 52: 1583-1587.

Waylen, AL; Metwally, M; Jones, GL; Wilkinson, AJ; Ledger, WL. (2009). Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis [Review]. Hum Reprod Update 15: 31-44. http://dx.doi.org/10.1093/humupd/dmn046

Wei, SJ; Chang, RL; Merkler, KA; Gwynne, M; Cui, XX; Murthy, B; Huang, MT; Xie, JG; Lu, YP; Lou, YR; Jerina, DM; Conney, AH. (1999). Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene. Carcinogenesis 20: 1689-1696.

Weinberg, CR; Wilcox, AJ; Baird, DD. (1989). Reduced fecundability in women with prenatal exposure to cigarette smoking. Am J Epidemiol 129: 1072-1078.

Weinstein, D; Katz, ML; Kazmer, S. (1977). Chromosomal effects of carcinogens and non-carcinogens on WI-38 after short term exposures with and without metabolic activation. Mutat Res 46: 297-304. http://dx.doi.org/10.1016/0165-1161(77)90006-1

Wester, RC; Maibach, HI; Bucks, DA; Sedik, L; Melendres, J; Liao, C; Dizio, S. (1990). Percutaneous absorption of [14C]DDT and [14C]benzo[a]pyrene from soil. Fundam Appl Toxicol 15: 510-516.

Weyand, EH; Bevan, DR. (1986). Benzo(a)pyrene disposition and metabolism in rats following intratracheal instillation. Cancer Res 46: 5655-5661.

Weyand, EH; Bevan, DR. (1987). Species differences in disposition of benzo[a]pyrene. Drug Metab Dispos 15: 442-448.

Weyand, EH; Chen, YC; Wu, Y; Koganti, A; Dunsford, HA; Rodriguez, LV. (1995). Differences in the tumorigenic activity of a pure hydrocarbon and a complex mixture following ingestion: Benzo[a]pyrene vs manufactured gas plant residue. Chem Res Toxicol 8: 949-954. http://dx.doi.org/10.1021/tx00049a008

Weyand, EH; He, ZM; Ghodrati, F; Wu, Y; Marshall, MV; Lavoie, EJ. (1992). Effect of fluorine substitution on benzo[j]fluoranthene genotoxicity. Chem Biol Interact 84: 37-53.

Weyand, EH; Lavoie, EJ. (1988). Comparison of PAH DNA adduct formation and tumor initiating activity in newborn mice. Proc Am Assoc Cancer Res 29: 98.

Whitwell, J; Fowler, P; Allars, S; Jenner, K; Lloyd, M; Wood, D; Smith, K; Young, J; Jeffrey, L; Kirkland, D. (2010). 5-Fluorouracil, colchicine, benzo[a]pyrene and cytosine arabinoside tested in the in vitro mammalian cell micronucleus test (MNvit) in Chinese hamster V79 cells at Covance Laboratories, Harrogate, UK in support of OECD draft Test Guideline 487. Mutat Res 702: 230-236. http://dx.doi.org/10.1016/j.mrgentox.2010.04.022

WHO (World Health Organization). (1996). 14.16. Polycunclear aromatic hydrocarbons. In Guidelines for drinking-water quality Second edition. http://www.who.int/water_sanitation_health/dwq/2edvol2p2c.pdf

WHO (World Health Organization). (1997). Guidelines for air qualtiy. http://www.airimpacts.org/documents/local/AQGUIDE.pdf

WHO (World Health Organization). (2000). Air qualtiy guidelines for Europe, second edition. Copenhagen, DK. http://www.euro.who.int/document/e71922.pdf/

WHO (World Health Organization). (2003). Polynuclear aromatic hydrocarbons in drinking water. (WHO/SDE/WSH/03.04/59). Geneva, Switzerland. http://www.who.int/water_sanitation_health/dwq/chemicals/polyaromahydrocarbons.pdf

Whyatt, RM; Santella, RM; Jedrychowski, W; Garte, SJ; Bell, DA; Ottman, R; Gladek-Yarborough, A; Cosma, G; Young, TL; Cooper, TB; Randall, MC; Manchester, DK; Perera, FP. (1998). Relationship between ambient air pollution and DNA damage in Polish mothers and newborns. Environ Health Perspect 106: 821-826.

Wielgosz, SM; Brauze, D; Pawlak, AL. (1991). Ah locus-associated differences in induction of sister-chromatid exchanges and in DNA adducts by benzo[a]pyrene in mice. Mutat Res 246: 129-137.

Wiencke, JK; Mcdowell, ML; Bodell, WJ. (1990). Molecular dosimetry of DNA adducts and sister chromatid exchanges in human lymphocytes treated with benzo[a]pyrene. Carcinogenesis 11: 1497-1502.

Wiersma, DA; Roth, RA. (1983a). The prediction of benzo[a]pyrene clearance by rat liver and lung from enzyme kinetic data. Mol Pharmacol 24: 300-308.

Wiersma, DA; Roth, RA. (1983b). Total body clearance of circulating benzo(a)pyrene in conscious rats: Effect of pretreatment with 3-methylcholanthrene and the role of liver and lung. J Pharmacol Exp Ther 226: 661-667.

Wijnhoven, SW; Kool, HJ; van Oostrom, CT; Beems, RB; Mullenders, LH; van Zeeland, AA; van der Horst, GT; Vrieling, H; van Steeg, H. (2000). The relationship between benzo[a]pyrene-induced mutagenesis and carcinogenesis in repair-deficient Cockayne syndrome group B mice. Cancer Res 60: 5681-5687.

Wilcke, W. (2000). SYNOPSIS Polycyclic aromatic hydrocarbons (PAHs) in soil A review. J Plant Nutr Soil Sci 163: 229248. http://dx.doi.org/10.1002/1522-2624(200006)163:3<229::AID-JPLN229>3.0.CO;2-6

Willems, MI; Roggeband, R; Baan, RA; Wilmer, JW; de Raat, WK; Lohman, PH. (1991). Monitoring the exposure of rats to benzo[a]pyrene by the determination of mutagenic activity in excreta, chromosome aberrations and sister chromatid exchanges in peripheral blood cells, and DNA adducts in peripheral blood lymphocytes and liver. Mutagenesis 6: 151-158.

Williams, GM; Laspia, MF; Dunkel, VC. (1982). Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and noncarcinogens. Mutat Res 97: 359-370. http://dx.doi.org/10.1016/0165-1161(82)90003-6

Williams, JA; Martin, FL; Muir, GH; Hewer, A; Grover, PL; Phillips, DH. (2000). Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 21: 1683-1689. http://dx.doi.org/10.1093/carcin/21.9.1683

Wilson, JS; Holland, LM. (1988). Periodic response difference in mouse epidermis chronically exposed to crude-oils or BaP: Males vs. females. Toxicology 50: 83-94. http://dx.doi.org/10.1016/0300-483X(88)90123-0

Withey, JR; Sedden, J; Law, FCP; Abedini, S. (1993). Distribution of benzo[a]pyrene in pregnant rats following inhalation exposure and a comparison with similar data obtained with pyrene. J Appl Toxicol 13: 193-202. http://dx.doi.org/10.1002/jat.2550130310

Wojciechowski, JP; Kaur, P; Sabharwal, PS. (1981). Comparison of metabolic systems required to activate pro-mutagens/carcinogens in vitro for sister-chromatid exchange studies. Mutat Res 88: 89-97.

Wolff, RK; Griffith, WC; Henderson, RF; Hahn, FF; Harkema, J. R.; Rebar, AH; Eidson, AF; Mcclellan, RO. (1989). Effects of repeated inhalation exposures to 1-nitropyrene, benzo(a)pyrene, Ga2O3 particles, and SO2 alone and in combinations on particle clearance, bronchoalveolar lavage fluid composition, and histopathology. J Toxicol Environ Health 27: 123-138. http://dx.doi.org/10.1080/15287398909531283

Wolff, S; Takehisa, S. (1977). Induction of sister chromatid exchanges in mammalian cells by low concentrations of mutagenic carcinogens that require metabolic activation as well as those that do not. Dev Toxicol Environ Sci 2: 193-200.

Wood, AW; Levin, W; Chang, RL; Huang, MT; Ryan, DE; Thomas, PE; Lehr, RE; Kumar, S; Koreeda, M; Akagi, H; Ittah, Y; Dansette, P; Yagi, H; Jerina, DM; Conney, AH. (1980). Mutagenicity and tumor-initiating activity of cyclopenta(c,d)pyrene and structurally related compounds. Cancer Res 40: 642-649.

Wood, AW; Levin, W; Lu, AYH; Yagi, H; Hernandez, O; Jerina, DM; Conney, AH. (1976). Metabolism of benzo[a]pyrene and benzo[a]pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J Biol Chem 251: 4882-4890.

Wormhoudt, LW; Commandeur, JN; Vermeulen, NP. (1999). Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity [Review]. Crit Rev Toxicol 29: 59-124. http://dx.doi.org/10.1080/10408449991349186

Wormley, DD; Chirwa, S; Nayyar, T; Wu, J; Johnson, S; Brown, LA; Harris, E; Hood, DB. (2004). Inhaled benzo(a)pyrene impairs long-term potentiation in the F1 generation rat dentate gyrus. Cell Mol Biol (Noisy-le-grand) 50: 715-721.

Wu, J; Hou, H; Ritz, B; Chen, Y. (2010). Exposure to polycyclic aromatic hydrocarbons and missed abortion in early pregnancy in a Chinese population. Sci Total Environ 408: 2312-2318. http://dx.doi.org/10.1016/j.scitotenv.2010.02.028

Wu, J; Ramesh, A; Nayyar, T; Hood, DB. (2003a). Assessment of metabolites and AhR and CYP1A1 mRNA expression subsequent to prenatal exposure to inhaled benzo(a)pyrene. Int J Dev Neurosci 21: 333-346.

Wu, MT; Pan, CH; Huang, YL; Tsai, PJ; Chen, CJ; Wu, TN. (2003b). Urinary excretion of 8-hydroxy-2-deoxyguanosine and 1-hydroxypyrene in coke-oven workers. Environ Mol Mutagen 42: 98-105. http://dx.doi.org/10.1002/em.10176

Wu, MT; Simpson, CD; Christiani, DC; Hecht, SS. (2002). Relationship of exposure to coke-oven emissions and urinary metabolites of benzo(a)pyrene and pyrene in coke-oven workers. Cancer Epidemiol Biomarkers Prev 11: 311-314.

Wu, Q; Suzuki, JS; Zaha, H; Lin, TM; Peterson, RE; Tohyama, C; Ohsako, S. (2008). Differences in gene expression and benzo[a]pyrene-induced DNA adduct formation in the liver of three strains of female mice with identical AhRb2 genotype treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin and/or benzo[a]pyrene. J Appl Toxicol 28: 724-733. http://dx.doi.org/10.1002/jat.1331

Wu, X; Gu, J; Spitz, MR. (2007). Mutagen sensitivity: a genetic predisposition factor for cancer [Review]. Cancer Res 67: 3493-3495. http://dx.doi.org/10.1158/0008-5472.CAN-06-4137

Wu, X; Roth, JA; Zhao, H; Luo, S; Zheng, YL; Chiang, S; Spitz, MR. (2005). Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Res 65: 349-357.

Wynder, EL; Fritz, L; Furth, N. (1957). Effect of concentration of benzopyrene in skin carcinogenesis. J Natl Cancer Inst 19: 361-370.

Wynder, EL; Hoffmann, D. (1959). A study of tobacco carcinogenesis. VII. The role of higher polycyclic hydrocarbons. Cancer 12: 1079-1086. http://dx.doi.org/10.1002/1097-0142(195911/12)12:6<1079::AID-CNCR2820120604>3.0.CO;2-I

Xu, C; Chen, J; Qiu, Z; Zhao, Q; Luo, J; Yang, L; Zeng, H; Huang, Y; Zhang, L; Cao, J; Shu, W. (2010). Ovotoxicity and PPAR-mediated aromatase downregulation in female Sprague-Dawley rats following combined oral exposure to benzo[a]pyrene and di-(2-ethylhexyl) phthalate. Toxicol Lett 199: 323-332. http://dx.doi.org/10.1016/j.toxlet.2010.09.015

Xu, Z; Brown, LM; Pan, GW; Liu, TF; Gao, GS; Stone, BJ; Cao, RM; Guan, DX; Sheng, JH; Yan, ZS; Dosemeci, M; Fraumeni, JF; Blot, WJ. (1996). Cancer risks among iron and steel workers in Anshan, China, Part II: Case-control studies of lung and stomach cancer. Am J Ind Med 30: 7-15. http://dx.doi.org/10.1002/(SICI)1097-0274(199607)30:1<7::AID-AJIM2>3.0.CO;2-#

Yamasaki, H. (1990). Gap junctional intercellular communication and carcinogenesis [Review]. Carcinogenesis 11: 1051-1058.

Yamazaki, H; Kakiuchi, Y. (1989). The uptake and distribution of benzo(a)pyrene in rat after continuous oral administration. Toxicol Environ Chem 24: 95-104. http://dx.doi.org/10.1080/02772248909357480

Yang, H; Mazur-Melnyk, M; de Boer, JG; Glickman, BW. (1999). A comparison of mutational specificity of mutations induced by S9-activated B[a]P and benzo[a]pyrene-7,8-diol-9,10-epoxide at the endogenous aprt gene in CHO cells. Mutat Res 423: 23-32.

Yang, JJ; Roy, TA; Krueger, AJ; Neil, W; Mackerer, CR. (1989). In vitro and in vivo percutaneous absorption of benzo[a]pyrene from petroleum crude-fortified soil in the rat. Bull Environ Contam Toxicol 43: 207-214.

Yang, SYN; Connell, DW; Hawker, DW; Kayal, SI. (1991). Polycyclic aromatic hydrocarbons in air, soil and vegetation in the vicinity of an urban roadway. Sci Total Environ 102: 229-240. http://dx.doi.org/10.1016/0048-9697(91)90317-8

Yauk, CL; Jackson, K; Malowany, M; Williams, A. (2011). Lack of change in microRNA expression in adult mouse liver following treatment with benzo(a)pyrene despite robust mRNA transcriptional response. Mutat Res 722: 131-139. http://dx.doi.org/10.1016/j.mrgentox.2010.02.012

Young, C; Cherrie, J; Van Tongeren, M; Fortunato, L; Hutchings, S; Rushton, L. (2012). The burden of occupational cancer in Great Britain: Non-melanoma skin cancer. Sudbury, Suffolk: Health and Safety Executive (HSE). http://www.hse.gov.uk/research/rrhtm/rr928.htm

Zeilmaker, MJ; van Eijkeren, JCH. (1997). Modeling of Ah-receptor dependent P450 induction I. Cellular model definition and its corporation in a PBPK model of 2,3,7,8-TCDD. (604138.001). Bilthoven, The Netherlands: National Institute of Public Health and the Environment (RIVM). http://www.rivm.nl/bibliotheek/rapporten/604138001.html

Zeilmaker, MJ; van Eijkeren, JCH; Kroese, ED. (1999a). PBPK simulated DNA adduct formation: Relevance for the risk assessment of benzo(a)pyrene. (658603 009). Bilthoven, The Netherlands: National Institute of Public Health and the Environment (RIVM). http://www.rivm.nl/bibliotheek/rapporten/658603009.html

Zeilmaker, MJ; Van Eijkeren, JCH; Olling, M. (1999b). A PBPK-model for B(a)P in the rat relating dose and liver DNA-adduct level. (RIVM Report 658603 008). Bilthoven, The Netherlands: National Institute of Public Health and the Environment (RIVM). http://www.rivm.nl/bibliotheek/rapporten/658603008.pdf

Zhang, HM; Nie, JS; Li, X; Niu, Q. (2012). Characteristic analysis of peripheral blood mononuclear cell apoptosis in coke oven workers. J Occup Health 54: 44-50. http://dx.doi.org/10.1539/joh.11-0155-OA

Zhang, YJ; Li, Y; Deleo, VA; Santella, RM. (1990). Detection of DNA adducts in skin biopsies of coal tar-treated psoriasis patients: immunofluorescence and 32P postlabeling. Skin Pharmacol Physiol 3: 171-179. http://dx.doi.org/10.1159/000210867

Zheng, SJ; Tian, HJ; Cao, J; Gao, YQ. (2010). Exposure to di(n-butyl)phthalate and benzo(a)pyrene alters IL-1β secretion and subset expression of testicular macrophages, resulting in decreased testosterone production in rats. Toxicol Appl Pharmacol 248: 28-37. http://dx.doi.org/10.1016/j.taap.2010.07.008

ED_006137A_00009570-00333

Zheng, Z; Fang, JL; Lazarus, P. (2002). Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30: 397-403. http://dx.doi.org/10.1124/dmd.30.4.397

Zijlstra, JA; Vogel, EW. (1984). Mutagenicity of 7,12-dimethylbenz[a]anthracene and some other aromatic mutagens in Drosophila melanogaster. Mutat Res 125: 243-261. http://dx.doi.org/10.1016/0027-5107(84)90074-5